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Ageing is defined as a system-wide, gradual loss in overall organ and tissue 
function across the lifespan of an organism, and in humans is the single largest 
risk factor for most chronic diseases. Thanks to ongoing improvements in 
healthcare, human life expectancy is steadily rising, but the proportion of life 
spent free of chronic disease (known as healthspan) is not extending concurrently 
in our increasingly aged population. Socio-economic costs are growing, both in 
terms of healthcare spending and quality of life. A central goal of ageing research 
therefore is to find methods of extending healthspan. However, ageing is a 
complex, heterogeneous process and the underlying mechanisms of ageing and 
determinants of lifespan/healthspan are still not well understood.  
RNA regulators of gene expression are important factors in the ageing process, 
and I hypothesise that they may have potential to affect healthspan, or act as 
biomarkers of ageing. In this thesis, I have examined some of these RNA 
regulatory factors and their associations with ageing and lifespan in mammals. In 
order to do this, I assessed the expression patterns of RNA regulatory factors in 
two mouse models and a human cohort. In one mouse model, I found that both 
mRNA splicing regulatory factors and microRNAs are associated with strain-
specific longevity during normal ageing, and that it is possible that these 
regulators play a causal role in determining strain lifespan. In the second mouse 
model, I showed these splicing factors to be associated with dietary restriction (a 
known treatment for extension of lifespan) and provided evidence that they could 
be mechanistically involved in the lifespan response to dietary restriction. I also 
showed that expression levels of these splicing factors were associated with 
cognitive decline and reduction in physical ability in humans. 
4 
These results indicate that correct RNA regulation is a key component of the 
ageing process and suggests that the factors that govern these processes may 
represent useful future targets for healthpan intervention in ageing people. 
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Peptidylprolyl Isomerase A (H. 
Sapiens/M.musculus) 
PPT Purdue Pegboard Test 
pre-mRNA Precursor Messenger RNA 
Pten Phosphatase And Tensin Homolog 
qRT-PCR 
Quantitative Real-Time Polymerase Chain 
Reaction 
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Ran Ras-related Nuclear Protein 
RISC RNA Induced Silencing Complex 
RNA Ribonucleic Acid 
RNP Ribonucleoprotein 
ROS Reactive Oxygen Species 
Rps6ka3 Ribosomal Protein S6 Kinase A3 (M.musculus) 
RT Reverse Transcription 
SASP Senescence Associated Secretory Phenotype 
siRNA Small Interfering RNA 
SF1 Splicing Factor 1 
SF3B1/Sf3b1 
Splicing Factor 3b Subunit 1 
(H. Sapiens/M.musculus) 
SFRS18/Sfrs18 
Splicing Factor, Arginine/Serine-Rich 18  
(NB. Nomenclature has changed to 
PNISR/Pnisr)  
(H. Sapiens/M.musculus) 
Smad4 SMAD Family Member 4 (M.musculus) 
snoRNA Small Nucleolar RNA 
snRNA Small Nuclear RNA 
snRNP Small Nuclear Ribonucleoproteins 
SR Serine and Arginine Rich 
SRSF1/Srsf1 
Serine And Arginine Rich Splicing Factor 1  
(H. Sapiens/M.musculus) 
SRSF2/Srsf2 
Serine And Arginine Rich Splicing Factor 2  
(H. Sapiens/M.musculus) 
SRSF3/Srsf3 
Serine And Arginine Rich Splicing Factor 3  
(H. Sapiens/M.musculus) 
SRSF6/Srsf6 
Serine And Arginine Rich Splicing Factor 6  
(H. Sapiens/M.musculus) 
SRSF7/Srsf7 
Serine And Arginine Rich Splicing Factor 7  
(H. Sapiens/M.musculus) 
SS Splice Site 
STAT1 
Signal Transducer And Activator Of 
Transcription 1 (H. Sapiens) 
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TAC Taqman™ Array Cards 
Taq polymerase Thermus aquaticus DNA polymerase 
TGF-beta 
Transforming Growth Factor Beta 1 
(H. Sapiens) 
Tm Melting Temperature 
TMT Trail Making Test 
TNF Tumor Necrosis Factor (H. Sapiens) 
TRA2β/Tra2β 
Transformer 2 Beta Homolog  
(H. Sapiens/M.musculus) 
TRP53 Tumor Protein P53 (H. Sapiens) 
ULT Ultra-Low Temperature 
UTR Untranslated Region 
UV Ultraviolet 
VCAN Versican (H. Sapiens) 
VILO™ Variable In, Linear Out 
WRN Werner Syndrome RecQ Like Helicase 
XPC 
XPC Complex Subunit, DNA Damage 
Recognition And Repair Factor 
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1.1 Impact of an ageing population 
It is widely recognised that human life expectancy is increasing worldwide (Figure 
1.1a)1, and as a consequence there is a strong trend towards greater numbers of 
elderly individuals in the general population1. Although the lower-income 
countries lag behind those with higher income, the same trend is beginning to 
show in the projected figures for the year 21001. Globally, this increase in 
numbers of the elderly is almost universally coupled with a downturn in birth rates, 
resulting in a progressively larger old-age dependency ratio (Figure 1.1b)1. The 
importance of this increase in the dependency ratio becomes apparent when we 
consider the socio-economic impact of a populace that is projected to be 
increasingly biased in numbers of older individuals. As can be seen in Figure 
1.1c, according to the 2018 figures from the Office of Budget Responsibility, in 
the UK the overwhelming majority (≈75%) of expenditure in terms of health and 
adult social care is concentrated in the 65-and-over age group2. Given this fact, 
along with the predicted increase in the elderly and reduction in numbers of 
working-age individuals, it is not unreasonable to conclude that increased strain 
will be placed on healthcare providers and their funding systems in the 
foreseeable future.  
Of course, the view presented above is purely economical and does not consider 
the human and quality of life aspects of such a change in demographics. There 
is little doubt that ageing is the largest single risk factor for a host of common 
ailments including cancer, cardiovascular disease, neurodegeneration etc.3; the 
observed trend towards increased numbers of more elderly individuals goes 
hand-in-hand with increased incidence of such diseases and so decreased 
quality of life.  
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Figure 1.1: Historic and predicted population dynamics  
Shown here are plots of worldwide life expectancy and dependency ratios, along with recent UK 
healthcare spending. Panel a shows worldwide life expectancy in years at birth from 1955 to 2100. 
Panel b shows worldwide dependency ratio calculated as the number of over 65s per 100 
“working age” individuals (20-64 years old). Panel c shows stacked plots of 2018 figures for 
healthcare spending and adult social care spending by age group, in pounds per capita in the UK. 
Data for panels a & b were taken from the United Nations World Population Prospects 20171, 
while data for panel c were taken from the Office of Budget Responsibility (OBR) Fiscal 
Sustainability Report, July 20182. 
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Gerontologists have therefore been working for many years towards a greater 
understanding of the ageing process and the underlying determinants of later life 
health, in a bid to improve outcomes and potentially alleviate some of the future 
negative socio-economic impact. 
1.2 Mechanisms of ageing 
Ageing is generally defined as a progressive loss of physiological function leading 
to reduced survival and is a process which affects most living organisms4. 
However, the fact that there are some exceptions to this observation whereby 
certain species appear to show negligible ageing (data from AnAge database5), 
coupled with the fact that large amounts of variation in lifespan exist between 
biologically very similar organisms, rules out the idea that ageing is simply a result 
of wear-and-tear over time6. There is still debate surrounding the basic causes of 
ageing and discussion also continues into the reason why organisms age at all. 
Several theories exist which each go some way toward an answer to these 
questions. These theories are not mutually exclusive7, and it seems plausible that 
a unifying theory of ageing mechanisms could include aspects drawn from many. 
In the next sections, I will discuss the development of evolutionary theories of 
ageing, followed by a brief description of the popular mechanistic hypotheses 
thought to contribute to ageing, grouped into the error-based theories and 
programmed theories. 
1.3 Evolutionary theories of ageing 
Theories relating to the evolution of ageing have been discussed since the mid-
19th century shortly after the publication of Darwin’s On the Origin of Species8, 
since it was not immediately apparent how observations of ageing processes and 
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species-specific lifespan could comfortably fit Darwin’s natural selection 
hypothesis. Around the turn of the century, August Weismann presented a series 
of hypotheses in an effort to explain ageing in the context of natural selection 
(reviewed by Kirkwood & Cremer9). His initial ideas were centred around species-
level selection and proposed that once an individual had performed “its share in 
this work […towards the maintenance of the species…] it has fulfilled its duty and 
it may die”9. This was later shown to be a somewhat circular argument and did 
not account for within-species selection, so is now largely disregarded as a 
workable theory. However, two of Weismann’s central arguments proved to be 
pivotal to subsequent theories of ageing: the first was the recognition that there 
is a fundamental difference between the ‘immortal’ germ line and ‘mortal’ soma10, 
while the second was the suggestion of a limit to the reproductive potential of 
somatic cells. His views were opposed by other scholars at the time and did not 
attain wide recognition, however although his theories were incomplete in certain 
respects, these concepts provided a basis for several strands of the later theories 
of ageing, including disposable soma, programmed longevity and replicative 
senescence (see sections 1.3.3, 1.5.1 and 1.6.1). 
Modern evolutionary theories of ageing generally fit into one of three categories; 
mutation accumulation, antagonistic pleiotropy and disposable soma. Although 
there have been a number of refinements to these theories, the basic arguments 
as initially described in each case are still valid. 
1.3.1 Mutation accumulation 
In the years following Weismann’s death in 1914, few hypotheses regarding the 
mechanism of ageing were proposed, and it was not until 1952 that a further in-
depth examination of the evolution of ageing was undertaken by Peter Medawar. 
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In a lecture given at University College London (later published as ‘An Unsolved 
Problem of Biology’11), he proposed a theory which underpins all modern 
evolutionary theories of ageing, in that the forces of natural selection decline with 
age, particularly after the organism has reached an age at which it would have 
the ability to reproduce. 
The basic premise is that since all organisms will eventually die, whether through 
disease, starvation, cold, predation, accident etc., traits conferring an early-life 
advantage will be actively selected for, rather than those with late-life beneficial 
effects, simply due to progressively smaller numbers of individuals on which 
natural selection can act. He also argued that this effect would only be apparent 
after reaching reproductive age, as natural selection can only act upon inherited 
traits. For example, a mutant allele causing death before reproductive age would 
be very strongly selected against, as few (if any) individuals would survive long 
enough to pass this to their offspring, whereas a mutant allele with fatal effect 
after reproduction would have reduced selection pressure upon it, as it would be 
inherited by the offspring and would thus only affect the organism’s ability to have 
more descendants.  
In short, Medawar suggested that declining survivorship and fertility during 
normal lifespan causes selection forces to progressively weaken until there is 
little or no opposition to the accumulation of mutant alleles with deleterious effects 
in late life, and that ageing is effectively a by-product of the build-up of these late-
acting harmful mutations. 
1.3.2 Antagonistic pleiotropy 
George Williams’ paper of 19576 expanded on Medawar’s hypothesis, adding the 
concept of antagonistic pleiotropy. Pleiotropy occurs when one gene affects two 
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seemingly unrelated traits. In the context of antagonistic pleiotropy in relation to 
ageing theory, a special kind of effect is assumed whereby an allele of a gene 
has opposite effects on evolutionary fitness at different ages. With this 
assumption in mind alongside Medawar’s idea of selection pressure declining 
over time, it becomes evident that an allele which has a beneficial early-life effect 
would be positively selected for despite any late-life deleterious effects, and vice 
versa. Logically, this would lead to a similar accumulation of late-life harmful 
effect alleles as proposed in Medawar’s theory, but also provides a more robust 
explanation for the persistence of such harmful alleles in a population. Several 
genes have since been shown to act in this manner, with late-life links to 
increased risk of cancer, Huntingdon’s disease and osteoporosis but early-life 
advantages in terms of increased fertility and decreased risk of other illnesses12. 
1.3.3 Disposable soma 
The disposable soma theory of ageing was first proposed in the late 1970s by 
Thomas Kirkwood13,14, although the basis of his theory owes something to the 
earlier ideas of Weismann, Medawar and Williams. This hypothesis relies on 
recognition that somatic cells and reproductive cells in a multicellular organism 
have diverging requirements in order to maximise whole-organism fitness. 
Effectively this can be thought of as the soma playing a support role in order for 
the reproductive cells to fulfil their ultimate purpose of continuing the germ line 
through reproduction. A second observation fundamental to the disposable soma 
theory is that organisms have a requirement to allocate resources in such a way 
that maximises their evolutionary fitness. 
Given that each individual somatic cell has a limited life expectancy (as proposed 
by Medawar) and upon death all the resources invested into it are lost, logically 
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the amount of investment in the repair and maintenance of the soma will be some 
amount less than that required for it to last indefinitely. The optimal amount of 
investment will vary from species to species depending on the surrounding 
environment, but in all cases too low an investment will result in degradation of 
the soma before reproduction has taken place (which is clearly an unacceptable 
outcome in terms of fitness), while any investment in maintaining the soma over 
and above that required for it to reach its expected lifespan confers no additional 
advantage. In the latter situation it would actually improve overall fitness to reduce 
investment in somatic maintenance and use those resources elsewhere, for 
example faster growth or increased fecundity. 
As with the preceding theories of ageing, the disposable soma hypothesis 
predicts that ageing is a result of an accumulation of harmful late-life traits, 
although it arrives at this point through a different mode of action, i.e. 
accumulation of cellular damage due to reduced maintenance rather than 
differential selective pressures on harmful alleles. 
1.4 Error-based theories of ageing 
1.4.1 Rate of living 
The rate of living hypothesis is based on the observations made in 1908 by Max 
Rubner15 that the lifespan of mammals increases with size, and that mass-
specific metabolic rates decrease with size. Formalised by Raymond Pearl in 
192816, the theory states that lifespan and metabolic rate are inversely correlated 
due to a limited supply of “inherent vitality” being available throughout life. While 
this theory still holds some attraction thanks to its apparent logic, there are many 
examples of animals which do not conform to the proposed negative correlation 
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between metabolism and lifespan17, casting doubt on the validity of this theory as 
originally presented by Pearl. However, there have been substantial refinements 
to the basic theory which have led to the more widely accepted free radical and 
oxidative stress theories of ageing as I will discuss in the following sections. 
1.4.2 Free radicals 
In 1956, Denham Harman proposed a mechanism which could potentially explain 
the observations underlying the rate of living theory without relying on the 
assumption of a finite lifetime supply of energy. He argued that oxygen free 
radicals produced during normal metabolic oxygen consumption cause damage 
to biological molecules (proteins, nucleic acids and lipids etc.), leading to ageing 
and ultimately death through accumulation of this oxidative damage18. The fact 
that the production rate of free radicals is strongly correlated with metabolic 
activity provided the necessary link to the rate of living theory, however Harman’s 
mechanistic insight did not address any of the shortcomings of the rate of living 
theory discussed in section 1.4.1. 
1.4.3 Oxidative stress 
The oxidative stress theory builds upon the free radical concept but includes 
some important refinements. Firstly, the recognition that other reactive molecules 
produced by normal metabolism can also cause oxidative damage; these 
damaging molecules along with the free radicals are collectively termed reactive 
oxygen species (ROS). Secondly, the fact that organisms have mechanisms to 
both prevent and repair oxidative damage caused by ROS19. These additional 
considerations give the oxidative stress model greater capacity to explain 
observations of ageing and lifespan, although a number of exceptions exist where 
this theory does not hold true15. Further research in this field has implicated 
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membrane fatty acid composition as a potential determinant of distinct species 
lifespans, which is plausible given the known variability in sensitivity to oxidative 
damage shown by different fatty acids15,20. 
1.4.4 Protein damage and autophagy 
Protein damage has often been postulated as a driver of the ageing process. 
Perhaps the earliest instance is the cross-linking theory of Johan Bjorksten, 
originally proposed in the early 1940s and expanded in later work21,22, essentially 
arguing that intra- or inter-molecular bonds between macromolecules (with 
particular reference to proteins) formed either through the action of naturally 
occurring small molecules or direct reaction between molecules, would lead to a 
build-up of immobilised, non-functional proteins, resulting in the ageing 
phenotype. 
Leslie Orgel later developed a theory encompassing both DNA and protein 
machinery23,24 which stated that errors in proteins (particularly those involved in 
translating genetic information) could potentially reduce their specificity, thereby 
causing increased error rates in subsequent protein synthesis. This would 
produce a positive feedback loop, eventually leading to an “error catastrophe” 
situation at which point the cell would no longer be viable. While careful not to 
claim that it was the direct cause of organismal ageing, he argued that this loss 
of viability could be contributing to the ageing process.  
Since these early theories, there has been less focus on protein damage as a 
central cause of ageing in and of itself (indeed Orgel’s hypothesis has largely 
been disproven through experimental testing), however it is widely recognised 
that loss of proteostasis is a key element of the ageing phenotype25 and also 
plays a major role in many age-related diseases26. 
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One important aspect of the proteostasis network implicated in ageing and 
lifespan is autophagy – an evolutionarily conserved protein degradation system 
in eukaryotic cells allowing for the destruction of unnecessary or damaged cellular 
components27. In model organisms, autophagy has been found to decline with 
age, and experimental over- or under-expression of key components of the 
autophagy machinery have been shown to respectively increase or decrease 
lifespan (reviewed by Bareja et al.28), all of which suggests that autophagy is an 
important influence in the ageing phenotype. 
1.4.5 DNA damage 
Since DNA is central to all life, it was inevitable that it should be implicated in the 
ageing process. The first mentions of DNA having a role in the context of ageing 
were in a 1958 paper by Gioacchino Failla29 and another a year later from Leo 
Szilard30 which introduced the idea that DNA could potentially play an important 
role in ageing, however these early theories focused entirely on DNA mutations 
as the potential ageing mechanism.  
It was later recognised that DNA alterations could take two distinct forms, and 
have varying effects dependant on the severity and genomic location31-33: 
1. Mutations; defined as changes in the nucleotide sequence (deletions, 
insertions, substitutions or rearrangements) which can lead to functional 
changes to proteins. 
2. DNA damage; defined as a change to the structure of the DNA molecule, 
which can cause changes to gene expression and cellular function, 
impairment of transcription, cell cycle arrest and can in certain cases lead 
to apoptosis. 
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The realisation that DNA damage (as described in point 2) can also lead to 
mutations during the process of DNA repair and/or replication led to an expansion 
in the framework of the DNA-oriented theories of ageing and a shift towards the 
now more widely accepted DNA damage theory of ageing (reviewed by Gensler 
& Bernstein31, Vijg & Dollé32, Hoeijmakers33, Freitas & de Magalhães34 and Ou & 
Schumacher35). 
DNA damage can be caused by both exogenous influences, including chemicals, 
radiation, viruses etc. as well as endogenous factors such as spontaneous 
chemical reactions and ROS34. Damage can take the form of abasic sites, inter- 
and intra-strand crosslinks, bulky chemical adducts, UV-induced photoproducts, 
deamination or oxidative modifications of bases and DNA strand breaks. All of 
these types of damage have the potential to induce mutations through incorrect 
repair or replication of the damaged DNA, which can lead to cancer, cell-cycle 
arrest, senescence or apoptosis. It is also possible for certain types of DNA 
damage to act as barriers to transcription or arrest replication, which can cause 
cell death or senescence33,34. 
While it is estimated that many thousands of instances of DNA damage occur in 
every human cell on a daily basis36, it is also the case that several highly 
conserved and effective DNA repair mechanisms exist to rapidly deal with the 
damage, maintaining genomic integrity within the cell thereby avoiding apoptosis 
or senescence. These include non-homologous end joining (NHEJ), homologous 
recombination (HR), base excision repair (BER), nucleotide excision repair (NER) 
and several other more specialised mechanisms (all of these genome 
maintenance pathways have been reviewed in depth by Hoeijmakers33, Freitas & 
de Magalhães34 and Ou & Schumacher35). 
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There is a compelling case for DNA damage to be regarded as a factor in the 
ageing process. Experiments in both model organisms37 and in humans38 have 
shown that DNA damage accumulates during life, and there is also evidence that 
activity of DNA repair pathways declines with age39. It is also notable that 
defective DNA repair genes are implicated in all known diseases characterised 
by accelerated ageing (known as progeroid syndromes). Werner Syndrome, 
Hutchison-Gilford Progeria, Xeroderma Pigmentosum, Bloom Syndrome, 
Cockayne Syndrome, Ataxia Telangiestasia and several others are all 
characterised by progeroid phenotypes, and in each case the gene(s) disrupted 
are known to be either directly involved in, or closely linked to, DNA repair 
pathways39. Finally, there have been numerous experiments showing that 
manipulation of genes in these pathways can cause changes in ageing and/or 
lifespan phenotypes in model organisms39 lending further weight to the argument 
that DNA damage plays a significant role in the mechanisms of ageing. 
All the above arguments refer to the nuclear DNA complement, however there is 
also some evidence that DNA damage in the mitochondrial genome (mtDNA) 
may also play a part in the ageing process. It has been shown that mtDNA 
mutations increase with age and that transgenic mice engineered for artificially 
high mtDNA mutation rates show shortened lifespan and premature ageing 
phenotypes. That being said, there is still debate as to whether such mtDNA 
damage is a causal factor or simply correlated with ageing40. 
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1.5 Programmed theories of ageing 
1.5.1 Programmed longevity 
The idea of programmed longevity relies on the assumption that the declines 
seen in function and reproductive capacity during ageing are the result of 
genetically predetermined processes (in a similar manner to early life 
developmental processes) and therefore must fulfil some adaptive role in order 
to be favoured by natural selection41. Arguments in favour of an evolutionary 
advantage conferred by ageing as a fixed programme usually revolve around a 
perceived need to prevent over-population, to remove older individuals that may 
compete for resources with younger (fitter/more fertile) kin, or to promote turnover 
of generations, thus enhancing evolutionary change42.  
The theory of programmed longevity can be traced back to the work of 
Weismann9 and his assertion that the contribution to survival of the species (i.e. 
reproduction) is the overriding reason for the existence of the individual. In 
general however, most gerontologists do not subscribe to the idea of 
programmed longevity as the fundamental mechanism of ageing due to its 
reliance on species-level or group-level selection, which is accepted to be a 
weaker evolutionary force than selection at the individual level43. 
Programmed longevity is an attractive premise as it offers a simple explanation 
for the observation that ageing is essentially universal and appears to be 
relatively uniform in its effects within species. It also theoretically allows for the 
existence of clearly defined ageing genes or pathways which could potentially be 
switched off, thereby opening the door to the concept of a ‘magic bullet’ cure for 
ageing which has its own rather obvious appeal44. However, it remains a 
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controversial standpoint, generating a huge amount of debate and little 
consensus between proponents from both sides of the argument41,42,44-49.  
1.5.2 Endocrine system 
It has long been known that hormonal regulation is imperative to the maintenance 
of homeostasis and stress responses, and that during the ageing process there 
is a functional decline of the endocrine system in terms of hypothalamic sensitivity 
and responsiveness, hormone production and tissue sensitivity to hormonal 
signals50-52. Based on this knowledge, Vladimir Dilman proposed the 
Neuroendocrine Theory of Ageing53,54 in which he argued that the ageing 
phenotype is driven by this decline in function, and by extension the loss of 
homeostasis caused by the decline. However, he also postulated that the 
progressive deterioration of endocrine function is a continuation of the necessary 
deviation from homeostasis required for growth and development during early 
life, and so can be categorised as a programmed cause of ageing. While Dilman’s 
somewhat controversial theory is not widely accepted as likely to be a 
fundamental cause of ageing, there is ample evidence that the endocrine system 
has an critical role in the ageing process55. 
Age-related changes in levels of sex hormones are of course associated with the 
menopause in females and the less dramatic andropause in males, both of which 
have been linked to increased risk of several chronic diseases common in the 
elderly including osteoporosis, heart disease and declining cognitive function. 
Decreases in adrenal steroid hormones have been correlated with conditions 
such as depression, type 2 diabetes and Alzheimer’s disease. Dysfunction of 
hormone production by the thyroid also results in increased risk of certain 
pathologies, e.g. atrial fibrillation, reduced bone-mineral density and dementia56.  
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However, the most persuasive evidence for endocrine involvement in the 
underlying mechanisms of ageing is found in the nutrient sensing pathways: 
1. Insulin and insulin-like growth factor signalling 
The ‘insulin and insulin-like growth factor signal cascade’ (usually shortened to 
Insulin/IGF-1 signalling or IIS) is a well conserved system which regulates growth, 
metabolism and stress resistance in response to nutrient availability57,58. This 
pathway was first linked to ageing and lifespan in Caenorhabditis elegans; it was 
found that mutations in daf-2 (an IIS receptor ortholog), in the presence of a 
functional daf-16 gene (a downstream FOXO-family transcription factor which 
regulates hundreds of genes involved in stress resistance, immune function and 
metabolism58), led to a doubling of the animals’ lifespan59. It was later shown that 
mutations in IIS receptor orthologs in Drosophila melanogaster and mice resulted 
in similar lifespan increases60-62. In mammals, IGF-1 production is regulated by 
growth hormone (GH) (which does not have an ortholog in the simple model 
organisms), and several mutant mouse strains exist with reduced GH signalling, 
all of which display increased lifespan63. Additionally, both upstream regulators 
and downstream effectors of the IIS have been shown to affect lifespan and the 
ageing process in model organisms57. 
2. Mechanistic target of rapamycin 
The mechanistic (formerly “mammalian”) target of rapamycin (mTOR) is a 
serine/threonine kinase which acts as the catalytic subunit in two protein 
complexes, mTOR Complex 1 (mTORC1) and mTOR Complex 2 (mTORC2)64. 
These two complexes have somewhat different functions; mTORC1 regulates 
protein synthesis, lipid, nucleotide and glucose metabolism, as well as protein 
turnover in response to levels of growth factors, nutrients, oxygen and DNA 
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damage. mTORC2 is involved in the regulation of other kinases in several 
pathways related to proliferation and survival, primarily in response to signals 
from the IIS. Both complexes are central effectors in a number of pathways critical 
to cell growth, proliferation and survival65. 
Once again, experiments in C. elegans first indicated that mTOR was involved in 
the ageing process, where it was found that RNAi knockdowns of the mTOR 
ortholog, let-363, more than doubled the worms’ lifespan66. Subsequently, 
mutations in mTOR and other components of the mTORC1 pathway, as well as 
the use of rapamycin to directly target mTOR were shown to extend lifespan in 
yeast, fruit flies and mice (reviewed by Johnson et al.64). Finally, it has been 
shown that mTOR signalling is involved in the lifespan increases seen with dietary 
restriction in model organisms65,67,68. 
1.5.3 Immunosenescence and inflamm-ageing 
Age-related changes in the immune system are well documented69, and the 
progressive decline in naïve cells coupled with the increase in memory cells 
during this process would appear indicative of a ‘programmed’ function in ageing. 
These changes bring reduced ability to respond appropriately to infections and 
cancer, impaired wound-healing capacity and a predisposition towards increased 
tissue inflammation70. While the idea of a progressively weakening immune 
system would appear to be a reasonable mechanism for the development of 
ageing phenotypes per se, it is actually the case that few morbidities can be 
directly attributable to infection in the elderly and many age-related diseases start 
in young to middle age while the immune system remains efficient71. 
More likely as a direct candidate for mechanistic involvement in the ageing 
process is the chronic, sterile, low-grade inflammation seen during advancing 
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age, known as inflamm-ageing72. Certainly inflamm-ageing is a risk factor for 
many age-related diseases, e.g. heart failure, atherosclerosis, obesity, diabetes 
and neurodegenerative conditions73, however there is ample evidence that the 
increasing inflammatory background associated with advancing age is at least in 
part a product of senescent cells74 (see also section 1.6). 
Once again, it is not clear whether immunosenescence and inflamm-ageing can 
be classified as root causes of the ageing phenotype, however they undoubtedly 
play an important role in the process. 
1.6 Cellular senescence 
In most of the mechanisms outlined above, the late-life accumulation of 
deleterious traits is thought to manifest a negative effect (at least partially) 
through cellular senescence. Cellular senescence is defined as a permanent† 
state of cell-cycle arrest in response to different damaging stimuli75. The basic 
premise was first proposed by Weismann, who suggested the existence of a limit 
to the reproductive potential of somatic cells9, but it was not until Leonard Hayflick 
and Paul Moorhead showed this experimentally in their 1961 paper76, and coined 
the term ‘cellular senescence’, that the idea became more widely accepted. 
Senescent cells are known to be important in several biological processes, i.e. 
tumour suppression, wound healing, tissue repair and embryonic development, 
but in all these cases the presence of senescent cells is transient, and the cells 
are subsequently cleared by the immune system. During ageing however, there 
is a gradual accumulation of senescent cells, which is thought to be a potential 
source of late-life deleterious effects74. 
† This is the classical definition of senescence. As I will discuss in section 1.7.2, 
recent research from our group calls the permanence of senescence into question. 
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Apart from the suspension of the cell-cycle, senescence is characterised by 
altered cellular morphology, gene expression, metabolism, epigenome and 
secretory phenotype77. The senescence associated secretory phenotype (SASP) 
is a cocktail of pro-inflammatory cytokines, chemokines, growth factors and 
extracellular matrix-degrading proteins78 which is thought to serve as a signal to 
enable immune clearance of senescent cells and/or promote tissue repair77, 
however chronic SASP has been shown to induce senescence in neighbouring 
young cells as well as promoting chronic inflammation and tissue dysfunction79. 
Senescence can also affect cells that are normally non-proliferative (neurons, 
cardiomyocytes etc.) and while cell-cycle arrest is obviously not a defining feature 
of senescence in these cell types, they can display the other features of 
senescence, including secretion of SASP80. 
These features of senescent cells make them a good candidate for a driver of the 
ageing process as first proposed by Hayflick and Moorhead76, however it was not 
until the emergence of two pieces of work by Darren Baker in 2011 and 2016 that 
this idea was supported empirically. In his first set of experiments, a novel 
transgene was introduced into BubR1 progeroid mice allowing drug-inducible 
selective elimination of senescent cells. Life-long removal of senescent cells 
resulted in delayed onset of age-related disorders, while late-life removal 
attenuated the progression of existing age-related pathologies81. In his later work 
using the same transgenic system, it was found that clearance of senescent cells 
in wild-type mice resulted in extended median lifespan and delayed the age-
related deterioration of several organs82. 
Senescent cells have been implicated in a variety of age-related diseases, 
including cardiovascular disease, idiopathic pulmonary fibrosis, chronic 
obstructive pulmonary disease, insulin resistance, macular degeneration and 
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many more83,84. Along with the experimental evidence as described in the 
previous paragraph, there is a strong case for cellular senescence having a 
central role in the mechanism of ageing. 
1.6.1 Replicative senescence 
Replicative senescence, as originally described by Hayflick and Moorhead, is the 
suspension of cell cycle due to serial passage of cells in culture76,85, however in 
their works at the time no mechanism was described for this phenomenon. It was 
later discovered that telomere length plays an important role in senescence, both 
in vitro and in vivo86,87. Telomeres are non-coding chromosomal ‘caps’ consisting 
of hundreds to thousands of TTAGGG repeats which, along with specific 
telomere-associated proteins, serve to protect the ends of chromosomes88. In 
most mammalian cells (with the notable exception of the germ-line cells), 
telomere length is genetically determined during development and is not 
extended during adulthood due to stringent repression of telomerase, a 
specialised ribonucleoprotein responsible for telomere maintenance and 
extension89. Successive rounds of cell division therefore result in gradual 
shortening of the telomeres, eventually leading to disruption of the protective cap 
which in turn elicits a DNA damage response, leading to cell-cycle arrest and 
senescence87. 
1.6.2 Stress-induced senescence 
Senescence can also be induced by factors other than repeated cell divisions. 
Stressors such as DNA damage, oxidative stress and expression of oncogenes 
have all been shown to cause premature senescence through activation of the 
p53/p21 or p38/p16/Rb cell cycle arrest pathways90-93. It was originally thought 
that these causes were independent of telomere length, however more recent 
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evidence suggests that the routes to replicative and stress-induced senescence 
are not mutually exclusive93. 
1.7 The Hallmarks of ageing 
1.7.1 Current perspective 
In a landmark paper published in 2013, Carlos López-Otin et al. described a set 
of molecular and cellular hallmarks of ageing in an effort to outline the defining 
characteristics of ageing and the mechanisms involved94. The authors used a 
specific set of criteria to determine these hallmarks, as follows: 
1. Each hallmark should manifest during normal ageing. 
2. Each hallmark should accelerate ageing when experimentally aggravated. 
3. Each hallmark should retard ageing when experimentally ameliorated. 
The hallmarks that they identified as fulfilling all these criteria are summarised in 
Figure 1.2. 
I have already described most of these hallmarks as they fall under one or more 
of the theories of ageing in the preceding sections, with the exception of 
‘Epigenetic alterations’ and ‘Stem cell exhaustion’, which I shall address briefly 
here: 
1. Epigenetic alterations 
Several different epigenetic alterations have been implicated in the ageing 
process; however, these largely appear to exert their effects through one of the 
mechanisms described above. 
Histone modifications meet the criteria for a hallmark, however they appear to act 
through regulation of genes in the IIS pathway described in section 1.5.295. The 
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sirtuin class of deacetylases, which act on histone markers, have also been 
implicated in determination of lifespan, although again they seem to exert their 
influence through pathways such as IIS, NF-κB signalling, glucose homeostasis 
and genomic stability94.  
  
Figure 1.2: Hallmarks of ageing 
The nine hallmarks of ageing proposed to determine the ageing phenotype, as described in Carlos 
López-Otin’s 2013 publication (reproduced from López-Otin et al.94, with permission from 
Elsevier; © 2013). 
 
Patterns of DNA methylation at CpG dinucleotides change significantly during 
ageing. These changes are remarkably consistent to the extent that they can be 
used to predict biological age from the methylation status at a relatively small 
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subset of CpG sites. In 2013, Steve Horvath used this predictable shift in DNA 
methylation to develop an epigenetic clock96 algorithm, which is highly accurate 
in its predictions of age across multiple tissues, using information from just 353 
CpG sites. Other epigenetic clock models have since been developed with 
varying levels of accuracy in different tissues97, and DNA methylation has also 
been found to be a promising marker for estimation of the number of stem cell 
divisions in tissues, a metric known as the ‘mitotic clock’, which is useful in both 
estimation of tissue ageing and also for predicting cancer risk98.  However, while 
it is true that DNA methylation is strongly correlated with advancing age and may 
be seen to play an important role in the ageing process, it would appear to do so 
through the regulation of gene expression (see section 1.8.2). For example, 
around half of the 353 CpGs used in Horvath’s clock are in gene promoter 
regions, and the remainder are in enhancer sequences97. It is also the case that 
there is currently no compelling evidence that these patterns of methylation 
change directly affect lifespan. 
A number of microRNAs (miRNAs) have also been shown to associate with 
lifespan99 (see also chapter 4100), however by the very nature of miRNAs as 
regulatory non-coding RNAs, their method of action is through the modulation of 
other mechanistic pathways. I discuss these in more detail in section 1.8.9. 
2. Stem cell exhaustion 
Declining ability to regenerate tissues is a defining characteristic of the ageing 
process, and one that is largely driven by reduced competence of stem cells. 
While this is without doubt a highly important factor in the development of age-
associated phenotypes, the loss of stem cell capacity is thought to be driven by 
one or more of the age-associated damages as described previously94. 
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1.7.2 Adding a 10th hallmark: Altered control of gene expression. 
Our group’s research and the work contained within this thesis have brought us 
to the conclusion that a 10th hallmark could potentially be added to the list as 
described by López-Otin et al., namely ‘Altered control of gene expression’. 
Although altered control of gene expression is, to an extent, implied in the 
‘Epigenetic alterations’ hallmark, we feel that it fulfils the criteria (as laid out in 
López-Otin’s paper) in its own right. 
It has been found in several studies that changes in levels of key regulators of 
gene expression are associated with normal ageing101-103, lifespan (see chapters 
3104, 4100 and 5105) and with future age-related clinical outcomes (chapter 6106). 
Much of our group’s work has focused specifically on the factors regulating 
alternative mRNA splicing (see section 1.8.4), and we have also shown that it is 
possible to restore replicatively senescent cells to an apparently more youthful, 
proliferative state through modulation of splicing factor expression using 
resveratrol and its analogues, as well as specific hydrogen sulphide donors107,108. 
Given this evidence, it seems that there is a strong case for altered control of 
gene expression to be included as one of the fundamental hallmarks of ageing. 
1.8 Control of gene expression 
Not only does the control of gene expression satisfy the criteria of a hallmark of 
ageing, it is also known to be a key player in the development of ageing 
phenotypes. Adaptive, plastic patterns of gene expression are vital to 
maintenance of homeostasis and to effective cellular responses to stress109, 
which are known to be highly important factors in the ageing process110,111. 
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There are several ways by which gene expression can be regulated, which I will 
describe in turn: 
1.8.1 Histone modifications 
Human genomic DNA is packaged in the nucleus as chromatin, a highly 
compacted state necessary to retain order and enable the entire genome to fit 
inside. The basic unit of chromatin is the ‘nucleosome core particle’, in which 145-
147 base pairs of DNA are wrapped around an octamer of histone proteins112. 
Nucleosomes tend to block transcription either physically or by making sections 
of DNA unavailable for transcription factor binding, however mechanisms exist 
which can alter nucleosome positioning and thus affect gene expression113. Apart 
from these remodelling mechanisms, individual histones can be post-
translationally modified in many ways including methylation, acetylation, 
phosphorylation etc. which are able not only to affect gene expression, but can 
also have other downstream effects on pathways such as DNA repair and 
apoptosis112. 
1.8.2 DNA methylation 
DNA methylation is well known to affect gene expression. The majority of DNA 
methylation in mammals can be defined as the presence of a methyl group on 
the cytosine of a CpG dinucleotide. CpGs tend to be concentrated in CpG islands, 
found commonly around promotor sites. CpG islands are predominantly 
hypomethylated in the case of actively transcribed genes and conversely are 
hypermethylated when a gene is silenced114. There is also increasing evidence 
that DNA methylation within the gene body can also impact on gene 
expression115. 
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1.8.3 Transcriptional regulation 
An important aspect of gene expression lies in the control of transcription of the 
genomic DNA to RNA. This can be at the level of chromatin state and thus 
availability of a gene for transcription112, sequence and strength of promoter 
elements116, DNA polymerase activity117, presence or binding of transcriptional 
enhancers118, genomic landscape119 and post-transcriptional alterations120. The 
fact that such levels of fine control over expression exist is testament to the vital 
role that tight regulation of expression plays in maintenance of a stable cellular 
environment while also allowing for adaptive responses to external challenges. 
1.8.4 mRNA processing 
Once transcribed, a precursor mRNA (pre-mRNA) must be processed into a 
mature mRNA for correct and efficient translation. The DNA templates (and 
therefore the transcribed pre-mRNAs) of the vast majority of eukaryotic genes 
contain both non-coding intronic sequences and coding exonic sequences. In 
order to produce a mature mRNA, the introns must be removed by RNA splicing, 
a 5’ cap is added, and the molecule is polyadenylated via addition of a polyA tail 
at the 3’ end (see Figure 1.3). All these steps are subject to regulatory processes 




Figure 1.3 mRNA processing 
Shown here are the steps involved in processing of a pre-mRNA transcript to a mature mRNA 
molecule; removal of introns by splicing, addition of 5’ cap and polyadenylation. 
 
1.8.5 RNA splicing 
As mentioned in section 1.8.4, most eukaryotic genes contain non-coding introns 
which are spliced out during mRNA processing, and the coding exons are ligated 
to form the mature mRNA. RNA splicing is catalysed by the spliceosome, a large, 
dynamic ribonucleoprotein (RNP) complex which is recruited to splice sites 
through recognition of short, highly conserved sequences at the 5’ splice site 
(SS), 3’ SS, branch site and polypyrimidine tract124,125. Splice site choice is also 
determined by a set of cis-acting auxiliary splice site elements and trans-acting 
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splicing factors which act to increase or decrease the likelihood of a particular 
splice event going ahead. The cis-acting sequence elements are known as exonic 
splicing enhancers (ESE), exonic splicing silencers (ESS), intronic splicing 
enhancers (ISE) and intronic splicing silencers (ISS). The trans-acting splicing 
factors are split into two classes, the serine/arginine rich (SR) proteins and the 
heterogeneous nuclear ribonucleoproteins (hnRNP). Generally, the SR proteins 
bind to ESE and ISE sequences and are splice enhancing, while the hnRNPs 
bind to ESS and ISS sequences and are splice inhibitory. However, there are 
incidences where these splicing factors can in fact exert effects in the opposite 
direction, indeed it is usually the combinatorial effect of binding multiple different 
splicing factors (both enhancers and inhibitors) and thus the exact balance 
achieved at any given splice site that ultimately determines the outcome of the 
splicing event126. 
There are in fact two spliceosome complexes in eukaryotes, the U2-dependent 
and the U12-dependent spliceosome. The U12-dependent spliceosome is often 
referred to as the ‘minor’ spliceosome, as U12-type introns account for less than 
0.5% of introns in any given genome127. While slightly less efficient than U2-
dependent splicing, the U12-dependent spliceosomal components are analogous 
and the reaction occurs in a similar manner. For this reason, I will focus on the 
U2-dependent spliceosome in this text. 
1.8.6 The spliceosome and catalysis of splicing 
The U2-dependent spliceosome is assembled from five uridine-rich small nuclear 
ribonucleoproteins (snRNPs) known as U1, U2, U4, U5 and U6, along with a large 
number of non-snRNP proteins. The assembly is a multi-stage process with 
several remodelling and conformational changes throughout, leading from a 
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recognition stage through two consecutive transesterification reactions to the final 
spliced mRNA (Figure 1.4). 
Spliceosome assembly begins with formation of the E complex, via recruitment 
of the U1 snRNP to the 5’ SS and the interaction of the non-snRNP factors SF1, 
U2AF65 and U2AF35 with the branch point (BP), polypyrimidine tract (PPT) and 
3’ SS respectively124,125,128. The U2 snRNP then binds to the BP, producing the 
A complex (or prespliceosome). The U2AF heterodimer and SF1 then detach and 
the tri-snRNP (made up of the U5 and U4/U6 snRNPs in a heterotrimer) joins U1 
and U2 to form the B complex (or pre-catalytic spliceosome). Subsequent 
conformation changes and the disengagement of the U1 and U4 snRNPs leads 
to the active B complex (Bact complex), followed by a further activation reaction 
giving rise to the catalytically active B* complex, in which the U2/U6 structure is 
responsible for the first catalytic step129; cleaving the 5’SS and forming the lariat 
structure of the intron124,125. 
This reaction generates the C complex, consisting of the U2, U5 and U6 snRNPs 
bound to the free exon and the exon/lariat intermediate. Further conformational 
changes occur followed by the second catalytic step, whereby the lariat is cleaved 
from the 3’SS and the two exons are ligated to form the spliced mRNA 




Figure 1.4 Pre-mRNA splicing by the U2-dependent spliceosome 
Steps involved in the recruitment of snRNPs, conformational changes and catalysis of intron 
removal by the U2-dependent spliceosome. Several spatial alterations occur to the spliceosome, 
along with changes in the milieu of subunits involved, in order to recognise the splice sites and 
enact the transesterification reactions necessary to produce a fully spliced mRNA. See section 
1.8.6 for full details. SS: Splice Site, BP: Branch Point, PPT: Polypyrimidine tract. 
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1.8.7 Constitutive and alternative splicing 
Constitutive splicing is the process by which introns are removed in the same 
manner every time for a given transcript, whereas alternative splicing is a 
departure from the canonical splicing pattern, allowing for a single gene to give 
rise to multiple mature mRNA products and therefore multiple protein isoforms. 
Over 95% of human genes have been shown to be alternatively spliced130, and 
alternative splicing is thought to be the major mechanism behind the discrepancy 
between the number of genes observed in the human genome (≈19,000), and the 
number of proteins produced (>90,000)131.  
The most common form of alternative splicing involves cassette-type exons, 
which are either included or skipped in the final mRNA, however several other 
types of alternative splicing have been identified, including; alternative 3’ and 5’ 
SS, intron retention, mutually exclusive exons, alternative promoters and 
alternative polyadenylation sites132. These different types of alternative splicing 
are illustrated in Figure 1.5. 
Apart from conferring the ability to produce an extended proteome, alternative 
splicing can also play a regulatory role. For example, alternate isoforms may 
contain non-coding sequence which can regulate translational efficiency133, or the 
inclusion of a ‘poison’ exon with an in-frame premature stop codon can trigger 
nonsense-mediated decay pathways, as can several other splicing events134, 




Figure 1.5 Alternative splicing events 
Schematic showing the various types of alternative splicing events, and how these can produce 
many distinct variations of mature mRNA transcripts from a single pre-mRNA (reproduced from 
Blencowe132, with permission from Elsevier; © 2006). 
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1.8.8 Non-coding RNAs 
It is known that most transcripts produced from eukaryotic genomes are in fact 
non-coding114. Several classes of non-coding RNA (ncRNA) exist; small 
interfering RNAs (siRNA), long non-coding RNAs (lncRNA), long intergenic non-
coding RNAs (lincRNA), piwi-interacting RNAs (piRNA) and microRNAs 
(miRNA). All of these classes have been found to affect gene expression at 
different stages, from transcription to splicing, mRNA degradation and 
translation114,135. ncRNA biogenesis and modes of action have been reviewed 
extensively elsewhere135,136, however for the purposes of this thesis I will describe 
miRNAs in more detail in the following section. 
1.8.9 MicroRNA biogenesis and action 
MiRNAs are short (usually 21-25 nucleotides) regulatory ncRNA molecules which 
exert their effect on gene expression largely by targeting mRNA transcripts for 
translational repression or degradation137.  
MiRNAs are transcribed as long, primary miRNAs (pri-miRNA) by RNA 
polymerase II (Pol II) or RNA polymerase III (Pol III)138. MiRNA genes are often 
in the form of clusters of individual miRNAs which are expressed in a poly-
cistronic manner, and can be found in intergenic regions, introns and in some 
cases in exons137. The pri-mRNA transcript is then cleaved within the nucleus by 
the Drosha RNase III enzyme into a short stem-loop precursor miRNA (pre-
miRNA) structure, which is then exported to the cytoplasm through the action of 
the Exportin 5-Ran-GTP complex137-139. Once in the cytoplasm, the pre-miRNA 
is further cleaved by another RNAse III enzyme known as Dicer, leaving a linear 
miRNA duplex which is bound by the Argonaute 2 (Ago2) protein. Ago2 facilitates 
the unwinding of the miRNA duplex so that the active ‘guide’ strand can be 
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separated from the ‘passenger’ strand (which in most cases is subsequently 
degraded). The Ago2 and guide strand then recruit diverse groups of proteins in 
order to form various RNA-induced silencing complexes (RISC)138,139. The RISC 
is then guided to target transcripts by virtue of a 6-8 base ‘seed sequence’ of the 
bound miRNA. Complementary base pairing of this sequence with the 3’ 
untranslated region (UTR) of the target mRNA leads to its repression or 
degradation137,139 (see Figure 1.6 for schematic of this process). 
 
Figure 1.6 MicroRNA biogenesis and processing 
Schematic of the steps involved in production of a mature miRNA from primary transcript. Pri-
miRNA is transcribed from DNA template, cleaved by Drosha within the nucleus and exported via 
Exportin 5. Cytoplasmic Dicer then cleaves the stem-loop structure and the mature miRNA is 
loaded into the RISC via the action of Ago2. 
 
A single miRNA can target multiple mRNAs and many mRNAs have multiple 
miRNA binding sites in their 3’ UTR140. In this manner, miRNAs have the capacity 
to regulate complex networks such as those implicated in ageing and longevity141. 
1.9 Manipulation of ageing processes 
The desire to change the way we age is not a new phenomenon, indeed a 
‘Fountain of Youth’ has featured in mythological tales for thousands of years142. 
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However as alluded to in section 1.1, considering the current trends in worldwide 
demographics, there is a clear and growing need to develop means to improve 
healthy ageing before the socio-economic cost of age-related morbidities 
becomes an overwhelming pressure on our society and healthcare providers. 
1.9.1 Ageing, lifespan and healthspan 
Thus far, I have described the theories and mechanisms of ageing according to 
current observations. It is implied in such a narrative that ageing is heavily 
involved in the determination of lifespan, however there are two schools of 
thought on this. The more traditional viewpoint is that longevity is genetically 
determined and due to antagonistic pleiotropy there is an upper limit on lifespan 
even in the absence of age-related disease143-145, while ageing as a process is a 
product of the random accumulation of damage as described in section 1.4. The 
second, perhaps more controversial outlook is that lifespan is entirely a function 
of age-related damage, and therefore effective repair strategies could 
theoretically lead to extreme longevity146. 
Whichever of these ultimately proves to be true, arguably the more relevant 
consideration from the current perspective of public health and quality of life is 
healthspan. Healthspan can be defined as the period of life spent free from 
chronic age-related disease147. While healthspan is difficult to quantify in any 
meaningful sense147, conceptually it is self-evident that any treatments which 
could positively affect healthspan would be highly desirable. It is however almost 
certainly true that ageing, lifespan and healthspan are all intimately linked, 
therefore interventions designed to improve healthspan are likely to have effects 
on the ageing process and/or lifespan148. 
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1.9.2 Compression of morbidity 
The idea of compression of morbidity as a consequence of both social and 
scientific progress was introduced by James Fries in 1980149, and in essence 
refers to a postponement of the onset of chronic age-related illnesses, i.e. an 
increase in healthspan. However, when considering the case of an intervention 
to extend lifespan, this definition must be qualified. Figure 1.7 shows a theoretical 
situation whereby an intervention has been used which doubles the lifespan of 
an organism. 
 
Figure 1.7 Schematic showing different scenarios for lifespan extension 
Shown here are potential effects on healthspan in a theoretical example of lifespan extension 
(reproduced from Hansen & Kennedy150, with permission from Elsevier; © 2016). 
 
As can be seen, there are a range of possible outcomes of such a lifespan 
increase; 
A. No extension of healthspan; morbidity effectively tripled 
B. Healthspan extended; lifespan and morbidity extended by the same 
amount therefore morbidity doubled 
C. Healthspan extended; morbidity remains the same as before intervention 
D. Healthspan extended; true compression of morbidity 
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Logically, the reduction in time spent suffering from any morbidities should be the 
ultimate goal of any treatment for ageing, whether or not increased lifespan is a 
factor. Therefore the desirability of the outcome increases from top to bottom of 
this list, with scenario D being the best result for any treatment designed to 
increase lifespan150. However, it must also be said that a treatment which has no 
effect on lifespan extension yet confers a compression of morbidity would be just 
as important from a socio-economic perspective. The arguments for desirability 
of treatments that may have effects in the B or C categories are less clear-cut. 
1.9.3 Potential targets for intervention 
It has not been until relatively recently that the idea of treating ageing, rather than 
the symptoms of ageing (i.e. individual age-related diseases) has gained traction 
in medical and scientific fields151. However, it is now widely accepted that ageing 
is the process which gives rise to many late-life pathologies152, and much 
attention has turned to identifying potential target pathways and interventions to 
enhance healthy ageing. 
Several promising avenues are currently being investigated as therapeutic 








Table 1.1 Therapeutic strategies for ageing interventions 
Key targets and pathways with potential for lifespan and/or healthspan extension (Data taken 
from Trounson & McDonald153, Martinez & Blasco154, Campisi et al.155 and Hodgson et al.156). 
Intervention Pathway Mechanism/effect 
Rapamycin mTOR 
Central to nutrient sensing pathways 
and shown to affect lifespan and 
healthspan in model organisms 
Metformin Mitochondria 
Targets several ageing pathways, 
diabetic patients prescribed metformin 
display increased lifespan and reduced 
incidence of cancer 
Senolytics Senescent cells 
Senescence known to be associated 
with several age-related pathologies 
and clearance of senescent cells shown 
to affect lifespan and healthspan in 
model organisms 
Sirtuin activators Sirtuins 
Modifier of epigenetic marks on histone 
proteins, shown to be associated with 
lifespan and healthspan in model 
organisms  
NAD precursors NAD metabolism 
Critical coenzyme for sirtuins and other 
important enzymes, NAD+ levels known 
to decline with age - supplementation 
shown to be protective during ageing 
Telomerase Shortened telomeres 
Well known marker of ageing, transient 
activation has been shown to improve 
healthspan in model organisms 
Stem cells Stem cell exhaustion 
Key to regenerative capacity of tissues, 
several stem cell therapies currently in 
clinical trials with promising outlook 
Exercise Unknown 
Known to be essential for healthy 
ageing, associated with increased 
lifespan and healthspan in humans 
Dietary restriction 
Several, including 
mTOR & sirtuins 
Affects nutrient-sensing pathways, most 
robust method for increasing lifespan 
and healthspan in model organisms 
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1.10 Conclusion 
As discussed, ageing is a complex and heterogeneous process which is still 
relatively poorly understood. It is likely that the underlying cause of ageing is a 
network or combination of many of the aspects described in the preceding 
sections, therefore much work remains to be done to disentangle the effects of 
different pathways and mechanisms in the overall phenotype. It is also apparent 
that ageing, lifespan and healthspan are all intimately linked, so increasing our 
knowledge of any one of these could be expected to yield insights into other 
aspects. Previous findings from our research group lead us to postulate a central 
role for the regulation of gene expression in the ageing process and thus 
determination of lifespan and healthspan, however to date little is known about 
how these two complex networks interact with each other. Greater understanding 
of the role of RNA regulation in the ageing process could provide attractive targets 
for novel interventions or potential biomarkers of age-related disease. 
1.11 Research hypothesis 
We believe that regulators of gene expression (specifically mRNA splicing 
factors and microRNAs) are fundamentally involved in the ageing process 
and determination of lifespan in mammals, and that therefore these 
regulators may have potential either as biomarkers of ageing phenotypes 
or as targets for intervention to improve healthspan.  
1.12 Aims and objectives of thesis 
The overarching objective of this thesis was to increase our knowledge of the 
involvement of mRNA splicing factors and miRNAs in ageing and lifespan, from 
a mechanistic and predictive perspective, both in murine models and in humans. 
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1.12.1 Chapter 3: Changes in the expression of splicing factor transcripts and 
variations in alternative splicing are associated with lifespan in mice and humans. 
In this chapter, the aim was to characterise transcript expression profiles of 
splicing factors and alternatively spliced transcripts in mouse strains of varying 
median lifespan. 
To do this, transcript expression levels of a panel of splicing factors were to be 
measured in spleen and muscle tissues from both young and old mice of six 
different strains with median lifespan ranging from 623 to 1005 days. Expression 
levels would then be tested for correlations with age and strain lifespan. 
Following this, expression levels of two separate tissue-specific panels of 
alternatively spliced transcript isoforms would be measured in the same mice, 
and similarly tested for correlations with age and strain lifespan. 
Based on the results from these experiments, bioinformatic analysis of 
transcriptome-wide expression levels from a human cohort was to be carried out 
to assess whether any associations seen in the mouse model were also found in 
humans. 
1.12.2 Chapter 4: MicroRNAs miR-203-3p, miR-664-3p and miR-708-5p are 
associated with median strain lifespan in mice. 
The experiments in this chapter were intended to determine whether miRNAs 
may be associated with median strain lifespan in the spleen tissue taken from the 
same mouse collection as used in chapter 3. 
For this, a high-throughput approach was to be used for discovery; expression 
levels of 521 miRNAs would be tested in a subset of young animals from the 
longest- and shortest-lived strains. The top ten miRNAs displaying the most 
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significant differences in the discovery phase were then to be taken forward into 
a validation phase. Validation would consist of measuring expression levels of 
these ten miRNAs in all available spleen samples from young and old mice from 
all six strains of different median lifespan. Expression levels would then be tested 
for associations with median strain lifespan. 
For any miRNAs showing significant associations, bioinformatic analysis was to 
be carried out to identify pathways targeted by these miRNAs. Exemplar target 
genes would then be identified from these pathways in order to measure mRNA 
expression levels in the same samples to identify whether it was likely that 
miRNA-mediated regulation was taking place. 
1.12.3 Chapter 5: Dietary restriction in ILSXISS mice is associated with 
widespread changes in splicing regulatory factor expression levels. 
For this chapter, the aim was to determine whether splicing factor expression in 
a mouse model was mechanistically associated with dietary restriction (DR), an 
established modifier of lifespan. 
To achieve this, three strains of ILSXISS mice would be used as they have been 
shown to have reproducibly variable responses to DR, one displaying lifespan 
extension, one lifespan reduction and a third showing no change. Brain, heart 
and kidney tissues were to be collected both from mice fed ad libitum (AL) and 
from mice under 40% DR conditions, for two different lengths of treatment; two 
months and ten months. 
Transcript expression levels of a panel of splicing factors would then be 
measured in all samples and tested for associations with responder strain and 
DR regime. Furthermore, the data would be assessed for potential statistical 
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interactions between these two variables, which could indicate a mechanistic 
involvement of splicing factors in the different strain responses to DR. 
1.12.4 Chapter 6: The transcript expression levels of HNRNPM, HNRNPA0 and 
AKAP17A splicing factors may be predictively associated with ageing phenotypes 
in human peripheral blood. 
The aim of this chapter was to assess whether splicing factor transcript 
expression levels were an indicator of future health outcomes and as such could 
have potential applications as biomarkers 
To do this, an existing resource would be used; the InCHIANTI longitudinal study 
of human ageing. In this cohort, RNA from peripheral blood along with detailed 
anthropometric data from over 400 individuals is available for multiple follow-up 
study visits. 
Transcript expression levels of a panel of splicing factors would be measured in 
a set of samples from a baseline time-point and this data would then be used to 
test for associations with changes over time in age-related health measures. 
The health measures to be assessed initially would be the Mini Mental State 
Exam (MMSE) to evaluate cognitive decline, and mean hand-grip strength as one 
of the accepted measures of frailty. Any splicing factors found to be significantly 
associated with change in these outcomes would then be validated within the 
same cohort, using other measures of cognitive ability and frailty as well as 













2.1.1 Mouse tissues 
Two collections of mouse tissues were used in this thesis, both of which were 
kindly provided to us by collaborators. 
The first of these collections was used to generate the data in chapters 3 & 4 and 
was supplied by Professor Luanne Peters of the Jackson Laboratory Nathan 
Shock Center of Excellence in the Basic Biology of Aging, Bar Harbor, ME, USA. 
The tissues used in the studies described here were collected as part of a much 
larger cross-sectional and longitudinal study into lifespan and ageing phenotypes 
across 31 strains of inbred mouse157-159. The animal husbandry and sample 
collection methodologies have been described at length in the 2009 publication 
reporting the study design and initial findings from the larger study157. Abridged 
versions of these procedures are given in sections 3.7.1, 4.7.1 and 
Supplementary data S1. 
The second collection was used to generate the data for chapter 5 and was 
supplied by Professor Colin Selman of the Institute of Biodiversity Animal Health 
& Comparative Medicine, University of Glasgow, UK. These tissues were 
collected as part of a study into the effects of dietary restriction on metabolic 
function in mice160,161. Again, animal husbandry/sample collection have been 
covered in detail elsewhere160,161, with an abridged version given in section 5.5.1. 
2.1.2 Human blood samples 
Peripheral blood from a human cohort was used to generate the data in chapters 
3 & 6. Blood samples were made available through a collaboration with the 
InCHIANTI study of Aging, a longitudinal study of ageing that has been running 
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since 1998 in the Tuscany region of Italy. The InCHIANTI study has collected a 
vast quantity of data on a host of different aspects of ageing – to date over 350 
primary research papers have been published based on data from this 
resource162. Full details of participant recruitment, follow-up procedures, 
assessments and tests performed during the study etc. have all previously been 
described in many publications deriving from this invaluable resource163,164. 
Excerpts of the procedures used which pertain to this thesis are given in sections 
3.7.8, 6.5.1 and 6.5.6. 
2.2 RNA extractions 
2.2.1 RNA protection strategies 
As RNA is a particularly labile molecule and subject to rapid degradation by 
ubiquitous, naturally occurring RNase enzymes, steps must be taken to preserve 
the integrity of the transcriptome in any study that concerns gene expression. The 
most effective method for stabilisation of RNA is to snap-freeze samples in liquid 
nitrogen (-196°C) on collection, however there are additional reagents and 
procedures that are designed to enhance and/or replace this rapid freezing. 
Three different strategies were used in this thesis, one for each of the sample 
sets described above in section 2.1, as each one was from a different source. 
For the mouse tissue samples from the Jackson Laboratory Nathan Shock Center 
of Excellence in the Basic Biology of Aging, RNAlater® (a commercial RNA 
stabilisation solution: Thermo Fisher, Waltham, MA, USA) was used; RNAlater® 
is a combination of sodium citrate, EDTA and ammonium sulphate which 
permeates tissues and cells rapidly in order to protect the cellular RNA while 
inactivating RNases, and has been shown to be effective for up to one week at 
76 
room temperature. In this case, the samples were submerged in the solution at 
the point of dissection followed by snap-freezing using liquid nitrogen. Samples 
were then kept in Ultra-Low Temperature (ULT) storage (-80°C) before being 
shipped to the UK on dry ice. On receipt, the samples were returned to ULT 
storage until RNA extractions could be performed. As the RNAlater® protects the 
RNA at higher temperatures, it is not necessary to work on dry ice with frozen 
tissue and samples can be allowed to defrost within the solution, therefore 
handling and preparation of tissue for RNA extractions is greatly simplified. 
The tissue samples from the Institute of Biodiversity Animal Health & 
Comparative Medicine were snap-frozen in liquid nitrogen at the point of 
dissection and kept in ULT storage until shipping without use of additional RNA 
stabilisation measures. In order to preserve RNA integrity prior to and during the 
extraction process, another commercial RNA stabilisation solution, RNAlater®-
ICE Frozen Tissue Transition Solution (Thermo Fisher, Waltham, MA, USA) was 
used. RNAlater®-ICE is based on RNAlater® but is designed specifically to protect 
RNA during the transition of snap-frozen tissues to a thawed state which 
facilitates handling during RNA extraction. RNAlater®-ICE was cooled to -80°C 
and added to the frozen tissue samples in small batches (to avoid excessive 
thawing during this step), after which the samples were then allowed to thaw 
overnight at -20°C. Samples were then returned to ULT storage until RNA 
extractions were performed, and as with RNAlater®, the ability to work with the 
samples at room temperature during extraction without the potential for RNA 
degradation is highly beneficial. 
Finally, the peripheral blood samples from the InCHIANTI cohort were collected 
into PAXgene Blood RNA Tubes (IVD) (PreAnalytiX GmbH, Hombrechtikon, 
Switzerland). These are commercially available tubes which form part of a 
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workflow specifically designed to stabilise RNA from blood samples. The tubes 
contain a stabilisation reagent, which must be mixed with the blood. After blood 
samples were collected into PAXgene tubes, the tubes were inverted 8-10 times 
and then left at room temperature for a minimum of 2 hours and a maximum of 
72 hours before transfer to -20°C for 24 hours, and finally into ULT storage. Blood 
samples were then shipped to the UK on dry ice and returned to ULT storage 
before RNA extraction using the PAXgene workflow as detailed below in section 
2.2.3. 
2.2.2 Tissue extractions 
RNA was extracted from mouse spleen, skeletal muscle, brain, heart and kidney 
tissue for subsequent analysis in chapters 3, 4 & 5, using a classical phenol-
chloroform methodology. TRI Reagent® Solution was used for all these 
extractions. TRI Reagent® contains phenol and guanidine thiocyanate which 
assist with cell lysis, assure immediate inhibition of RNase activity and partition 
the RNA into the aqueous phase. In the protocol used in this thesis, 10mM MgCl2 
was added to the TRI Reagent® before use, as it has previously been reported 
that when using phenol-chloroform extraction, certain low-GC content 
microRNAs are selectively lost during extraction (in comparison to other column-
based methods). The addition of Mg2+ ions stabilises RNA-RNA interactions and 
allows longer cellular RNAs to act as ‘carriers’ for microRNAs during 
precipitation165.  
In all extractions performed, tissue samples and a 5mm stainless steel bead were 
added to 1ml of TRI Reagent® (with MgCl2) in a round-bottomed Eppendorf tube. 
Samples were then placed into a Retsch Bead Mill (Retsch Technology GmbH, 
Haan, Germany) and tissue completely homogenised at a frequency of 30 cycles 
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per second. 15 minutes was sufficient for all tissues except skeletal muscle, which 
required 30 minutes to achieve complete homogenisation. Samples were then 
centrifuged at 13,872 x g at 4°C for 10 minutes to pellet the remaining larger cell 
debris. The supernatant was transferred to a new Eppendorf tube and 200μl of 
chloroform was added to assist with phase separation. A further centrifugation at 
21,100 x g at 4°C for 20 minutes resulted in full separation of the phases, after 
which the upper aqueous phase containing the RNA was transferred to another 
new Eppendorf tube. 1.2μl of GlycoBlue™ Coprecipitant (Thermo Fisher, 
Waltham, MA, USA) was added (final concentration ≈40μg/ml) along with 500μl 
of 100% isopropanol, prior to an overnight precipitation step at -20°C. Following 
precipitation, samples were centrifuged at 21,100 x g at 4°C for 1 hour to pellet 
the RNA. The pellet was washed twice in 75% ethanol, air-dried for ≈15 minutes 
and re-suspended in either RNase-free dH2O or 1X TE Buffer pH8.0 (Thermo 
Fisher, Waltham, MA, USA). 
2.2.3 Blood extractions 
RNA was extracted from human blood samples using the PAXgene Blood RNA 
Kit (Qiagen, Hilden, Germany) and the QIAcube robotic semi-automated 
extraction protocol. PAXgene Blood RNA Tubes were completely thawed and 
allowed to stand at room temperature for at least 2 hours before extraction. The 
tubes were centrifuged at 5000 x g for 10 minutes, the supernatant was removed 
and 4ml of RNase-free water added to the cell pellet. To wash the cell pellet, it 
was re-suspended by vortexing and then re-pelleted by a further centrifugation at 
5000 x g for 10 minutes. Supernatant was once again discarded and 350μl of 
lysis buffer was added. At this point, the lysed cells were transferred to the 
QIAcube robot, which handled the remainder of the protocol. Briefly, the QIAcube 
performed a proteinase K incubation then passed the resultant treated lysate 
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through a PAXgene shredder column to further fragment cell debris. Ethanol was 
added to the flow-through from the shredder column to create conditions which 
favour RNA binding. This flow-through was then applied to a PAXgene RNA spin 
column, in which a silica membrane captures the RNA while contaminants can 
pass through. Several wash steps and a DNase I treatment were then performed 
before RNA was eluted in a proprietary elution buffer and heat denatured. 
2.2.4 RNA quantification 
All RNA samples were quantified using a NanoDrop spectrophotometer 
(NanoDrop, Wilmington, DE, USA), and where appropriate, diluted to a final 
concentration of ≈500ng/μl (using the appropriate elution buffer) in order to 
facilitate downstream normalisation of RNA input quantities. 
2.3 Reverse transcription 
Reverse transcription (RT) is the process whereby single-stranded 
complementary DNA (cDNA) is synthesised from an RNA template. This process 
serves two main purposes; firstly, the cDNA is much more stable than RNA 
therefore after processing, samples are much more robust. Secondly, most 
downstream workflows such as quantitative real-time polymerase chain reaction 
(qRT-PCR) etc. rely on enzymes which require a DNA substrate. 
RT reactions are catalysed by reverse transcriptases, a class of enzymes most 
commonly used by retroviruses to replicate their genomes but also found in some 
non-retroviruses as well as eukaryotes. Commercially available kits generally 
contain recombinant versions of Avian Myeloblastosis Virus (AMV) Reverse 
Transcriptase or Moloney Murine Leukemia Virus (M-MuLV or MMLV) Reverse 
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Transcriptase, engineered for specific desirable qualities such as greater 
temperature stability or higher processivity. 
In this thesis, three different RT kits were used: for the gene expression analyses, 
Invitrogen™ SuperScript™ VILO™ cDNA Synthesis Kit (Thermo Fisher, 
Waltham, MA, USA) was used in chapters 3, 4 & 6 while EvoScript Universal 
cDNA Master kit (Roche LifeScience, Burgess Hill, West Sussex, UK) was used 
in chapter 5. Applied Biosystems™ TaqMan™ MicroRNA Reverse Transcription 
Kit was used for the microRNA analysis in chapter 4. 
2.3.1 SuperScript™ VILO™ reverse transcription 
Invitrogen™ SuperScript™ VILO™ cDNA Synthesis Kit is a two-tube format kit, 
with an “Enzyme mix” tube containing SuperScript™ III reverse transcriptase (a 
genetically engineered MMLV-derived enzyme with reduced RNase H activity 
and improved thermostability), RNaseOUT™ Recombinant Ribonuclease 
Inhibitor, and a proprietary helper protein. A second “Reaction mix” tube contains 
random primers, MgCl2, and dNTPs in a proprietary buffer. 
Different input quantities of RNA were used in each chapter of this thesis, 
dependant on the availability of starting material and the planned usage of the 
cDNA, however as a general rule all RNA samples were normalised to a specified 
concentration before being added to an RT reaction containing 1X “Enzyme mix”, 
1X “Reaction mix” and RNase-free dH2O to a final volume of 20μl. Reactions 
were placed onto a thermal cycler where the following incubations were carried 
out: 25°C for 10 minutes, 42°C for 60 minutes, 85°C for 5 minutes and a final hold 
at 4°C. 
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Full details of RNA input quantities and any subsequent cDNA dilutions for the 
different approaches used in each chapter are given in sections 3.7.5, 4.7.9 and 
6.5.4. 
2.3.2 EvoScript Universal cDNA reverse transcription 
EvoScript Universal cDNA Master kit is also a two-tube format kit, with an 
“Enzyme mix” tube containing a proprietary enzyme blend and Protector RNase 
Inhibitor. A second “Reaction buffer” tube contains random primers, anchored 
oligo(dT)18, dNTP, and Mg(OAc)2. Unlike the SuperScript™ III reverse 
transcriptase, EvoScript reverse transcriptase retains RNase H activity which 
removes the RNA template after cDNA synthesis, allowing PCR primers to more 
easily bind the cDNA. As this is the case, extra care must be taken to add the 
“Enzyme mix” just before incubation to avoid digestion of the sample. 
RNA samples were normalised to 500ng/μl, and 1μl of this was added to an RT 
reaction containing 1X “Reaction buffer” and RNase-free dH2O to a final volume 
of 18μl, samples were then placed on ice for 5 minutes to allow primers to anneal 
to the RNA, after which 2μl of “Enzyme mix” was added to give a 1X concentration 
in a final volume of 20μl. Reactions were placed onto a thermal cycler where the 
following incubations were carried out: 42°C for 30 minutes, 85°C for 5 minutes, 
65°C for 15 minutes and a final hold at 4°C. cDNA samples were then diluted to 
ensure sufficient material for further analysis; details are given in section 5.5.4. 
2.3.3 TaqMan™ MicroRNA reverse transcription 
Applied Biosystems™ TaqMan™ MicroRNA Reverse Transcription Kit is a multi-
component kit including MultiScribe™ reverse transcriptase (a recombinant 
MMLV-derived enzyme with reduced RNase H activity), and other requisite 
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reagents in separate tubes such that the kit can be used for different applications, 
depending on the priming strategy used. In chapter 4, this kit was used for two 
different RT approaches, one for high-throughput microRNA screening and 
another for targeted microRNA expression measurement. 
For the high-throughput screening, Megaplex™ RT Primers, Rodent Pool Set 
v3.0 (Thermo Fisher, Waltham, MA, USA) were used. The Megaplex™ RT Primer 
pool set is supplied as separate A and B pools, which between them contain all 
the primers necessary to reverse transcribe 521 unique microRNAs. Due to this, 
the following procedure was carried out twice, once for pool A and once for pool 
B: RNA samples were normalised to 400ng/μl, and 1μl of this was added to an 
RT reaction containing 1X Megaplex™ RT Primers, 20mM dNTPs with dTTP, 
75U MultiScribe™ Reverse Transcriptase, 1X RT Buffer, 3mM MgCl2, 2U RNase 
Inhibitor and RNase-free dH2O to a final volume of 7.5μl. Reactions were 
incubated on ice for 5 minutes, after which they were placed onto a thermal cycler 
where the following steps were carried out: 40 cycles of 16°C for 2 minutes, 42°C 
for 1 minute and 50°C for 1 second, followed by a single step of 85°C for 5 
minutes and a final hold at 4°C. 
For the targeted expression measurement, specific RT primers were used. These 
are provided when purchasing individual TaqMan™ microRNA qRT-PCR assays 
and can be multiplexed into an RT pool which can then be used in a similar 
manner to the Megaplex™ pools described in the previous paragraph. For the 
experiments described here, equal volumes of 13 microRNA RT primers (listed 
in Supplementary table S19) were combined into a multiplex pool for use in the 
RT. RNA samples were normalised to 60ng/μl, and 1μl of this was added to an 
RT reaction containing 13μl of the RT primer multiplex (as described above), 
10 mM dNTPs (with dTTP), 100 U MultiScribe™ Reverse Transcriptase, 1X RT 
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Buffer, 7.6U RNase Inhibitor and RNase-free dH2O to a final volume of 30μl. 
Reactions were placed onto a thermal cycler where the following incubations 
were carried out: 16 °C for 30 minutes, 42 °C for 30 minutes, 85 °C for 5 minutes 
and a final hold at 4 °C. 
2.4 Quantitative Real-Time Polymerase Chain Reaction  
Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) is a method by 
which gene expression levels can be directly quantified in cDNA which has been 
reverse transcribed from cellular RNA samples. The basis of qRT-PCR is the 
polymerase chain reaction (PCR), a technique first devised in the early 1980s to 
amplify specific short regions of DNA through thermal cycling with a DNA 
polymerase enzyme. PCR requires a template DNA molecule to amplify and 
uses; 1) a pair of oligonucleotide primers (each one designed to opposite strands 
of the DNA molecule and specific to the target region in question), 2) a 
thermostable DNA polymerase enzyme (most commonly Taq polymerase, so 
called due to its origin in the thermophilic Thermus aquaticus bacteria), 3) 
deoxynucleoside triphosphates (dNTPs, which will form the base-pairs of the new 
DNA strand), 4) magnesium ions (usually in the form of MgCl2, a required cofactor 
for Taq polymerase) and 5) an aqueous buffer to provide optimum stability and 
activity of the Taq polymerase. With all these components present in a reaction, 
repeated cycles of heating and cooling to predefined temperatures (thermal 
cycling) serve to sequentially denature the template DNA, anneal the primers and 
extend new DNA strands complementary to the target region of the template, 
resulting in an exponential amplification of said target until a plateau is reached 
due to accumulation of amplification products (amplicons)166 (Figure 2.1a & 2.1b). 
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While this technique is extremely useful for the amplification of DNA, the fact that 
all reactions using a given set of primers will reach a similar plateau level, as an 
end-point assay it is not suitable for measurement of the input quantity of template 
DNA. However, in the early 1990s researchers realised that the kinetics of 
accumulation of amplicons during a PCR reaction is directly related to the starting 
number of copies of the template DNA molecule and thus the dynamics of the 
amplification curve differ with template input concentration. Given this knowledge, 
it was discovered that by tracking a reaction in real-time using a fluorescent DNA 
marker it was indeed possible to determine the input quantity of DNA, based on 
the number of cycles at which the fluorescence produced crosses a pre-defined 
threshold167 (Figure 2.1c). Subsequent refinements to this technique led to the 
development of several chemistries for detection and measurement of 
amplification, collectively known as quantitative Real-Time PCR or qRT-PCR. 
There are two relatively broad categories of qRT-PCR chemistry: 
2.4.1 Intercalating dyes 
Intercalating dyes, such as SYBR Green I and similar DNA-binding dyes, 
fluoresce preferentially when bound to double-stranded DNA (ds-DNA), therefore 
giving an increase in fluorescence proportional to the increasing numbers of ds-
DNA amplicons produced during each round of amplification. While these dyes 
benefit from simplicity and only require the design of a single pair of sequence-
specific primers, they have a major drawback in their lack of specificity. Any ds-
DNA present in the reaction will fluoresce, thus non-specific amplicons or primer-





Figure 2.1: Schematic representation of PCR/qRT-PCR kinetics 
Shown here are depictions of a theoretical PCR reaction. Panel a. shows the process by which a 
target region of DNA is amplified in successive cycles of a reaction, panel b. shows the overall 
reaction kinetics indicating the three phases of an amplification reaction and panel c. shows the 
kinetics of two theoretical qRT-PCR reactions with differing input quantities of template DNA. 
(Panel a. adapted from royalty-free online resource: https://slideplayer.com/slide/13784204/) 
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2.4.2 Oligonucleotide probes 
Oligonucleotide probes are short oligonucleotides, complementary to a specific 
target sequence within the PCR amplicon which are added to the reaction along 
with standard PCR primers. These usually utilise both a fluorescent reporter and 
some means of quenching the reporter, which serve to ensure that fluorescence 
is detected only when the amplicon of interest is present. Detection is normally 
achieved through some type of conformational or spatial change in the 
reporter/quencher relationship, allowing the reporter to fluoresce. By virtue of the 
specific design of the probe and the fact that they will only produce fluorescence 
when the target amplicon is detected, they benefit from hugely increased 
accuracy in comparison to intercalating dye chemistries. There are many probe-
based chemistries available, but probably the most commonly used is a 
combination of forward and reverse PCR primer along with a fluorescent 
hydrolysis probe, which together are more widely known as TaqMan™ assays (a 
brand name of Roche Diagnostics and Applied Biosystems which has become 
synonymous with the chemistry itself). The hydrolysis probes employed in 
TaqMan™ assays carry a reporter fluorophore covalently attached to the 5’ end, 
a non-fluorescent quencher (NFQ) at the 3’ end and a Minor Groove Binding 
(MGB) domain attached via a flexible linker. The MGB acts to stabilise probe 
binding to its complementary sequence and raises the melting temperature (Tm) 
of the probe by up to 10°C, allowing for shorter oligonucleotides to be designed 
which in turn gives both higher specificity and lower background fluorescence. In 
their native conformation, the fluorophore and quencher are in close proximity 
therefore very little fluorescence is detectable. During the annealing step of 
thermal cycling, these probes will bind to the target along with the PCR primers. 
During the extension step of PCR, the probe is cleaved by the 5’ to 3’ exonuclease 
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activity of Taq polymerase, leading to the fluorophore and quencher being 
decoupled. As these are no longer close enough together to allow quenching to 
occur, the result is a fluorescent signal proportional to the number of cleaved 
probes and also therefore the number of amplicons in the reaction (Figure 2.2). 
In this thesis, qRT-PCR has been carried out exclusively using Taqman™ 
assays. 
 
Figure 2.2: Schematic of hydrolysis probe qRT-PCR chemistry 
Shown here is the principle by which Taqman™ assays detect a specific amplicon during a qPCR 
reaction. Taqman™ probes have a Minor Groove Binding domain attached at the 3’ end (not 
shown). Fluorescence is denoted by the lightning bolt icons (reproduced from Yuan et al.168, with 
permission from American Association for Clinical Chemistry, Inc; © 2000). 
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2.4.3 Measurement of gene expression 
Perhaps one the most important recent developments in the field of gene 
expression was the marriage of reverse transcription with qRT-PCR in the mid-
1990s, which for the first time allowed true quantitative analysis of expression 
levels of mRNA transcripts. By quantifying the amount of cDNA reverse-
transcribed from a cellular RNA sample, this technique allows researchers to 
determine the amount of transcription taking place (gene expression), at a 
specific time-point, for any given gene or genes. 
As alluded to in section 2.4, quantification is achieved through the capture of 
fluorescence data, specifically the point at which the fluorescence produced by a 
given sample crosses a pre-defined threshold (Figure 2.1c). This point is termed 
the cycle threshold or CT value, and forms the basic unit of measurement of all 
qRT-PCR analyses. The threshold is arbitrarily defined independently for each 
gene in a particular study, however two rules must be obeyed when placing a 
threshold; 1) it must be sufficiently far above the baseline fluorescence so as not 
to be affected by background noise, and 2) it must be within the linear portion of 
the exponential phase of the amplification curve. Assuming these rules are 
adhered to, the exact positioning of the threshold is irrelevant, as the relative 
difference between CT values will remain equal. For most analyses, proprietary 
software provided by qRT-PCR instrument manufacturers will set the baseline 
and threshold parameters automatically, with baseline measurements usually 
being averaged across all samples between cycles 3 and 15, and the threshold 
being set in the linear phase a minimum of ten standard deviations above the 
baseline value. In certain cases in this thesis, it was necessary to alter these 
default settings, however descriptions of any alterations are provided in the 
supplementary data wherever this has been done. 
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There are two methods for measuring gene expression using qRT-PCR; absolute 
and relative quantification. 
Absolute quantification relies on use of a standard curve prepared via a serial 
dilution from a stock containing a known number of template molecules. CT values 
from this standard curve are plotted on a log-scale graph in order to produce a 
straight-line plot against which CT values of unknown samples are compared, 
giving a measurement of number of copies per sample169. The absolute 
quantification approach is useful in certain cases where exact number of copies 
is required (for example in the calculation of viral load170), but more often relative 
quantification of expression will suffice. 
Relative quantification compares CT values of one set of samples relative to CT 
values of a second set (for example treated vs control samples or similar) and 
gives a measurement in fold-change in expression between the two sample sets. 
This approach dispenses with the time-consuming step of preparing a highly 
accurate, precisely quantified standard curve for each set of reactions as is 
required in absolute quantification. 
In both of these methodologies, some means of normalising potential 
discrepancies in input quantity of total RNA is required. Such variance can arise 
from inherent technical variability in the accuracy of RNA measurement, or from 
(human) pipetting error during the RT and/or qRT-PCR set-up steps and, if not 
accounted for, could potentially result in gross over- or under-estimation of gene 
expression changes. Such correction is achieved through the inclusion of 
endogenous control genes in the experimental design. These are also known as 
housekeeping genes as they are usually involved in pathways or structural 
elements that are fundamental to cellular processes and/or survival and therefore 
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likely to be expressed at stable levels across different experimental conditions. 
CT values for endogenous control genes are collected from the samples in the 
experiment (along with the CT values for the genes of interest), and these are 
used for downstream normalisation. This normalisation is discussed in more 
detail in section 2.4.6. 
In this thesis, relative quantification has been the method of choice for 
quantification of gene expression. 
2.4.4 Taqman™ Array qRT-PCR 
Taqman™ Array microfluidics cards (Thermo Fisher, Waltham, MA, USA) were 
used to generate data for chapters 3, 4 & 6. The Taqman™ Array system consists 
of a foil-backed card overlaid with an arrangement of plastic microfluidic channels 
connecting 384 reaction chambers of 1μl volume, each of which contains a 
lyophilised Taqman™ assay. The cards can be purchased in several pre-
configured layouts or alternatively can be custom designed to contain any 
required selection of Taqman™ assays. Up to eight samples can be loaded onto 
a card, with differing numbers of assays per sample according to the chosen 
layout.  
The Taqman™ MicroRNA Arrays used in this thesis contain a single reaction per 
assay for each sample, whereas the Taqman™ Low Density Arrays custom gene 
expression cards contain duplicate reactions per assay for each sample. 
RNA samples were first reverse transcribed using the SuperScript™ VILO™ 
cDNA Synthesis Kit as described in section 2.3.1. The resulting 20μl of cDNA 
was mixed with 50μl of TaqMan™ Universal Master Mix II, no UNG (Thermo 
Fisher, Waltham, MA, USA) and 30μl RNase-free dH2O. The resulting reaction 
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mixture was then loaded onto the array through a loading port at one end of the 
card. Once loaded, the Taqman™ Array cards were centrifuged twice for 1 minute 
at 216 x g in order to distribute the mixture through the microfluidics channels and 
into each of the reaction chambers. The chambers were then sealed using a 
proprietary tool and the card loaded onto a qRT-PCR machine with correct 
capability to run this format of array. In this thesis, Taqman™ Array cards were 
all run on an Applied Biosystems™ 7900HT Fast Real-Time PCR System 
(Thermo Fisher, Waltham, MA, USA). Cycling conditions were a single cycle of 
50°C for 2 minutes followed by a single cycle of 94.5°C for 10 minutes then 40-
50 cycles of 97°C for 30 seconds and 59.7°C for 1 minute. Details of array types 
used, specific assay configurations, cycling conditions and endogenous controls 
for the arrays run in each chapter are given in sections 3.7.6, 4.7.4, 6.5.4, 
Supplementary Data S2 and Supplementary tables S18 & S27. 
NB. Taqman™ Arrays are referred to in this thesis as both Taqman™ MicroRNA 
Arrays and Taqman™ Low Density Arrays (TLDA) depending on the format in 
use (pre-designed microRNA cards or custom gene expression cards), however 
all array cards have recently been renamed by Thermo Fisher as Taqman™ 
Array Cards (TAC). 
2.4.5 Manual 384-well qRT-PCR  
Single-tube Taqman™ Assays (Thermo Fisher, Waltham, MA, USA) were used 
to generate data for chapters 4 & 5. Experiments using these assays were 
performed in manually loaded 384-well plates and run on either an Applied 
Biosystems™ 7900HT Fast Real-Time PCR System, Applied Biosystems™ 
QuantStudio 12K Flex Real-Time PCR System or Applied Biosystems™ 
QuantStudio 6 Flex Real-Time PCR System. Minor variations in the exact 
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contents of each reaction exist between the experiments in different chapters, 
dependent on the RNA availability and the type of assay being used for each 
experiment. Full details of reaction mixes for each experiment are given in 
sections 4.7.5, 4.7.9 and 5.5.5. In general, cDNA, Taqman™ Assay, TaqMan™ 
Universal Master Mix II, no UNG and RNase-free dH2O were mixed in appropriate 
volumes to give a 5μl final reaction volume per well. Individual cDNA samples 
were run using three technical replicates, with these replicates mixed as a single 
large volume before being loaded onto the 384-well plate to minimise pipetting 
error. Cycling conditions were a single cycle of 95°C for 10 minutes, followed by 
40-50 cycles of 95°C for 15 seconds and 60°C for 1 minute. Details of Taqman™ 
Assays and endogenous controls used in each chapter are given in 
Supplementary tables S19, S20 & S21. 
2.4.6 Relative quantification 
There are three approaches for calculating relative gene expression levels from 
qRT-PCR data; the 2-ΔΔCT method, the Pfaffl method171 and sigmoidal curve-
fitting.  
The 2-ΔΔCT method is the simplest and most commonly used form of relative 
quantification calculation. As mentioned in section 2.4.3, CT values are collected 
from each sample for the genes of interest (GOI) and endogenous control (EC) 
gene(s). It is worth noting that more than one EC is often included in the 
experimental design and an average (or geometric mean) of the CT values of 
these genes may be used. The first part of the 2-ΔΔCT calculation is within-sample 
normalisation using the EC gene(s) to account for any variation in RNA/cDNA 
input. This is achieved by subtracting the EC CT value from the GOI CT value, 
resulting in a ΔCT value. The next step is to calculate the change in ΔCT value 
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relative to a calibrator sample or samples; the calibrator(s) are not a fixed entity 
and will be different depending on the experimental design and aim. For example, 
a set of control samples, zero time-point samples, or even a population median 
are all potentially valid calibrators for particular data sets. Subtracting each 
sample’s ΔCT value from the chosen calibrator(s) ΔCT value gives the ΔΔCT value 
for each sample (and effectively sets the calibrator(s) to zero). The ΔΔCT value 
represents the change in expression of each sample relative to the calibrator, but 
in its current state is a function of the number of cycles difference, so requires 
transformation to give a more understandable fold-change measurement. 
Assuming a doubling of PCR product in every cycle, the formula 2-ΔΔCT converts 
this cycle difference value into a fold-change value, which can then be used for 
statistical analysis. The main disadvantage of the 2-ΔΔCT method is that it relies on 
the assumption that all assay efficiencies are approximately equivalent, and 
preferably in the region of 100%. 
The Pfaffl method is based on the same equations as the 2-ΔΔCT method but also 
incorporates the PCR efficiency of each assay into the fold-change calculations, 
which is particularly useful when measurements have been carried out with 
assays with variable efficiencies. However, this approach does require 
construction of standard curves to test assay efficiencies, although unlike 
absolute quantification it does not require the standards to be present alongside 
every set of reactions171.  
Sigmoidal curve-fitting dispenses with the need for any standard curves by fitting 
the fluorescence data to a non-linear regression model, resulting in a quantitative 
measure of target quantity in arbitrary units. The disadvantage of sigmoidal curve-
fitting is the complexity of calculation and that each reaction must be fitted to the 
model individually, so analysis of this type requires specialist software. Some 
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examples of this type of software are now available but are generally targeted at 
more high-throughput applications172. 
Throughout this thesis, the 2-ΔΔCT method was the analysis type employed for 
relative quantification of gene expression. This method was used since all qRT-
PCR was performed using either inventoried Taqman™ Assays from Thermo 
Fisher (Waltham, MA, USA) which are validated to perform at an efficiency 
between 95% and 105%, or if custom assays were used, these were 
experimentally validated to be within the same range. 
In the case of the manual 384-well qRT-PCR analyses, prior to the 2-ΔΔCT step 
standard deviations of the three technical replicate CT values were manually 
checked and any samples showing a deviation >0.5 cycles had outlying CT values 
removed. However, this step was not possible for either type of Taqman™ Array 
used in this thesis as they contained a maximum of two technical replicates per 
sample. 
2.5 Statistical approaches 
2.5.1 Transformations 
qRT-PCR data was subject to transformations appropriate to the dataset in each 
chapter. In chapters 3 & 4, a log10 transformation was used, whereas a natural 
log was used in chapters 5 & 6. Transformations were chosen based on visual 
inspection of the data in each case as empirical tests of normality such as 
Kolmogorov-Smirnov or Shapiro-Wilk tests tend to overestimate non-normality on 
larger datasets, such as those in this thesis173. 
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2.5.2 Outlier detection 
In chapters 3 & 4, due to the smaller relative size of the datasets involved, no 
formal outlier detection strategy was applied beyond the removal of any samples 
missing >50% of data points across all genes measured. For chapters 5 & 6 
(which correspondingly have larger datasets), a combination of univariate and 
multivariate outlier detection was used. Univariate detection was carried out first 
using standardised z-scores followed by multivariate detection by means of a 
Mahalanobis distance calculation. Full details of outlier detection approaches are 
given in sections 5.5.6 and 6.5.5. 
2.5.3 Student’s t-test 
The Student’s t-test was used in chapter 3 to compare mean gene expression 
values. Details are given in section 4.7.10. 
2.5.4 Linear regressions 
Data analyses in chapters 3, 4, 5 and 6 were carried out using linear regression 
models including varying numbers of covariates. In all cases, gene expression 
was entered into the model as the dependent variable and all other relevant 
covariates added as independent variables. Exact details of the regression 
parameters and the software used to run the models are given in sections 3.7.6, 
3.7.8, 4.7.11, 5.5.7 and 6.5.8. 
2.5.5 Binary logistic regressions 
Binary logistic regression was used as a secondary analysis in chapter 3 in order 
to assess the potential effects of non-linearity on the results of the linear 
regressions. Details are given in section 3.7.6. 
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2.5.6 Interaction terms 
Interaction terms were included between two categorical variables in certain 
regression models to determine whether one variable could potentially be 
mediating the effect of the other variable on gene expression levels (see Figure 
5.5). Full details of interaction analyses used in this thesis are given in sections 
3.7.6, 4.7.6 and 5.5.7. 
2.5.7 ANCOVA 
Analyses of covariance (ANCOVA) were used in chapter 5 to test for differences 
in mean gene expression across different groups with the inclusion of a single 
covariate. Details are given in section 5.5.7. 
2.5.8 Multiple testing 
Different strategies were employed in order to account for increased potential for 
Type I errors due to multiple testing. 
No p-value correction was used in chapter 3, as the genes in question were 
chosen a priori based on previous work and only one phenotype was tested. 
In chapter 4, Bonferroni correction174 was used for the two microRNA analyses 
carried out: n=279 tests, p=0.000179 for the discovery set, and n=10 tests, 
p=0.005 for the validation set. However, no correction was made for the mRNA 
target follow-up analyses as the genes tested were chosen a priori based on the 
microRNA target predictions. 
A false discovery rate (FDR) control method proposed by Benjamini, Krieger and 
Yekutieli175 was used for the data in chapter 5. As the potential for correlations 
within and between the results was particularly high in the inbred recombinant 
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mouse strains used in this chapter, Bonferroni correction was not appropriate due 
to the fact that a lack of inter-dependence between findings is assumed for correct 
implementation of this procedure.  
Chapter 6 also used Bonferroni correction, although in this case the correction 
was limited to the number of phenotypes tested (n=6, p=0.00833), as the genes 
tested were once again chosen a priori based on previous findings. Although the 
human cohort in this chapter would most likely present fewer correlations than 
the inbred mice from chapter 5, the phenotypes tested had potential to show a 
degree of correlation, so proper handling of multiple testing in this case was not 
straight-forward. Both full Bonferroni or FDR-type correction may well have been 
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3.3 Abstract 
Dysregulation of splicing factor expression and altered alternative splicing are 
associated with ageing in humans and other species, and also with replicative 
senescence in cultured cells. Here, we assess whether expression changes of 
key splicing regulator genes and consequent effects on alternative splicing are 
also associated with strain longevity in old and young mice, across 6 different 
mouse strains with varying lifespan (A/J, NOD.B10Sn-H2b/J, PWD.Phj, 
129S1/SvlmJ, C57BL/6J and WSB/EiJ). Splicing factor expression and changes 
to alternative splicing were associated with strain lifespan in spleen and to a 
lesser extent in muscle. These changes mainly involved hnRNP splicing inhibitor 
transcripts with most changes more marked in spleens of young animals from 
long-lived strains. Changes in spleen isoform expression were suggestive of 
reduced cellular senescence and retained cellular proliferative capacity in long-
lived strains. Changes in muscle isoform expression were consistent with 
reduced pro-inflammatory signalling in longer-lived strains. Two splicing 
regulators, HNRNPA1 and HNRNPA2B1, were also associated with parental 
longevity in humans, in the InCHIANTI ageing study. Splicing factors may 
represent a driver, mediator or early marker of lifespan in mouse, as expression 
differences were present in the young animals of long-lived strains. Changes to 
alternative splicing patterns of key senescence genes in spleen and key 
remodelling genes in muscle suggest that correct regulation of alternative splicing 
may enhance lifespan in mice. Expression of some splicing factors in humans 
was also associated with parental longevity, suggesting that splicing regulation 




Ageing is a dynamic, multisystem process, which is highly heterogeneous in 
humans with some people surviving disease-free until advanced age whilst 
others succumb to age-related conditions in mid-life. The factors underlying 
individual lifespan are currently unclear, but increasing our understanding of 
determinants of longevity and ‘healthspan’ are key aims for the future. 
Correct expression and regulation of genes is critical for maintenance of cellular 
and organismal function. Alternative splicing, the process by which single genes 
can make multiple gene products in an adaptive and reactive fashion is a key part 
of this process176. Indeed, breakdown in the regulation of mRNA splicing is a 
prominent feature in many age-related diseases such as Alzheimer’s disease, 
Parkinson’s disease and several tumour types177-180. This may indicate that 
defects in the splicing machinery may cause the cellular response to stress to be 
less specific, with effects on cellular resiliency and accumulation of DNA damage. 
We have previously identified deregulation of splicing factor expression and 
alternative splicing as a key factor in normal human and cellular ageing101,103. 
Alternatively expressed isoforms also demonstrate tissue-specific differences in 
ageing, as they do for many other phenomena103. Splicing factors themselves 
demonstrate high species conservation181, whereas patterns of alternative 
splicing are partially determined by genetic differences and may be species 
specific. Splicing patterns show drastically more interspecies variability than gene 
expression with only 50% of alternatively expressed isoforms being conserved 
between species182. Alternatively regulated splice sites demonstrating temporal, 
spatial or reactive expression are less likely to show species conservation183. 
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Several splicing factors have been suggested to be involved in organismal 
lifespan. The pre-mRNA processing factor 19 homologue (SNEV) protein, 
important for spliceosome assembly and mRNA processing, has been shown to 
suppress cellular senescence and suppress apoptosis when phosphorylated by 
the ataxia-telangiectasia (ATM) kinase in endothelial cells184. The DNA damage 
protein ATM also appears to be an important regulator of splicing factor 
expression in our previous work, since targeted gene knockdown of the ATM 
gene resulted in increased levels of splicing factor expression in fibroblasts103. 
There is also evidence from systemic models. A network-based model of genes 
altered by calorific restriction across 17 tissues in mice revealed that the largest 
and most responsive gene regulatory module was associated with mRNA 
processing, with a disproportionally large number of genes being involved in 
splicing, metabolism, processing and biosynthesis of mRNA185. Finally, a study 
of the relationship between copy number variation (CNV) and longevity in humans 
revealed that lifespan-associated CNVs were preferentially located in or near 
genes encoding proteins involved in splicing control. This led them to conclude 
that genetic variation that disrupts the processes of alternative splicing may have 
long-term effects on lifespan186. 
The study of inbred strains of mice has proven fruitful in uncovering factors 
associated with lifespan, as for other phenotypes. The Jackson Laboratory has 
characterized 30 strains of mice, for ageing and longevity-related traits157,158. 
Initial work with this resource identified that plasma IGF1 levels were related to 
lifespan in rodents157. This collection, together with the associated repository of 
mouse phenome data, represents a rich resource187. Here, we have harnessed 
this resource to assess the contribution of regulation of alternative splicing to 
longevity in mice. 
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We have systematically assessed the expression of splicing factors previously 
demonstrated to be altered in human ageing in relation to lifespan in six mouse 
strains of different longevities. Our study design is illustrated in Figure 3.1. 
Splicing factor expression and alternative splicing of key genes are associated 
with lifespan in mouse spleen tissue and to a lesser extent in mouse muscle, 
suggesting that ageing effects may be driven by immune tissues. Some strain 
differences in expression are most marked in the young mice, suggesting that 
they may represent determinants or early markers of longevity rather than 
representing secondary effects of ageing. We also identified differences in 
expression levels of alternatively expressed isoforms of key ageing genes 
indicative of reduced cellular senescence, maintained cellular proliferative 
capacity (spleen) and reduced pro-inflammatory signalling (muscle) in long-lived 
mouse strains. Two splicing factors, HNRNPA2B1 and HNRNPA1, were also 
associated with parental longevity in a large population study of ageing, 







Figure 3.1: Schematic of study design 
This figure shows the experimental strategy employed to assess the effects of strain longevity 




3.5.1 Splicing factor transcript expression is associated with lifespan in mouse 
spleen and to a lesser extent in muscle tissues 
We assessed splicing factors that we have previously demonstrated to be altered 
in human ageing in relation to lifespan in 6 mouse strains of different longevities 
and in samples from both old and young mice as in Figure 3.1. The expression 
of 8/15 and 3/15 splicing factors was associated with strain lifespan in mouse 
spleen and muscle tissue, respectively. 
In spleen, we found associations between strain lifespan and the expression of 
the Hnrnpa1, Hnrnpa2b1, Hnrnpk, Hnrnpm, Hnrnpul2, Sf3b1, Srsf3 and Tra2b 
genes (beta coefficients -0.40, -0.26, -0.32, -0.31, -0.22, -0.13 and -0.36; P = 
0.01, 0.02, 0.003, 0.003, 0.04, 0.05, 0.02 and 0.02, respectively; Figure 3.2A, 
Supplementary table S1). When an analysis was carried out to assess 
interactions between strain lifespan and mouse age, we found effects in both 
young and old mice of long-lived strains for all associated genes except Hnrnpul2. 
In the case of Hnrnpa1 and Hnrnpa2b1 genes, these differences were more 
marked in the young mice of long-lived strains (beta coefficients -0.14 and -0.19, 
P = 0.001 and <0.0001 in the young long-lived mice compared with -0.09 and -
0.12; P = 0.01 and 0.02 for the old long-lived mice for Hnrnpa1 and Hnrnpa2b1, 
respectively; Supplementary table S9). For Srsf3, the associations between 
splicing factor expression/age and splicing factor expression/strain median 
lifespan appear to be comparable, whereas for Tra2b, our data suggest that the 
effects of age are stronger than those of lifespan (Supplementary table S9). The 
majority (5/8) of the splicing factors demonstrating association of expression 
differences with lifespan belonged to the hnRNP class of splicing inhibitors, with 
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only 2 splicing activators (Srsf3 and Tra2b) showing expression changes with 
lifespan. The remaining associated splicing factor, Sf3b1, encodes a component 
of the U2 snRNP in the core spliceosome complex, rather than a splicing 
regulator. When data were assessed by binary logistic regression to allow for 
nonlinearity of response, all but one (Hnrnpul2) of the splicing regulators 
associated with lifespan in spleen remained associated with median strain 
lifespan (Supplementary table S10). 
Fewer splicing factors were associated with strain lifespan in muscle tissue 
(Figure 3.2B, Supplementary table S2). Hnrnpa0 expression was found to be 
positively correlated with long life (beta coefficient 0.36; P = 0.01), whereas 
Hnrnpd and Srsf3 transcripts both demonstrated reduced expression (beta 
coefficients -0.24 and -0.40; P = 0.03 and 0.02, respectively). Interaction analysis 
revealed that the Srsf3 effect was again driven by effects in the young animals of 
the long-lived strains (beta coefficient -0.14, P = 0.01 in the young long-lived mice 
compared with beta coefficient -0.05, P = 0.28 in the old long-lived mice; 
Supplementary table S9). Again 2/3 lifespan-associated splicing factors 
represented hnRNP splicing inhibitors rather than SRSF splicing activators. 
When data were assessed by binary logistic regression to allow for nonlinearity 
of response, all of the splicing regulators associated with lifespan in muscle 
remained associated with median strain lifespan (Supplementary table S11). 
Effects were tissue specific, with little overlap between lifespan-associated 





Figure 3.2: Splicing factor expression according to mouse lifespan 
This plot illustrates association between median lifespan and splicing factor expression in total 
RNA from spleen (A) or muscle (B) tissues in mice of 6 strains of different longevities, as assessed 
by linear regression against median strain lifespan. The identity of specific splicing factors is given 
on the x-axis. The log10 P-values for associations between lifespan and splicing factor expression 
from mice of strains with different lifespans and of different ages are given on the y-axis. Direction 
of effect is also indicated; data appearing above the zero line on the y-axis represent positive 
associations, whilst data appearing below the zero line represent negative associations. Analysis 
including all animals in the sample is given by dark grey bars, in young animals only by medium 
grey bars and in old animals only by light grey bars. The dotted line refers to a P-value cut-off for 
statistical significance of P = 0.05. 
109 
3.5.2 Alternatively spliced genes demonstrate longevity-associated isoform 
changes in mouse spleen and muscle tissue 
In spleen, we found splicing differences in association with lifespan for 4/8 genes 
tested (Figure 3.3A; Supplementary table S3). Both uc008toi.1 and uc008toh.1 
transcripts encoding p16INK4A and p14ARF isoforms of the Cdkn2a gene were 
expressed at lower levels in the long-lived strains (beta coefficients -0.43 and -
0.59; P = 0.002 and <0.0001 for uc008toi.1 [p16INK4A] and uc008toh.1 
[p14ARF], respectively). Analysis of the interaction of strain longevity and mouse 
age revealed that although the effects on Cdkn2a isoform expression increased 
with age as expected in both average-lived and long-lived mice, the increase in 
expression was much less marked in the old long-lived mice than in old mice of 
average lifespan (beta coefficients 0.44 and 0.50, P = <0.0001 and <0.0001 for 
the old average-lived mice compared with beta coefficients 0.22 and 0.27, P = 
0.01 and 0.001 for the old long-lived mice; Supplementary table S9). 
We also found expression of the uc007bju.2 isoform only of the Fn1 gene to be 
increased in the long-lived strains (beta coefficient 0.25, P = 0.02). There is 
increased expression of the long isoform of the Trp53 gene encoding full-length 
p53 (uc007jql.2/uc007jqn.2), but reduced expression of the truncated p53AS 
isoforms (uc011xww.1/uc007jqm.2; beta coefficients 0.41 and -0.35, P = 0.009 
and 0.03 for full-length Trp53 and truncated p53AS isoforms, respectively). 
Assessment of the interaction between strain longevity and mouse age revealed 
that expression of the full-length p53 isoform is only significantly increased in the 
young animals of long-lived strains (in comparison with young animals of short-
lived strains P = 0.004; the older animals were not significantly different to young 
short-lived strains P > 0.05) and that diminished expression of p53AS was only 
significantly decreased in the old animals of long-lived strains (P = 0.009, in 
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comparison with young animals of short-lived strains; other groups were P > 0.05, 
Supplementary table S9). Finally, expression of the full-length uc007rjg.1 isoform 
of the Vcan gene is upregulated (beta coefficient 0.34, P = 0.001). 
In mouse muscle, expression of isoforms of all five genes tested in relation to 
lifespan was altered (Figure 3.3B, Supplementary table S4). First, expression of 
the full-length uc008mht.1 isoform of the Il1b gene was reduced in the long-lived 
strains (beta coefficient -0.46, P = 0.007), whilst the intron-retained uc008mhu.1 
Il1b isoform was unaffected. Interaction analysis revealed that this difference was 
limited to the young mice of the long-lived strains (P = 0.004 for young long-lived 
mice compared with P = 0.34 for the old long-lived mice). Expression levels of 
the intron-retained uc008wuv.1 and full-length uc008wuw.1 isoforms of the Il6 
gene were also reduced (beta coefficient -0.48, P = 0.006 and -0.28, P = 0.01, 
respectively). Interaction analyses revealed that the effects on the intron-retained 
isoform were significant in the young long-lived mice only (P = 0.04 for young 
long-lived mice compared with P = 0.72 for old long-lived mice; Supplementary 
table S9). 
Expression of the uc012cyg.1/uc008rlx.1 isoforms which encode the long full-
length forms of the Nfkb1 gene was greater in long-lived strains (beta coefficient 
0.31, P = 0.005). No difference was seen in the expression of the noncoding 
truncated uc012cyf.1 Nfkb1 isoform. Isoform usage for the Stat1 gene in long-
lived strains differed; the uc007axz.1 and uc007aya.2 isoforms of Stat1 that both 
encode ‘variant 2’ of the STAT1 protein demonstrated diminished expression in 
the long-lived strains (beta coefficients -0.63, P = <0.0001), whereas the Stat1 
uc007ayc.2 isoform encoding ‘variant 1’ demonstrated increased expression in 
the long-lived strains (beta coefficient 0.46, P = 0.007). Interaction analysis 
revealed that the decrease in Stat1 variant 2 expression was present only in the 
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old long-lived mice (P = 0.01 in old long-lived mice compared with P = 0.28 in the 
young long-lived mice; Supplementary table S9). The greater Stat1 variant 1 
expression was driven by effects in the young long-lived mice (P = 0.03 in young 
long-lived mice compared with P = 0.95 in old long-lived mice). Transcript 
uc007ayb.2, encoding Stat1 ‘variant 3’, was also upregulated (beta coefficient 
0.33, P = 0.005) although this was seen in both young and old animals of long-
lived strains. Finally, expression of both the uc012arb.2 and uc008cgs.2 isoforms 
of the Tnf gene which encode TNF variants 1 and 2 were reduced in muscle (beta 
coefficients -0.27 and -0.18, P = 0.02 and 0.04 for uc012arb.2 and uc008cgs.2, 
respectively). Interaction analyses revealed that the effect for Tnf variant 1 is most 
marked in the old long-lived animals (P = 0.008 in the old long-lived animals 





Figure 3.3: The expression of alternative isoforms of key genes according 
to mouse lifespan 
This plot illustrates association between median lifespan and the expression of alternatively 
expressed isoforms of key genes in total RNA from spleen (A) or muscle (B) tissues in mice of 6 
strains of different longevities as assessed by linear regression against median strain lifespan. 
The identity of specific splicing factors is given on the x-axis. The log10 P-values for associations 
between lifespan and splicing factor expression from mice of strains with different lifespans and 
of different ages are given on the y-axis. Direction of effect is also indicated; data appearing above 
the zero line on the y-axis represent positive associations, whilst data appearing below the zero 
line represent negative associations. Analysis including all animals in the sample is given by dark 
grey bars, in young animals only by medium grey bars and in old animals only by light grey bars. 
The dotted line refers to a P-value cut-off for statistical significance of P = 0.05. 
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3.5.3 Few splicing factors are associated with age in mouse spleen and muscle 
tissues 
Associations between mouse age and splicing factor expression were less 
marked than those seen for strain longevity (Figure 3.4A, 3.4B, Supplementary 
tables S5 and S6). In spleen, we found reduced expression of the Hnrnpa2b1, 
Srsf1, Srsf3 and Tra2b transcripts in old mice (beta coefficients -0.46, -0.34, -0.45 
and -0.53; P = 0.005, 0.05, 0.007 and 0.008, respectively). Effects on Srsf1, Srsf3 
and Tra2b expression were evident in old animals of both average-lived and long-
lived strains, but interaction analysis revealed that the age-associated difference 
in Hnrnpa2b1 expression was most marked in the old animals of strains of 
average lifespan (beta coefficients -0.11, P = 0.02 in the old long-lived animals 
compared to beta coefficient -0.13 P = <0.0001 in the old average-lived animals). 
Age-associated changes to splicing factor expression were much less evident in 
muscle tissue, with only Hnrnpa1 demonstrating increased expression (beta 
coefficient 0.22, P = 0.05). Analysis of cluster patterns for age revealed 
considerable inter- and intrastrain heterogeneity in splicing factor expression 




Figure 3.4: Splicing factor expression according to mouse age 
This plot illustrates association between age and splicing factor expression in total RNA from 
spleen (A) or muscle (B) tissues in young (6 months) vs. old (20–22 months) mice. The identity 
of specific splicing factors is given on the x-axis. The log10 P-values for associations between age 
and splicing factor expression from mice of different ages and of different strains are given on the 
y-axis. Direction of effect is also indicated; data appearing above the zero line on the y-axis 
represent positive associations, whilst data appearing below the zero line represent negative 
associations. Analysis including all animals in the sample is given by dark grey bars, in animals 
of average-lived strains only by medium grey bars and in long-lived animals only by light grey 
bars. The dotted line refers to a P-value cut-off for statistical significance of P = 0.05. 
  
115 
3.5.4 Alternatively expressed isoforms demonstrate differential expression with 
age in mouse spleen and muscle tissue 
Despite the small numbers of splicing factors demonstrating age-associated 
differences in splicing factor expression, we noted differences in alternative 
splicing in both spleen and muscle from aged mice (Figure 3.5A, 3.5B, 
Supplementary tables S7 and S8). 
In mouse spleen, we identified increased expression of both uc008toi.1 and 
uc008toh.1 transcripts encoding p16INK4A and p14ARF isoforms of the Cdkn2a 
gene in the old animals as expected (beta coefficients 0.40 and 0.53, P = <0.0001 
and <0.0001, respectively). Interaction analyses revealed the age-associated 
increase in both Cdkn2a isoforms to be significantly reduced in old animals of 
long-lived strains as described above. We also identified decreased expression 
of both uc008yrw.1 (full length) and uc008yrx.1 (exon skipped) isoforms of the 
Chek2 gene with increasing age (beta coefficients -0.33 and -0.35, P = 0.02 and 
0.01, respectively). Interaction analyses between mouse age and strain longevity 
revealed that reduced expression of the full-length Chek2 isoform was more 
marked in the old animals of the long-lived strains (beta coefficient -0.26, P = 
<0.0001 in the old long-lived animals compared with beta coefficient -0.24, P = 
0.003 in the old average-lived animals; Supplementary table S9). Trp53 isoforms 
also demonstrated effects with age in mouse spleen. With age, there was a 
reduction in levels of transcripts encoding both full-length p53 
(uc007jql.2/uc007jqn.2) and also those encoding the truncated alternatively 
spliced p53AS (uc007jqm.2) isoform (beta coefficients -0.24 and -0.24, P = 0.02 
and 0.03, respectively). 
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In mouse muscle, we found increased expression of both the full-length 
(uc008mht.1) and the intron-inclusion (uc008mhu.1) Il1b transcripts with age 
(beta coefficients 0.37 and 0.39, P = 0.001 and <0.0001). The old animals also 
demonstrated elevated expression of the uc008wuv.1 isoform of the Il6 gene, 
which contains a retention of intron 4 relative to the consensus transcript (beta 
coefficient 0.44, P = 0.003). Old animals also demonstrated reduction of 
uc007ayd.2, uc007aya.2, uc007ayb.2 and uc007ayc.2 isoforms of the Stat1 
gene, with the effects on uc007aya.2 being revealed by interaction analysis 
between mouse age and strain lifespan to be present exclusively in the old 





Figure 3.5: The expression of alternative isoforms of key genes according 
to mouse age 
This plot illustrates association between the expression of age and the expression of alternatively 
expressed isoforms of key genes in total RNA from spleen (A) or muscle (B) tissues in young (6 
months) vs. old (20–22 months) mice. The identity of isoforms is given on the x-axis. The log10 P-
values for associations between age and the expression of alternative isoforms from mice of 
different ages and of different strains are given on the y-axis. Direction of effect is also indicated; 
data appearing above the zero line on the y-axis represent positive associations, whilst data 
appearing below the zero line represent negative associations. Analysis including all animals in 
the sample is given by dark grey bars, in animals of average-lived strains only by medium grey 
bars and in long-lived animals only by light grey bars. The dotted line refers to a P-value cut-off 
for statistical significance of P = 0.05. 
118 
3.5.5 The expression of some splicing factors is associated with parental 
longevity in a large human population 
We examined the expression of 15 splicing factors identified through the mouse 
work described in this study and previous analyses103 and determined that 2 
genes, HNRNPA2B1 and HNRNPA1, demonstrated associations of their 
expression with parental longevity, as defined in Dutta et al.188 in the human 
InCHIANTI population study as well as in mice (Table 3.1). HNRNPA2B1 
transcripts demonstrated increased expression in the offspring of long-lived 
parents (beta coefficient 0.12, P = 0.017), whereas HNRNPA1 demonstrated 
reduced expression in the offspring of long-lived parents (beta coefficient -0.09; 
P = 0.035, respectively; Table 3.1). Hnrnpa1 demonstrates reduced expression 
in association with longevity in both man and mouse, whereas Hnrnpa2b1 shows 
elevated expression with longevity in people, but reduced expression with 
longevity in mice. 
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Table 3.1: Associations between splicing factor expression and parental 
longevity in humans (the InCHIANTI population) 
The relationship of parental longevity with expression of 15 unique splicing factors in 405 
individuals by multivariate linear regression. Genes demonstrating significant associations at P = 
<0.05 are indicated in bold underlined text. 
 






HNRNPA2B1 ILMN_1886493 0.116 0.020 0.212 0.017 
HNRNPA1 ILMN_1676091 -0.091 -0.176 -0.006 0.035 
HNRNPA2B1 ILMN_2369682 0.088 0.002 0.175 0.044 
TRA2B ILMN_1742798 0.092 -0.001 0.186 0.051 
HNRNPA1 ILMN_1661346 0.069 -0.004 0.143 0.065 
SRSF1 ILMN_1795341 0.082 -0.008 0.171 0.073 
HNRNPD ILMN_2321451 0.088 -0.010 0.186 0.078 
HNRNPK ILMN_1701753 -0.066 -0.176 0.043 0.232 
HNRNPUL2 ILMN_2072091 0.076 -0.053 0.205 0.246 
HNRNPK ILMN_2378048 0.060 -0.058 0.178 0.319 
SRSF18 ILMN_2161357 0.068 -0.072 0.209 0.341 
HNRNPUL2 ILMN_1810327 0.055 -0.066 0.176 0.374 
HNRNPA1 ILMN_2220283 0.034 -0.051 0.119 0.432 
SRSF2 ILMN_1696407 0.047 -0.074 0.167 0.446 
HNRNPD ILMN_1751368 -0.034 -0.137 0.068 0.511 
SRSF6 ILMN_1697469 0.033 -0.077 0.143 0.552 
SRSF6 ILMN_1754304 0.030 -0.078 0.138 0.585 
HNRNPA0 ILMN_1753279 -0.035 -0.164 0.095 0.598 
HNRNPA1 ILMN_1663447 -0.034 -0.168 0.101 0.624 
HNRNPA1 ILMN_1720745 0.025 -0.080 0.131 0.637 
HNRNPM ILMN_2385173 -0.029 -0.161 0.103 0.668 
SRSF6 ILMN_1805371 -0.026 -0.149 0.096 0.673 
SF3B1 ILMN_1712347 -0.022 -0.151 0.107 0.738 
SF3B1 ILMN_1705151 0.017 -0.091 0.125 0.754 
HNRNPM ILMN_1745385 -0.016 -0.119 0.086 0.756 
HNRNPA1 ILMN_2175075 -0.012 -0.126 0.102 0.838 
SRSF3 ILMN_2389582 0.004 -0.118 0.125 0.951 
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3.5.6 Genetic variation within Hnrnpa2b1 and Hnrnpa1 that is discrepant between 
strains is unlikely to contribute to differences in gene expression 
We have carried out a bioinformatic analysis of the potential for genetic variation 
that is discrepant between strains of mice to affect the regulation of the 
Hnrnpa2b1 and Hnrnpa1 genes. These genes were selected because their 
expression is associated with longevity in both mouse and man. The Hnrnpa2b1 
gene harbours 14 genetic variants that are discordant between strains. Two of 
these variants, rs51031918 and rs252413833, are associated with changes to 
the binding efficiencies of SRSF2 and SRSF5 splicing enhancers (see 
Supplementary table S12). These changes are, however, very subtle and may 
not adversely affect SRSF2 or SRSF5 binding. Similarly, two Hnrnpa1 variants 
(rs32398879 and rs50030666) are discordant between the strains. One of these, 
rs50030666, lies in a cassette exon which is intronic in some Hnrnpa1 isoforms, 
but coding in others (see Supplementary table S12). The coding change causes 
the substitution of glycine residue for a similarly sized serine residue with 
equivalent charge. No other predicted effects of genetic variation on transcription 
factor binding, RNA regulatory elements (A-rich elements, C to U RNA editing 




Splicing factor expression has been shown to be conclusively associated with 
chronological age in humans101 and also with cellular senescence in multiple 
human primary cell lines in culture103, indicating that these factors may be linked 
with cellular plasticity and adaptability during the ageing process. Here, we have 
assessed the potential relationships between splicing factor expression and 
alternative splicing with strain longevity across 6 mouse strains of variable 
medium to long lifespans, in both young and old animals. We also assessed 
associations between splicing factor expression and parental longevity in the 
offspring of long-lived parents in humans.  
We have found that over half of the splicing factors tested are associated with 
longevity in mouse spleen, and to a lesser extent in mouse muscle and that these 
changes are accompanied by alterations to the profile of selected alternatively 
expressed isoforms in both tissues. Two splicing factors, HNRNPA1 and 
HNRNPA2B1, also showed evidence of an association with parental longevity in 
humans. These results, to our knowledge, represent the first link between the 
regulation of alternative splicing and inherited longevity traits in mammals. 
In spleen, 7/15 splicing factors tested demonstrated associations with strain 
longevity in both young and old animals, with effects being predominant in the 
young animals of longer-lived strains suggesting that these differences in splicing 
factor expression are not the end result of ageing processes as such, but rather 
may represent fundamental differences in factor expression that drive or 
contribute to the ageing process. It is possible that changes happening early on 
in life may set the scene for future longevity, which is an interesting concept given 
that several genes such as Foxo1, known to be associated with extended 
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lifespan, are developmental genes189. It is very difficult to predict what the 
consequence of these changes will be to the overall level or pattern of splicing in 
long-lived mice or humans, since splice site choice at any given exon: intron 
junction is determined by the balance of activators and repressors, and that this 
balance is individually determined for each splice site in each gene176. However, 
diminished splicing factor expression may be beneficial in younger animals, since 
both SRSF and hnRNP splicing factors are known to have oncogenic features190-
192. Lower splicing factor expression in younger animals may thus protect against 
an earlier death from malignancy. 
We also found clear evidence to suggest tissue specificity of effect which is very 
common in studies of splicing with 8/15 (53%) splicing factors showing 
associations with strain longevity in spleen, but only 3/15 (20%) in muscle. It 
would be interesting to determine whether the splicing events targeted by these 
sets of splicing factors also show associations between median strain lifespan 
and splice site usage, but such analysis would be very difficult due to degeneracy 
of splicing factor binding sites, potential for compensation by other splicing factors 
and the fact that splice site usage is dependent on the balance of enhancers and 
silencers rather than on the binding of a specific splicing factor per se. The pattern 
of longevity-associated splicing regulator transcripts showed little overlap 
between the spleen and muscle data sets, with only changes to Srsf3 expression 
being common to both tissues. This is in line with our previous findings, as we 
have previously shown that although fibroblasts and endothelial cells that have 
undergone in vitro senescence both show deregulation of splicing factors, the 
patterns of precisely which regulators are altered show quite marked differences 
between cell types103. Spleen is a lymphoid organ, consisting of large numbers 
of white blood cells. Most of the transcripts extracted from spleen will arise from 
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B cells, T cells and mononuclear phagocytes. Our findings may thus reflect the 
hypothesis that ageing of the immune system is one of the drivers of development 
of ageing phenotypes193. It should also be considered that the preponderance of 
splicing factor expression changes in spleen compared with muscle could also 
reflect an accelerated rate of ageing and more extensive tissue modification in 
spleen compared to muscle. White blood cells are also highly heterogeneous, 
reactive and proliferative but relatively unspecialized compared to the highly 
differentiated non-proliferative muscle cells. It may be that muscle requires less 
adaptive response than spleen cells, since it has a defined and tightly regulated 
function with less need to respond to environmental challenge. 
Previous work from our group has identified that offspring of long-lived parents 
may have better health188,194. In the current study, two of the associations 
between splicing factor expression and longevity were also seen in RNA samples 
derived from the peripheral blood of participants in the InCHIANTI study163, where 
we found relationships between expression of the HNRNPA2B1 and HNRNPA1 
transcripts and parental longevity. HNRNPA2B1 demonstrated increased 
expression in blood RNA from people with at least one long-lived parent, whereas 
parental longevity (as a continuous trait reflecting the combined age at death of 
both parents) was associated with lower HNRNPA1 expression (Table 3.1). 
Hnrnpa1 is also downregulated with greater lifespan in mouse splenocytes, but 
the HNRNPA2B1 effect in humans is reversed compared to what we observe in 
the mice. This may be because the association between Hnrnpa2b1 expression 
and longevity is most marked in the young animals of the long-lived strains, and 
our human subjects are mostly elderly, with a mean age of approximately 75 
years101. Interestingly, both Hnrnpa2b1 and Hnrnpa1 are known to be 
determinants of lifespan in Drosophila species, by virtue of their regulation of the 
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TDP-43 protein195. TDP-43 is crucial in fruit flies for correct splicing and regulation 
of mRNA stability and is associated with amyotrophic lobar sclerosis and 
frontotemporal lobar degeneration in humans196,197. Mutations have also been 
described in age-related diseases such as Alzheimer’s, Parkinson’s and 
Huntington’s diseases198. Recent studies have shown that the action of TDP-43 
relies on its ability to tether hnRNPA2B1 and hnRNPA1 proteins, and disruption 
or abolition of this association dramatically reduces lifespan in Drosophila195. 
The consequences of altered splicing in spleen give a broad picture of altered 
expression and processing of genes involved in reduced cell senescence, 
superior DNA repair and retained cellular proliferative capacity in the long-lived 
strains. Old animals of long-lived strains of mice expressed reduced amounts of 
Cdkn2a isoforms compared with old animals of average-lived strains. Cdkn2a is 
an important marker of cellular senescence199 and ablation of Cdkn2a expression 
reverses ageing phenotypes in klotho mice200, indicating that old animals of long-
lived strains may have lower levels of senescent cells. Young animals of longer-
lived strains also expressed profiles of Trp53 isoforms consistent with enhanced 
transcription and cell growth properties compared to young animals of average-
lived strains, since they express higher levels of full-length p53 and lower levels 
of truncated p53AS which is thought to have antagonistic function201-203. Altered 
splicing of inflammatory genes involved in muscle remodelling produces a picture 
consistent with lower levels of pro-inflammatory signalling by virtue of lower levels 
of Il1b and Il6 expression in young animals and reduced Tnf signalling in the older 
animals of long-lived strains. 
We saw fewer associations of splicing factor expression with chronological age 
than we expected based on our previous human data. Our previous work 
suggests that splicing factor expression is strongly associated with age in humans 
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and with cellular senescence in human cell models101,103. In our human work, the 
per-year age-related changes in splicing factor expression were also relatively 
small (beta coefficients ranging from -0.01 to 0.005)103, which may explain why 
strong effects were not seen in the current mouse study where our sample 
numbers were much smaller. There is also considerable interstrain heterogeneity 
for most splicing factors; the young animals of one strain may express lower basal 
levels of splicing factors than the older animals of another and effects of ageing 
may thus be difficult to detect in small numbers of samples (Supplementary figure 
S1). These data suggest that the associations of splicing factor expression with 
longevity across strains may actually be considerably larger than effects of age 
alone on splicing factor expression within strains. Again, most changes seen in 
this study were seen in spleen, which is consistent with a key role in senescence 
for immune-mediated drivers of ageing and ageing phenotypes. 
The limitations of our study include the relatively small sample sizes, restriction 
of our analyses to a small number of tissues, and the fact that we have assessed 
splicing patterns only at the mRNA level. Gene expression is a highly variable 
parameter in biological systems, so future experiments are likely to need larger 
sample sizes and assessment of potential effects in other tissue types, as well as 
assessment of effects on protein levels. Although the genes tested were selected 
a priori and therefore do not require adjustment for multiple testing, one must 
recognize that this does not entirely remove the possibility of false positives. It 
must also be considered that differences in splicing factor and isoform expression 
may arise not only from changes in the amount of transcription, but also from 
differences in the relative stabilities of different isoforms. These changes may 
form part of the mechanistic basis for our associations, as we would not expect 
stability changes unrelated to longevity to associate statistically with strain 
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median lifespan. Finally, in the human follow up work described here, we were 
also restricted by the availability of expression data for all interesting splicing 
factors on the array and the likelihood that any effects were likely to be moderate 
on a per-year basis as they were in our previous human age data. This is likely 
to have reduced our power in the human study, and thus further work in larger 
populations is now required to definitively explore this possibility in human 
subjects. 
Another potential caveat is that the splicing factor expression differences we have 
discovered in this study reflect other strain differences that are unrelated to 
longevity. Whilst this is a possibility, the links between splicing factor expression 
and ageing in humans and other animals are well documented from our previous 
work101,103 and that of other groups204. Our observation that the lifespan-
associated expression changes relating to Hnnrpa2b1 and Hnrnpa1 we observe 
in mice are also translatable to humans is also supportive of our conclusions. 
More broadly, the importance of splicing factors in determination of lifespan is 
also suggested by studies of the effects of calorific restriction in mice185 and 
studies of the relationship between copy number variant (CNV) polymorphisms 
and longevity in humans186. 
Some of the genetic differences between strains may actually contribute 
mechanistically to the differences in strain median lifespan. To that effect, we 
carried out a bioinformatic analysis on the potential for genetic variation 
discordant between strains to lead to gene regulation differences for Hnrnpa2b1 
and Hnrnpa1, where we also found effects in man. We discovered some minor 
changes to the bioinformatically predicted strength of SRSF2 and SRSF5 binding 
within Hnrnpa2b1 and a potential amino acid change for an alternatively 
expressed isoform of Hnrnpa1. Although these predictions are interesting, the 
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predicted effects of the changes on Hnrnpa2b1 or Hnrnpa1 expression or activity 
are likely to be slight. The splicing effects cause only a slight alteration to 
predicted binding efficiency of SRSF2 or SRSF5, and the coding change involves 
the substitution of a serine for a glycine in an alternatively spliced cassette exon 
of Hnrnpa1, which may not comprise the major isoform at this locus. These amino 
acids are in any case of similar size and charge and may not cause much change 
to protein functionality. It is likely the effects on median strain longevity arise from 
multiple changes in many genes. 
To be able to assign definitive causality for a role for splicing factors as 
determinants of longevity, it would be necessary to carry out detailed functional 
experiments in vivo and in vitro, which could form the basis for future studies. 
Such studies could comprise constitutive or conditional knockout or 
overexpression studies in animal models followed by assessment of effects on 
lifespan, or in vitro manipulation of splicing factor levels followed by investigation 
of effects on cellular senescence. Such an approach has previously been 
employed for the Hnrnpa1 and Hnrnpa2b1 genes where upregulation of the 
Hnrnpa1 gene or the Hnrnpa2 isoform of the Hnrnpa2b1 gene in mouse 
hepatocarcinoma cells was shown to cause activation of the RAS-MAPK-ERK 
pathway205. This is potentially important since a recent study has shown that 
activation of the RAS-ERK-ETS pathway is a key determinant of lifespan in 
Drosophila species206. 
Both in vivo and in vitro studies to moderate the levels or activity of splicing factors 
in relation to longevity would not be without caveat. Splice site choice is a 
complex phenomenon and relies upon the balance of splicing activators or 
silencers, rather than the activity of a single splicing factor per se176. This finding, 
together with observations that exon and intron splicing enhancers and silencers 
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often cluster near splice sites, raises the possibility of compensation between 
splicing regulatory factors. Selective modulation of a single splicing factor may 
not then show direct effects on longevity, effects would most probably only be 
noted after knockdown or overexpression of multiple splicing factors which would 
have technical challenges both in vitro and in vivo.  
This study reports the first evidence of a link between expression of splicing 
regulator genes and strain lifespan in mice, together with data in support of 
potential roles for HNRNPA1 and HNRNPA2B1 in parental longevity in humans. 
We hypothesize that an influence of splicing factor expression on longevity may 
be mediated by slower immune ageing and a protection from malignancy in the 
young mice of long-lived strains by virtue of restricting expression of SR and 
hnRNP proteins which have oncogenic potential in young animals. Both of the 
splicing factor transcripts demonstrating reduced expression in the old long-lived 
mice belonged to the hnRNP class of splicing regulators, indicating that these 
mice may have less inhibition of splice site usage and be better able to maintain 
splicing, and therefore cellular plasticity into older age. The changes in splicing 
factor expression in the spleen are accompanied by changes in alternatively 
spliced genes indicative of reduced cell senescence, superior DNA repair and 
retained cellular proliferative capacity, and changes in splicing factor expression 
in muscle are indicative of lower pro-inflammatory signalling. Our data highlight 
the importance of regulation of mRNA processing in determination of lifespan and 
suggest that splicing factors may provide novel points of intervention for future 
therapies to reduce disease burden in old age. Moreover, since some of these 
strains (e.g. C57BL/6J, A/J) are commonly used for the creation and cross-
breeding of genetically modified mice, strain-specific alterations in alternative 
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splicing could account for unexpected contributions to the final phenotype arising 
from the genetic background. 
3.7 Experimental Procedures 
3.7.1 Mouse strains used for analysis 
Strains were chosen on the basis of differential lifespan (A/J, NOD.B10Sn-H2b/J, 
PWD.Phj, 129S1/SvlmJ, C57BL/6J and WSB/EiJ; see Table 3.2 for lifespan 
details) that were measured in a longitudinal study157-159 at Jackson Laboratory 
Nathan Shock Center of Excellence in the Basic Biology of Aging. Strains with 
extremely short lifespans (median lifespan less than 600 days) were excluded on 
the basis that a short lifespan may be associated with significant comorbidities. 
Characteristics of the mice and the numbers of animals used in each category 
are given in Table 3.2. All mice used in this study were male. All tissues were 
obtained from the mice of a cross-sectional study that was conducted at the same 
period of time and in the same mouse room with the longitudinal study. Animal 
housing conditions have been fully described previously157,159. Briefly, mice were 
fed ad libitum an autoclaved pellet diet with 6% fat and acidified water (pH 2.8–
3.1). Animals were kept on a 12:12-h light/dark cycle at 50% relative humidity at 
21–23 °C, in a restricted access specific pathogen-free barrier facility. Mice were 
housed four animals per pen in individually ventilated polycarbonate cages 
supplied with HEPA-filtered air and were tested quarterly for (and were free of) 
common viral, bacterial and mycoplasmal species. Mice were inspected daily and 
excluded if ill. At 6 or 20/22 months of age, mice were euthanized by CO2 
asphyxiation, followed by blood collection via cardiac puncture and cervical 
dislocation. A detailed description of the tissue collection procedure is given in 
Supplementary table S1. Immediately after death, spleen and quadriceps muscle 
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tissues were excised and snap-frozen in vapour-phase liquid nitrogen for storage 
within 5 min of collection. Tissues were stored at -80 °C. 
3.7.2 Splicing factor candidate genes for analysis 
An a priori list of splicing factor candidate genes were chosen on the basis that 
they were associated with human ageing in populations and in primary human 
cell lines that had undergone in vitro senescence in our previous work101,103. The 
list of genes included the positive regulatory splicing factors Srsf1, Srsf2, Srsf3, 
Srsf6, Srsf18 and Tra2b, the negative regulatory splicing inhibitors Hnrnpa0, 
Hnrnpa1, Hnrnpa2b1, Hnrnpd, Hnrnph3, Hnrnpk, Hnrnpm, Hnrnpul2 and the 
Sf3b1 subunit of the U2 spliceosome snRNP, which we have previously shown 
to be associated with age-related altered DNA methylation207. Assays were 
obtained in custom TaqMan low-density array (TLDA) format from Life 
Technologies (Foster City, CA, USA). Assay Identifiers are given in 
Supplementary table S2. 
3.7.3 Alternatively spliced target genes in spleen 
Genes were chosen for assessment of alternative splicing in spleen on the basis 
of potential roles in cellular senescence (Cdkn2a), cell cycle regulation (Trp53, 
Myc), extracellular matrix (Fn1, Vcan) or DNA damage response (Atm, Chek2), 
since these genes may also be important in determination of lifespan. We 
designed TaqMan quantitative real-time PCR assays to identify specific isoforms 
or groups of isoforms (if large numbers of common regions rendered the design 
of specific probes impossible). Assays were obtained in custom TaqMan low-
density array (TLDA) format from Life Technologies. Assay Identifiers are given 
in Supplementary data S2. A list of transcripts captured by each assay are given 
in Supplementary data S3.
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Table 3.2: Characteristics of mouse strains 
The mean lifespan and the maximum lifespan (20% longest lived) are given for each strain used in this study. All mice used in this study were male. Young mice were 
6 months old, and old mice were 20–22 months old. Muscle tissue was taken from the quadriceps. 
*Strain Max Age = the mean of the longest lived 20% within each strain. Data for median and maximum lifespans are given in Yuan et al. (2011) from a longitudinal 
study that was performed in conjunction with the cross-sectional study described in the present paper. 
 
Strain Strain Median lifespan (days) Strain Max Age (days)* Longevity class N Young N Old 
A/J 623 785 Average lifespan 
Spleen - 7 
Muscle - 8 
Spleen - 7 
Muscle - 7 
NOD.B10Sn-H2b/J 696 954 Average lifespan 
Spleen - 4 
Muscle - 4 
Spleen - 6 
Muscle - 6 
PWD/PhJ 813 956 Average lifespan 
Spleen - 5 
Muscle - 4 
Spleen - 6 
Muscle - 6 
129S1/SvlmJ 882 1044 Long-lived 
Spleen - 10 
Muscle - 4 
Spleen - 10 
Muscle - 10 
C57BL/6J 901 1061 Long-lived 
Spleen - 10 
Muscle - 10 
Spleen - 8 
Muscle - 9 
WSB/EiJ 1005 1213 Long-lived 
Spleen - 5 
Muscle - 5 
Spleen - 10 




3.7.4 Alternatively spliced target genes in muscle 
Genes were selected for analysis of alternative splicing in muscle on the basis of 
potential roles in inflammatory processes relating to muscle remodelling since we 
have shown in our previous work that these processes are key determinants of 
muscle strength in older humans208,209. Our gene list included isoforms of the Il1b, 
Il6, Nfkb1, Stat1 and Tnf genes. As above, TaqMan quantitative real-time PCR 
assays were designed to identify specific isoforms or groups of isoforms (if large 
numbers of common regions rendered the design of specific probes impossible). 
Assays were obtained in custom TaqMan low-density array (TLDA) format from 
Life Technologies. Assay Identifiers are given in Supplementary data S2. 
3.7.5 RNA extraction and reverse transcription 
Tissue samples were removed from storage and placed in 1 mL TRI Reagent® 
solution supplemented with the addition of 10 mM MgCl2 to aid recovery of 
microRNAs for future analysis165. Samples were then completely homogenized 
(15mins for spleen samples, 30mins for muscle samples) using a bead mill 
(Retsch Technology GmbH, Haan, Germany). Phase separation was carried out 
using chloroform. Total RNA was precipitated from the aqueous phase by means 
of an overnight incubation at -20 °C with isopropanol. RNA pellets were then 
ethanol-washed twice and resuspended in RNase-free dH2O. RNA quality and 
concentration was assessed by Nanodrop spectrophotometry (Wilmington, DE, 
USA). Complementary DNA (cDNA) was then reverse transcribed from 100 ng 
total RNA using the Invitrogen VILO cDNA synthesis kit (Life Technologies) in 20 
μL reactions according to manufacturer’s instructions. 
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3.7.6 Quantitative real-time PCR and data analysis 
Quantitative RT–PCRs were performed on the ABI 7900HT platform (Life 
Technologies) on the TaqMan low-density array (TLDA) platform. Cycling 
conditions were 50 °C for 2 min, 94.5 °C for 10 min and 50 cycles of 97 °C for 30 
s and 57.9 °C for 1 min. The reaction mixes included 50 μL TaqMan® Universal 
PCR Mastermix II (no AmpErase® UNG) (Life Technologies), 30 μL dH2O and 20 
μL cDNA template. 100 μL reaction solution was dispensed into the TLDA card 
chamber and centrifuged twice for 1 min at 216  g to ensure distribution of 
solution to each well. The expression of transcripts in each sample was measured 
in duplicate replicates. The comparative CT technique was used to calculate the 
expression of each test transcript210. Expression was assessed relative to the 
global mean of expression and normalized to the median level of expression for 
each individual transcript. Data were log-transformed to ensure normal 
distribution of data. Associations of transcript expression were assessed by linear 
regression against age, or lifespan as appropriate. Associations of transcript 
expression with mouse age were assessed in all animals and in animals of 
average-lived or long-lived strains individually, and associations of transcript 
expression with strain lifespan were assessed in all animals and in young and old 
groups individually. We also assessed the effect of potential nonlinearity of 
response for the splicing factor genes in spleen and muscle by a secondary 
analysis using binary logistic regression on data split by the median lifespan of 
all the strains. These statistical analyses were carried out using SPSS v.22 (IBM, 
North Castle, NY, USA). Interaction between strain longevity and mouse age was 
assessed using data categorized into average-lived or long-lived on the basis of 
interstrain median lifespan and was carried out in STATA v.14 (StataCorp, 
College Station, TX, USA). 
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3.7.7 Gene expression cluster analysis for heterogeneity of splicing factor 
expression with age 
The expression of each gene was z-transformed to be on the scale of standard 
deviations from the mean, and then the expression values for each gene were 
plotted against the corresponding sample to generate a heat map. Hierarchical 
clustering methods were used to group similar expression profiles together. This 
analysis was done using the ‘HEATMAP.2’ package in R statistical software 
package v3.1.1 (Vienna, Austria). 
3.7.8 Association between splicing factor expression and parental longevity in the 
InCHIANTI population 
The participants in the InCHIANTI study aged 65+ years were categorized based 
on the age at death of their parents, the parental longevity score (PLS). 
Participants (total n = 405) were classified as either ‘two short-lived parents’ (n = 
17), ‘one short- and one intermediate-lived parent’ (n = 140), ‘two intermediate-
lived parents’ (n = 190) or ‘any long-lived parents’ (n = 58). Short-, intermediate- 
and long-lived cut-offs were calculated separately for mothers and fathers based 
on the normal distribution of age at death in the cohort, as described in Dutta et 
al.188. The cut-offs for mothers were as follows: short-lived (49–72 years), 
intermediate-lived (72–95 years) and long-lived (> 95 years); mothers aged < 49 
years at death were classed as premature and excluded. The cut-offs for fathers 
were: short-lived (52–67 years), intermediate-lived (68–89 years) and long-lived 
(> 89 years); fathers aged < 52 years at death were classed as premature and 
excluded. 
To assess the association between the gene expression levels of the 15 splicing 
factor genes in whole blood as defined in our previous work103 and parental 
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longevity score, linear regression models were carried out using R statistical 
software package v3.1.1 (Vienna, Austria), with gene expression as the 
dependent variable. Models were adjusted for age, sex, waist circumference, 
highest education level attained, smoking (pack-years), study site, batches and 
cell counts (neutrophils, monocytes, basophils, eosinophils and whole white 
blood cell count). Gene expression data were rank-normalized prior to analysis 
to remove any skew. 
3.7.9 Bioinformatic assessment of potential regulatory effects of genetic variation 
within Hnrnpa2b1 and Hnrnpa1 genes 
To assess the potential for genetic variation to contribute to splicing factor 
expression differences that we observe between strains, we have carried out a 
detailed examination of the strain-discordant genetic differences in the splicing 
factor genes Hnrnpa2b1 and Hnrnpa1, which demonstrate links with longevity in 
both mouse and man. Complete genome sequence data were available for 4 of 
the strains we have used in our analysis (C57BL/6J, 129S1/SvImJ, A/J and 
WSB/EiJ). SNPs discordant between strains were examined for evidence of 
effects on gene regulation by a variety of bioinformatic approaches. Firstly, SNPs 
located in the 5’ UTR of the Hnrnpa2b1 or Hnrnpa1 genes were assessed for 
position relative to known transcription factor binding sites using REGRNA2.0 
(http://regrna2.mbc.nctu.edu.tw/), an integrated web server tool that allows 
screening for potential regulatory elements. Secondly, intronic SNPs were 
assessed for their ability to interrupt exon and intron splicing enhancer and 
silencer loci using REGRNA2.0 and ESEFINDER (http://rulai.cshl.edu/cgi-
bin/tools/ESE3/esefinder.cgi?process=home), a specific tool for the identification 
of splicing regulatory elements. Finally, sequences in the 3’ untranslated region 
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were screened for ability to disrupt elements with potential to disrupt elements 
important for mRNA stability (A-rich elements, C to U RNA editing sites and 
miRNA binding sites) using REGRNA2.0. 
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MicroRNAs (miRNAs) are small non-coding RNA species that have been shown 
to have roles in multiple processes that occur in higher eukaryotes. They act by 
binding to specific sequences in the 3’ untranslated region of their target genes 
and causing the transcripts to be degraded by the RNA-induced silencing 
complex (RISC). MicroRNAs have previously been reported to demonstrate 
altered expression in several ageing phenotypes such as cellular senescence 
and age itself. Here, we have measured the expression levels of 521 small 
regulatory microRNAs (miRNAs) in spleen tissue from young and old animals of 
6 mouse strains with different median strain lifespans by quantitative real-time 
PCR. Expression levels of 3 microRNAs were robustly associated with strain 
lifespan, after correction for multiple statistical testing (miR-203-3p [β-
coefficient = −0.6447, p = 4.8  10−11], miR-664-3p [β-coefficient = 0.5552, 
p = 5.1  10−8] and miR-708-5p [β-coefficient = 0.4986, p = 1.6  10−6]). Pathway 
analysis of binding sites for these three microRNAs revealed enrichment of target 
genes involved in key ageing and longevity pathways including mTOR, FOXO 
and MAPK, most of which also demonstrated associations with longevity. Our 
results suggest that miR-203-3p, miR-664-3p and miR-708-5p may be implicated 





Although lifestyle and environmental factors are the major influences on lifespan, 
inherited factors remain important, with approximately 25% of the variation in 
lifespan attributable to genetics211,212. This is reflected in the observation that 
children of longer-lived parents have lower levels of age-related disease, lower 
all-cause mortality and greater life expectancy than those with shorter-lived 
parents188,194. In addition to the contribution of ‘conventional’ genetics, there is 
increasing evidence that epigenetic factors such as DNA methylation, histone 
modifications, and fine tuning of gene expression by small non-coding RNA 
regulators such as microRNAs (miRNAs) may also contribute significantly to 
ageing and longevity213,214. 
MicroRNAs (miRNAs) are short, non-coding RNAs that regulate mRNA 
expression215. Targets are recognized by virtue of sequence complementarity 
between specific sequences in the 3’ untranslated region (3’ UTR) of mRNA 
transcripts. Once bound, miRNAs act to either repress translation of the mRNA 
or target it for degradation. A single miRNA can target multiple mRNAs and many 
mRNAs have multiple miRNA binding sites in their 3’ UTR140. In this manner, 
miRNAs have the capacity to regulate complex networks such as those 
implicated in ageing and longevity141. Several of the ‘hallmarks’ of ageing94 
including cellular senescence and genomic instability have been shown to be 
associated with multiple miRNAs216. Moreover, in several cases, individual 
miRNAs (or families of miRNAs) are associated with more than one of these 
processes216. Nevertheless, while several studies have implicated miRNAs in 
prediction of lifespan in C. elegans217-219, less is known about their potential role 
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in mammalian lifespan. Identification of determinants of longevity is a key aim in 
identifying biomarkers of healthy ageing. 
Inbred strains of mice, with very well defined phenotypic characteristics and fully 
characterized genetics have proved a useful tool in understanding complex 
phenotypes such as ageing104,157,158. In the present study, we assessed the 
potential role of miRNAs in longevity using spleen tissue from 6 inbred strains of 
mice of different median strain lifespans104,157,158. These mice have median strain 
lifespans ranging from 623 days to 1005 days and as a result we have previously 
used them for our studies of the factors influencing lifespan104,187. We carried out 
a high-throughput screen of 521 miRNAs in the young animals of the 2 strains at 
the extremes of the lifespan range, to identify candidate miRNAs associated with 
longer lifespan. We then tested for associations between median strain lifespan 
and the expression of the emerging miRNAs in young and old mice of all 6 strains, 
to determine whether these were robust associations. We found that 3 miRNAs, 
miR-203-3p, miR-664-3p and miR-708-5p, were all associated with lifespan in 
these mice. Subsequent bioinformatic analyses of pathways predicted to be 
targeted by these miRNAs included several that are known to be involved in 
determining lifespan e.g. FoxO220, mTOR221 and stem cell pluripotency pathways. 
Furthermore, genes predicted to be targeted by these miRNAs also show 
evidence of associations with median strain longevity. Our results suggest that 
differential regulation of key ageing and longevity pathways by miRNAs may 





4.5.1 High-throughput MicroRNA Arrays 
We carried out a near-global, high throughput screen of expression of 521 
miRNAs in spleen samples of young animals culled at 6 months of age from the 
2 mouse strains from our collection showing the most marked divergence in 
lifespan (A/J; 623 days and WSB/EiJ; 1005 days) by qRT-PCR using TaqMan® 
MicroRNA Array cards. 279 miRNAs were found to be expressed above the limit 
of detection and of these, 5 (miR-297b-5p, miR-708-5p, miR-224-5p, miR-203-3p 
and miR-327) were shown to be differentially expressed between average-lived 
and long-lived strains after correction for multiple testing (significance cutoff: 
p <0.0002). Five additional miRNAs (miR-664-3p, miR-592-5p, miR-484, miR-
687 and miR-192-5p) showed expression differences which were close to 
significance (significance cut-off: p <0.002). The results for these 10 miRNAs are 





Table 4.1: MicroRNAs with strongest association between expression and 
lifespan in spleen tissue from young mice of shortest-lived and longest-
lived strains (A/J and WSB/EiJ respectively) 
MicroRNAs significantly associated below the Bonferroni-corrected significance threshold 
(p <0.0002) are shown in bold italics. The ten most strongly associated microRNAs followed up 
in the targeted analysis are shown in italics. P-values were determined using independent sample 
t-tests on log-transformed relative expression data from TaqMan® MicroRNA Array cards. 
 
MicroRNA Assay ID Mean Difference 
95% CI of the difference 
p-value 
Upper Lower 
mmu-miR-297b-5p 4.29 4.53 4.05 1.64x10-11 
mmu-miR-708 0.47 0.59 0.36 5.80x10-6 
mmu-miR-224 -0.97 -0.63 -1.30 0.0001 
mmu-miR-203 -0.55 -0.35 -0.75 0.0002 
rno-miR-327 -3.70 -2.33 -5.07 0.0002 
mmu-miR-664 0.46 0.66 0.27 0.0005 
mmu-miR-592 0.50 0.73 0.27 0.0008 
mmu-miR-484 0.33 0.49 0.17 0.001 
mmu-miR-687 5.02 7.58 2.46 0.002 
mmu-miR-192 0.31 0.47 0.15 0.002 
 
 
4.5.2 Targeted microRNA Expression 
We then measured the expression levels of the 10 miRNAs demonstrating 
significant or near significant associations with median strain lifespan in spleen 
samples from both young and old animals of all 6 mouse strains. We found that 
3 miRNAs; miR-203-3p, miR-664-3p and miR-708-5p were associated with 
median strain lifespan (Supplementary table S14). These 3 miRNAs were also 
associated with strain median lifespan in a replication sub analysis excluding all 
animals included in the discovery analysis (Supplementary table S15). Analysis 
of expression in relation to age of the animals revealed that miR-203-3p was not 
significantly associated with age whereas both miR664-3p and miR-708-5p were 
positively associated (see Supplementary table S16). This finding led us to 
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perform an analysis to detect interactions between miRNA expression, age, and 
median strain lifespan, results of which are given in Supplementary table S17. 
MicroRNA miR-203-3p showed significantly reduced expression in both young 
and old animals of strains of longer lifespan when considered separately, as well 
as in the analysis of old and young animals of different median strain lifespans 
combined, after correction for multiple testing (β-coefficients = −0.64, −0.67 and 
−0.67; p = 4.78  10−11, 3.60  10−6 and 4.74  10−7 for all, young and old analyses 
respectively, see Supplementary table S14 and Figure 4.1a-c). Interaction 
analysis revealed no significant difference between young and old animals of 
average-lifespan strains (β-coefficient = −0.05; SE = 0.08; p = 0.55, see 
Supplementary table S17 and Figure 4.2). However, significant expression 
differences were seen between strains of average lifespan and long lifespan, with 
the most marked differences occurring in the young animals of long-lived strains 
(β-coefficient = −0.29; SE = 0.08; p = 0.004 compared with β-coefficient = −0.17; 
SE = 0.08; p = 0.03 in the old animals of long-lived strains, see Supplementary 
table S17 and Figure 4.2). 
Conversely, miR-664-3p demonstrated increased expression in strains of longer 
lifespan in both old and young animals, after correction for multiple testing (β-
coefficient = 0.56, p = 5.12  10−8, see Supplementary table S14 and Figure 4.1d). 
When expression was analyzed in young animals only, a trend was observed but 
this did not meet multiple testing criteria (β-coefficient = 0.42, p = 0.008, see 
Supplementary table S14 and Figure 4.1e) while in the analysis of old animals 
only, a significant association with lifespan was seen (β-coefficient = 0.75, 
p = 3.93  10−9, see Supplementary table S14 and Figure 4.1f). Analysis of strain 
lifespan and age interactions for miR-664-3p showed significant differences in 
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expression between young and old animals of average lifespan (β-
coefficient = 0.15; p = 0.04, see Supplementary table S17 and Figure 4.2). 
Significant differences were also apparent when comparing expression of miR-
664-3p between strains of average lifespan and long lifespan, although the effect 
was much more marked in the old animals of long-lived strains (β-
coefficient = 0.18; p = 0.01 in young long-lived animals compared with β-
coefficient = 0.46; p = 6.59  10−10, see Supplementary table S17 and Figure 4.2). 
MicroRNA miR-708-5p also showed increased expression in strains of longer 
lifespan in the combined analysis of old and young animals, after correction for 
multiple testing (β-coefficient = 0.50; p = 1.61  10−6, see Supplementary table 
S14 and Figure 4.1g). Again, when expression was analyzed in young animals 
only, a trend was observed that did not meet multiple testing criteria (β-
coefficient = 0.36; p = 0.02, see Supplementary table S14 and Figure 4.1h) while 
the analysis of old animals only showed a significant association with lifespan (β-
coefficient = 0.64, p = 2.70  10−6, see Supplementary table S14 and Figure 4.1i). 
Interaction analysis for miR-708-5p showed no significant difference in 
expression between young and old animals of average lifespan (β-
coefficient = 0.12; p = 0.33, see Supplementary table S17 and Figure 4.2). 
Significant differences were observed between average-lived and long-lived 
strains, but these were only present in the old animals (β-coefficient = 0.08; 
p = 0.49 in young long-lived animals compared with β-coefficient = 0.31; p = 0.007 







Figure 4.1: MicroRNA expression against lifespan as measured in targeted 
assessment of all available mouse strains 
Box-and-whisker plots of relative microRNA expression for the 3 microRNAs found to be 
significantly associated with strain lifespan in the targeted assessment. Strains and median 
lifespan in days are given on the x-axis, while the y-axis shows mean log-transformed relative 
expression. Dark grey boxes show data for all mice analyzed, mid-grey boxes show data for 
young mice only and light grey boxes show data for old mice only. (a,b and c) expression data 







Figure 4.2: Longevity:Age interactions for microRNAs significantly 
associated with strain lifespan 
This graph shows the relative expression changes in all mouse strains, categorized based on 
whether the median individual strain lifespan was above or below the median lifespan calculated 
across all strains, with ‘Average-lived’ being <847.5 days and ‘Long-lived’ >847.5 days. Young 
mice are 6 months and old mice are 20–22 months old. All changes are shown in relation to the 
young animals of the average-lived strains. Average-lived/old mice are shown in light grey, long-
lived/young in mid-grey and long-lived/old animals in dark grey. Error bars denote the 95% 




4.5.3 Pathways Analysis 
The lifespan effects of miR-203-3p, miR-664-3p and miR-708-5p are probably 
mediated by altered regulation of their target genes. We therefore used a gene 
set enrichment bioinformatic prediction approach specialized for miRNA 
targets222 to determine the biochemical and functional pathways that are enriched 
for genes targeted by the 3 microRNAs significantly associated with strain 
lifespan. We identified 15 pathways that were predicted to be enriched in miR-
203-3p, miR-664-3p or miR-708-5p target genes, many of which are known to be 
associated with ageing or longevity (see Table 4.2). Prominent pathways targeted 
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by all 3 miRNAs include the ‘FoxO signalling pathway (mmu04068)’ and ‘mTOR 
signalling pathway (mmu04150)’, which contain 16 and 11 genes with predicted 
miR-203-3p, miR-664-3p and miR-708-5p binding sites (FDR-adjusted p-
values = 0.02 and 0.01 respectively). Also predicted to be enriched for miR-203-
3p, miR-664-3p and miR-708-5p binding sites are the ‘Pathways in cancer 
(mmu05200)’ pathway, the ‘MAPK signalling pathway (mmu04010), the 
‘signalling pathways regulating pluripotency of stem cells (mmu04550)’ pathway 
and the ‘TGF-beta signalling pathway (mmu04350)’, with 33, 26, 14 and 10 genes 
targeted respectively (FDR-adjusted p-values = 0.03, 0.005, 0.05 and 0.0001 
respectively). To provide empirical evidence that the genes identified to lie within 
these pathways also showed associations with longevity, we characterized the 
expression of selected target genes in relation to median strain lifespan. We 
identified that the 7/9 of these target genes were indeed associated with longevity 




Table 4.2: Pathways affected by longevity-associated microRNAs 
DIANA-mirPath v3.0 software222 was used to determine pathways targeted by the microRNAs 
associated with strain lifespan, using predicted targets from the DIANA-microT-CDS v5.0 
algorithm. Pathways are listed in order of the number of genes which are predicted to interact 
with these microRNAs. 
 






Pathways in cancer (mmu05200) 0.03 33 3 
MAPK signalling pathway (mmu04010) 0.005 26 3 
FoxO signalling pathway (mmu04068) 0.016 16 3 
Transcriptional misregulation in cancer 
(mmu05202) 
0.03 15 3 
Signalling pathways regulating pluripotency of 
stem cells (mmu04550) 
0.05 14 3 
Thyroid hormone signalling pathway 
(mmu04919) 
0.002 12 2 
mTOR signalling pathway (mmu04150) 0.01 11 3 
Long-term potentiation (mmu04720) 0.01 11 3 
TGF-beta signalling pathway (mmu04350) 0.0001 10 3 
Long-term depression (mmu04730) 0.002 10 2 
Chronic myeloid leukaemia (mmu05220) 0.02 9 3 
Amphetamine addiction (mmu05031) 0.02 8 2 
Thyroid hormone synthesis (mmu04918) 0.0004 6 3 
ECM-receptor interaction (mmu04512) 0.023 6 2 
Glycosphingolipid biosynthesis - lacto and 
neolacto series (mmu00601) 
1.46x10-9 4 2 
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Table 4.3: Association of predicted target mRNA expression and lifespan in mouse spleen tissue across 6 strains of different 
longevities 
Data from mice of all ages, young mice only (6 months) and old mice only (20–22 months) are given separately. For each gene, the associated pathway is given, along 
with the microRNA predicted to target the transcript. mRNAs significantly associated below the significance threshold (p < 0.05) are shown in bold italics. P-values 


























Signalling pathways regulating 
pluripotency of stem cells (mmu04550) 
mmu-miR-664-3p -0.12 0.00 0.26 -0.38 0.00 0.01 0.19 0.00 0.19 
Dusp5 MAPK signalling pathway (mmu04010) mmu-miR-203-3p -0.17 0.00 0.11 -0.37 0.00 0.02 0.03 0.00 0.84 
Fgf7 
Pathways in cancer (mmu05200) 
mmu-miR-664-3p -0.08 0.00 0.48 -0.24 0.00 0.14 0.11 0.00 0.45 
MAPK signalling pathway (mmu04010) 
Gabarapl1 FoxO signalling pathway (mmu04068) mmu-miR-203-3p -0.12 0.00 0.26 -0.48 0.00 0.001 0.29 0.00 0.05 
Mmp9 Pathways in cancer (mmu05200) mmu-miR-664-3p 0.45 0.00 <0.001 0.35 0.00 0.02 0.59 0.00 <0.001 
Pten 
FoxO signalling pathway (mmu04068) 
mmu-miR-664-3p 0.18 0.00 0.09 -0.17 0.00 0.29 0.40 0.00 0.004 mTOR signalling pathway (mmu04150) 
Pathways in cancer (mmu05200) 
Rps6ka3 
mTOR signalling pathway (mmu04150) 
mmu-miR-664-3p 0.07 0.00 0.54 -0.16 0.00 0.31 0.31 0.00 0.03 
MAPK signalling pathway (mmu04010) 
Smad4 
Pathways in cancer (mmu05200) 
mmu-miR-664-3p -0.36 0.00 <0.001 -0.38 0.00 0.02 -0.41 0.00 0.004 
FoxO signalling pathway (mmu04068) 
Signalling pathways regulating 
pluripotency of stem cells (mmu04550) 
Zfhx3 
Signalling pathways regulating 
pluripotency of stem cells (mmu04550) 
mmu-miR-664-3p 





Even once the effects of lifestyle and environment are considered, conventional 
genetics cannot account for all of the variation in mammalian lifespan and other 
factors, such as epigenetic regulation of key genes, have also been suggested to 
play a role. Here we show that three miRNAs; miR-203-3p, miR-664-3p and miR-
708-5p, are significantly associated with strain lifespan in mouse spleen. 
The expression of miR-203-3p was negatively correlated with longer lifespan. 
Although effects were seen in both young and old animals of long-lived strains, 
the most marked effects were noted in the young animals, suggesting that 
modulated expression of this miRNA may be a determining factor in longevity 
rather than simply a consequence of advancing age. Elevated levels of miR-203-
3p have previously been shown to suppress “stemness” in mouse keratinocytes 
with several studies finding that higher levels of miR-203-3p expression promote 
terminal differentiation, repress proliferation and induce senescence in human 
melanoma cells223-225. This microRNA has also been shown to be up-regulated in 
senescence in human in vitro models using WI-38 human diploid fibroblast 
cells226 and human melanoma cells227. The p63 and caveolin genes are known 
to be targets of miR-203-3p228. p63 is a member of the p53 family of transcription 
factors and the absence of expression of one of its isoforms, TAp63, has been 
shown to lead to senescence and premature ageing of epidermal and dermal 
precursors229. Caveolin is thought to have a tumor-suppressor function at early 
stages of malignant transformation230, to contribute to immune senescence231 
and the ability of aged cells to respond to oxidative stress232. Our finding of 
reduced miR-203-3p expression in long-lived mouse strains may be indicative of 
a phenotype in which cells have greater proliferative and adaptive capacity 
152 
 
alongside a reduced propensity to become senescent, all of which could create 
favorable conditions for increased longevity. miR-203 was also one of the 
miRNAs demonstrated to be inversely associated with lifespan in a longitudinal 
study of human serum samples from the Baltimore Longitudinal Study of Aging 
(BLSA)233. 
Conversely, expression of miR-664-3p showed a positive correlation with longer 
lifespan in our data. In contrast to miR-203-3p, the changes we noted were most 
evident in the old animals of the long-lived strains, suggesting that increased 
expression of miR-664-3p may be a later life effect on longevity. In comparison 
with miR-203-3p, miR-664-3p has not been extensively studied, with conflicting 
conclusions having been drawn by different research groups. It has been linked 
to both pro- and anti-proliferative action in different tumor types234,235, which 
complicates any attempts at prediction of putative function in terms of longevity. 
However, elevated hsa-miR-664 expression has been noted in human blood 
samples from nonagenarians and centenarians compared with samples from 
younger individuals236, indicating that in human populations, the expression of 
this miRNA also correlates with longevity. 
MicroRNA miR-708-5p was also positively correlated with longer lifespan. Again, 
the changes we noted were most evident in the old animals of the long-lived 
strains, suggesting that increased expression of miR-708-5p may also be a later 
life effect on longevity. In human cells, hsa-miR-708 has been shown to have a 
tumor-suppressor function in several human cancer types237-239. Reduced 
expression of hsa-miR-708 expression has also been seen in blood taken from 
old individuals in comparison to young individuals240. In our data, elevated, rather 
than decreased miR-708-5p expression was found to be associated with longer 
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lifespan. This may be partially explained if the effects on miR-708-5p expression 
reflect a balance between protection from malignancy and maintained 
proliferative capacity. 
The effects of altered miRNA expression on median strain lifespan will be 
mediated by altered regulation of their target genes. Gene set enrichment 
analysis using the DIANA miRPath webtool222 reveals 15 pathways that are 
enriched for miR-203-3p, miR-664-3p and miR-708-5p target genes. The 
expression of the majority of the genes enriched for longevity-associated miRNA 
binding sites also demonstrated associations with longevity (Table 4.3). Although 
not all of these relationships were entirely straightforward in terms of the direction 
of effect one would predict based on expression differences of the specific 
miRNAs, this is to be expected, since transcripts will be targeted by many 
miRNAs in addition to the one tested, and several of our candidates are targeted 
by multiple miRNAs, often with antagonistic relationships with longevity. For 
example, Zfhx3, in the ‘pluripotency of stem cells’ pathway is targeted by both 
mmu-miR-203-3p and mmu-664-3p, one of which is negatively associated with 
lifespan and the other positively. MicroRNAs have also been previously reported 
to be associated with both positive and negative associations with the expression 
of their target genes241. 
Most notable amongst the pathways we found were FoxO signalling, mTOR, 
MAPK signaling, pathways regulating pluripotency of stem cells, TGF-beta 
signaling and pathways involved in cancer. FoxO is well known to be involved in 
the regulation of lifespan, with strong evidence that alterations in proteins in this 
pathway can radically increase lifespan in several model organisms as well as 
humans, while mTOR inhibition has also been shown to increase lifespan in 
154 
 
several species, from yeast to mice242. The observation that many of the 
pathways implicated contain genes that are known to control shared outcomes 
such as apoptosis, cell cycle regulation, differentiation, proliferation, cell survival, 
autophagy and DNA repair adds strength to the hypothesis that miR-203-3p, miR-
664-3p and miR-708-5p may have functionality in terms of longevity. Our group 
has previously shown that other aspects of RNA processing and regulation are 
important in ageing and longevity in humans, in animal models and in 
vitro101,103,104. The results of the present study provide further evidence that post-
transcriptional control of mRNA expression is a key factor in the ageing process 
and determination of lifespan. 
The use of mouse tissues from very well characterized inbred strains is a strength 
of our study and allows us to be precise about the genetics and phenotypes 
associated with each strain, and allows assessment of median strain lifespan with 
some confidence. Spleen is an appropriate tissue for analysis, given the known 
role of the immune system and inflammation as drivers of ageing193. However, 
our study cannot comment on the potential tissue-specificity of the effects we 
have seen and may not be representative of mechanism elsewhere in the 
organism. We also recognize that there are both strain-specific and age-related 
differences in the cellular composition of the spleen. While strain differences in 
the cell types found in mouse spleen are apparent, the kinetics of change of cell 
composition with age are similar at different stages of life in separate mouse 
strains where this has been measured243. It must also be mentioned that there is 
a relatively large amount of inter-individual cell-type variation, in some cases 
more pronounced than the inter-strain variability243,244. Unfortunately, data on 
splenic cellular composition for the strains used in this paper are not available, 
however while we cannot definitively state that all of our findings are not linked to 
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age-related cell-type changes in the splenic make-up, the associations that are 
present only in the young mice are far less likely to be influenced by such 
changes. Our use of a wide-spectrum discovery phase in a limited sample set, 
followed by targeted validation and replication of results in a larger inclusive 
cohort ensures robust results, but we recognize that for some of the mouse 
strains analyzed, low numbers of samples may have affected the statistical power 
to detect more subtle changes. The use of pathways analysis also allows a larger 
‘systems’-based assessment of the effects of deregulation of modules of miRNAs 
in determination of longevity. Of course, it must be recognized that these results 
are from an in silico predictive algorithm and are not necessarily indicative of 
actual interactions in vivo or in vitro. Finally, it is possible that the effects we see 
may derive from differences between the strains unrelated to longevity. However, 
evidence suggests that there are links between both miR-664-3p and miR-203-
3p and lifespan in human studies233,236, suggesting that unrelated strain 
differences alone probably do not account for our observations, at least for these 
microRNAs. 
In conclusion, we present evidence that three miRNAs, miR-203-3p, miR-664-3p 
and miR-708-5p are robustly associated with median strain lifespan in 6 well-
characterized inbred strains of mice, and that both early life (miR-203-3p) and 
later life (miR-664-3p and miR-708-5p) changes in their expression may 
modulate the expression of target genes in several very well-known ageing and 
longevity pathways. These studies demonstrate the importance of miRNAs in 
determination of mammalian longevity and raise the possibility that they may 





4.7.1 Mouse tissue used in the study 
Samples of spleen tissue were obtained from mice of six strains (A/J, 
NOD.B10Sn-H2b/J, PWD/PhJ, 129S1/SvImJ, C57BL/6J and WSB/EiJ), selected 
for having variable life expectancy (see Table 4.4 for details of lifespan, numbers 
of animals used in each category and their respective characteristics). Median 
lifespan was measured in a longitudinal study157,159 at Jackson Laboratory 
Nathan Shock Center of Excellence in the Basic Biology of Aging. All tissues used 
in the present study were taken from male animals which were part of a cross 
sectional study being run at the same time, in the same mouse room as the 
longitudinal study mentioned above. All experiments were carried out in 
accordance with National Institutes of Health Laboratory Animal Care Guidelines 
and was approved by the Animal Care and Use Committee (ACUC) of The 
Jackson Laboratory. Details of mouse strains used and animal husbandry have 
been previously published104. Spleen tissue was excised immediately after death, 
placed into RNA-later storage solution (Sigma-Aldrich, St. Louis, MO, USA) and 





Table 4.4: Mouse strains and characteristics 
Median lifespan and maximum age (average of longest-surviving 20% of animals) are given for 










n Young    
(6 
months) 
n Old         
(20/22 
months) 













129S1/SvlmJ 882 1044 Long-lived 8 8 
C57BL/6J 901 1061 Long-lived 10 9 
WSB/EiJ 1005 1213 Long-lived 5 10 
 
 
4.7.2 MicroRNA candidate transcripts for analysis 
To determine which microRNA transcripts to assess for association with 
longevity, an initial high-throughput array analysis was performed to measure the 
expression of a wide spectrum of microRNAs. In an attempt to ensure the best 
possible chance of detecting differences with lifespan, the arrays were run using 
all available samples from young animals (sacrificed at 6 months old) of A/J and 
WSB/EiJ, the two strains at either extreme of lifespan (623 days for A/J and 1005 
days for WSB/EiJ). The top 10 most significantly associated microRNAs from this 
analysis were followed up with targeted microRNA expression experiments in old 
and young animals from all 6 strains. 
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4.7.3 RNA Extraction 
Tissue samples were removed from RNA-later storage solution and placed in 
1 mL TRI Reagent® Solution (Thermo Fisher, Waltham, MA, USA) supplemented 
with the addition of 10 mM MgCl2 to aid recovery of microRNAs165. Samples were 
then completely homogenized for 15 mins in a bead mill (Retsch Technology 
GmbH, Haan, Germany). Phase separation was carried out using chloroform. 
Total RNA was precipitated from the aqueous phase by means of an overnight 
incubation at −20 °C with isopropanol. RNA pellets were then ethanol-washed 
twice and re-suspended in RNase-free dH2O. RNA quality and concentration was 
assessed by NanoDrop spectrophotometry (NanoDrop, Wilmington, DE, USA). 
4.7.4 High-throughput MicroRNA Arrays 
MegaPlex Reverse Transcription 400ng of RNA per reaction was reverse 
transcribed using the TaqMan® MicroRNA Reverse Transcription Kit and 
Megaplex™ RT Primers, Rodent Pool Set v3.0 (Thermo Fisher, Waltham, MA, 
USA) in separate reactions for Pool A and Pool B, according to the 
manufacturer’s instructions. 
MicroRNA Array qRT-PCR Expression of a wide spectrum of microRNAs was 
measured using Quantitative RT-PCR, performed on the ABI 7900HT platform 
(Thermo Fisher, Waltham, MA, USA), using both TaqMan® Rodent MicroRNA A 
Array v2.0 and TaqMan® Rodent MicroRNA Array B cards (Thermo Fisher, 
Waltham, MA, USA). Supplementary table S18 lists the 521 unique microRNAs 
tested using this approach. Reaction mixes included 415 μl Taqman® Universal 
PCR Master Mix II (no AmpErase® UNG) (Thermo Fisher, Waltham, MA, USA), 
407.5 μl dH2O and 7.5 μl cDNA template from Pool A or Pool B Megaplex™ 
reverse transcriptions as appropriate. 100 μl of reaction solution for each sample 
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was dispensed into all chambers of an array card (again, A or B accordingly), 
then centrifuged twice for 1 minute at 1000 rpm to ensure distribution of solution 
to each well. Amplification conditions were 50 °C for 2 minutes, 94.5 °C for 
10 minutes, followed by 50 cycles of 97 °C for 30 seconds and 57.9 °C for 
1 minute. 
4.7.5 Targeted MicroRNA Expression 
Multiplex Reverse Transcription 60 ng of RNA per reaction was reverse 
transcribed using the TaqMan® MicroRNA Reverse Transcription Kit and RT 
primers provided with the TaqMan® MicroRNA Assays detailed in Supplementary 
table S19 (Thermo Fisher, Waltham, MA, USA). Each reaction contained 1 μl 
each of all the RT primers of the microRNAs to be analyzed, 10 mM dNTPs (with 
dTTP), 100 U MultiScribe™ Reverse Transcriptase, 1X Reverse Transcription 
Buffer, 7.6U RNase Inhibitor and dH2O to a final volume of 30 μl. The thermal 
profile for the reactions was 16 °C for 30 minutes, 42 °C for 30 minutes, 85 °C for 
5 minutes and a final hold at 4 °C. 
Individual microRNA qRT-PCR MicroRNA expression was measured using 
Quantitative RT-PCR, performed on the ABI 7900HT platform (Thermo Fisher, 
Waltham, MA, USA), using the TaqMan® MicroRNA Assays detailed in 
Supplementary table S19 (Thermo Fisher, Waltham, MA, USA). Reactions were 
run in triplicate on 384-well plates, using one assay per plate containing all 
samples. Each reaction included 2.5 μl TaqMan® Universal Master Mix II (no 
AmpErase® UNG) and 0.25 μl TaqMan® MicroRNA Assay (Thermo Fisher, 
Waltham, MA, USA), 0.5 μl cDNA (multiplex reverse transcribed as indicated 
above) and dH2O to a final volume of 5 μl. Amplification conditions were a single 
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cycle of 95 °C for 10 minutes, followed by 50 cycles of 95 °C for 15 seconds and 
60 °C for 1 minute. 
4.7.6 Interaction analysis 
Analyses of interactions between mouse age and strain longevity were carried 
out for the three significantly associated microRNAs using data categorized 
based on whether the median individual strain lifespan was above or below the 
median lifespan calculated across all strains, with ‘average-lived’ being <847.5 
days and ‘long-lived’ >847.5 days (see Table 4.4 for details). Interaction terms for 
the relationship between age and median strain longevity were included. 
Analyses were carried out in STATA 14 (StataCorp, College Station, TX, USA). 
4.7.7 Pathway analysis 
Pathway analysis was carried out with DIANA-miRPath v3.0222, using predicted 
microRNA targets from the DIANA-microT-CDS v5.0 algorithm245 and Gene 
Ontology genesets derived from KEGG. The p-value threshold was set to 0.05 
and MicroT threshold to 0.8. 
4.7.8 Predicted target mRNA candidates for analysis 
Target genes for validation were selected based on the MiTG scores taken from 
the DIANA-microT-CDS v5.0 algorithm245. We elected to assess the two genes 
with the highest MiTG score from each of the three pathways with the highest 
numbers of genes predicted to be targeted by the microRNAs in question; 
‘Pathways in cancer’ (mmu05200), ‘MAPK signalling pathway’ (mmu04010) and 
‘FoxO signalling pathway’ (mmu04068). We also decided to assess the two 
genes with the highest MiTG score from the ‘mTOR signalling pathway’ 
(mmu04150) and ‘Signalling pathways regulating pluripotency of stem cells’ 
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(mmu04550), as these were likely to be of interest in relation to lifespan. One 
other gene was picked (Smad4), as it is the only one to be present in 3 of the 5 
pathways we had elected to pursue and is also present in 5 of the 15 pathways 
identified from DIANA-miRPath222. 
4.7.9 Predicted Target mRNA Expression 
Reverse Transcription 200 ng of RNA per reaction was reverse transcribed 
using the SuperScript® VILO™ cDNA Synthesis Kit (Thermo Fisher, Waltham, 
MA, USA) in 20 μl reactions, according to the manufacturer’s instructions. Each 
cDNA was then diluted with 10 μl of water to give sufficient volume to carry out 
the necessary qPCR reactions. 
Predicted target mRNA qRT-PCR Predicted target mRNA expression was 
measured using Quantitative RT-PCR, performed on the QuantStudio 12 K Flex 
platform (Thermo Fisher, Waltham, MA, USA), using the TaqMan® Gene 
Expression Assays detailed in Supplementary table S20 (Thermo Fisher, 
Waltham, MA, USA). Reactions were run in triplicate on 384-well plates, using 
one assay per plate containing all samples. Each reaction included 2.5 μl 
TaqMan® Universal Master Mix II (no AmpErase® UNG) and 0.25 μl TaqMan® 
Gene Expression Assay (Thermo Fisher, Waltham, MA, USA), 0.5 μl cDNA 
(reverse transcribed as indicated above) and dH2O to a final volume of 5 μl. 
Amplification conditions were a single cycle of 95 °C for 10 minutes, followed by 
40 cycles of 95 °C for 15 seconds and 60 °C for 1 minute. 
4.7.10 Relative quantification 
In all experiments described here, the ∆∆Ct method was used to calculate relative 
expression levels of the microRNAs tested210. Expression was assessed relative 
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to the global mean of the 279 expressed microRNAs and normalized to the mean 
level of expression of each individual transcript in the shorter lifespan animals 
(A/J) for the high-throughput microRNA arrays. Data were log transformed to 
ensure normal distribution and differences in expression were tested with 
independent t-tests, using SPSS v22 (IBM, North Castle, NY, USA). For the 
targeted microRNA experiments, expression was assessed relative to the mean 
expression of three endogenous control small RNA species (snoRNA202, U6 
snRNA and U87 snRNA) and normalized to the median level of expression for 
each individual transcript across all samples. Data were log10 transformed to 
ensure normal distribution. For the predicted target mRNA experiments, 
expression was assessed relative to the mean expression of two endogenous 
control genes (Gusb and Idh3b) and normalized to the median level of expression 
for each individual transcript across all samples. Data were log10 transformed to 
ensure normal distribution. 
4.7.11 Statistical approach 
Associations between both miRNA and mRNA target expression and median 
strain lifespan were assessed using linear regression. The relationships between 
these parameters were assessed in both young and old animals of all 6 strains. 
We also assessed the relationship between median strain lifespan and miRNA 
expression in the animals not originally tested in the global analysis, to comprise 
an independent replication. Regressions were carried out using SPSS v22 (IBM, 
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Dietary restriction (DR) represents one of the most reproducible interventions to 
extend lifespan and improve health outcomes in a wide range of species, but 
substantial variability in DR response has been observed, both between and 
within species. The mechanisms underlying this variation in effect are still not well 
characterised. Splicing regulatory factors have been implicated in the pathways 
linked with DR-induced longevity in C. elegans and are associated with lifespan 
itself in mice and humans.  
We used qRT-PCR to measure the expression levels of a panel of 16 age- and 
lifespan-associated splicing regulatory factors in brain, heart and kidney derived 
from three recombinant inbred strains of mice with variable lifespan responses to 
short-term (2 months) or long-term (10 months) 40% DR to determine their 
relationship to DR-induced longevity. 
We identified 3 patterns of association; i) splicing factors associated with DR 
alone, ii) splicing factors associated with strain alone or iii) splicing factors 
associated with both DR and strain. Tissue specific variation was noted in 
response to short-term or long-term DR, with the majority of effects noted in brain 
following long-term DR in the positive responder strain TejJ89. Association in 
heart and kidney were less evident, and occurred following short-term DR. 
Splicing factors associated with both DR and strain may be mechanistically 
involved in strain-specific differences in response to DR. We provide here 
evidence concordant with a role for some splicing factors in the lifespan 





Since the lifespan extension effects of dietary restriction (DR) were first reported 
in the early 1900s246,247, intensive effort has focused on characterisation of the 
underlying mechanism(s) in model organisms248-250. Several studies have shown 
the beneficial effects of DR in terms of extended lifespan to be conserved across 
many species ranging from single-celled organisms to non-human primates251-
254. To date no lifespan data are available in humans, although there are many 
opinions as to the potential for DR to affect human lifespan250,255-258. 
Notwithstanding the reported effects on lifespan, there remains clear evidence 
that DR results in multiple health benefits in many organisms including 
humans258-261. These benefits could contribute to extended ‘health span’ (the 
period of life spent free from age-related chronic diseases) in ageing human 
populations, which is arguably far more relevant from a public health perspective 
than increasing lifespan alone. However, the exact nature of the mechanism(s) 
which lead to such benefits remains the subject of discussion. There is therefore 
a need to elucidate the pathways underlying the actions of DR in order to better 
understand how it could potentially be used to extend ‘health span’ in human 
populations. 
When discussing DR as a potential intervention, it must be recognised that the 
universality of the beneficial effects is far from clear cut. In animal models, 
lifespan extension results vary with the experimental methodology used; animal 
husbandry conditions, level of DR imposed, age at initiation of DR and method of 
introduction of DR may all influence the amount of extension reported262-264. 
Genetics is clearly also an important factor to be considered, especially given that 
studies conducted across different species show highly variable effects, with 
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several reports showing dietary restriction to have no effect, or even a negative 
effect on lifespan250,262,265. However, such disparity is not limited to cross-species 
differences; two studies from 2010266,267 tested a large number of ILSXISS 
recombinant inbred mouse strains and reported wide variability in lifespan 
response to 40% DR, both lifespan extension and lifespan reduction were 
observed in similar numbers of strains in each of these experiments. It is currently 
unclear as to what caused the variation in response to DR, although a number of 
reasons have been suggested262. However, the simple fact that such variation 
exists presents valuable opportunities to study the molecular mechanisms 
involved in differential lifespan response to dietary restriction. 
One molecular mechanism with potential to play a role in the DR response is 
alternative mRNA splicing; components of the machinery that regulates this 
process have previously been implicated in DR in C.elegans67 . Alternative 
splicing is known to be a contributor to cellular plasticity and is a key element of 
the homeostatic stress response, both of which are important factors in the 
ageing process110,268. Dysregulated splicing is also a major feature of age-related 
diseases including Alzheimer’s disease, Parkinson’s disease and several tumour 
types177-179. Regulation of alternative splicing events is complex and 
multifactorial, however trans-acting splicing factors are necessary to determine 
the outcome of any particular splicing event126. The Serine Arginine-rich (SR) 
family of splicing factors and the heterogeneous nuclear ribonucleoprotein 
(HNRNP) family of splicing factors usually, but not exclusively, have stimulatory 
and inhibitory roles respectively in the determination of splice site usage176. We 
have previously shown that alternative splicing and splicing factor expression are 
deregulated during normal human ageing101 and that splicing factor expression 
levels are associated with lifespan in mice and humans104. We have also 
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demonstrated changes in splicing factor expression in senescent cells from 
multiple human tissue types in vitro103,108 and recently we reported the reversal 
of several senescent cell phenotypes through moderation of splicing factor 
expression levels using resveratrol analogues, hydrogen sulfide donors or 
inhibition of the ERK or AKT signalling pathways in cultured human cells107,269,270. 
Given the emerging importance of splicing factors in the ageing phenotype and 
links to longevity, we hypothesised that their expression may be altered under 
DR conditions, and may present some insight into the role of alternative splicing 
in the effects of DR. To explore this, we measured splicing factor transcript 
expression levels in three recombinant ILSXISS mouse strains with differential 
responses to short-term or long-term 40% DR. We identified striking tissue 
specificity in expression profiles. The expression of some splicing factors was 
associated with exposure to either short-term or long-term DR, or both, but 
demonstrated no associations with strain. Others demonstrated strain specific 
responses but were unrelated to DR status. Some splicing factors however 
demonstrated interactions between both strain and DR, and may underlie the 
observed strain specificity in DR response. 
5.5 Materials and Methods 
5.5.1 ILSXISS Mice 
The mouse strains used in the present study have been extensively described 
elsewhere161,266,267,271,272. In brief, the ILSXISS recombinant inbred (RI) mouse 
strains were originally derived from a cross between inbred long sleep (ILS) and 
inbred short sleep (ISS) mice. These two strains were developed from an original 
eight-way cross using heterogeneous stock; A, AKR, BALB/c, C3H/2, C57BL, 
171 
 
DBA/2, IsBi and RIII, the offspring of which were subsequently bred for differential 
ethanol sensitivity, giving the long and short sleep models. Over 20 successive 
generations of inbreeding of these progenitor strains (ILS X ISS) resulted in >75 
ILSXISS RI lines, each genetically distinct from each other266. These lines have 
previously been shown to have variable lifespan responses to DR, making them 
ideal for exploration of the mechanisms underlying DR-induced lifespan 
extension266,267.  
Mice from three of these strains were chosen for use in the present study, on the 
basis of replicable responses to 40% DR across two previous independent 
studies with no significant strain-specific differences in median lifespan under AL 
conditions266,267. Only female mice were used in the present study for consistency 
since one previous study267 did not include male mice. Lifespan measurements 
from the Liao study266 therefore could not be corroborated for both sexes. Mice 
were maintained in groups of 4 post-weaning in shoebox cages (48 cm × 15 cm 
× 13 cm), with AL access to water and standard chow (CRM(P), Research Diets 
Services, LBS Biotech, UK; Atwater Fuel Energy-protein 22%, carbohydrate 
69%, fat 9%) and maintained on a 12L/12D cycle (lights on 0700–1900h) at 22 ± 
2 °C.  
One of the strains chosen showed an extension of lifespan under life-long 40% 
DR (TejJ89), one showed a lifespan reduction response to 40% DR (TejJ114) 
and one exhibited no response to 40% DR (TejJ48) relative to strain-specific ad 
libitum fed controls. There is some debate as to whether these strain responses 
truly reflect each strain’s true potential for lifespan extension or simply that a 40% 
DR regime is sub-optimal in the cases of TejJ48 and TejJ114262. However for 
purposes of clarity, the strains will be referred to as positive-, negative- and non-
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responder strains since these are the responses that have previously been 
reported under 40% DR161,266,267. Mice were introduced to DR in a graded fashion; 
at 10 weeks of age mice were exposed to 10% DR (90% of AL feeding), at 11 
weeks this was increased to 20% DR, and from 12 weeks of age until the 
termination of the experiment mice were exposed to 40% DR, relative to their 
appropriate strain-specific AL controls. Mice were given either ad libitum (AL) 
feed or short- (2 months) or long-term (10 months) 40% DR, as previously 
published161. Brain, heart and kidney tissue samples were collected as part of a 
previous study, therefore full details of animal husbandry conditions, DR 
protocols and treatment of dissected tissues have all been previously described 
in Mulvey et al161. All experiments were carried out under a licence from the UK 
Home Office (Project Licence 60/4504) and followed the “principles of laboratory 
animal care” (NIH Publication No.86-23, revised 1985). 
5.5.2 Splicing factor candidate genes for analysis 
An a priori list of splicing factor candidate genes were chosen based on 
associations previously seen in multiple human ageing cohorts and in senescent 
primary human cell lines101,103,107,108. Some of the splicing factors in this list have 
also been shown to associate with lifespan in both mice and humans104. The list 
of genes included the negative regulatory splicing factors Hnrnpa0, Hnrnpa1, 
Hnrnpa2b1, Hnrnpd, Hnrnph3, Hnrnpk, Hnrnpm, Hnrnpul2, the positive 
regulatory splicing enhancers Pnisr, Srsf1, Srsf2, Srsf3, Srsf6, Tra2b and the core 
components of the spliceosome Sf1 and Sf3b1. Expression assays were 
obtained in single-tube TaqMan® Assays-on-Demand™ format (ThermoFisher, 
Waltham, MA, USA). Assay Identifiers are given in Supplementary table S21. 
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5.5.3 RNA extraction 
Snap-frozen tissues were first treated with RNAlater™-ICE Frozen Tissue 
Transition Solution (ThermoFisher, Waltham, MA, USA) according to the 
manufacturer’s instructions, in order to allow handling of the tissue without RNA 
degradation occurring due to thawing of sample. Tissue sections were then 
placed in 1 ml TRI Reagent® Solution (ThermoFisher, Waltham, MA, USA) 
supplemented with the addition of 10mM MgCl2 to aid recovery of microRNAs165. 
Samples were then completely homogenised in a bead mill (Retsch Technology 
GmbH, Haan, Germany) at a frequency of 30 cycles per second for 15 mins. 
Phase separation was carried out using chloroform. Total RNA was precipitated 
from the aqueous phase by means of an overnight incubation at -20°C with 
isopropanol. 1.2µl Invitrogen™ GlycoBlue™ Coprecipitant (ThermoFisher, 
Waltham, MA, USA) was added prior to incubation to aid pellet recovery. RNA 
pellets were then ethanol-washed twice and re-suspended in 1 x TE buffer, 
pH8.0. RNA quality and concentration were assessed by NanoDrop 
spectrophotometry (NanoDrop, Wilmington, DE, USA).  
5.5.4 Reverse transcription 
500ng of total RNA was reverse transcribed using EvoScript Universal cDNA 
Master kit (Roche LifeScience, Burgess Hill, West Sussex, UK) in 20µl reactions, 
according to the manufacturer’s instructions except for a change to the extension 
phase of the reaction: a step of 30 min at 65°C was used instead of 15 min at 
65°C. Resulting cDNA was then diluted to a final volume of 80µl with dH2O to 
ensure sufficient volume for all subsequent qRT-PCR reactions. 
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5.5.5 Quantitative real-time PCR 
1.0µl cDNA (reverse transcribed as indicated above) was added to a 5µl qRT-
PCR reaction including 2.5µl TaqMan® Universal Master Mix II, no UNG 
(ThermoFisher, Waltham, MA, USA) and 0.125µl TaqMan® Assays-on-
Demand™ probe and primer mix (corresponding to 450nM each primer and 
125nM probe). Reactions were run in triplicate on 384-well plates using the 
QuantStudio 6 Flex Real-Time PCR System (ThermoFisher, Waltham, MA, 
USA). Amplification conditions were a single cycle of 95°C for 10 min followed by 
40 cycles of 95°C for 15 s and 60°C for 1 min. As this study consisted of a 
collection of 288 samples, three separate plates were required to run all samples 
with each Taqman® assay. To mitigate the effects of plate-to-plate variation, two 
approaches were used. Firstly, samples were randomised before being assigned 
to a plate such that any given plate did not contain all the samples from one strain, 
tissue or DR condition. Secondly, internal calibrator samples were used: 6 
samples were chosen at random from the collection and separate to the main 
workflow, each sample was reverse-transcribed 3 times and diluted as described 
above. The 3 resulting cDNA samples were then pooled for each sample, mixed 
thoroughly and added as extra samples to each plate. These internal calibrator 
samples were used in the downstream analysis to normalise across plates. 
5.5.6 Data preparation 
EDS files were uploaded to the ThermoFisher Cloud (ThermoFisher, Waltham, 
MA, USA) and analysed using the Relative Quantification qPCR App within the 
software (https://www.thermofisher.com/uk/en/home/cloud.html). This platform was used 
to manually set Baseline and Threshold for each assay (see Supplementary table 
S21 for values) and to ensure there were no apparent outliers before further 
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analysis. One sample was excluded from the TejJ89 dataset at this stage as 
expression data was missing for >50% of all genes measured. Output was 
imported into Excel (Microsoft, Redmond, WA, USA) and the CT values used for 
analysis using the comparative CT method. First, raw CT values were corrected 
using the internal calibrator samples from each of the three plates. Corrected CT 
data from all genes measured, endogenous controls, calculated averages and 
geometric means of these controls along with calculated ‘global’ averages and 
geometric means across all genes measured were then uploaded to the 
RefFinder webtool273 to establish the most stable gene(s). This returned the 
‘global’ geometric mean value across all genes measured as the most stable and 
thus the most appropriate for the ΔCT normalisation step. At this point, ΔΔCT 
expression calculations were performed for each strain separately; expression 
for each transcript was calculated relative to the average expression in the ad-
libitum fed animals, for each tissue individually and separately for long-term and 
short-term treatments. Following the ΔΔCT normalisation, the fold-changes were 
calculated using the 2-ΔΔCT method, followed by an additional normalisation using 
the geometric mean expression of the non-responder strain (TejJ48) as a 
baseline.  
This final normalisation step was intended to account for any minor changes in 
splicing factor expression caused by DR, but presumably unrelated to the 
lifespan-alteration response seen in the positive (TejJ89) and negative (TejJ114) 
responder strains. The expression profiles of splicing factors in the non-
responder strain (TejJ48) under DR conditions are shown in Supplementary 
figure S2 and Supplementary table S22. As can be seen, there are very few 
significant alterations in expression levels (and none that meet multiple testing 
criteria), although a certain amount of deviation from zero can be seen. These 
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deviations in expression are likely to be brought about through the imposition of 
a DR regime, however owing to the lack of response in this strain it is reasonable 
to assume that they are highly unlikely to be contributory to the responses seen 
in the other strains. As such, normalisation using these minor deviations should 
merely remove a certain amount of ‘background’ from the positive- and negative-
responder strain data. As a consequence of this normalisation, the data from 
TejJ48 were effectively set as a zero point against which TejJ89 and TejJ114 
were compared, so results for TejJ48 are presented only in supplementary data. 
Data were log transformed to ensure normal distribution and outlier detection was 
then performed in SPSS (IBM, Armonk, NY, USA). Univariate outliers were 
identified using standardised z-scores, with any individual measures for each 
gene falling outside the cut-off (set at 3 standard deviations from the mean) being 
discarded. Multivariate outliers were identified using a regression model with 
Mahalanobis distance as an output, followed by comparison of the calculated 
Mahalanobis distances with the critical χ2 value for the dataset274. One sample 
from the TejJ89 dataset for which the Mahalanobis distance exceeded the critical 
χ2 was discarded, leaving a total of n = 286 samples to take forward for statistical 
testing. The characteristics of this final set of samples are summarised in Table 
5.1. 
5.5.7 Statistical analysis 
Differences in gene expression were tested using ANCOVA between 1) DR and 
AL feeding regimes and 2) TejJ89 and TejJ114 positive and negative responder 
strains under DR conditions. qRT-PCR plate was included as a co-variate in order 
to control for any batch effects across the 3 plates used for each gene expression 
assay. Linear regression models were then performed using DR status and 
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responder strain as independent variables and including an interaction term to 
determine the presence of moderating effects between the two variables. 
ANCOVAs and regressions were carried out in STATA v15.1 (StataCorp, College 
Station, TX, USA). Benjamini, Krieger and Yekutieli false discovery rate (FDR) 
calculations175 were performed using GraphPad Prism 8.1.1 (GraphPad 




Table 5.1: Details of mice used in the study 
Shown here are the numbers of animals included in each feeding regime and diet for each tissue 
in each strain of mouse used in the current study. 
 
  




2 month 8 
10 month 8 
DR 
2 month 8 
10 month 8 
Heart 
AL 
2 month 8 
10 month 7 
DR 
2 month 8 
10 month 8 
Kidney 
AL 
2 month 7 
10 month 8 
DR 
2 month 7 




2 month 8 
10 month 8 
DR 
2 month 8 
10 month 8 
Heart 
AL 
2 month 8 
10 month 8 
DR 
2 month 9 
10 month 8 
Kidney 
AL 
2 month 8 
10 month 10 
DR 
2 month 8 




2 month 8 
10 month 8 
DR 
2 month 8 
10 month 8 
Heart 
AL 
2 month 8 
10 month 8 
DR 
2 month 8 
10 month 8 
Kidney 
AL 
2 month 8 
10 month 7 
DR 
2 month 9 




5.6.1 Splicing factors demonstrate altered expression levels under DR conditions 
(‘DR associated factors’) 
We identified that several splicing factors displayed differential expression levels 
with short-term or long-term DR, and that these differences displayed striking 
tissue specificity (Figure 5.1, Supplementary tables S22, S23 and S24). In brain, 
most of the expression changes we observed were associated with long-term 
40% DR, mainly in the positive responder strain TejJ89 and largely belonging to 
the Hnrnp class of splicing inhibitors. Expression levels of over half (9/16) of the 
splicing factors tested were significantly altered with DR at a nominal level, with 
4 of these (Hnrnpa0, Hnrnpa1, Hnrnph3 and Hnrnpk) remaining statistically 
significant after correction for multiple testing. Conversely, following short-term 
40% DR in brain, differences were seen equally frequently in positively and 
negatively responding strains and mainly involved Srsf splicing activators or core 
spliceosome components, although only one (Srsf6) met multiple testing criteria 
(Figure 5.2a & 5.2b). In heart, we identified most alterations in conjunction with 
short-term DR, with almost all differences being found in the negative responder 
strain TejJ114, involving both Srsf and Hnrnp splicing factors, the majority of 
which (Hnrnpa1, Hnrnpa2b1, Hnrnpd, Srsf6 and Sf1) were significant after 
correcting for multiple testing (Figure 5.3a & 5.3b). Finally, in kidney, as we saw 
in the heart, most of the changes we identified were in conjunction with short-
term DR but occurred in both positively and negatively responsive strains. 
Differences found involved mainly Srsf splicing activators or core components of 
the spliceosome, and 5 out of 14 of these (Hnrnpa1, Srsf1, Srsf6, Tra2b and Sf1) 




Figure 5.1 Tissue-specificity of splicing factor expression under 40% DR 
conditions 
Heatmaps depicting post-ANCOVA marginal effects for log fold-change in 40% DR expression 
levels of each transcript (when compared to AL). Data from short-term and long-term 40% DR 
regimes are shown for each tissue separately. Panel a shows data for the positive responder 
(TejJ89) and panel b for the negative responder (TejJ114). Transcripts up-regulated in 40% DR 





Figure 5.2: Effects of 40% DR on splicing factor expression in brain tissue 
Shown here are transcript expression levels in ILSXISS mouse brain tissue under short-term and 
long-term DR conditions. Panel a shows expression under short-term 40% DR, panel b shows 
expression under long-term 40% DR. Plots show post-estimation marginal effects from the linear 
regressions used for interaction analysis. Data points represent log fold-change in DR expression 
levels of each transcript (when compared to AL), separately for the two mouse strains. Significant 
differences are denoted with stars:  = p<0.05,  = p<0.01,  = p<0.001. Stars indicated in 
black denote associations which meet the multiple testing threshold, while those in grey represent 
nominal associations. Data for the positive responder strain (TejJ89) is shown as solid points and 
line in black, while the negative responder strain (TejJ114) is shown as open points and dashed 





Figure 5.3: Effects of 40% DR on splicing factor expression in heart tissue  
Shown here are transcript expression levels in ILSXISS mouse heart tissue under short-term and 
long-term DR conditions. Panel a shows expression under short-term 40% DR, panel b shows 
expression under long-term 40% DR. Plots show post-estimation marginal effects from the linear 
regressions used for interaction analysis. Data points represent log fold-change in DR expression 
levels of each transcript (when compared to AL), separately for the two mouse strains. Significant 
differences are denoted with stars:  = p<0.05,  = p<0.01,  = p<0.001. Stars indicated in 
black denote associations which meet the multiple testing threshold, while those in grey represent 
nominal associations Data for the positive responder strain (TejJ89) is shown as solid points and 
line in black, while the negative responder strain (TejJ114) is shown as open points and dashed 





Figure 5.4: Effects of 40% DR on splicing factor expression in kidney tissue  
Shown here are transcript expression levels in ILSXISS mouse kidney tissue under short-term 
and long-term DR conditions. Panel a shows expression under short-term 40% DR, panel b 
shows expression under long-term 40% DR. Plots show post-estimation marginal effects from the 
linear regressions used for interaction analysis. Data points represent log fold-change in DR 
expression levels of each transcript (when compared to AL), separately for the two mouse strains. 
Significant differences are denoted with stars:  = p<0.05,  = p<0.01,  = p<0.001. Stars 
indicated in black denote associations which meet the multiple testing threshold, while those in 
grey represent nominal associations. Data for the positive responder strain (TejJ89) is shown as 
solid points and line in black, while the negative responder strain (TejJ114) is shown as open 
points and dashed line in grey. The null point is indicated by a dotted line. Error bars represent 
95% confidence intervals. 
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5.6.2 Splicing factors demonstrate different patterns of expression with DR in 
positive and negative responder strains (‘strain-associated factors’) 
We next identified splicing factors that demonstrated differences in expression 
patterns between the positive and negative responder strains under short-term 
or long-term 40% DR. With the exception of brain, most of the differential 
expression levels in the two strains were present under short-term DR conditions 
(Supplementary table S25). In brain, only expression of Hnrnpa0 and Srsf2 
differed between strains under short-term DR, and only Srsf2 remained 
significant after correction for multiple testing (Figure 5.2a). Many more 
incidences where the positive and negative responder strains demonstrated 
differences in splicing factor expression were evident in brain in response to long-
term DR; 11/16 genes exhibited differential expression between strains under 
these conditions, with 6 of these (Hnrnpa2b1, Hnrnpd, Hnrnph3, Hnrnpk, Srsf6 
and Sf1) meeting the multiple testing threshold (Figure 5.2b). Several differences 
between strains were apparent in heart under conditions of short-term DR, which 
involved both Srsf and Hnrnp transcripts (Figure 5.3a), although only one of these 
(Hnrnpd) was significant when corrected for multiple testing. Fewer expression 
differences were apparent overall under long-term DR in heart (Figure 5.3b), 
however 2 of these (Hnrnpul2 and Srsf3) met multiple testing criteria. Kidney 
demonstrated fewer alterations than either brain or heart, with differences seen 
only in response to short-term DR, although 2 of these (Hnrnpa1 and Sf1) met 
the multiple testing threshold (Figure 5.4a & 5.4b). 
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5.6.3 Expression levels of some splicing factors are associated with both lifespan 
effects and DR (‘interacting factors’) 
Some of the most interesting associations are those in which splicing factor 
expression is associated with both DR and strain. In such cases it is reasonable 
to postulate that those transcripts may be involved in pathways which contribute 
to the observed responses to 40% DR within each strain, but are also playing 
some part in the differences seen in strain-specific lifespan response, and so 
these splicing factors may comprise part of the molecular mechanism behind the 
response to DR. We therefore sought to identify situations where a statistical 
interaction was apparent between DR, strain and splicing factor expression 
(Supplementary table S26). In brain, only Srsf2 displayed a nominal interaction 
under short-term DR conditions (Figure 5.2a), whereas under long-term DR, 9 of 
16 splicing factors tested showed at least nominal interactions, with 4 of these 
(Hnrnpa1, Hnrnpa2b1, Hnrnph3 and Hnrnpk) significant after correction for 
multiple testing (Figure 5.2b). In heart, far fewer interactions were apparent 
overall, with 3 of the 16 splicing factors having nominally significant interactions 
under short-term DR (Figure 5.3a) and only 1 nominal interaction was detected 
under long-term DR conditions (Figure 5.3b), however none of these were 
significant after correction for multiple testing. Finally, in kidney tissue only 2 
transcripts were found to show interactions, and only under conditions of short-
term DR, with one of these (Sf1) meeting the criteria for multiple testing (Figure 





Lifespan extension as a result of dietary restriction (DR) has been recognised for 
over a century246,247 and has since been the subject of intensive research. The 
relationship between DR and lifespan is however sometimes unclear, with 
variation in the lifespan effect reported both across and within species250,262,265-
267. It is apparent therefore that our understanding of the mechanistic basis 
underpinning responses to DR is not complete, and that other influences exist 
which may explain some of the observed strain heterogeneity. One such 
influence may be the interface between the environmental stimulus (DR) and 
factors moderating the expression or activity of gene expression. While many 
such factors exist, one that is highly likely to play a part is alternative splicing, as 
it is a fundamental component of the response of cells to external and internal 
stimuli121, and components of the splicing machinery have previously been 
implicated in response to DR67,185. Here, we have measured transcript expression 
levels of an a priori panel of age- or senescence-related splicing regulatory 
factors in brain, heart and kidney tissue taken from three ILSXISS recombinant 
inbred mouse strains with previously reported different lifespan responses to 40% 
DR. Animals were exposed to both short-term and long-term 40% DR and 
subsequent analyses were performed to characterise expression differences 
related to DR alone, differences only related to strain, and effects attributable to 
both. Our results show that expression levels of several splicing factor transcripts 
are significantly affected by either short-term or long-term DR, that there are 
significant differences in expression levels of some transcripts between positive 
and negative responder strains, and that there are strong tissue specific 
influences on both effects. Furthermore, some splicing factors demonstrate 
statistical interactions between their expression, DR and strain lifespan response, 
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which may indicate mechanistic involvement in the divergent lifespan response 
to DR observed in these mouse strains under DR conditions. 
Dietary restriction has been shown to be linked to lifespan, with multiple pathways 
involved including those involved in genomic stability, proteostasis, inflammation, 
autophagy, mitochondrial function, oxidative damage and nutrient signalling 
pathways (IIS, IGF-1, SIRT, AMPK and mTOR)242,275. It is known that the ability 
to respond to internal and external sources of cellular stress is an important factor 
in successful ageing110, and that transcriptomic responsiveness plays a large part 
in this, including the plasticity of response that is achieved through alternative 
splicing268. A recent study has shown that the splicing factor SF1 is necessary for 
lifespan extension by DR in C. elegans, specifically through the modulation of 
TORC1 pathway components67. Our previous work has shown that both 
alternative splicing and more specifically the expression levels of splicing 
regulatory factors that control it, are associated with ageing in humans101, cellular 
senescence in vitro103,108 and lifespan in animal models104. Recently we also 
showed that alteration of splicing factor levels using small molecules such as 
resveratrol analogues, hydrogen sulfide donors or inhibitors of ERK or AKT 
signalling can reverse senescence phenotypes in vitro107,269,270. Given this 
evidence, it is reasonable to hypothesise that regulation of alternative splicing 
may play a role in the lifespan modification response following DR.  
The results presented here are consistent with a hypothesis that altered splicing 
regulation may form part of the mechanistic response to DR in mice. We propose 
that the splicing factors we tested can be classified into three broad classes: 1) 
DR-associated factors. Expression of these splicing factors is significantly 
affected by DR, but no differences are apparent between strains, suggesting that 
although they may have some association to DR, they are unlikely to contribute 
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to any strain-specific differences seen in the DR response. 2) Strain-associated 
factors. Expression of these splicing factors is significantly different between 
strains but do not differ between AL and DR. 3) Interacting factors. Splicing 
factors showing statistically significant interactions between DR and strain 
lifespan response in terms of their expression. Where such interactions exist, the 
associations between splicing factor expression and either DR or responder 
strain (or both), coupled with a statistically significant mediation effect between 
the two variables (Figure 5.5), suggests that these splicing factors may be 
mechanistically involved in defining the divergent lifespan response observed in 
these mouse strains under 40% DR. 
 
Figure 5.5: Directionality of effects and potential moderating interactions 
This figure shows the likely interplay between the variables measured in the present study. Direct 
effects are shown as solid black arrows, while interactions where one variable could be 
moderating the effect exerted between other variables are shown as dashed arrows. 
 
Splicing factors showing statistical interactions between strain and DR were very 
common in brain, particularly in response to long-term DR. This may reflect a 
more pressing need for the brain to moderate gene output to maintain 
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homeostatic control than is necessary in the other tissues. It is interesting to note 
that within the splicing factors affected in the brain, a preponderance of the 
differences noted between AL and DR (7 out of 8) are observed in the positive 
responder strain while only 3 of 8 are altered in the negative responder. Few 
associations were shared between tissues, with only Srsf6 and Hnrnpa1 showing 
patterns that were shared between brain and heart (Srsf6) or brain and kidney 
(Hnrnpa1).  
Our study has several strengths, including a comprehensive assessment of 
strain-, tissue- and duration effects. There are of course also limitations to this 
work; it would have been advantageous to measure alternative isoform 
expression of target genes of these splicing factors to determine whether they 
could actively be affecting alternative splicing. Another caveat to the work is that 
optimally, protein levels of splicing factors would be informative. Unfortunately 
this was not possible due to limits on starting material. We have used an FDR 
approach to account for multiple testing, following the two-stage linear step-up 
procedure of Benjamini, Krieger and Yekutieli175. However, it must be recognised 
that although relatively modest, correlations do exist between expression levels 
of many splicing factors (Figure 5.6) and that further correlations are likely to exist 
between different DR treatments and indeed to an extent between the different 
mouse strains. All of this suggests that the tests performed here are not 
completely independent, which in turn greatly complicates any sensible 
application of multiple testing criteria. In addition, while groups of 8 animals per 
condition is reasonable for a study of this type, there may be an impact on 
statistical power which could result in Type II errors. Therefore, we recognise that 
the multiple testing threshold applied here may be overly severe, and as such 
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have presented nominal findings alongside those which are FDR-corrected, 
although we recognise that careful interpretation must be applied to such results. 
In summary, this study has shown that the expression of splicing factor transcripts 
shows widespread alterations in response to dietary restriction, and that these 
are highly tissue specific. It is also apparent that certain transcripts show 
interactions between the effects of DR, expression levels and strain lifespan 





Figure 5.6 Correlations between splicing factor expression levels 
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Chapter 6  
Data Chapter. 
The transcript expression levels of HNRNPM, 
HNRNPA0 and AKAP17A splicing factors may be 
predictively associated with ageing phenotypes 
in human peripheral blood. 
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Dysregulation of splicing factor expression is emerging as a driver of human 
ageing; levels of transcripts encoding splicing regulators have previously been 
implicated in ageing and cellular senescence both in vitro and in vivo. We 
measured the expression levels of an a priori panel of 20 age- or senescence-
associated splicing factors by qRT-PCR in peripheral blood samples from the 
InCHIANTI Study of Aging, and assessed longitudinal relationships with human 
ageing phenotypes (cognitive decline and physical ability) using multivariate 
linear regression. AKAP17A, HNRNPA0 and HNRNPM transcript levels were all 
predictively associated with severe decline in MMSE score (p = 0.007, 0.001 and 
0.008 respectively). Further analyses also found expression of these genes was 
associated with a performance decline in two other cognitive measures; the Trail 
Making Test and the Purdue Pegboard Test. AKAP17A was nominally associated 
with a decline in mean hand-grip strength (p = 0.023), and further analyses found 
nominal associations with two other physical ability measures; the Epidemiologic 
Studies of the Elderly – Short Physical Performance Battery and calculated speed 
(m/s) during a timed 400m fast walking test. These data add weight to the 
hypothesis that splicing dysregulation may contribute to the development of some 





There is an intimate relationship between stress responses and successful 
ageing110 yet the ability to respond appropriately to stressful environments and to 
maintain systemic homeostasis declines with age in multiple species276-278. 
Cellular responses to external and internal stressors are mediated at the level of 
genomic plasticity, in particular at the level of the transcriptome. Several 
mechanisms are known to play a part in the diversity of response, including 
transcriptional regulation at the level of polymerase activity117, post-
transcriptional regulation120, epigenetics279 and genomic landscape119. 
Alternative splicing comprises a key part of the homeostatic response to 
stress121,280,281, and dysregulation of this process is now emerging as a new and 
important driver of cellular ageing101,103,282. Over 95% of genes are capable of 
producing more than one mRNA product under different conditions and 
alternatively-expressed mRNAs can have profoundly different temporal or spatial 
expression patterns, or demonstrate major differences in functionality283-285. 
Alternative splicing decisions are made by a series of trans-acting splicing 
regulatory proteins termed splicing factors. These are the Serine Arginine-rich 
(SR) family of splicing factors which usually, but not exclusively, promote splice 
site usage, and the heterogeneous nuclear ribonucleoprotein (HNRNP) family of 
splicing factors which are usually, but not exclusively, associated with inhibition 
of splice site usage176. SR proteins and HNRNPs bind to exon/intron splicing 
enhancer (ESE/ISE) or silencer (ESS/ISS) elements in the vicinity of the splice 
sites and the balance of activators and inhibitors at any given splice site regulates 
splice site usage126. The expression levels of splicing regulators is known to be 
associated with ageing; of 7 gene ontology pathways robustly associated with 
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age in a large cross-sectional population study of human ageing, 6 were directly 
involved in mRNA splicing processes101. Splicing factor expression is also 
associated with lifespan in mice and humans104. Alterations in splicing factor 
expression have also been reported in senescent human cells of multiple tissue 
types103,108 and restoration of splicing factor expression to levels consistent with 
a younger profile was sufficient to reverse multiple senescent cell phenotypes in 
senescent human fibroblasts in vitro107. 
We have previously observed disruption of splicing factor expression in human 
senescent cells103,108, and demonstrated that experimental manipulation of 
splicing factor expression is capable of inducing rescue from the senescent cell 
phenotype107,269,270. Although we have demonstrated epidemiological links with 
ageing itself, and reversal of cellular senescence in vitro, evidence that the 
phenomena we observe in vitro is linked with downstream ageing phenotypes is 
lacking. In this study, we addressed this question by measurement of the 
expression of an a priori panel of age- and senescence-related splicing factor 
genes in human peripheral blood mRNA from the InCHIANTI study of Aging. We 
used samples from two follow-up visits (FU3; 2007 – 2010 and FU4; 2012 - 2014) 
of the InCHIANTI study of Aging, and related their expression to changes in 
recorded measures of two important human ageing phenotypes; cognitive and 
physical function. We initially used the Mini Mental State Exam (MMSE) score 
and mean hand-grip strength to identify putative associations between splicing 
factor expression and changes in cognitive or physical ability respectively. We 
then assessed expression of these transcripts against other cognitive and 
physical measures available in the dataset. In each case, a set of sub-analyses 
were also performed to test the robustness of the findings. 
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We found that the expression of three splicing factor genes, HNRNPM, 
HNRNPA0 and AKAP17A may be predictive for change in this population; all 
three genes were associated with cognitive decline as measured by the Mini-
Mental State Examination (MMSE), Trail-Making Tests part A and B (TMT A/B), 
and the Purdue Pegboard Test (PPT). AKAP17A was also associated with a 
decline in physical ability as measured by hand-grip strength, the Epidemiologic 
Studies of the Elderly – Short Physical Performance Battery (EPESE-SPPB) and 
calculated speed during a timed 400m fast walking test. Our data suggest that 
age-associated dysregulation of splicing factor expression in ageing humans may 
contribute to the development of downstream ageing outcomes. 
6.5 Methods 
6.5.1 InCHIANTI cohort and selection of participants 
The InCHIANTI study of Aging is a population study of ageing163. Participants 
undertook detailed assessment of health and lifestyle parameters at baseline, 
and again at 3 subsequent follow-ups (FU2; 2004 – 2006, FU3; 2007 – 2010 and 
FU4; 2012 - 2014). The present study used participants from the third and fourth 
follow-up visits (FU3 and FU4). RNA samples and clinical/phenotypic data were 
already available for 698 participants at FU3. The collection of the FU4 samples 
and data comprise part of this study. During the FU4 interviews in 2012/13, blood 
and clinical/phenotypic data were collected from 455 study participants. These 
data were cross-checked against RNA samples and clinical/phenotypic data 
already held from FU3, to ensure that sample and phenotypic data was available 
from both collections. 393 individuals fitted these criteria, of which 9 died shortly 
after the FU4 visit and so were excluded from the analysis. From the remaining 
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384 eligible samples, 300 were randomly selected from the cohort to be analysed 
for expression of splicing factor genes. Anthropometric parameters and blood cell 
subtypes in FU4 were measured as previously163. 
6.5.2 Splicing factor candidate genes for analysis 
An a priori list of splicing factor candidate genes were chosen based on 
associations we had documented with human ageing in multiple populations and 
in senescent primary human cell lines in our previous work101,103,107. We have 
also found associations of components of this gene set with lifespan in both mice 
and humans104. The list of genes included the positive regulatory splicing factors 
AKAP17A, SRSF1, SRSF2, SRSF3, SRSF6, SRSF7, PNISR and TRA2B, the 
negative regulatory splicing inhibitors HNRNPA0, HNRNPA1, HNRNPA2B1, 
HNRNPD, HNRNPH3, HNRNPK, HNRNPM, HNRNPUL2 and the IMP3, 
LSM14A, LSM2 and SF3B1 core components of the spliceosome. Expression 
assays were obtained in custom TaqMan® low-density array (TLDA) format 
(ThermoFisher, Waltham, MA, USA). Assay Identifiers are given in 
Supplementary table S27. 
6.5.3 RNA Collection and Extraction 
2.5ml of peripheral blood was collected from each participant into PAXgene Blood 
RNA Tubes (IVD) (PreAnalytiX GmbH, Hombrechtikon, Switzerland). Blood tubes 
were then treated according to the manufacturer’s instructions and subsequently 
cold-chain shipped to the UK. RNA extractions were then carried out using the 
PAXgene Blood mRNA Kit (Qiagen, Hilden, Germany), according to 
manufacturer’s instructions. Samples were assessed for RNA quality and 
quantity by Nanodrop spectrophotometry (NanoDrop, Wilmington, DE, USA). 
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6.5.4 Reverse Transcription and quantitative RT-PCR 
100ng of total RNA was reverse transcribed using SuperScript® VILO™ cDNA 
Synthesis Kit (ThermoFisher, Waltham, MA, USA) in 20μl reactions, according to 
the manufacturer’s instructions. 20μl cDNA (reverse transcribed as indicated 
above) was added to 50μl TaqMan® Universal Master Mix II, no UNG 
(ThermoFisher, Waltham, MA, USA) and 30μl RNase-free dH2O, then loaded 
onto TaqMan® Low-Density Array 384-Well Microfluidic cards. 100μL reaction 
solution was dispensed into each TLDA card chamber and the card centrifuged 
twice for 1 min at 216 x g to ensure distribution of solution to each well. The 
expression of transcripts in each sample was measured in duplicate replicates. 
Cards were run on the 7900HT Fast Real-Time PCR System (ThermoFisher, 
Waltham, MA, USA). Amplification conditions were as follows: a single cycle of 
50°C for 2 minutes, a single cycle of 94.5°C for 10 minutes followed by 40 cycles 
of 97°C for 30 seconds and 59.7°C for 1 minute. 
6.5.5 Data preparation 
SDS files were uploaded to the ThermoFisher Cloud (ThermoFisher, Waltham, 
MA, USA) and analysed using the Relative Quantification qPCR App 
encompassed within the software (https://www.thermofisher.com/uk/en/home/cloud.html). 
This platform was used to manually set Baseline and Threshold for each assay 
(see Supplementary table S27 for values) and to ensure there were no apparent 
outliers before further analysis. One sample was excluded at this stage as 
expression data was missing for all genes measured. Output was imported into 
Excel (Microsoft, Redmond, WA, USA) and the CT values used for analysis using 
the comparative CT method. The most stable genes for use as endogenous 
controls were determined from the raw data using the RefFinder webtool273, 
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which returned the geometric mean value across all genes measured as the most 
stable control, and thus the most appropriate for the ΔCT normalisation step. 
Expression was then calculated relative to the median expression for each 
individual transcript. Data were log transformed to ensure normal distribution. 
Outlier detection was performed in SPSS (IBM, Armonk, NY, USA). Univariate 
outliers were identified using standardised z-scores, with any individual measures 
for each gene falling outside the cut-off (set at 3 standard deviations from the 
mean) being discarded. Multivariate outliers were identified using a regression 
model with Mahalanobis distance as an output, followed by comparison of the 
calculated Mahalanobis distances with the critical χ2 value for the dataset274. One 
sample for which the Mahalanobis distance exceeded the critical χ2 was 
discarded, leaving a total of n=298 samples to take forward for statistical testing. 













Table 6.1: Participant details  
Characteristics of the InCHIANTI participants used in the present study. Panel A shows summary 
of non-clinical details, panel B shows summary results of clinical/laboratory tests and panel C 
shows summary results of phenotypic measures used for analysis. 
A. 
  Follow-up 3 Follow-up 4 
  n % n % 
Participants  298 100 298 100 
Age (years) 
30-39 21 7.05 11 3.69 
40-49 31 10.40 28 9.40 
50-59 31 10.40 28 9.40 
60-69 35 11.74 34 11.41 
70-79 111 37.25 38 12.75 
80-89 67 22.48 142 47.65 
90-100 2 0.67 17 5.70 
Gender 
Male 136 45.64 136 45.64 




None 159 53.36 NO DATA 
<20 79 26.51 NO DATA 
20-39 44 14.76 NO DATA 
40+ 16 5.37 NO DATA 
Site 
Greve 140 46.98 140 46.98 
Bagno a Ripoli 158 53.02 158 53.02 
Education 
level attained 
Nothing 28 9.4 24 8.05 
Elementary 121 40.6 125 41.95 
Secondary 51 17.11 59 19.80 
High School 46 15.44 58 19.46 
Professional school 33 11.07 11 3.69 
University or 
equivalent 
19 6.38 21 7.05 
 
B. 








Age (years) 67.69 15.68 30.00 94.00 72.92 15.68 35.00 
100.0
0 
BMI 26.97 4.27 15.01 42.99 26.86 4.42 13.39 41.19 
White blood cell 
count (n, K/ul) 
6.39 1.60 2.10 13.00 6.16 1.72 2.30 16.59 
Neutrophils (%) 56.61 8.61 26.20 81.20 56.50 9.23 22.20 88.40 
Lymphocytes (%) 31.56 8.04 9.80 59.90 32.47 8.70 8.30 63.30 
Monocytes (%) 8.08 2.22 3.70 21.30 7.36 2.28 1.60 24.40 
Eosinophils (%) 3.19 2.20 0.00 21.50 3.21 2.02 0.00 13.00 








Table 6.1 (cont.) 
 
C. 











296 27.22 3.18 14.00 30.00 25.71 5.11 0.00 30.00 
Trail-Making Test 
Part A (mins) 
268 0.91 0.62 0.23 5.00 1.13 0.83 0.25 5.00 
Trail-Making Test 
Part B (mins) 
179 1.56 1.02 0.47 5.00 1.91 1.19 0.52 5.00 
Mean hand-grip 
strength (Kg) 
285 29.67 12.28 10.00 70.75 28.11 12.14 5.00 65.50 
 
 
6.5.6 Phenotypic outcomes for analysis 
The current study analysed the associations of splicing factor gene expression at 
FU3 with the following cognitive phenotypic outcomes; MMSE score, Trail-
Making-Test (TMT A&B) and Purdue Pegboard Test (as measures of cognitive 
function), along with hand-grip strength, EPESE-SPPB composite score and 
calculated speed during a 400m fast walk (as measures of physical ability). 
MMSE score was measured at both FU3 and FU4 using the standard test, after 
which the data was corrected to adjust for incomplete tests. This was calculated 
using the score attained as a proportion of the maximum possible points for the 
parts of the test that were completed. Decline in MMSE score was calculated by 
subtracting the score at FU4 from the score at FU3. Time taken to complete the 
Trail-Making-Tests part A and B were measured in seconds at both FU3 and FU4 
using the standard tests. Decline in performance on the tests was calculated by 
subtracting the score at FU4 from the score at FU3. Decline in seconds was then 
converted to a decline in fractions of a minute prior to analysis. The Purdue 
Pegboard Test was administered as standard (although data for the assembly 
portion of the test was not available), and scores for number of pegs placed in 
the board for right-hand, left-hand and both-hands were summed to give a total 
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number of pegs placed during the test. Decline in performance on the test was 
calculated by subtracting the total number of pegs placed at FU4 from the total 
number of pegs placed at FU3. 
Hand-grip strength was measured in kilograms at both FU3 and FU4 using a 
dynamometer, with two separate measurements taken for each hand. Mean 
hand-grip strength was used for the analyses in this study, and was calculated 
as the mean of all 4 hand-grip strength measurements across both hands. 
Decline in mean hand-grip strength was calculated by subtracting the 
measurement at FU4 from the measurement at FU3. The EPESE-SPPB was 
administered and scored as described elsewhere286, and a composite score 
generated from the sub-scores of the 3 activities performed: repeated chair-
stand, standing balance and 4m normal pace walk. Decline in performance was 
calculated by subtracting the composite score at FU4 from the composite score 
at FU3. The 400m fast walk was performed by completing 20 laps of a 20m circuit 
with a maximum of 2 stops if the subject required. Speed in m/s was calculated 
over the entire distance (any individuals who did not complete the test were 
excluded from further analysis), and decline in performance was calculated by 
subtracting the speed at FU4 from the speed at FU3. 
6.5.7 Sub-analyses for robustness testing 
For all phenotypes, any associations found in the full cohort were then tested for 
robustness through four sub-analyses on different subsets of the data. 
First, individuals with the lowest initial scores (at FU3) were excluded from the 
analysis, to avoid confounding due to the inclusion of participants already on a 
trajectory to decline. For MMSE score, the cut-off was set at >=28, as a score 
above 28 is clearly indicative of a lack of cognitive impairment. In the case of 
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mean hand-grip strength, the cut-offs used were those previously reported as a 
consensus definition of sarcopenia by The European Working Group on 
Sarcopenia in Older People (EWGSOP)287, i.e. <20kg for females and <30kg for 
males. For all the other phenotypes analysed, the dataset at FU3 was divided 
into quintiles, with the lowest scoring quintile being excluded from this sub-
analysis. 
Second, an analysis was carried out using only the eldest participants aged >= 
70 years at FU3 to exclude any potential confounding effects from younger 
participants. Declining cognitive and physical ability are predominantly features 
of ageing, and measures such as mean hand-grip strength and MMSE are likely 
to perform poorly in measuring change of function in young, non-compromised 
individuals. 
Third, some individuals measured showed an apparent improvement in 
performance over time between FU3 and FU4, which may reflect a degree of 
measurement error. To test this, we first calculated an allowed error of 5% (as a 
fraction of the total range of change measured), then removed any individuals 
with scores showing an increase greater than the allowed error between the 
follow-ups, for each phenotype. 
Finally, participants were categorised into mild or severe decline classes, to 
assess whether the associations seen were specific to either group of individuals. 
Decline in MMSE score was categorised for sub-analysis as follows; ‘No decline’ 
(score change of -1 to +7, based on a 5% allowable error calculated as described 
above), ‘Mild decline’ (-2 to -8), and ‘Severe decline’ (-9 to -22). While opinion 
differs as to what amounts to a significant rate of change in MMSE during 
cognitive decline, we chose to classify a severe decline as a drop in MMSE score 
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of >3 per annum on average, based on information from several previous studies 
288-290. Analysis of categorised MMSE decline was carried out using the ‘No 
decline’ class as the comparator. 
Decline in mean hand-grip strength was categorised as follows; quintiles of 
change in mean hand-grip were calculated separately for males and females, 
after which the respective 20% of males and females displaying the largest 
decline in mean hand-grip strength were together designated as the ‘Severe 
decline’ class (mean hand-grip change of -3.75kg to -22kg). The remainder of the 
cohort was divided into ‘No decline’ (-1kg to +15.5kg, based on a 5% allowable 
error calculated as described above) and ‘Mild decline’ (-1.25kg to -6kg) 
categories. Analysis of categorised mean hand-grip strength decline was carried 
out using the ‘No decline’ class as the comparator. 
For all other measures used for analysis, categorisation was carried out by 
dividing using the cohort into quintiles based on the change in score, and the 
quintile with the greatest decline in performance designated as the ‘Severe 
decline’ class. The remainder of the cohort was divided into ‘No decline’ and ‘Mild 
decline’ classes using the same method as described above for MMSE and mean 
hand-grip strength. Analysis of categorised variables was carried out using the 
‘No decline’ class as the comparator in all cases. 
6.5.8 Statistical Analysis 
Associations of gene expression with cognitive and physical phenotype 
measures were assessed using multivariate linear regression models. All models 
were adjusted for age, sex, BMI, smoking (lifetime pack-years), highest education 
level attained, study site, TLDA batch and cell counts (neutrophils, lymphocytes, 
monocytes, eosinophils and overall white blood cell count). Regressions were 
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carried out in STATA SE v15.1 (StataCorp, College Station, TX, USA). Pearson 
correlation tests were carried out in SPSS (IBM, Armonk, NY, USA) to assess 
relationships between splicing factor expression levels, phenotypic measures 
and established biomarkers of ageing. 
6.6 Results 
6.6.1 AKAP17A, HNRNPA0 and HNRNPM transcript levels are associated with 
change in MMSE score 
MMSE is a commonly used measure of cognitive decline288-290. HNRNPM 
expression showed a significant association with decline in MMSE score in the 
entire cohort (β-coefficient -0.005, p = 0.006), with HNRNPA0 also showing a 
nominal association (β-coefficient -0.003, p = 0.019). In both cases individuals 
with lower expression levels at the early time-point (FU3) had subsequently 
experienced a greater drop in MMSE score (Figure 6.1, Supplementary table 
S28). The remaining splicing factor genes did not demonstrate associations 






Figure 6.1: Associations of splicing factor expression with MMSE score and 
mean hand-grip strength 
Forest plots showing splicing factor expression in relation to (a.) decline in corrected MMSE 
scores and (b.) mean hand-grip strength in the InCHIANTI human ageing cohort. Individual 
splicing factors are indicated on the y-axis while β-coefficients of change in log expression per 
unit change in measurements are given on the x-axis. Positive values denote an increase in 
expression with larger decline in score while negative values denote a decrease in expression 
with larger decline in score. Error bars denote 95% confidence intervals, significance is shown 
using stars as follows: * = p<0.05, ** = p<0.01. Stars indicated in black denote associations which 
meet multiple testing thresholds, while those in grey represent nominal associations 
 
To test the robustness of our findings we carried out four sub-analyses. Similar 
sub-analyses were also used on all other associations found in the present study 
and full details can be found in the Methods. In brief, regression models were 
repeated on the following subsets of data: firstly we removed individuals with low 
starting scores, secondly only individuals over 70 years of age were included, 
thirdly any individuals showing an increase in performance over time were 
excluded, and finally participants were categorised into ‘mild’ or ‘severe’ decline 
classes.  
Although AKAP17A showed only a trend with MMSE decline in the initial analysis, 
the observation that it had the largest β-coefficient, coupled with a suggestive p-
value of 0.077 merited its inclusion in these further analyses. As can be seen in 
Figure 6.2a, 6.3a and 6.4a (Supplementary table S29), both HNRNPA0 and 
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HNRNPM remained at least nominally associated with decline in MMSE score 
across all sub-analyses, and significantly associated with severe decline in the 
categorised analysis. AKAP17A on the other hand was only nominally associated 
with decline in MMSE in the sub-analysis excluding the individuals displaying an 
apparent improvement over time, but in the categorised analysis a significant 
association was also seen between AKAP17A expression and severe decline. 
To assess whether these findings represent independent effects or could be 
driven by co-ordinate expression of the three genes, we carried out correlation 
analysis. Correlations between the 3 genes in question were only moderate (R 
values: HNRNPA0 & HNRNPM: 0.282, HNRNPA0 & AKAP17A: 0.239, HNRNPM 
& AKAP17A: 0.440 (Supplementary table S30). 
6.6.2 Expression of HNRNPA0, HNRNPM and AKAP17A transcripts are also 
associated with two other measures of cognitive ability 
The Trail Making Test (TMT) is another widely used test for cognitive assessment 
which addresses visual scanning, graphomotor speed and executive function291. 
Figure 6.2b&c, 6.3b&c and 6.4b&c (Supplementary table S31) show AKAP17A 
and HNRNPA0 transcript levels were at least nominally associated with increased 
time to complete TMT-A, both in the full cohort (β-coefficients 0.057 and 0.028, p 
= 0.009 and 0.004 for AKAP17A and HNRNPA0 respectively) and in all sub-
analyses with the exception of the categorised analysis for AKAP17A. HNRNPM 
expression was nominally associated with increased time to complete TMT-B, but 
only in the full cohort (β-coefficient 0.026, p = 0.036) and categorised analyses. 
In all cases, lower expression levels were associated with an increase in the time 
taken to complete the test (i.e. a decline in performance). 
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The Purdue Pegboard Test (PPT) was originally developed as a tool to evaluate 
fine manual dexterity but has since been used for assessments of cognitive 
function292,293. As shown in Figure 6.2d, 6.3d and 6.4d (Supplementary table 
S31), all three transcripts were nominally associated with a performance decline 
in the full cohort (β-coefficients -0.005, -0.002 and -0.002, p = 0.012, 0.047 and 
0.044 for AKAP17A, HNRNPA0 and HNRNPM respectively). While AKAP17A 
and HNRNPA0 transcript levels were found to be significantly associated with 
performance decline in some of the sub-analyses, HNRNPM showed no such 
further associations. 
Pearson correlations were also carried out to assess relationships between the 
aspects of cognition being measured by MMSE, TMT and PPT. Correlations 
between the measures were relatively weak (R values range from -0.381 to 




Figure 6.2: Sub-analyses of AKAP17A associations with measures of 
cognitive function 
Bar charts showing the associations between expression of AKAP17A and change in 
performance in tests of cognitive function. Panel (a.) shows associations with MMSE score, panel 
(b.) shows associations with TMT-A, panel (c.) shows associations with TMT-B and panel (d.) 
shows associations with PPT. Different sub-analyses are plotted separately as indicated in the 
figure legend. Error bars denote 95% confidence intervals, significance is shown using stars as 
follows: * = p<0.05, ** = p<0.01. Stars indicated in black denote associations which meet multiple 
testing thresholds, while those in grey represent nominal associations 
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Figure 6.3: Sub-analyses of HNRNPA0 associations with measures of 
cognitive function 
Bar charts showing the associations between expression of HNRNPA0 and change in 
performance in tests of cognitive function. Panel (a.) shows associations with MMSE score, panel 
(b.) shows associations with TMT-A, panel (c.) shows associations with TMT-B and panel (d.) 
shows associations with PPT. Different sub-analyses are plotted separately as indicated in the 
figure legend. Error bars denote 95% confidence intervals, significance is shown using stars as 
follows: * = p<0.05, ** = p<0.01. Stars indicated in black denote associations which meet multiple 
testing thresholds, while those in grey represent nominal associations 
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Figure 6.4: Sub-analyses of HNRNPM associations with measures of 
cognitive function 
Bar charts showing the associations between expression of HNRNPM and change in 
performance in tests of cognitive function. Panel (a.) shows associations with MMSE score, panel 
(b.) shows associations with TMT-A, panel (c.) shows associations with TMT-B and panel (d.) 
shows associations with PPT. Different sub-analyses are plotted separately as indicated in the 
figure legend. Error bars denote 95% confidence intervals, significance is shown using stars as 
follows: * = p<0.05, ** = p<0.01. Stars indicated in black denote associations which meet multiple 
testing thresholds, while those in grey represent nominal associations 
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6.6.3 Expression of AKAP17A transcript is associated with mean hand-grip 
strength 
Hand-grip strength, a measure of muscle weakness, is a useful indicator of 
physical functioning and health-related quality of life in the elderly294. Of the 
transcripts tested, only AKAP17A transcript levels were nominally associated with 
decline in hand-grip strength between FU3 and FU4 (β-coefficient -0.006, p = 
0.023) (Figure 6.1, Supplementary table S33). As shown in Figure 6.5a 
(Supplementary table S34), robustness testing of this finding revealed one 
nominal and one significant association in the sub-analyses, and no associations 
with the categorised data. 
6.6.4 Expression of AKAP17A transcript is also associated with two other 
measures of physical ability 
The Epidemiologic Studies of the Elderly – Short Physical Performance Battery 
(EPESE-SPPB) is a validated measure of lower body function and is predictive 
of several important health outcomes, including mortality295. AKAP17A 
expression was found to be nominally associated with decline in the EPESE-
SPPB composite score (β-coefficient -0.011, p = 0.048), and as can be seen in 
Figure 6.5b (Supplementary table S35), subsequent testing showed it also to be 
nominally associated in two of the sub-analyses. 
Another measure of physical ability that was available in the data set was the 
calculated speed (m/s) during a timed 400m fast walking test. Once again, 
AKAP17A expression was found to be nominally associated with decline in 
walking speed (β-coefficient -0.252, p = 0.013). Figure 6.5c (Supplementary table 
S35) shows that this nominal association only held true in one sub-analysis. 
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Finally, Pearson correlations were carried out to assess relationships between 
the aspects of physical ability being measured. Again, correlations between the 
measures were relatively weak (R values range from 0.217 to 0.357, see 
Supplementary table S32b). 
Figure 6.5: Sub-analyses of AKAP17A associations with measures of 
physical ability 
Bar charts showing the associations between expression of AKAP17A and change in 
performance in tests of physical ability. Panel (a.) shows associations with mean hand-grip 
strength, panel (b.) shows associations with the EPESE-SPPB composite score and panel (c.) 
shows associations with calculated speed (m/s) during a 400m fast walking test. Different sub-
analyses are plotted separately as indicated in the figure legend. Error bars denote 95% 
confidence intervals, significance is shown using stars as follows: * = p<0.05, ** = p<0.01. Stars 
indicated in black denote associations which meet multiple testing thresholds, while those in grey 
represent nominal associations 
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6.6.5 HNRNPA0, HNRNPM and AKAP17A transcripts show correlations with 
known biomarkers of ageing 
To test whether these transcripts might share expression patterns with levels of 
recognised biomarkers of ageing296, where such measures were available in our 
dataset, we carried out Pearson correlations between transcript expression levels 
and measurements of interleukin-6 (IL-6), albumin and total erythrocyte numbers. 
Significant correlations were found between: AKAP17A expression and IL-6 
levels (R value = 0.144, p = 0.013); HNRNPA0 expression and both IL-6 and 
erythrocyte number (R values = -0.200 and 0.115, p = 0.001 and 0.048 
respectively); HNRNPM expression and albumin levels (R value = -0.137, p = 
0.018). 
6.7 Discussion 
The human genome is equipped with mechanisms to generate transcriptomic 
diversity from a relatively small DNA complement130. This transcriptomic diversity 
underpins our ability to respond appropriately to internal and external 
environmental challenges, while the failure of such cellular stress responses 
contributes to ageing itself and to age-related diseases110. Alternative splicing is 
one of the major mechanisms for generation of such diversity268, and is regulated 
by the combinatorial binding of a set of trans-acting activating and inhibitory 
proteins termed splicing factors to cis- sequence control elements126. 
Dysregulation of splicing factor expression occurs with human ageing at the 
epidemiological and cellular levels 101,103, and is also associated with longevity in 
animal models 104. These changes are drivers of cellular ageing, since restoration 
of splicing factor levels is able to reverse multiple senescence phenotypes in 
aged human cells in vitro 107,269,270. In the work described here, we provide 
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evidence that changes in splicing factor expression are not only present in in vitro 
data, but may also contribute to the development of downstream ageing 
phenotypes in older people. We report predictive associations between the 
transcript expression levels of three splicing factor genes, HNRNPM, HNRNPA0 
and AKAP17A with ageing phenotypes in a human population study, the 
InCHIANTI study of Aging163. 
HNRNPM, HNRNPA0 and AKAP17A transcript levels were predictively 
associated with a decline in MMSE score as well as a decline in performance on 
the Trail-Making Test parts A & B and the Purdue Pegboard Test. Associations 
between transcript expression of all 3 genes and ageing phenotypes were 
strongest in the individuals with severe cognitive decline as measured by MMSE. 
It is possible that these three splicing factors are not independently associated 
with the traits in question, but correlations between them are only moderate. 
HNRNPM and HNRNPA0 encode splicing inhibitor proteins that have roles in 
determining the splicing patterns of several genes with relevance to brain 
physiology. TDP-43 is one of the major proteins involved with Amyotrophic lateral 
sclerosis (ALS) and Frontotemporal Dementia (FTD) in humans297. HNRNPM 
and HNRNPA0 are both known to interact with TDP-43298, and mutations in other 
HNRNPs have been described in patients with ALS299. In Drosophila species, 
depletion of the fly homologue of HNRNPM (Rump) is associated with loss of 
neuronal dendritic terminal branches; a phenotype that could be partially restored 
by the addition of a Rump transgene300. HNRNPM has also been demonstrated 
to directly regulate alternative splicing of the dopamine receptor 2 (DRD2) gene, 
whereby it inhibits the inclusion of exon 6301. DRD2 splice variants have 
previously been implicated with schizophrenia and impaired cognitive function in 
humans302,303. Similarly, increased protein expression of Hnrnpa0 in 
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hippocampus has been shown to be associated with memory formation and 
consolidation in mice304. AKAP17A, otherwise known as SFSR17A, is an X-linked 
gene encoding a splicing regulatory factor that also has roles in targeting protein 
kinase A anchoring protein to splicing factor compartments305. It is a poorly 
characterised gene, but has been previously associated with the development of 
Alzheimer’s disease; sequences deriving from this gene appear twice amongst 
probes that best differentiate Alzheimer’s disease brain samples from controls306.  
AKAP17A was also found to be associated with decline over time in measures of 
physical function, although the sporadic nature of replication of this association 
in the sub-analyses suggests that either this finding is less robust, or the 
measurements themselves are more subject to variation. No functional role for 
AKAP17A has previously been reported in relation to muscle function. 
Although the changes reported here represent changes in peripheral blood, 
similar changes to splicing regulation have been reported in senescent cell lines 
from other, less accessible tissues107,108. Splicing factor expression is ubiquitous, 
although changes in the exact composition of the splicing factor milieu will occur 
from tissue to tissue. We postulate that the expression patterns of splicing factors 
in peripheral blood may at least partly reflect changes in less accessible tissues. 
We previously demonstrated that senescence-related changes in splicing factor 
expression in endothelial cells and cardiomyocytes are preserved in human 
peripheral blood, and resultant changes in the alternative splicing of the VEGFA 
gene are associated with incident and prevalent coronary artery disease108. Both 




Our study has several strengths; the use of a longitudinal population study has 
allowed some assessment of causality of effect. Placed in the context of the 
known dysregulation of splicing factor expression in human and animal ageing, 
their associations with longevity in both animals and humans67,104 and the 
observation that correction of splicing factor levels is sufficient to reverse 
senescence phenotypes in vitro107 suggests that these changes may be a driver 
of ageing rather than an effect. The data presented here suggest that the 
presence of dysregulated splicing factor transcripts before the emergence of 
overt disease in peripheral blood may contribute to the development of age-
related phenotypes such as cognitive decline. Our finding that expression of 
these transcripts correlate with established biomarkers of ageing is also 
suggestive that they may be indicative of future outcomes. Our study is not 
without limitations however; we have only assessed splicing factor expression at 
the level of the mRNA transcript for reasons of practicality. It is possible that 
processes such as post-transcriptional regulation of mRNA transcripts or altered 
protein kinetics may also contribute and would not be identified in our study. 
However, the observation of phenotypic changes in senescent cells in vitro 
strongly suggests that these changes may also occur at the protein level. Our 
study cohort is also relatively small in comparison to some resources. It is 
however exquisitely well characterised and features longitudinal waves of 
samples which many other studies do not. These observations require replication 
in an additional dataset in the future. However, we have measures from two 
waves of the study, which although they comprise the same people, represent 
completely separate sample collection, sample handling and analytical subsets.  
We recognise that although an adjustment for multiple testing has been applied 
at the level of phenotype (i.e. accounting for 6 measurements) throughout this 
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study, there remains a risk of Type I error in the results presented by using a 
significance level of p=0.0083 as the corrected threshold. However, the genes 
tested represented an a priori list on the basis of known associations with age or 
cellular senescence101,103, and we show here that although moderate, 
correlations do exist between splicing factor expression levels as well as between 
the measured phenotypic outcomes (Supplementary tables S30 & S32), all of 
which complicate a sensible implementation of multiple testing criteria. It is also 
possible that the statistical power of this study may be limited given the number 
of samples and the observed effect sizes, leading to potential inflation of Type II 
error. Therefore, either Bonferroni or Benjamini-Hochberg correction for both the 
number of genes and phenotypes seem likely to be overly stringent for this 
dataset, however the issue of multiple testing persists, so without independent 
validation of the findings presented here, we must be conservative with any 
interpretation of these results. 
We present here evidence to suggest that expression levels of HNRNPM, 
HNRNPA0 and AKAP17A genes may be associated with cognitive decline, whilst 
AKAP17A levels may be associated with decline in physical performance in a 
human population. These findings suggest that the age-related splicing factor 
changes we have previously reported in vitro and in vivo may contribute to the 
development of downstream ageing phenotypes in older humans. Given 
validation of these findings in an independent data set, splicing factor expression 
could comprise a relatively non-invasive biomarker of cognitive decline or 
physical ability in the future, which could be assessed from samples collected 
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7.1 Summary of thesis 
Current demographic trends predict that the elderly will make up an ever-
increasing proportion of the world’s population, and that dependency ratios will 
increase because of this. Advancing age is known to be the largest risk factor for 
most chronic diseases, therefore the progressive ageing of the population will 
bring increased incidence of morbidities and the associated socio-economic 
impact. 
Ageing is a complex and heterogeneous process with a host of potential 
pathways contributing to the process. Understanding the interplay between these 
mechanisms and their regulation will be essential to the development of 
strategies aimed at increasing healthspan and alleviating the negative effects of 
age-related disease. 
I have investigated the role of RNA regulatory processes in ageing and lifespan, 
both in model organisms and in humans, to provide some insight into the ways in 
which this regulation could be involved in the development of the ageing 
phenotype and determination of lifespan/healthspan. 
7.2 Summary of data chapters 
7.2.1 Chapter 3: Changes in the expression of splicing factor transcripts and 
variations in alternative splicing are associated with lifespan in mice and humans. 
Summary 
In chapter 3, I investigated the relationship of splicing factor transcript expression 
and alternatively expressed isoforms with age and strain lifespan in mice. The 
mouse husbandry and determination of median strain lifespan were carried out 
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by collaborators at the Jackson laboratory Nathan Shock Centre of Excellence in 
the Basic Biology of Aging, who provided flash-frozen tissue for RNA extractions. 
We were supplied with spleen and quadriceps muscle samples from both young 
(6 month old) and old (20-22 month old) animals from six strains with varying 
median lifespan (range: 623 days to 1005 days). I measured expression levels of 
splicing factors and alternative isoforms using qRT-PCR on custom Taqman™ 
Low Density Arrays (TLDA) and tested this data for associations with age and 
median strain lifespan. 
It was found that several splicing factors were associated with both age and strain 
lifespan, in a highly tissue-specific manner. Importantly, these expression 
differences were apparent in young animals of the long-lived strains, suggesting 
that splicing factors may represent a determinant of lifespan. It was also shown 
that shifts in isoform expression seemed to be indicative of reduced cellular 
senescence and pro-inflammatory signalling in long-lived strains, potentially 
contributing to the longevity phenotype. 
The splicing factors that had shown significant results in the mouse work were 
then tested in pre-existing microarray-based gene expression data from a human 
cohort, to assess whether they were associated with parental longevity score (as 
a proxy measure for longevity188). Two of the splicing factors also showed 
associations in humans, strengthening the case that splicing factors are central 
to the pathways involved in mammalian ageing. 
Limitations to this chapter were the relatively small number of animals available 
for testing from each strain, and the fact that splicing patterns were only assessed 




Importance of findings 
To my knowledge, this work represented the first reported indication that 
regulation of alternative splicing may be involved in determination of longevity in 
mammals. Shortly after publication of this work, Will Mair’s lab at Harvard 
published a study showing that the splicing factor SF1 modulates longevity in C. 
elegans67, further strengthening our argument. 
Future work 
To address the limitations of this study, it would be advantageous to extend the 
current experiments to include a larger sample size, a greater number of tissues, 
as well as analysis of splicing patterns at the level of protein synthesis. 
Further in vitro and in vivo experiments could also be performed to establish 
causality and mechanism in terms of the role of splicing factors in determining 
lifespan. These could take the form of manipulation of splicing factor expression 
in cell culture and/or conditional knockout studies in model organisms. 
7.2.2 Chapter 4: MicroRNAs miR-203-3p, miR-664-3p and miR-708-5p are 
associated with median strain lifespan in mice. 
Summary 
In chapter 4, I examined the relationship between miRNA expression levels and 
median strain lifespan in mice. The spleen tissue used was from the same 
collection of six strains (and two ages) as used in chapter 3 (see section 7.2.1). I 
measured near-global miRNA expression in a subset of samples using a high-
throughput qRT-PCR approach, followed by a targeted validation step in all 
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available samples. Expression levels of three miRNAs were found to be robustly 
associated with strain lifespan by this method. 
Pathway analysis was carried out for these three miRNAs and target genes from 
several of the predicted target pathways were chosen for further analysis. I then 
measured expression levels of the mRNAs of the chosen genes and tested for 
associations of these with lifespan. Almost all of the genes in question also 
proved to show expression levels associated with lifespan, suggesting that these 
miRNAs are having some functional effect in the determination of lifespan. 
Limitations to this chapter were the relatively small number of animals available 
for testing from each strain, the use of a single tissue for analysis and the potential 
for cell-type variations due to the plastic nature of splenic tissue. 
Importance of findings 
While miRNAs had already been implicated in lifespan regulation of C. elegans 
and Drosophila prior to this work, only a very small number of miRNAs were 
known to have roles in longevity in mice, and these had usually been discovered 
in a single strain. This study represents a screen of six independent strains and 
has found associations of miRNAs with lifespan that had not previously been 
described. These findings add to the evidence suggesting that RNA regulation of 
gene expression is important in determining lifespan. 
Future work 
Similar to chapter 3, to address the limitations of this study it would be 
advantageous to extend the current experiments to include a larger sample size 
and a greater number of tissues. 
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To assess the importance of these miRNAs in the ageing process, further 
experiments using miRNA mimics or antagomirs could be carried out, either in 
vitro using primary cells - measuring cellular senescence as an output, or in 
model organisms to determine whether any effects on lifespan could be detected 
in vivo. 
7.2.3 Chapter 5: Dietary restriction in ILSXISS mice is associated with 
widespread changes in splicing regulatory factor expression levels. 
Summary 
In chapter 5, I investigated the relationship between splicing factor expression 
and strain lifespan response to dietary restriction (DR) in mice. The mouse 
husbandry was carried out by collaborators at the Institute of Biodiversity Animal 
Health & Comparative Medicine at the University of Glasgow, who provided flash-
frozen tissue for RNA extractions. We were supplied with brain, heart and kidney 
tissues from three strains of mice known to show differing lifespan responses to 
DR treatment. Tissues were taken from a set of animals allowed ad libitum (AL) 
feeding and a second set kept under 40% DR conditions, for two separate lengths 
of treatment; two months and ten months. I measured splicing factor transcript 
expression levels in all of these samples and tested for associations with DR in 
short- and long-term treatments, as well as associations with strain response. 
Three distinct groups of associations were found: 
1. Splicing factors associated with DR only 
2. Splicing factors associated with strain only 
3. Splicing factors associated with both DR and strain 
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The third group represent splicing factors which could be involved in the 
mechanisms determining strain-specific lifespan response to DR. The 
associations found were both tissue- and duration-specific. 
Limitations to this chapter were the fact that only levels of splicing factors were 
measured, and not alternatively spliced isoforms or protein. 
Importance of findings 
At the time of publication of this chapter, post-transcriptional RNA processing and 
alternative splicing had previously been linked to ageing and lifespan in model 
organisms308, and the aforementioned publication from the Mair lab67 (see section 
7.2.1) had shown that a splicing factor was directly involved in the lifespan 
extension seen under DR in C. elegans. However, to my knowledge this is the 
first study to examine the role of splicing factors during DR in multiple tissues 
from mice displaying variable lifespan response to the treatment and therefore 
able to offer mechanistic insights into the role of splicing in determination of 
lifespan in a mammalian system. 
Future work 
To address the limitations of this study, it would be useful to assess splicing factor 
expression at the protein level, and to test expression levels of alternatively 
spliced isoform transcripts. Considering the shifts seen in splicing factors, it is 
likely that changes would be apparent in isoform expression of alternatively 
spliced genes. It would therefore be highly informative to obtain transcriptome-
wide isoform level data from these samples to determine which transcripts are 
showing isoform ratio shifts in the different responder strains. If candidate genes 
were revealed by such work, it would also be interesting to deliver splice-
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switching oligos into model organisms, in a tissue-specific manner, to assess 
potential non-autonomous effects on longevity from isoform shifts of key genes 
in different tissues. 
7.2.4 Chapter 6: The transcript expression levels of HNRNPM, HNRNPA0 and 
AKAP17A splicing factors may be predictively associated with ageing phenotypes 
in human peripheral blood. 
Summary 
In chapter 6, I examined the relationship between splicing factor expression and 
a set of measures of two human ageing phenotypes; cognitive decline and 
reduced physical ability. Peripheral blood samples and detailed anthropometric 
data were collected from participants by collaborators involved in the InCHIANTI 
study of Aging, a longitudinal population study of human ageing in the Chianti 
region of Italy163 which has been running since 1998. We were supplied with 
blood samples and data from two of the follow-up visits in the study. I measured 
splicing factor transcript expression levels in the blood samples from the earlier 
time-point and tested for associations with decline in measures of cognitive 
function and physical ability. 
Expression levels of three splicing factors were found to predict change in 
cognitive performance, and one of these also predicted change in physical 
performance. Correlations were also found between expression levels of these 
three splicing factors and established biomarkers of ageing. These findings 
further reinforce the idea that splicing factors are central to the ageing process 
and also provide evidence that altered regulation of alternative splicing may be a 
driver in the development of ageing phenotypes. 
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Limitations to this chapter were that our findings were based on a single human 
cohort, also that measurements were only carried out for splicing factors at the 
mRNA level, and not alternatively spliced isoforms or protein. 
Importance of findings 
To my knowledge, this is the first report of a link between the expression of 
splicing regulatory factors and future health outcomes in a human population. The 
fact that these splicing factors display altered expression levels before overt 
changes in phenotype suggests that they may be mechanistically involved in the 
development of age-related phenotypes, and opens the possibility that they could 
serve as non-invasive biomarkers of declining health. 
Future work 
To address the limitations of this chapter, it would be desirable to find a separate 
longitudinal cohort study of ageing with RNA samples and similarly detailed 
anthropometric data available at multiple time-points in order to validate these 
findings. It would also be useful to assess splicing factor expression at the protein 
level. Measurements of isoform expression levels of alternatively spliced genes 
in these samples could add further valuable insights into mechanisms underlying 
development of age-related phenotypes. 
7.3 Discussion of thesis 
This thesis investigates the ways in which aspects of RNA regulation contribute 
to the ageing process and determination of lifespan in mammals. To achieve this, 
I have used two different murine models and a human cohort to identify 
associations and patterns of change in expression levels of splicing factor 
transcripts, miRNAs and alternatively expressed mRNAs. In the first mouse 
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model, I assessed the role of splicing factors, alternative splicing and miRNAs in 
normal ageing and with strain lifespan. In the second mouse model, I considered 
splicing factors under DR conditions, a well-known modifier of lifespan. In the 
human cohort, I validated findings from the first mouse model as well as 
assessing splicing factors as predictive markers of future health outcomes. 
Through this work I have shown that splicing factors are associated with lifespan 
in mice, and with parental longevity score in human peripheral blood. I then 
showed that alternatively spliced isoforms of key age-related genes are 
expressed differently according to mouse strain lifespan. Given that some of 
these associations were found in the young mice, further investigation into 
potential age/lifespan interactions suggested that these expression patterns 
could be determinants of longevity. Following on from this, I showed that three 
specific miRNAs are robustly longevity-associated in these mice. In silico 
pathway analysis of the predicted gene targets of these microRNAs implicated 
signalling cascades known to be involved in ageing, and expression levels of 
selected mRNA transcripts from these pathways were also shown to associate 
with strain lifespan, suggesting that the three miRNAs are affecting the 
determination of lifespan through modulation of gene expression levels in 
important age-related pathways. Once again, the presence of these associations 
in young mice and subsequent interaction analyses suggested that these effects 
could be determining lifespan. 
I then showed that splicing factor transcripts are associated with variable lifespan 
response in tissues taken from mice housed under 40% DR conditions. 
Expression patterns were highly tissue-specific and showed distinct differences 
with short- and long-term DR exposure. Interaction analyses between strain 
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response and DR status revealed that splicing factor expression may have a 
mechanistic involvement in determining lifespan response and perhaps suggests 
a splicing-driven homeostatic adaptation to DR conditions.  
Finally, I showed that expression levels of three splicing factor transcripts were 
predictively associated with future declines in several different measures of 
cognitive and physical ability in a human cohort, indicating that patterns of mRNA 
splicing regulation may create conditions which determine healthspan and/or 
lifespan. 
Disrupted splicing is a feature of many human diseases309-311, and several age-
related disorders are known to be directly caused by altered splicing 
patterns312,313, for example: 
• Mutations in the ABCR gene have been shown to disrupt splice sites, resulting 
in age-related macular degeneration314-316.  
• Retention of intronic sequences in the ENG and ANKRD1 genes cause 
vascular disease317  and heart disease318 respectively.  
• Alternative splicing of exon 10 in the MAPT gene disturbs the 3R-tau:4R-tau 
protein ratio which in turn causes a set of neurodegenerative diseases 
collectively known as ‘tauopathies’ including frontotemporal dementia and 
Alzheimer’s disease319.  
• A panel of genes known to be involved in alternative splicing are also 
implicated in the onset of amyotrophic lateral sclerosis320,321. 
It is also the case that many of the progeroid syndromes can be caused by 
splicing defects in key genes. Hutchinson-Gilford Progeria is caused by a 
mutation in the LMNA gene which creates a cryptic splice site in exon 11 and thus 
produces ‘progerin’, a pathogenic form of the lamin A nuclear envelope protein322. 
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Around half of the pathogenic mutations in the WRN helicase gene responsible 
for Werner syndrome are either truncations due to exon skipping or splicing 
mutations323. Branch-point site mutations in the XPC gene cause skipping of exon 
4, reduced protein levels, and have been associated with pathogenesis of 
xeroderma pigmentosum324. All known Cockayne syndrome subtypes are 
associated with mutations in either the ERCC6 or ERCC8 gene, which include 
splicing alterations325. Finally, ataxia telangiectasia is caused by mutations in the 
ATM gene, which in ≈90% of cases either truncate the transcript or affect 
splicing326. 
Added to this, many key genes in the age-related signalling pathways are 
alternatively spliced. In the IIS pathway, the insulin receptor gene (IR) is known 
to produce two alternative splice isoforms; IR-A and IR-B327, while IGF-1 
produces at least three isoforms, IGF-1Ea, IGF-1Eb and IGF-1Ec, each of which 
activates IIS in a different manner328. The mTOR pathway is known to feature at 
least 20 alternatively spliced genes, including mTOR itself312. The tumour 
suppressor transcription factor p53 is involved in several age-related processes91 
and is also a regulator of the IIS and mTOR pathways329. Alternative splicing of 
p53 produces a truncated isoform (p44 in mice, p47 in humans), increased 
expression of which shortens healthspan and lifespan in mice330. 
All the above evidence points to a central role for alternative splicing in ageing, 
lifespan and healthspan. The work that I have presented in this thesis goes a step 
further and suggests not only that alternative splicing and its regulation are 
associated with ageing and longevity, but also that there is a strong likelihood 
that they play a causal role in the determination of lifespan in mammals. 
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Very large numbers of miRNAs are known to be both correlated with and/or 
causative of progression of many diseases, both age-related and otherwise331-
335. A smaller number have also been shown to affect expression of the genes 
causing the premature ageing phenotypes seen in Hutchinson-Gilford progeria336 
and Werner syndrome337. 
It is also recognised that many miRNAs interact with genes in the signalling 
pathways involved in ageing and lifespan. A number of miRNAs have been shown 
to modulate ageing and/or lifespan by targeting genes in the IIS pathway99, and 
others are known to target elements of the mTOR pathway338. Several of these 
miRNAs and their functions are also well conserved from invertebrates through 
to mammals99, implying a key role in the regulation of these pathways. 
A review by Lorna Harries216 describes 85 miRNAs currently known to be involved 
in the ageing process, and how these relate to López-Otin’s hallmarks of 
ageing94. Interestingly, over 20% of the miRNAs described potentially target 
genes involved in more than one of the hallmarks, raising the possibility that 
networks of miRNAs may act in a coordinate fashion to allow fine control over 
several different aspects of the ageing process at once. 
Once again, existing evidence strongly suggests miRNAs play an important role 
in ageing longevity. The work presented in this thesis strengthens this hypothesis, 
implicates miRNAs that had not previously been associated with lifespan and 
indicates that they could be a causal factor in determination of lifespan. 
7.4 Conclusion 
Regulation of gene expression at the RNA level is clearly an important factor in 
ageing and determination of lifespan/healthspan. This thesis reinforces the 
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current knowledge and builds upon it, providing novel insights into the roles of 
splicing factors, alternative splicing and miRNAs in these processes.  
The finding that aspects of the RNA regulatory network show differential patterns 
of expression in young mice of different strain lifespan, coupled with the discovery 
that levels of specific splicing factors are predictive of human ageing phenotypes, 
raises the exciting possibility that direct modulation of RNA regulatory processes 
could potentially be harnessed to improve human healthspan. Alternatively, 
elements of the RNA regulatory machinery may have use as biomarkers of future 
health outcomes, allowing for application of health maintenance interventions at 
an earlier stage. 
This work, along with existing and currently unpublished data, constitute a 
growing body of evidence underlining the importance of RNA regulation in ageing. 
Taken together with the fact that López-Otin’s criteria have largely been met in 
terms of defining core mechanisms of ageing, I feel that there may be a case for 
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Supplementary Figure S1 (Chapter 3): Heat maps demonstrating inter- and 
intra-strain heterogeneity in splicing factor expression by age.  
Splicing factor expression is given along the bottom of each heat map. Mouse age is given on the 
Y-axis. No clustering of expression signatures in young or old mice is noted. Data are Z-scored, 







Supplementary Figure S2 (Chapter 5): Changes in splicing factor 
expression in non-responder strain (TejJ48) under DR conditions  
Plots illustrating changes in splicing factor expression with DR in the non-responder strain of 
ILSXISS mice (TejJ48). Plot a shows mean differences between AL and DR in brain tissue under 
short-term DR, b shows mean differences between AL and DR in brain tissue under long-term 
DR, c shows mean differences between AL and DR in heart tissue under short-term DR, d shows 
mean differences between AL and DR in heart tissue under long-term DR, e shows mean 
differences between AL and DR in kidney tissue under short-term DR and f shows mean 
differences between AL and DR in kidney tissue under long-term DR. Error bars represent 95% 
confidence intervals and significant differences in splicing factor expression are denoted by stars: 





Supplementary Table S1 (Chapter 3): Splicing factor expression in mouse spleen tissue by lifespan, across 6 strains of different 
longevities 
Data from mice of all ages, young mice only (6 months) and old mice only (20-22 months) are given separately. Data with statistically-significant effects at <0.05 are 
given in bold, underlined italic text. Tra2β was not expressed in PWD/Phj mice so this strain was excluded from the analysis for this marker. P values were determined 
from linear regression of logged data. 




Std Error P value 
Beta 
coefficient 
Std Error P value 
Beta 
coefficient 
Std Error P value 
Hnrnpa0 0.175 0.01 0.10 0.297 0.02 0.06 0.075 0.02 0.62 
Hnrnpa1 -0.151 0.01 0.16 -0.396 0.01 0.01 0.061 0.01 0.69 
Hnrnpa2b1 -0.256 0.01 0.02 -0.578 0.01 <0.0001 0.036 0.01 0.81 
Hnrnpd -0.021 0.01 0.85 0.020 0.12 0.90 -0.045 0.02 0.76 
Hnrnph3 -0.133 0.01 0.22 -0.193 0.01 0.23 -0.098 0.02 0.513 
Hnrnpk -0.316 0.01 0.003 -0.288 0.02 0.07 -0.337 0.02 0.02 
Hnrnpm -0.310 0.01 0.003 -0.307 0.01 0.051 -0.312 0.01 0.03 
Hnrnpul2 -0.223 0.01 0.04 -0.214 0.01 0.18 -0.231 0.01 0.12 
Sf3b1 -0.212 0.01 0.05 -0.267 0.01 0.09 -0.174 0.01 0.24 
Srsf18 0.062 0.01 0.57 0.041 0.02 0.80 0.073 0.02 0.63 
Srsf1 -0.092 0.01 0.39 -0.253 0.02 0.11 0.047 0.02 0.76 
Srsf2 -0.208 0.01 0.052 -0.224 0.02 0.16 -0.189 0.02 0.20 
Srsf3 -0.130 0.01 0.23 -0.362 0.02 0.02 0.125 0.01 0.40 
Srsf6 -0.157 0.01 0.14 -0.132 0.02 0.41 -0.176 0.01 0.24 




Supplementary Table S2 (Chapter 3): Splicing factor expression in mouse muscle tissue by lifespan across 6 strains of different 
longevities 
Data from mice of all ages, young mice only (6 months) and old mice only (20-22 months) are given separately. Data with statistically-significant effects at <0.05 are 
given in underlined, bold, italic text. Tra2β was not expressed in PWD/Phj mice so this strain was excluded from the analysis for this marker. P values were determined 
from linear regression of logged data. 




Std Error P value 
Beta 
coefficient 
Std Error P value 
Beta 
coefficient 
Std Error P value 
Hnrnpa0 0.124 0.02 0.27 -0.086 0.03 0.62 0.357 0.02 0.01 
Hnrnpa1 -0.093 0.01 0.40 -0.200 0.01 0.25 -0.037 0.01 0.80 
Hnrnpa2b1 0.005 0.02 0.96 -0.166 0.03 0.34 0.231 0.02 0.11 
Hnrnpd -0.238 0.01 0.03 -0.177 0.01 0.31 -0.321 0.01 0.03 
Hnrnph3 -0.048 0.02 0.67 -0.227 0.03 0.19 0.115 0.02 0.44 
Hnrnpk -0.146 0.01 0.19 -0.030 0.02 0.86 -0.239 0.02 0.10 
Hnrnpm -0.019 0.01 0.86 -0.211 0.02 0.23 0.168 0.01 0.25 
Hnrnpul2 -0.050 0.02 0.66 -0.223 0.03 0.20 0.152 0.02 0.30 
Sf3b1 -0.165 0.02 0.14 -0.298 0.03 0.08 -0.008 0.02 0.96 
Srsf18 -0.180 0.01 0.10 -0.315 0.03 0.07 -0.047 0.02 0.75 
Srsf1 0.147 0.02 0.19 0.209 0.03 0.23 0.092 0.02 0.54 
Srsf2 -0.177 0.01 0.11 -0.264 0.01 0.13 -0.134 0.01 0.36 
Srsf3 -0.093 0.01 0.40 -0.396 0.01 0.02 0.105 0.01 0.48 
Srsf6 -0.066 0.02 0.55 -0.136 0.03 0.44 0.023 0.02 0.88 





Supplementary Table S3 (Chapter 3): Alternative isoform expression in mouse spleen tissue by lifespan across 6 strains of 
different longevities 
Data from mice of all ages, young (6 months) and old (24 months) are given separately. UCSC transcript Identities identified by each probe set are given under the 
gene names. Data with statistically-significant effects at <0.05 are given in bold, underlined italic text. P values were determined from linear regression on logged data. 




Std Error P value 
Beta 
coefficient 
Std Error P value 
Beta 
coefficient 




0.038 0.01 0.73 0.151 0.05 0.35 -0.054 0.01 0.71 
Atm-2 
uc012gtj.1 
-0.001 0.01 0.99 0.148 0.02 0.36 -0.162 0.01 0.27 
Cdkn2a-1 
Uc008toi.1 
-0.164 0.02 0.13 0.186 0.02 0.26 -0.433 0.03 0.002 
Cdkn2a-2 
uc008toh.1 
-0.247 0.02 0.02 0.108 0.02 0.51 -0.590 0.02 <0.0001 
Chek2-1 
uc008yrw.1 
-0.102 0.02 0.34 -0.281 0.02 0.08 0.070 0.02 0.63 
Chek2-2 
uc008yrx.1 
-0.066 0.01 0.54 -0.292 0.02 0.07 0.154 0.02 0.29 
Fn1-1 
uc007bju.2 




-0.044 0.02 0.68 -0.030 0.02 0.86 -0.064 0.03 0.66 
Lmna-1 
uc008pvj.3 









Supplementary Table S3 (cont.) 




Std Error P value 
Beta 
coefficient 
Std Error P value 
Beta 
coefficient 
Std Error P value 
Myc-1 
uc007vyh.2 










0.144 0.02 0.18 0.406 0.01 0.009 -0.025 0.01 0.86 
Trp53-2 
uc011xww.1 
-0.236 0.01 0.03 -0.250 0.01 0.12 -0.214 0.07 0.14 
Trp53-3 
uc007jqm.2 
-0.230 0.01 0.03 -0.352 0.01 0.03 -0.121 0.01 0.41 
Vcan-1 
uc007rjg.1 
0.365 0.02 0.001 0.570 0.03 <0.0001 0.243 0.04 0.09 
Vcan-2 
uc011zck.1 





Supplementary Table S4 (Chapter 3): Alternative isoform expression in mouse muscle tissue by lifespan across 6 strains of 
different longevities 
Data from mice of all ages, young (6 months) and old (20-22 months) are given separately. Data with statistically-significant effects at <0.05 are given in bold, underlined 
italic text. P values were determined from linear regression of logged data. 




Std Error P value 
Beta 
coefficient 
Std Error P value 
Beta 
coefficient 
Std Error P value 
Il1b-2 





















0.076 0.02 0.51 -0.071 0.03 0.69 0.294 0.01 0.05 
Nfkb1-2 










Supplementary Table S4 (cont.) 




Std Error P value 
Beta 
coefficient 
Std Error P value 
Beta 
coefficient 




0.313 0.01 0.005 0.257 0.02 0.15 0.371 0.01 0.01 
Stat1-1 
















0.219 0.01 0.052 0.429 0.01 0.01 0.096 0.01 0.53 
Stat1-5 
uc007ayb.2 0.332 0.01 0.005 0.378 0.02 0.03 0.299 0.02 0.04 
Stat1-6 








-0.233 0.02 0.04 -0.183 0.03 0.31 -0.280 0.02 0.06 
Tnf-3 




Supplementary Table S5 (Chapter 3): Splicing factor expression in mouse spleen tissue by age in young (6 months) and old (20-
22 months) mice 
Data from mice of all strains, average-lived strains (median age <847.5 days) and long-lived (median lifespan >847.5 days) strains are given separately. Data with 
statistically-significant effects at <0.05 are given in bold, underlined italic text. Tra2β was not expressed in PWD/Phj mice so this strain was excluded from the analysis 
for this marker. P values were determined from linear regression analysis of logged data. 




Std Error P value 
Beta 
coefficient 
Std Error P value 
Beta 
coefficient 
Std Error P value 
Hnrnpa0 -0.031 0.04 0.77 0.018 0.05 0.92 -0.053 0.05 0.70 
Hnrnpa1 -0.015 0.03 0.89 -0.278 0.04 0.11 0.134 0.03 0.34 
Hnrnpa2b1 -0.035 0.04 0.74 -0.460 0.05 0.005 0.248 0.04 0.07 
Hnrnpd 0.038 0.03 0.73 -0.043 0.06 0.81 0.094 0.04 0.50 
Hnrnph3 -0.170 0.03 0.11 -0.278 0.06 0.11 -0.09 0.04 0.54 
Hnrnpk 0.012 0.04 0.91 0.081 0.07 0.64 -0.104 0.03 0.46 
Hnrnpm -0.034 0.03 0.75 -0.108 0.05 0.54 -0.001 0.04 0.99 
Hnrnpul2 0.018 0.03 0.87 -0.042 0.06 0.81 0.059 0.04 0.68 
Sf3B1 0.000 0.03 0.99 -0.073 0.05 0.68 0.05 0.04 0.72 
Srsf18 0.158 0.04 0.14 0.098 0.06 0.58 0.193 0.06 0.17 
Srsf1 -0.157 0.04 0.14 -0.341 0.06 0.05 -0.042 0.05 0.76 
Srsf2 -0.178 0.04 0.10 -0.266 0.07 0.12 -0.150 0.04 0.284 
Srsf3 -0.215 0.04 0.04 -0.449 0.07 0.007 -0.007 0.04 0.96 
Srsf6 -0.082 0.04 0.45 -0.124 0.06 0.48 -0.068 0.03 0.63 




Supplementary Table S6 (Chapter 3): Splicing factor expression in mouse muscle tissue by age in young (6 months) and old (20-
22 months) mice 
Data from mice of all strains, average-lived strains (mean lifespan <847.5 days) and long-lived strains (mean lifespan >847.5 days) are given separately. Data with 
statistically-significant effects at <0.05 are given in bold, underlined italic text. Tra2β was not expressed in PWD/Phj mice so this strain was excluded from the analysis 
for this marker. P values were determined from linear regression of logged data. 




Std Error P value 
Beta 
coefficient 
Std Error P value 
Beta 
coefficient 
Std Error P value 
Hnrnpa0 0.123 0.05 0.27 -0.057 0.08 0.75 0.236 0.07 0.11 
Hnrnpa1 0.217 0.03 0.05 0.174 0.04 0.32 0.267 0.05 0.07 
Hnrnpa2b1 -0.048 0.06 0.67 -0.228 0.08 0.19 0.075 0.07 0.61 
Hnrnpd 0.123 0.03 0.27 0.221 0.04 0.20 0.113 0.04 0.44 
Hnrnph3 -0.001 0.06 0.99 -0.184 0.08 0.29 0.122 0.08 0.41 
Hnrnpk -0.046 0.04 0.68 0.086 0.07 0.62 -0.128 0.05 0.39 
Hnrnpm 0.187 0.04 0.09 0.040 0.05 0.82 0.281 0.05 0.053 
Hnrnpul2 0.029 0.05 0.80 -0.134 0.07 0.44 0.128 0.08 0.39 
Sf3B1 0.017 0.06 0.88 -0.146 0.08 0.40 0.127 0.08 0.39 
Srsf18 0.095 0.05 0.39 -0.055 0.07 0.76 0.222 0.07 0.13 
Srsf1 -0.046 0.06 0.68 0.016 0.10 0.93 -0.114 0.07 0.44 
Srsf2 0.084 0.03 0.45 0.134 0.04 0.44 0.083 0.05 0.58 
Srsf3 0.100 0.04 0.37 -0.086 0.05 0.62 0.272 0.04 0.06 
Srsf6 -0.100 0.06 0.37 -0.159 0.08 0.36 -0.063 0.09 0.67 




Supplementary Table S7 (Chapter 3): Alternative isoform expression in mouse spleen tissue by age in young (6 months) and old 
(20 -22 months) mice 
Data from mice of all strains, average-lived strains (mean lifespan <847.5 days) and long-lived strains (mean lifespan (>847 days) are given separately. UCSC transcript 
Identities identified by each probe set are given under the gene names. Data with statistically-significant effects at <0.05 are given in bold, underlined italic text. P 
values were determined from linear regression of logged data. 




Std Error P value 
Beta 
coefficient 
Std Error P value 
Beta 
coefficient 




-0.044 0.04 0.69 0.127 0.06 0.47 -0.156 0.05 0.36 
Atm-2 
uc012gtj.1 
-0.072 0.04 0.50 0.163 0.06 0.35 -0.277 0.05 0.10 
Cdkn2a-1 
uc008toi.1 
0.399 0.06 <0.0001 0.659 0.09 <0.0001 0.224 0.08 0.10 
Cdkn2a-2 
uc008toh.1 
0.529 0.06 <0.0001 0.815 0.06 <0.0001 0.346 0.08 0.007 
Chek2-1 
uc008yrw.1 
-0.331 0.05 0.002 -0.499 0.07 0.002 -0.227 0.07 0.10 
Chek2-2 
uc008yrx.1 
-0.349 0.05 0.001 -0.542 0.06 0.001 -0.232 0.06 0.10 
Fn1-1 
uc007bju.2 




0.105 0.05 0.33 0.167 0.06 0.34 0.086 0.08 0.54 
Lmna-1 
uc008pvj.3 




-0.198 0.05 0.06 -0.335 0.09 0.05 -0.101 0.06 0.47 
Myc-1 
uc007vyh.2 




Supplementary Table S7 (cont.) 




Std Error P value 
Beta 
coefficient 
Std Error P value 
Beta 
coefficient 










-0.243 0.02 0.02 0.007 0.03 0.97 -0.407 0.02 0.002 
Trp53-2 
uc011xww.1 
-0.114 0.02 0.29 -0.06 0.03 0.73 -0.147 0.03 0.29 
Trp53-3 
uc007jqm.2 
-0.240 0.03 0.03 -0.313 0.05 0.07 -0.194 0.04 0.16 
Vcan-1 
uc007rjg.1 
0.063 0.09 0.56 0.198 0.11 0.26 0.004 0.13 0.98 
Vcan-2 
uc011zck.1 




Supplementary Table S8 (Chapter 3): Alternative isoform expression in mouse muscle tissue by age in young (6 months) and old 
(20 -22 months) mice 
Data from mice of all strains, average-lived strains (mean lifespan <847.5 days) and long-lived strains (mean lifespan (>847 days) are given separately. UCSC transcript 
Identities identified by each probe set are given under the gene names. Data with statistically-significant effects at <0.05 are given in bold, underlined italic text. P 
values were determined from linear regression of logged data. 




Std Error P value 
Beta 
coefficient 
Std Error P value 
Beta 
coefficient 
Std Error P value 
Il1b-2 





















0.083 0.06 0.45 -0.110 0.06 0.54 0.161 0.09 0.29 
Nfkb1-2 









Supplementary Table S8 (cont.) 




Std Error P value 
Beta 
coefficient 
Std Error P value 
Beta 
coefficient 




-0.107 0.04 0.35 -0.170 0.07 0.34 -0.091 0.05 0.55 
Stat1-1 
















-0.203 0.03 0.07 -0.014 0.04 0.94 -0.321 0.05 0.03 
Stat1-5 
uc007ayb.2 -0.059 0.05 0.61 0.242 0.04 0.17 -0.020 0.07 0.89 
Stat1-6 








0.053 0.06 0.64 0.178 0.09 0.32 0.002 0.08 0.99 
Tnf-3 




Supplementary Table S9 (Chapter 3): Analyses of potential interactions 
between mouse strain longevity and mouse age 
Std. Err = standard error, 95% Ci = 95% Confidence intervals. Average lived strains have a 
lifespan of <847.5 days, long-lived strains have a mean lifespan of >847.5 days. Young mice are 
6 months, old mice are 20-22 months old. Statistically significant results are indicated in bold 
underlined text. 
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-0.23 to -0.05 
























-0.12 to 0.07 
-0.20 to -0.02 























-0.30 to -0.08 
-0.28 to -0.07 

























-0.30 to -0.07 
-0.23 to -0.26 
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0.25 to 0.63 
-0.09 to 0.27 
























0.32 to 0.67 
-0.12 to 0.20 
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-0.30 to 0.001 
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-0.10 to 0.10 
0.12 to 0.21 
























-0.16 to 0.20 
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Supplementary Table S10 (Chapter 3): Splicing factor expression in mouse spleen tissue by lifespan, across 6 strains of different 
longevities by binary logistic regression 
Data from mice of all ages, young mice only (6 months) and old mice only (20-22 months) are given separately. Data with statistically-significant effects at <0.05 are 
given in bold, underlined italic text. Tra2β was not expressed in PWD/Phj mice so this strain was excluded from the analysis for this marker. P values were determined 
from binary logistic regression of logged data. P values marked by stars are also significant in linear regression analysis. 




Std Error P value 
Beta 
coefficient 
Std Error P value 
Beta 
coefficient 
Std Error P value 
Hnrnpa0 1.80 1.31 0.17 2.27 1.95 0.24 1.40 1.78 0.43 
Hnrnpa1 -5.78 2.05 0.005 -10.40 3.63 0.004* -2.50 2.53 0.32 
Hnrnpa2b1 -2.89 1.47 0.05* -10.23 3.36 0.002* 1.38 1.91 0.47 
Hnrnpd -0.90 1.42 0.54 -3.11 1.28 0.26 -0.06 1.62 0.98 
Hnrnph3 1.00 1.43 0.49 -1.19 2.85 0.67 1.83 1.76 0.30 
Hnrnpk -9.50 2.28 <0.0001* -9.42 7.05 0.008 -9.55 2.99 0.001* 
Hnrnpm -8.23 2.34 <0.0001* -10.67 6.72 0.01 -6.70 5.49 0.02* 
Hnrnpul2 -2.88 3.37 0.07* -4.70 2.95 0.09 -1.84 1.90 0.33 
Sf3b1 -4.79 1.81 0.008* -8.00 3.44 0.02 -3.17 2.11 0.13 
Srsf18 -1.96 1.18 0.10 -2.57 1.79 0.15 -1.47 1.62 0.36 
Srsf1 -2.45 1.36 0.07 -5.28 2.46 0.03 -0.766 1.76 0.66 
Srsf2 -5.96 1.63 <0.0001 -8.01 3.03 0.008* -5.18 2.09 0.01 
Srsf3 -2.61 1.35 0.054 -6.16 2.35 0.009 0.49 2.03 0.81 
Srsf6 -6.07 1.98 0.002 -6.90 3.11 0.03 -5.55 2.63 0.04 




Supplementary Table S11 (Chapter 3): Splicing factor expression in mouse muscle tissue by lifespan across 6 strains of different 
longevities by binary logistic regression analysis 
Data from mice of all ages, young mice only (6 months) and old mice only (20-22 months) are given separately. Data with statistically-significant effects at <0.05 are 
given in underlined, bold, italic text. Tra2β was not expressed in PWD/Phj mice so this strain was excluded from the analysis for this marker. P values were determined 
from binary logistic regression of logged data. P values marked by stars are also significant in linear regression analysis. 




Std Error P value 
Beta 
coefficient 
Std Error P value 
Beta 
coefficient 
Std Error P value 
Hnrnpa0 2.20 1.11 0.05 0.33 1.21 0.79 6.08 2.30 0.008* 
Hnrnpa1 -2.39 1.60 0.13 -3.70 2.48 0.14 -1.91 2.22 0.39 
Hnrnpa2b1 0.66 0.95 0.49 -0.48 1.11 0.62 3.60 2.01 0.07 
Hnrnpd -6.27 2.09 0.003* -4.29 2.64 0.10 -9.40 3.45 0.006* 
Hnrnph3 0.16 0.89 0.86 -1.06 1.31 0.42 1.44 1.33 0.23 
Hnrnpk -4.52 1.47 0.002 -2.55 1.90 0.18 -6.99 2.49 0.005 
Hnrnpm -0.02 1.42 0.99 -1.55 1.90 0.41 2.15 2.50 0.39 
Hnrnpul2 0.08 0.94 0.93 -0.79 1.19 0.51 1.67 1.64 0.31 
Sf3b1 -0.71 0.89 0.43 -1.34 1.25 0.28 0.34 1.55 0.83 
Srsf18 -1.76 1.06 0.10 -2.63 1.68 0.12 -1.05 1.62 0.52 
Srsf1 0.94 0.88 0.29 1.16 1.19 0.33 0.72 1.34 0.59 
Srsf2 -3.32 1.62 0.04 -4.02 2.74 0.14 -3.14 2.03 0.12 
Srsf3 -2.99 1.52 0.05 -7.90 3.24 0.02* -0.95 1.82 0.61 
Srsf6 -0.39 0.79 0.63 -0.43 1.03 0.68 -0.22 1.27 0.86 




Supplementary Table S12 (Chapter 3): Genetic variation within the mouse Hnrnpa2b1 and Hnrnpa1 genes and its predicted effect 
on gene regulation 
This table gives the SNP identifiers, chromosomal location, gene position and predicted effect on amino acid sequence or parameters of gene regulation for the mouse 
Hnrnpa2b1 and Hnrnpa1 genes. 5’ UTR = 5’ untranslated region, I = intron, C = coding, SRE = splicing regulatory element, 3’ UTR = 3’ untranslated region. ARE = A-
rich element, C>U = C to U RNA editing site, miR = microRNA binding, TF = transcription factor binding. Where 2 alternative gene position is given, this is due to the 
possibility that the SNP is located in different genetic regions for different isoforms. ‘/ ‘= not applicable. 






SRE ARE C>U miR 
Hnrnpa2b1 

































rs234970481 6:51465354 I / / NO / / / 
rs229198021 6:51465605 I / / NO / / / 
rs250280372 6:51465935 I / / NO / / / 
rs226722250 6:51466015 I / / NO / / / 
rs47522479 6:51466888 I / / NO / / / 
rs51031918 6:51467084 I / / POSSIBLE / / / 
rs252413833 6:51467157 I / / POSSIBLE / / / 
rs235452001 6:51469308 I / / NO / / / 
rs239268432 6:51469567 I / / NO / / / 
rs228820180 6:51469765 5’UTR NO / / / / / 
rs257262812 6:51470336 Intergenic NO / / / / / 
Hnrnpa1 



















Supplementary Table S13 (Chapter 4): Association of MicroRNA expression 
and lifespan in spleen tissue from young mice of shortest-lived and 
longest-lived strains (A/J and WSB/EiJ respectively) 
MicroRNAs significantly associated above the Bonferroni-corrected significance threshold 
(p<0.000179) are shown in bold italics. The ten most strongly associated microRNAs followed up 
in the targeted analysis are shown in italics. Shown in plain bold are the 6 small RNAs commonly 
used as endogenous controls. P-values were determined using independent sample t-tests on 
log-transformed relative expression data from TaqMan® MicroRNA Array cards. 
    95% CI of the difference   
MicroRNA Assay ID Mean Difference Upper Lower P-value 
mmu-miR-297b-5p 4.29 4.53 4.05 1.63E-11 
mmu-miR-708 0.47 0.58 0.36 5.46E-06 
mmu-miR-224 -0.97 -0.64 -1.30 0.0001 
mmu-miR-203 -0.55 -0.35 -0.74 0.0001 
rno-miR-327 -3.70 -2.33 -5.08 0.0002 
rno-miR-664 0.46 0.66 0.27 0.0005 
mmu-miR-592 0.50 0.73 0.27 0.0008 
mmu-miR-484 0.33 0.49 0.17 0.0014 
mmu-miR-687 5.02 7.58 2.46 0.0016 
mmu-miR-192 0.31 0.47 0.15 0.0018 
mmu-miR-760 -0.25 -0.11 -0.38 0.003 
mmu-miR-186* 0.31 0.49 0.14 0.003 
mmu-miR-690 0.39 0.63 0.15 0.005 
mmu-miR-31 0.43 0.69 0.16 0.005 
mmu-miR-126-5p 0.26 0.42 0.09 0.006 
mmu-miR-10a -0.23 -0.08 -0.38 0.007 
mmu-miR-130b* 0.36 0.59 0.12 0.007 
mmu-miR-20b 0.17 0.28 0.06 0.008 
mmu-miR-455* 0.25 0.42 0.08 0.009 
mmu-miR-449a -0.49 -0.15 -0.84 0.010 
mmu-miR-434-3p -0.28 -0.08 -0.49 0.011 
mmu-miR-376c -0.40 -0.10 -0.69 0.013 
mmu-miR-24-2* 0.17 0.29 0.04 0.013 
mmu-miR-511 -0.40 -0.09 -0.72 0.018 
rno-miR-20b-5p 0.26 0.47 0.05 0.020 
mmu-miR-210 0.21 0.37 0.04 0.020 
mmu-miR-194 0.18 0.32 0.03 0.021 
mmu-miR-411 -0.34 -0.06 -0.63 0.022 
mmu-miR-875-5p 1.20 2.19 0.21 0.023 
mmu-miR-340-3p -0.27 -0.05 -0.49 0.023 
mmu-miR-365 -0.17 -0.03 -0.32 0.023 
mmu-miR-186 0.20 0.36 0.03 0.023 
mmu-miR-539 -2.80 -0.48 -5.12 0.023 
mmu-miR-140 0.12 0.23 0.01 0.030 
mmu-miR-136 -0.42 -0.04 -0.79 0.033 
mmu-miR-130b 0.21 0.41 0.02 0.035 
mmu-miR-148b -0.31 -0.02 -0.59 0.036 
mmu-miR-31* 2.28 4.39 0.16 0.038 
mmu-miR-217 -2.76 -0.15 -5.37 0.040 
snoRNA135 -0.11 0.00 -0.21 0.042 
mmu-miR-193b 0.20 0.39 0.01 0.045 
mmu-miR-470* -1.83 -0.01 -3.66 0.049 
mmu-miR-877* 0.19 0.37 0.00 0.051 
mmu-miR-674* 0.16 0.31 0.00 0.051 
mmu-miR-193* 0.37 0.75 -0.01 0.055 
mmu-miR-700 -0.13 0.01 -0.26 0.059 
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    95% CI of the difference   
MicroRNA Assay ID Mean Difference Upper Lower P-value 
mmu-miR-15a -0.23 0.01 -0.46 0.060 
mmu-miR-152 -0.19 0.01 -0.40 0.061 
rno-miR-743a -1.29 0.08 -2.66 0.062 
mmu-miR-197 2.26 4.68 -0.16 0.064 
mmu-miR-34b-3p -0.22 0.02 -0.45 0.065 
mmu-miR-574-3p 0.15 0.31 -0.01 0.067 
mmu-miR-297a* 0.17 0.36 -0.02 0.067 
mmu-miR-674 2.44 5.12 -0.24 0.070 
mmu-miR-682 2.28 4.83 -0.26 0.072 
mmu-miR-720 -0.13 0.02 -0.27 0.081 
mmu-miR-92a 0.12 0.26 -0.02 0.089 
mmu-miR-149 0.10 0.22 -0.02 0.095 
mmu-miR-32 -0.24 0.05 -0.54 0.096 
mmu-miR-218 -0.14 0.04 -0.32 0.103 
mmu-miR-183* -0.35 0.09 -0.79 0.106 
mmu-miR-296-5p 0.22 0.49 -0.06 0.109 
mmu-miR-467b* -0.27 0.08 -0.62 0.119 
mmu-miR-345-5p -1.78 0.56 -4.12 0.119 
mmu-miR-335-5p 0.14 0.32 -0.04 0.120 
mmu-miR-29b -0.13 0.04 -0.30 0.129 
MammU6 0.19 0.45 -0.07 0.130 
mmu-miR-322 -0.17 0.06 -0.40 0.132 
mmu-miR-547 -1.25 0.48 -2.98 0.138 
mmu-miR-467a 0.16 0.37 -0.06 0.138 
mmu-miR-503 0.21 0.49 -0.08 0.141 
mmu-miR-322* -0.17 0.07 -0.40 0.142 
mmu-miR-184 -0.25 0.10 -0.61 0.143 
mmu-miR-195 -0.09 0.04 -0.21 0.145 
mmu-miR-685 0.11 0.28 -0.05 0.147 
mmu-miR-18a -0.14 0.06 -0.33 0.152 
mmu-miR-132 -0.09 0.04 -0.21 0.154 
mmu-miR-135a 1.25 3.08 -0.58 0.156 
mmu-miR-125b-5p -0.09 0.04 -0.21 0.156 
mmu-miR-129-3p 1.54 3.80 -0.73 0.159 
mmu-miR-25 0.12 0.30 -0.06 0.163 
mmu-miR-451 -0.18 0.09 -0.46 0.170 
mmu-miR-744* 1.13 2.88 -0.62 0.178 
mmu-miR-7a -1.04 0.57 -2.66 0.178 
mmu-miR-29a 0.07 0.18 -0.04 0.186 
mmu-miR-15b* 0.14 0.36 -0.08 0.191 
mmu-miR-148a -0.22 0.13 -0.58 0.192 
mmu-miR-384-5p 1.12 2.93 -0.69 0.194 
mmu-let-7c -0.15 0.09 -0.38 0.194 
mmu-miR-17 0.07 0.18 -0.04 0.197 
mmu-miR-211 -0.08 0.05 -0.22 0.204 
mmu-miR-188-5p 0.25 0.67 -0.17 0.205 
mmu-let-7b -0.16 0.11 -0.43 0.208 
mmu-miR-361 1.12 2.99 -0.76 0.211 
mmu-miR-409-3p 1.00 2.69 -0.70 0.217 
mmu-miR-9 1.04 2.81 -0.73 0.218 
mmu-miR-425* -0.16 0.11 -0.42 0.222 
mmu-miR-494 -0.25 0.19 -0.70 0.229 
mmu-miR-130a 0.15 0.40 -0.11 0.230 
snoRNA429 0.46 1.28 -0.36 0.236 
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    95% CI of the difference   
MicroRNA Assay ID Mean Difference Upper Lower P-value 
mmu-miR-103 -0.11 0.09 -0.31 0.236 
mmu-miR-29b* -0.36 0.28 -1.01 0.237 
mmu-miR-133a 0.12 0.34 -0.10 0.237 
mmu-miR-125a-5p 0.10 0.27 -0.08 0.238 
rno-miR-463 -0.10 0.08 -0.27 0.239 
mmu-miR-29a* 0.20 0.56 -0.16 0.244 
mmu-miR-29c* -0.11 0.09 -0.30 0.245 
mmu-miR-342-3p 0.09 0.26 -0.08 0.247 
mmu-miR-467c 1.16 3.28 -0.97 0.249 
mmu-miR-326 0.12 0.33 -0.10 0.252 
mmu-miR-342-5p 0.16 0.47 -0.14 0.253 
mmu-miR-30e* 0.09 0.27 -0.08 0.256 
mmu-miR-542-5p 0.89 2.56 -0.78 0.257 
mmu-miR-331-3p -0.08 0.07 -0.23 0.259 
mmu-miR-425 0.08 0.22 -0.07 0.268 
mmu-miR-467b 0.10 0.28 -0.09 0.268 
mmu-miR-30c -0.08 0.07 -0.23 0.270 
mmu-miR-128a 0.94 2.76 -0.88 0.274 
mmu-miR-410 -0.80 0.78 -2.38 0.283 
mmu-miR-7a* 0.09 0.27 -0.09 0.289 
mmu-miR-503* -0.15 0.16 -0.46 0.295 
mmu-miR-181a-1* 0.88 2.68 -0.92 0.299 
mmu-miR-335-3p 0.11 0.33 -0.12 0.303 
mmu-miR-20a* 0.16 0.49 -0.17 0.306 
mmu-miR-100 0.12 0.37 -0.13 0.309 
mmu-miR-190b 0.38 1.19 -0.42 0.313 
mmu-miR-878-3p -1.30 1.45 -4.05 0.313 
mmu-miR-30b -0.07 0.08 -0.22 0.313 
rno-miR-352 -0.93 1.04 -2.90 0.315 
mmu-miR-19b -0.08 0.09 -0.24 0.316 
rno-miR-224 -1.36 1.54 -4.27 0.317 
mmu-miR-143 -0.09 0.10 -0.27 0.319 
mmu-miR-652 0.11 0.34 -0.12 0.319 
mmu-miR-351 0.12 0.39 -0.14 0.322 
mmu-miR-804 0.75 2.36 -0.87 0.322 
mmu-miR-486 -0.16 0.19 -0.52 0.323 
mmu-miR-93* -0.08 0.09 -0.24 0.324 
mmu-miR-125a-3p 0.16 0.51 -0.19 0.326 
rno-miR-345-3p -0.17 0.21 -0.56 0.328 
mmu-miR-30a -0.08 0.10 -0.27 0.328 
mmu-miR-101b 0.07 0.22 -0.08 0.329 
rno-miR-136* -1.16 1.42 -3.74 0.337 
mmu-miR-28* -0.06 0.07 -0.19 0.339 
mmu-let-7g* 0.76 2.47 -0.96 0.343 
mmu-miR-466b-3-3p 0.82 2.69 -1.04 0.344 
mmu-miR-21* -0.17 0.23 -0.58 0.357 
mmu-miR-98 -0.14 0.18 -0.45 0.358 
rno-miR-351 0.05 0.17 -0.07 0.360 
mmu-miR-34a 0.95 3.21 -1.30 0.363 
mmu-miR-324-3p -0.11 0.16 -0.38 0.364 
mmu-miR-877 -0.08 0.11 -0.27 0.364 
mmu-miR-127 -0.27 0.38 -0.92 0.369 
mmu-miR-362-3p -0.25 0.36 -0.87 0.370 
mmu-miR-30e 0.08 0.27 -0.11 0.371 
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    95% CI of the difference   
MicroRNA Assay ID Mean Difference Upper Lower P-value 
mmu-miR-30a* -0.05 0.07 -0.16 0.377 
mmu-miR-27b -0.09 0.12 -0.30 0.377 
mmu-miR-324-5p -0.12 0.18 -0.43 0.384 
mmu-miR-680 -0.07 0.10 -0.24 0.388 
rno-miR-190b -0.74 1.11 -2.60 0.390 
mmu-miR-669a 0.82 2.87 -1.24 0.393 
mmu-miR-133b 0.14 0.49 -0.21 0.394 
mmu-miR-126-3p 0.06 0.22 -0.10 0.398 
rno-miR-7a* -0.04 0.07 -0.16 0.412 
mmu-miR-497 0.10 0.37 -0.17 0.414 
mmu-miR-30d -0.06 0.09 -0.21 0.420 
mmu-let-7a* -0.11 0.19 -0.42 0.425 
mmu-miR-155 -0.06 0.11 -0.24 0.428 
mmu-miR-350 0.10 0.36 -0.17 0.432 
mmu-miR-218-1* -0.77 1.36 -2.91 0.432 
mmu-miR-15a* 0.08 0.31 -0.15 0.438 
mmu-miR-187 -0.04 0.08 -0.16 0.441 
rno-miR-30d* -0.11 0.20 -0.42 0.441 
mmu-miR-146a -0.06 0.12 -0.24 0.446 
Y1 0.06 0.23 -0.11 0.447 
mmu-miR-135a* -0.08 0.15 -0.31 0.448 
mmu-miR-135b 0.19 0.72 -0.35 0.455 
rno-miR-148b-5p 0.12 0.49 -0.24 0.455 
mmu-miR-28 -0.12 0.23 -0.46 0.457 
rno-miR-1 0.64 2.50 -1.22 0.457 
mmu-miR-672 -0.11 0.21 -0.43 0.462 
mmu-miR-532-5p 0.09 0.34 -0.17 0.462 
mmu-miR-151-3p -0.05 0.10 -0.21 0.464 
mmu-miR-221 0.70 2.82 -1.43 0.478 
mmu-miR-181a 0.08 0.31 -0.16 0.483 
mmu-miR-532-3p 0.06 0.25 -0.13 0.486 
mmu-miR-676* 0.50 2.06 -1.07 0.491 
mmu-miR-378 0.11 0.47 -0.25 0.492 
mmu-miR-331-5p -0.09 0.19 -0.37 0.493 
mmu-miR-27a* -0.08 0.18 -0.35 0.497 
mmu-miR-106b* 0.09 0.37 -0.20 0.504 
mmu-miR-320 -0.06 0.14 -0.26 0.508 
mmu-miR-339-5p -0.06 0.15 -0.27 0.510 
mmu-miR-99b* -0.62 1.51 -2.75 0.526 
mmu-miR-214 -0.07 0.18 -0.33 0.532 
mmu-miR-338-3p 0.65 2.97 -1.67 0.540 
mmu-miR-34c* -0.10 0.26 -0.46 0.540 
mmu-miR-214* 0.07 0.32 -0.18 0.541 
mmu-miR-671-3p 0.08 0.38 -0.21 0.542 
mmu-miR-21 -0.03 0.09 -0.15 0.547 
mmu-let-7f -0.04 0.10 -0.18 0.548 
rno-miR-196c 0.25 1.14 -0.65 0.550 
mmu-let-7e -0.05 0.14 -0.25 0.568 
mmu-miR-124 0.76 3.65 -2.14 0.568 
snoRNA202 -0.05 0.15 -0.25 0.571 
mmu-miR-16 -0.03 0.10 -0.16 0.577 
mmu-miR-200a 0.16 0.81 -0.48 0.582 
mmu-miR-15b -0.04 0.13 -0.22 0.590 
mmu-miR-145 0.05 0.23 -0.14 0.591 
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    95% CI of the difference   
MicroRNA Assay ID Mean Difference Upper Lower P-value 
mmu-miR-376b* -0.24 0.73 -1.20 0.594 
mmu-miR-744 -0.05 0.15 -0.25 0.601 
mmu-miR-467d 0.43 2.21 -1.36 0.602 
mmu-miR-99a -0.05 0.17 -0.28 0.602 
mmu-miR-23b -0.07 0.21 -0.35 0.604 
mmu-miR-141 -0.10 0.32 -0.52 0.605 
mmu-miR-301a 0.06 0.32 -0.20 0.609 
mmu-miR-146b 0.05 0.26 -0.16 0.615 
mmu-miR-223 0.06 0.30 -0.19 0.618 
mmu-miR-106b -0.05 0.17 -0.26 0.634 
mmu-miR-339-3p -0.05 0.17 -0.26 0.643 
mmu-miR-872 -0.07 0.28 -0.43 0.646 
rno-miR-673 -0.14 0.51 -0.78 0.646 
mmu-miR-196b 0.05 0.32 -0.21 0.652 
mmu-miR-429 0.13 0.81 -0.56 0.679 
mmu-miR-26b* 0.04 0.27 -0.19 0.681 
mmu-miR-19a 0.04 0.24 -0.17 0.685 
mmu-miR-7b -0.12 0.56 -0.80 0.693 
mmu-miR-142-5p -0.03 0.14 -0.21 0.695 
mmu-miR-340-5p -0.04 0.16 -0.23 0.696 
mmu-miR-374 0.04 0.24 -0.16 0.697 
mmu-miR-676 0.04 0.27 -0.19 0.701 
mmu-miR-93 -0.03 0.15 -0.22 0.704 
rno-miR-204* 0.08 0.55 -0.39 0.709 
mmu-miR-500 0.55 3.78 -2.68 0.710 
mmu-let-7a -0.04 0.22 -0.31 0.713 
mmu-miR-101a 0.03 0.19 -0.13 0.717 
mmu-let-7g -0.03 0.13 -0.18 0.719 
mmu-miR-134 0.07 0.48 -0.35 0.724 
mmu-miR-99b 0.04 0.26 -0.19 0.726 
mmu-miR-16* -0.07 0.39 -0.53 0.727 
mmu-miR-301b 0.04 0.30 -0.22 0.728 
mmu-miR-805 -0.04 0.20 -0.27 0.739 
rno-miR-339-3p -0.03 0.19 -0.26 0.744 
mmu-miR-706 -0.04 0.22 -0.30 0.747 
mmu-miR-33* -0.04 0.25 -0.34 0.753 
mmu-miR-704 0.41 3.30 -2.47 0.753 
mmu-miR-27b* -0.07 0.43 -0.57 0.754 
mmu-miR-204 0.02 0.18 -0.14 0.757 
mmu-miR-673-5p 0.40 3.26 -2.46 0.757 
U87 -0.03 0.16 -0.21 0.759 
mmu-miR-125b* -0.06 0.38 -0.50 0.763 
mmu-miR-27a 0.03 0.23 -0.17 0.769 
mmu-miR-185 0.02 0.21 -0.16 0.774 
mmu-miR-26b 0.02 0.17 -0.13 0.774 
mmu-miR-1 0.06 0.58 -0.45 0.784 
mmu-miR-206 -0.18 1.37 -1.73 0.799 
mmu-miR-150 -0.02 0.15 -0.19 0.801 
mmu-miR-193 0.04 0.44 -0.35 0.805 
mmu-miR-199a-3p -0.02 0.15 -0.19 0.807 
mmu-miR-142-3p -0.02 0.19 -0.23 0.812 
mmu-miR-181c 0.04 0.45 -0.37 0.816 
mmu-miR-182 -0.05 0.43 -0.52 0.819 
mmu-miR-139-5p -0.02 0.14 -0.18 0.823 
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Supplementary Table S13 (cont.) 
    95% CI of the difference   
MicroRNA Assay ID Mean Difference Upper Lower P-value 
mmu-miR-200b -0.06 0.54 -0.67 0.824 
mmu-miR-466d-3p -0.03 0.25 -0.30 0.827 
mmu-miR-22* 0.03 0.30 -0.24 0.828 
mmu-miR-222 0.02 0.19 -0.16 0.845 
mmu-miR-200c 0.03 0.38 -0.32 0.847 
mmu-miR-24 -0.01 0.14 -0.17 0.852 
mmu-miR-138 0.02 0.23 -0.19 0.863 
mmu-miR-26a -0.01 0.15 -0.17 0.874 
mmu-miR-20a 0.01 0.13 -0.11 0.877 
mmu-miR-138* -0.04 0.65 -0.74 0.888 
mmu-let-7d -0.01 0.19 -0.22 0.896 
mmu-miR-667 -0.17 2.75 -3.10 0.897 
mmu-miR-328 -0.01 0.16 -0.18 0.900 
mmu-miR-191 -0.01 0.19 -0.21 0.900 
mmu-miR-872* 0.01 0.18 -0.16 0.907 
mmu-miR-29c -0.01 0.21 -0.24 0.909 
mmu-miR-696 -0.02 0.32 -0.36 0.909 
mmu-miR-376a 0.04 1.07 -0.98 0.928 
mmu-miR-18a* 0.01 0.31 -0.29 0.940 
mmu-miR-106a 0.01 0.19 -0.18 0.951 
mmu-miR-491 -0.01 0.38 -0.39 0.974 
mmu-let-7i 0.00 0.20 -0.21 0.975 
mmu-miR-678 -0.03 2.67 -2.72 0.982 
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Supplementary Table S14 (Chapter 4): Association of MicroRNA expression and lifespan in mouse spleen tissue across 6 strains 
of different longevities 
Data from mice of all ages, young mice only (6 months) and old mice only (20-22 months) are given separately. MicroRNAs significantly associated below the 
Bonferroni-corrected significance threshold (p<0.005) are shown in bold italics. P-values were determined from linear regression of log-transformed relative expression 
data. 




Std. Error P-value 
Beta 
coefficient 
Std. Error P-value 
Beta 
coefficient 
Std. Error P-value 
miR-192-5p 0.16 0.00 0.14 0.12 0.00 0.49 0.20 0.00 0.20 
miR-203-3p -0.64 0.00 <0.001 -0.67 0.00 <0.001 -0.67 0.00 <0.001 
miR-224-5p -0.09 0.00 0.44 -0.23 0.00 0.16 0.02 0.00 0.91 
miR-297b-5p 0.16 0.00 0.15 0.14 0.00 0.41 0.18 0.00 0.22 
miR-484 -0.07 0.00 0.55 -0.21 0.00 0.21 0.08 0.00 0.61 
miR-592 0.16 0.00 0.15 0.08 0.00 0.65 0.23 0.00 0.13 
miR-664-3p 0.56 0.00 <0.001 0.42 0.00 0.01 0.75 0.00 <0.001 
miR-687 0.20 0.00 0.11 0.17 0.00 0.39 0.23 0.00 0.18 
miR-708-5p 0.50 0.00 <0.001 0.37 0.00 0.02 0.64 0.00 <0.001 





Supplementary Table S15 (Chapter 4): Sub analysis of the relationship between miRNA expression and median strain longevity 
in spleen samples from animals not included in the initial global analysis 
Data from mice of all ages, young mice only (6 months) and old mice only (20-22 months) are given separately. MicroRNAs significantly associated below the 
Bonferroni-corrected significance threshold (p<0.005) are shown in bold italics. P-values were determined from linear regression of log-transformed relative expression 
data. 




Std. Error P-value 
Beta 
coefficient 
Std. Error P-value 
Beta 
coefficient 
Std. Error P-value 
miR-192-5p 0.08 0.00 0.50 -0.21 0.00 0.30 0.20 0.00 0.20 
miR-203-3p -0.51 0.00 <0.001 -0.10 0.00 0.64 -0.70 0.00 <0.001 
miR-224-5p 0.17 0.00 0.16 0.82 0.00 <0.001 0.02 0.00 0.90 
miR-297b-5p 0.11 0.00 0.38 -0.20 0.00 0.33 0.19 0.00 0.22 
miR-484 0.12 0.00 0.30 0.31 0.00 0.12 0.08 0.00 0.61 
miR-592 0.10 0.00 0.41 -0.38 0.00 0.06 0.22 0.00 0.15 
miR-664-3p 0.56 0.00 <0.001 0.47 0.00 0.02 0.75 0.00 <0.001 
miR-687 0.17 0.00 0.21 0.02 0.01 0.93 0.23 0.00 0.18 
miR-708-5p 0.41 0.00 <0.001 -0.50 0.01 0.01 0.64 0.00 <0.001 




Supplementary Table S16 (Chapter 4): Association of MicroRNA expression and age in mouse spleen tissue across 6 strains of 
different longevities 
Data from mice of all ages, ‘Average-lived’ mice only (<847.5 days) and ‘Long-lived’ mice only (>847.5 days) are given separately. MicroRNAs significantly associated 
below the Bonferroni-corrected significance threshold (p<0.005) are shown in bold italics. P-values were determined from linear regression of log-transformed relative 
expression data.  




Std. Error P-value 
Beta 
coefficient 
Std. Error P-value 
Beta 
coefficient 
Std. Error P-value 
miR-192-5p 0.12 0.04 0.27 0.00 0.07 0.99 0.20 0.05 0.16 
miR-203-3p 0.18 0.06 0.11 0.09 0.10 0.63 0.30 0.05 0.03 
miR-224-5p -0.01 0.11 0.95 -0.14 0.17 0.44 0.09 0.13 0.55 
miR-297b-5p -0.09 0.08 0.41 -0.10 0.15 0.58 -0.09 0.09 0.55 
miR-484 0.10 0.04 0.35 0.04 0.06 0.81 0.14 0.05 0.33 
miR-592 0.44 0.05 <0.001 0.37 0.07 0.03 0.57 0.06 <0.001 
miR-664-3p 0.04 0.41 0.77 0.12 0.41 0.58 0.02 0.62 0.90 
miR-687 0.26 0.08 0.02 0.12 0.17 0.49 0.50 0.06 <0.001 
miR-708-5p 0.03 0.09 0.77 -0.05 0.17 0.78 0.13 0.08 0.38 
rno-miR-327 -0.08 0.12 0.46 -0.07 0.22 0.72 -0.11 0.13 0.43 
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Supplementary Table S17 (Chapter 4): Analyses of potential interactions 
between mouse strain longevity and mouse age 
Std. Error = standard error, 95% CI = 95% confidence intervals. Mouse strains were categorised 
for this analysis based on whether the median individual strain lifespan was above or below the 
median lifespan calculated across all strains, with ‘Average-lived’ being <847.5 days and ‘Long-
lived’ >847.5 days. Young mice are 6 months and old mice are 20-22 months old. Statistically 
significant results are indicated in bold italic text. 
Longevity:age interactions - microRNAs associated with lifespan 
MicroRNA Sub-category β coefficient Std. Error 95% CI p-value 
mmu-miR-203-3p 
          
Average-lived/Young 0       
Average-lived/Old 0.05 0.08 -0.11 to 0.21 0.55 
Long-lived/Young -0.29 0.08 -0.44 to -0.13 0.0004 
Long-lived/Old -0.17 0.08 -0.32 to -0.02 0.03 
          
mmu-miR-664-3p 
          
Average-lived/Young 0       
Average-lived/Old 0.15 0.07 0.01 to 0.29 0.04 
Long-lived/Young 0.18 0.07 0.04 to 0.31 0.01 
Long-lived/Old 0.46 0.07 0.33 to 0.60 6.59E-10 
          
mmu-miR-708-5p 
          
Average-lived/Young 0       
Average-lived/Old 0.12 0.12 -0.12 to 0.36 0.33 
Long-lived/Young 0.08 0.12 -0.15 to 0.31 0.49 
Long-lived/Old 0.31 0.11 0.09 to 0.53 0.007 




Supplementary Table S18 (Chapter 4): Taqman® Low Density Array card 
contents 
Assay names and unique assay IDs are given for all microRNAs tested using each array layout. 
 
Rodent A Array v2.0 
Assay ID Assay Name Assay ID Assay Name Assay ID Assay Name 
000377 mmu-let-7a 002592 mmu-miR-291a-3p 002456 mmu-miR-503 
000378 mmu-let-7b 002537 mmu-miR-291b-5p 002084 mmu-miR-504 
000379 mmu-let-7c 002593 mmu-miR-292-3p 001655 mmu-miR-505 
002283 mmu-let-7d 001794 mmu-miR-293 002521 mmu-miR-509-3p 
002406 mmu-let-7e 001056 mmu-miR-294 002520 mmu-miR-509-5p 
000382 mmu-let-7f 000189 mmu-miR-295 002549 mmu-miR-511 
002282 mmu-let-7g 002101 mmu-miR-296-3p 002355 mmu-miR-532-3p 
002221 mmu-let-7i 000527 mmu-miR-296-5p 001518 mmu-miR-532-5p 
002222 mmu-miR-1 001626 mmu-miR-297b-5p 001286 mmu-miR-539 
000437 mmu-miR-100 002480 mmu-miR-297c 001310 mmu-miR-540-3p 
002253 mmu-miR-101a 002598 mmu-miR-298 002561 mmu-miR-540-5p 
000439 mmu-miR-103 002112 mmu-miR-29a 001284 mmu-miR-542-3p 
002465 mmu-miR-105 000413 mmu-miR-29b 002563 mmu-miR-542-5p 
002459 mmu-miR-106a 000587 mmu-miR-29c 002376 mmu-miR-543 
000442 mmu-miR-106b 000528 mmu-miR-301a 002550 mmu-miR-544 
000443 mmu-miR-107 002600 mmu-miR-301b 001312 mmu-miR-546 
000387 mmu-miR-10a 000529 mmu-miR-302a 002564 mmu-miR-547 
002218 mmu-miR-10b 000531 mmu-miR-302b 001535 mmu-miR-551b 
002245 mmu-miR-122 002558 mmu-miR-302c 002349 mmu-miR-574-3p 
001182 mmu-miR-124 000535 mmu-miR-302d 002567 mmu-miR-582-3p 
002199 mmu-miR-125a-3p 000417 mmu-miR-30a 002566 mmu-miR-582-5p 
002198 mmu-miR-125a-5p 000602 mmu-miR-30b 001984 mmu-miR-590-5p 
002378 mmu-miR-125b-3p 000419 mmu-miR-30c 002476 mmu-miR-598 
000449 mmu-miR-125b-5p 000420 mmu-miR-30d 001960 mmu-miR-615-3p 
002228 mmu-miR-126-3p 002223 mmu-miR-30e 002353 mmu-miR-615-5p 
000451 mmu-miR-126-5p 000185 mmu-miR-31 002352 mmu-miR-652 
000452 mmu-miR-127 002109 mmu-miR-32 002239 mmu-miR-654-3p 
002216 mmu-miR-128a 002277 mmu-miR-320 002522 mmu-miR-654-5p 
001184 mmu-miR-129-3p 001076 mmu-miR-322 002607 mmu-miR-665 
000590 mmu-miR-129-5p 002227 mmu-miR-323-3p 001952 mmu-miR-666-5p 
000454 mmu-miR-130a 002509 mmu-miR-324-3p 001949 mmu-miR-667 
000456 mmu-miR-130b 000539 mmu-miR-324-5p 001947 mmu-miR-668 
000457 mmu-miR-132 002510 mmu-miR-325 001683 mmu-miR-669a 
002246 mmu-miR-133a 000543 mmu-miR-328 002020 mmu-miR-670 
002247 mmu-miR-133b 000192 mmu-miR-329 002322 mmu-miR-671-3p 
001186 mmu-miR-134 002230 mmu-miR-330 002327 mmu-miR-672 
000460 mmu-miR-135a 000545 mmu-miR-331-3p 002021 mmu-miR-674 
002261 mmu-miR-135b 002233 mmu-miR-331-5p 001941 mmu-miR-675-3p 
002511 mmu-miR-136 002185 mmu-miR-335-3p 001940 mmu-miR-675-5p 
001129 mmu-miR-137 000546 mmu-miR-335-5p 001959 mmu-miR-676 
002284 mmu-miR-138 002532 mmu-miR-337-3p 001660 mmu-miR-677 
002546 mmu-miR-139-3p 002515 mmu-miR-337-5p 001662 mmu-miR-679 
002289 mmu-miR-139-5p 002252 mmu-miR-338-3p 001664 mmu-miR-680 
001187 mmu-miR-140 002533 mmu-miR-339-3p 001666 mmu-miR-682 
000463 mmu-miR-141 002257 mmu-miR-339-5p 001668 mmu-miR-683 
000464 mmu-miR-142-3p 002259 mmu-miR-340-3p 001669 mmu-miR-684 
002248 mmu-miR-142-5p 002258 mmu-miR-340-5p 001670 mmu-miR-685 
002249 mmu-miR-143 002260 mmu-miR-342-3p 001672 mmu-miR-686 
002278 mmu-miR-145 002527 mmu-miR-342-5p 001674 mmu-miR-687 
000468 mmu-miR-146a 001063 mmu-miR-344 002341 mmu-miR-708 
001097 mmu-miR-146b 002529 mmu-miR-345-3p 002457 mmu-miR-741 
002262 mmu-miR-147 002528 mmu-miR-345-5p 002038 mmu-miR-742 
000470 mmu-miR-148a 001064 mmu-miR-346 002469 mmu-miR-743a 
000471 mmu-miR-148b 000426 mmu-miR-34a 002471 mmu-miR-743b-3p 
000473 mmu-miR-150 002618 mmu-miR-34b-3p 002470 mmu-miR-743b-5p 
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Supplementary Table S18 (cont.) 
Rodent A Array v2.0 
Assay ID Assay Name Assay ID Assay Name Assay ID Assay Name 
001190 mmu-miR-151-3p 000428 mmu-miR-34c 002324 mmu-miR-744 
000475 mmu-miR-152 002530 mmu-miR-350 002027 mmu-miR-770-3p 
001191 mmu-miR-153 001067 mmu-miR-351 000268 mmu-miR-7a 
000477 mmu-miR-154 000554 mmu-miR-361 002555 mmu-miR-7b 
002571 mmu-miR-155 002616 mmu-miR-362-3p 002029 mmu-miR-802 
000389 mmu-miR-15a 001271 mmu-miR-363 002354 mmu-miR-871 
000390 mmu-miR-15b 001020 mmu-miR-365 002264 mmu-miR-872 
000391 mmu-miR-16 000555 mmu-miR-367 002356 mmu-miR-873 
002308 mmu-miR-17 000557 mmu-miR-369-3p 002268 mmu-miR-874 
000480 mmu-miR-181a 001021 mmu-miR-369-5p 002547 mmu-miR-875-3p 
000482 mmu-miR-181c 002275 mmu-miR-370 002464 mmu-miR-876-3p 
002599 mmu-miR-182 000564 mmu-miR-375 002463 mmu-miR-876-5p 
002269 mmu-miR-183 001069 mmu-miR-376a 002540 mmu-miR-878-5p 
000485 mmu-miR-184 002452 mmu-miR-376b 002472 mmu-miR-879 
002271 mmu-miR-185 002450 mmu-miR-376c 002609 mmu-miR-881 
002285 mmu-miR-186 000566 mmu-miR-377 002461 mmu-miR-883a-3p 
001193 mmu-miR-187 001138 mmu-miR-379 002611 mmu-miR-883a-5p 
002106 mmu-miR-188-3p 001071 mmu-miR-380-3p 002565 mmu-miR-883b-3p 
002320 mmu-miR-188-5p 002601 mmu-miR-380-5p 000583 mmu-miR-9 
002422 mmu-miR-18a 000571 mmu-miR-381 000430 mmu-miR-92a 
002466 mmu-miR-18b 000572 mmu-miR-382 001090 mmu-miR-93 
000489 mmu-miR-190 001767 mmu-miR-383 000186 mmu-miR-96 
002299 mmu-miR-191 002603 mmu-miR-384-3p 000577 mmu-miR-98 
000491 mmu-miR-192 002602 mmu-miR-384-5p 000435 mmu-miR-99a 
002250 mmu-miR-193 002332 mmu-miR-409-3p 000436 mmu-miR-99b 
002467 mmu-miR-193b 002331 mmu-miR-409-5p 002064 rno-miR-1 
000493 mmu-miR-194 001274 mmu-miR-410 002078 rno-miR-17-3p 
000494 mmu-miR-195 001610 mmu-miR-411 002048 rno-miR-190b 
002215 mmu-miR-196b 002340 mmu-miR-423-5p 002049 rno-miR-196c 
000497 mmu-miR-197 001516 mmu-miR-425 001315 rno-miR-207 
002304 mmu-miR-199a-3p 001077 mmu-miR-429 002052 rno-miR-20b-3p 
000498 mmu-miR-199a-5p 001979 mmu-miR-431 002077 rno-miR-219-1-3p 
000395 mmu-miR-19a 001028 mmu-miR-433 002390 rno-miR-219-2-3p 
000396 mmu-miR-19b 002604 mmu-miR-434-3p 000599 rno-miR-224 
000502 mmu-miR-200a 002581 mmu-miR-434-5p 001328 rno-miR-327 
002251 mmu-miR-200b 001029 mmu-miR-448 001329 rno-miR-333 
002300 mmu-miR-200c 001030 mmu-miR-449a 001331 rno-miR-336 
002578 mmu-miR-201 002539 mmu-miR-449b 002059 rno-miR-339-3p 
001195 mmu-miR-202-3p 002303 mmu-miR-450a-5p 001344 rno-miR-343 
000507 mmu-miR-203 001962 mmu-miR-450b-5p 001332 rno-miR-344-3p 
000508 mmu-miR-204 001141 mmu-miR-451 002060 rno-miR-344-5p 
000509 mmu-miR-205 001032 mmu-miR-452 002061 rno-miR-345-3p 
001198 mmu-miR-207 002484 mmu-miR-453 001333 rno-miR-346 
000511 mmu-miR-208 002455 mmu-miR-455 001334 rno-miR-347 
002290 mmu-miR-208b 001081 mmu-miR-464 001335 rno-miR-349 
000580 mmu-miR-20a 002040 mmu-miR-465a-3p 002063 rno-miR-351 
001014 mmu-miR-20b 001082 mmu-miR-465a-5p 001320 rno-miR-377 
000397 mmu-miR-21 002485 mmu-miR-465b-5p 001322 rno-miR-381 
000512 mmu-miR-210 002516 mmu-miR-466h 001317 rno-miR-409-5p 
001199 mmu-miR-211 002587 mmu-miR-467a 001343 rno-miR-421 
002306 mmu-miR-214 001671 mmu-miR-467b 001345 rno-miR-450a 
001200 mmu-miR-215 002517 mmu-miR-467c 002066 rno-miR-466b 
002220 mmu-miR-216a 002518 mmu-miR-467d 002067 rno-miR-466c 
002326 mmu-miR-216b 002568 mmu-miR-467e 001316 rno-miR-505 
002556 mmu-miR-217 001085 mmu-miR-468 002051 rno-miR-532-5p 
000521 mmu-miR-218 001086 mmu-miR-469 002065 rno-miR-543 
000522 mmu-miR-219 002588 mmu-miR-470 002053 rno-miR-598-5p 
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Supplementary Table S18 (cont.) 
Rodent A Array v2.0 
Assay ID Assay Name Assay ID Assay Name Assay ID Assay Name 
002468 mmu-miR-220 001821 mmu-miR-484 002054 rno-miR-673 
000524 mmu-miR-221 001278 mmu-miR-486 002055 rno-miR-742 
002276 mmu-miR-222 001285 mmu-miR-487b 002068 rno-miR-743b 
002295 mmu-miR-223 001659 mmu-miR-488 001990 rno-miR-758 
002553 mmu-miR-224 001302 mmu-miR-489 002057 rno-miR-760-5p 
000399 mmu-miR-23a 001037 mmu-miR-490 002069 rno-miR-871 
000400 mmu-miR-23b 001630 mmu-miR-491 002070 rno-miR-878 
000402 mmu-miR-24 002519 mmu-miR-493 002072 rno-miR-881 
000403 mmu-miR-25 002365 mmu-miR-494 000338 ath-miR159a 
000405 mmu-miR-26a 001663 mmu-miR-495 001973 Mamm U6  
000407 mmu-miR-26b 001953 mmu-miR-496 001230 snoRNA135 
000408 mmu-miR-27a 001346 mmu-miR-497 001232 snoRNA202 
000409 mmu-miR-27b 001352 mmu-miR-499 001712 U87 
000411 mmu-miR-28 002606 mmu-miR-500 001727 Y1 
002591 mmu-miR-290-3p 001651 mmu-miR-501-3p     
 
Rodent Array B 
Assay ID Assay Name Assay ID Assay Name Assay ID Assay Name 
002478 mmu-let-7a* 002498 mmu-miR-30b* 001642 mmu-miR-707 
002479 mmu-let-7c-1* 002495 mmu-miR-31* 001646 mmu-miR-711 
001178 mmu-let-7d* 002506 mmu-miR-322* 001961 mmu-miR-712* 
002492 mmu-let-7g* 001060 mmu-miR-325* 001648 mmu-miR-713 
002507 mmu-miR-101a* 001061 mmu-miR-326 001649 mmu-miR-715 
002531 mmu-miR-101b 002481 mmu-miR-327 001652 mmu-miR-717 
002572 mmu-miR-10b* 002136 mmu-miR-33* 001656 mmu-miR-718 
002508 mmu-miR-125b* 001062 mmu-miR-330* 001673 mmu-miR-719 
002229 mmu-miR-127* 002483 mmu-miR-343 001629 mmu-miR-720 
002460 mmu-miR-130b* 002584 mmu-miR-34c* 001657 mmu-miR-721 
001637 mmu-miR-133a* 002043 mmu-miR-374* 002034 mmu-miR-759 
002512 mmu-miR-136* 002482 mmu-miR-376a* 002028 mmu-miR-762 
002554 mmu-miR-138* 002451 mmu-miR-376b* 002033 mmu-miR-763 
002513 mmu-miR-141* 002523 mmu-miR-376c* 002032 mmu-miR-764-3p 
002514 mmu-miR-145* 001078 mmu-miR-433* 002031 mmu-miR-764-5p 
002453 mmu-miR-146b* 002525 mmu-miR-450a-3p 002044 mmu-miR-804 
002570 mmu-miR-150* 002582 mmu-miR-463* 002045 mmu-miR-805 
002488 mmu-miR-15a* 002586 mmu-miR-466a-3p 002542 mmu-miR-872* 
002489 mmu-miR-16* 002500 mmu-miR-466b-3-3p 002548 mmu-miR-877* 
002543 mmu-miR-17* 002534 mmu-miR-466d-5p 002541 mmu-miR-878-3p 
002270 mmu-miR-183* 001826 mmu-miR-467a* 002473 mmu-miR-879* 
002574 mmu-miR-186* 001684 mmu-miR-467b* 002475 mmu-miR-881* 
002490 mmu-miR-18a* 002569 mmu-miR-467e* 002231 mmu-miR-9* 
002576 mmu-miR-191* 002589 mmu-miR-470* 002496 mmu-miR-92a* 
002577 mmu-miR-193* 002560 mmu-miR-483* 001351 rno-miR-1* 
002477 mmu-miR-196a* 001943 mmu-miR-485* 002074 rno-miR-125b* 
001131 mmu-miR-199b* 002014 mmu-miR-488* 002075 rno-miR-135a* 
002544 mmu-miR-19a* 002536 mmu-miR-503* 002058 rno-miR-148b-5p 
002491 mmu-miR-20a* 002017 mmu-miR-592 002076 rno-miR-204* 
002524 mmu-miR-20b* 002449 mmu-miR-673-3p 001336 rno-miR-20a* 
002493 mmu-miR-21* 001956 mmu-miR-674* 002079 rno-miR-24-1* 
002293 mmu-miR-214* 001958 mmu-miR-676* 002080 rno-miR-25* 
002552 mmu-miR-218-1* 001675 mmu-miR-688 002082 rno-miR-29b-1* 
002494 mmu-miR-24-2* 001677 mmu-miR-690 001339 rno-miR-352 
002545 mmu-miR-28* 001678 mmu-miR-691 002081 rno-miR-379* 
002538 mmu-miR-291b-3p 001679 mmu-miR-692 001354 rno-miR-382* 
001055 mmu-miR-292-5p 002036 mmu-miR-693-3p 001353 rno-miR-489 
002594 mmu-miR-293* 001681 mmu-miR-694 001323 rno-miR-664 
002595 mmu-miR-294* 001627 mmu-miR-695 002056 rno-miR-743a 




Supplementary Table S18 (cont.) 
Rodent Array B 
Assay ID Assay Name Assay ID Assay Name Assay ID Assay Name 
000600 mmu-miR-299* 001631 mmu-miR-697 002073 rno-miR-99a* 
002497 mmu-miR-29b* 001632 mmu-miR-698 000338 ath-miR159a 
000191 mmu-miR-300 001634 mmu-miR-700 001973 Mamm U6  
002613 mmu-miR-300* 001635 mmu-miR-701 001230 snoRNA135 
002615 mmu-miR-302a* 001636 mmu-miR-702 001232 snoRNA202 
001307 mmu-miR-302b* 001639 mmu-miR-704 001712 U87 




Supplementary Table S19 (Chapter 4): MicroRNA assays used for targeted 
analysis 
Assay names, IDs and miRBase/NCBI information are given for the assays used to follow up the 
ten most strongly associated microRNAs from the TaqMan® MicroRNA Array analysis. 
Endogenous control small RNA assays used for this analysis are shown in italics. 
miRBase ID Assay Name Assay ID 
miRBase/NCBI 
Accession Number 
mmu-miR-192-5p hsa-miR-192 000491 MIMAT0000517 
mmu-miR-203-3p hsa-miR-203 000507 MIMAT0000236 
mmu-miR-224-5p mmu-miR-224 002553 MIMAT0000671 
mmu-miR-297b-5p mmu-miR-297b 001626 MIMAT0003480 
mmu-miR-484 hsa-miR-484 001821 MIMAT0003127 
mmu-mir-592-5p mmu-mir-592 002017 MIMAT0003730 
mmu-miR-664-3p rno-miR-664 001323 MIMAT0012774 
mmu-miR-687 mmu-miR-687 001674 MIMAT0003466 
mmu-miR-708-5p mmu-miR-708 002341 MIMAT0004828 
rno-miR-327 rno-miR-327 001328 MIMAT0000561 
N/A snoRNA202 001232 AF357327 
N/A U6 snRNA 001973 NR_004394 




Supplementary Table S20 (Chapter 4): mRNA assays used for predicted 
target analysis 
Assay IDs and NCBI information are given for the assays used to follow up the genes predicted 
to be targeted by the candidate microRNAs as determined by the DIANA-miRPath analysis. 
Endogenous control assays used for this analysis are shown in italics. 
Gene Symbol Assay ID NCBI Accession Number 
Acvr2a Mm01331097_m1  NM_007396.4 
Dusp5 Mm01266106_m1  NM_001085390.1 
Fgf7 Mm00433292_m1  NM_008008.4 
Gabarapl1  Mm00457880_m1  NM_020590.4 
Mmp9 Mm00442991_m1 NM_013599.3 
Pten Mm01212530_m1  NM_008960.2 
Rps6ka3  Mm00455829_m1 NM_148945.2 
Smad4  Mm01262405_m1  NM_008540.2 
Zfhx3 Mm01240016_m1  NM_007496.2 
Gusb Mm01197698_m1  NM_010368.1 





Supplementary Table S21 (Chapter 5): Taqman® Assays 
Splicing factor target genes, assay IDs and qPCR software settings for each transcript included 
in the current study. Endogenous control genes used are shown in bold italics. 
Target Assay ID Threshold Baseline Start Baseline End 
Hnrnpa0 Mm03809085_s1 0.075 3 22 
Hnrnpa1 Mm02528230_g1 0.098 3 18 
Hnrnpa2b1 Mm01325931_g1 0.145 3 18 
Hnrnpd Mm01201314_m1 0.112 3 21 
Hnrnph3 Mm01032120_g1 0.095 3 24 
Hnrnpk Mm01349462_m1 0.129 3 18 
Hnrnpm Mm00513070_m1 0.068 3 21 
Hnrnpul2 Mm01230949_m1 0.114 3 21 
Pnisr Mm01219239_m1 0.052 3 20 
Srsf1 Mm00557620_m1 0.123 3 21 
Srsf2 Mm00448705_m1 0.040 3 20 
Srsf3 Mm00786953_s1 0.044 3 23 
Srsf6 Mm00471475_m1 0.074 3 21 
Tra2b Mm00833637_mH 0.031 3 21 
Sf1 Mm00496060_m1 0.104 3 19 
Sf3b1 Mm00473100_m1 0.044 3 19 
Gusb Mm01197698_m1 0.092 3 21 
Idh3b Mm00504589_m1 0.112 3 18 





Supplementary Table S22 (Chapter 5): Changes in splicing factor 
expression with long-term and short-term 40% DR in non-responder mice 
Changes in splicing factor expression levels with long-term and short-term DR in brain, heart and 
kidney tissues from mice which display no change in lifespan under 40% DR conditions (TejJ89), 
by ANCOVA. A positive mean difference denotes an increase in expression levels under 40% DR 
conditions when compared to AL feeding. Transcripts showing nominal associations (p<0.05) are 
shown in italic and underlined. SE: standard error, 95% CI: 95% confidence intervals. 
  Brain – Short-term DR Brain – Long-term DR 
    
Mean 




















Hnrnpa0 0.360 0.203 0.102 0.803 -0.083 0.188 0.208 0.383 0.641 -0.264 
Hnrnpa1 0.326 0.187 0.109 0.739 -0.086 -0.175 0.204 0.407 0.269 -0.619 
Hnrnpa2b1 0.029 0.192 0.882 0.447 -0.389 0.161 0.113 0.182 0.408 -0.086 
Hnrnpd 0.200 0.121 0.123 0.463 -0.063 0.194 0.121 0.136 0.459 -0.070 
Hnrnph3 -0.192 0.135 0.181 0.103 -0.487 -0.063 0.161 0.701 0.287 -0.413 
Hnrnpk 0.082 0.112 0.482 0.329 -0.165 -0.131 0.131 0.335 0.153 -0.416 
Hnrnpm -0.220 0.211 0.318 0.240 -0.679 0.150 0.136 0.293 0.447 -0.147 
Hnrnpul2 0.027 0.121 0.830 0.291 -0.238 0.179 0.125 0.178 0.451 -0.094 
Pnisr -0.181 0.161 0.284 0.171 -0.532 0.305 0.186 0.126 0.709 -0.099 
Srsf1 -0.257 0.235 0.294 0.254 -0.769 0.044 0.144 0.766 0.357 -0.270 
Srsf2 -0.130 0.168 0.456 0.237 -0.496 -0.157 0.186 0.414 0.248 -0.562 
Srsf3 0.283 0.137 0.063 0.584 -0.018 -0.252 0.197 0.225 0.177 -0.681 
Srsf6 0.837 0.297 0.015 1.483 0.190 -0.187 0.251 0.470 0.359 -0.734 





Sf1 0.232 0.163 0.183 0.590 -0.127 -0.070 0.146 0.638 0.247 -0.388 
Sf3b1 -0.170 0.168 0.330 0.195 -0.536 -0.162 0.191 0.414 0.255 -0.578 
  Heart – Short-term DR Heart – Long-term DR 
    
Mean 




















Hnrnpa0 -0.135 0.111 0.249 0.108 -0.378 0.077 0.161 0.642 0.430 -0.277 
Hnrnpa1 -0.115 0.146 0.448 0.204 -0.433 0.112 0.190 0.566 0.531 -0.306 
Hnrnpa2b1 0.135 0.158 0.411 0.480 -0.210 -0.205 0.121 0.119 0.062 -0.473 
Hnrnpd 0.115 0.104 0.292 0.341 -0.112 -0.029 0.117 0.810 0.228 -0.286 
Hnrnph3 0.000 0.114 0.997 0.247 -0.248 0.056 0.113 0.630 0.303 -0.192 
Hnrnpk -0.065 0.153 0.681 0.269 -0.398 -0.156 0.157 0.340 0.189 -0.501 
Hnrnpm -0.195 0.193 0.332 0.225 -0.615 -0.029 0.080 0.721 0.149 -0.208 
Hnrnpul2 0.003 0.104 0.980 0.230 -0.224 -0.096 0.196 0.632 0.334 -0.527 
Pnisr 0.023 0.102 0.826 0.244 -0.199 0.109 0.171 0.535 0.485 -0.266 
Srsf1 -0.020 0.297 0.948 0.627 -0.666 0.280 0.290 0.355 0.918 -0.358 
Srsf2 -0.109 0.131 0.423 0.176 -0.394 0.208 0.154 0.205 0.547 -0.132 
Srsf3 0.113 0.142 0.439 0.422 -0.195 0.318 0.171 0.091 0.695 -0.059 
Srsf6 0.143 0.210 0.511 0.601 -0.316 0.020 0.212 0.928 0.487 -0.448 





Sf1 -0.239 0.190 0.232 0.174 -0.652 -0.219 0.213 0.327 0.250 -0.687 
Sf3b1 -0.021 0.175 0.905 0.363 -0.406 -0.048 0.214 0.826 0.423 -0.519 
  Kidney – Short-term DR Kidney – Long-term DR 
    
Mean 




















Hnrnpa0 -0.371 0.176 0.064 0.027 -0.769 0.028 0.199 0.891 0.462 -0.406 
Hnrnpa1 0.263 0.143 0.096 0.581 -0.056 0.141 0.130 0.300 0.426 -0.143 
Hnrnpa2b1 -0.137 0.153 0.395 0.210 -0.483 0.117 0.145 0.436 0.435 -0.201 
Hnrnpd -0.230 0.155 0.168 0.115 -0.575 -0.196 0.086 0.041 -0.010 -0.383 
Hnrnph3 -0.182 0.151 0.254 0.154 -0.519 0.088 0.174 0.624 0.467 -0.292 
Hnrnpk -0.360 0.165 0.054 0.007 -0.727 -0.082 0.074 0.290 0.079 -0.242 
Hnrnpm -0.047 0.213 0.829 0.428 -0.522 -0.129 0.090 0.178 0.067 -0.325 
Hnrnpul2 -0.101 0.256 0.703 0.469 -0.671 -0.403 0.134 0.011 -0.112 -0.695 
Pnisr 0.237 0.182 0.222 0.643 -0.169 -0.170 0.103 0.124 0.054 -0.394 
Srsf1 -0.148 0.141 0.316 0.165 -0.461 -0.016 0.100 0.874 0.202 -0.235 
Srsf2 0.316 0.191 0.128 0.740 -0.109 0.299 0.102 0.012 0.521 0.077 
Srsf3 -0.035 0.231 0.882 0.479 -0.549 0.154 0.165 0.367 0.513 -0.205 
Srsf6 -0.179 0.202 0.398 0.272 -0.630 0.093 0.133 0.500 0.383 -0.198 





Sf1 0.420 0.145 0.016 0.744 0.097 0.178 0.132 0.202 0.465 -0.109 




Supplementary Table S23 (Chapter 5): Changes in splicing factor 
expression with long-term and short-term 40% DR in positive responder 
mice 
Changes in splicing factor expression levels with long-term and short-term DR in brain, heart and 
kidney tissues from mice which display lifespan extension under 40% DR conditions (TejJ89), by 
ANCOVA. A positive mean difference denotes an increase in expression levels under 40% DR 
conditions when compared to AL feeding. Transcripts showing nominal associations (p<0.05) are 
shown in italic and underlined, those which meet correction for multiple testing (p<0.0045) are 
shown in bold italic and underlined. SE: standard error, 95% CI: 95% confidence intervals. 
 
  Brain – Short-term DR Brain – Long-term DR 
    
Mean 




















Hnrnpa0 -0.424 0.252 0.119 -0.974 0.126 -0.954 0.235 0.002 -1.478 -0.429 
Hnrnpa1 -0.240 0.187 0.223 -0.647 0.167 1.554 0.389 0.004 0.658 2.450 
Hnrnpa2b1 0.128 0.125 0.324 -0.143 0.400 0.508 0.228 0.047 0.007 1.009 
Hnrnpd 0.021 0.179 0.909 -0.370 0.412 0.360 0.204 0.106 -0.090 0.810 
Hnrnph3 0.085 0.135 0.542 -0.210 0.380 -1.595 0.293 <0.001 -2.272 -0.918 
Hnrnpk -0.312 0.179 0.107 -0.703 0.079 1.512 0.343 0.002 0.736 2.287 
Hnrnpm 0.061 0.164 0.717 -0.296 0.418 -0.167 0.195 0.409 -0.597 0.262 
Hnrnpul2 0.039 0.134 0.777 -0.254 0.331 0.122 0.142 0.407 -0.190 0.435 
Pnisr 0.078 0.168 0.651 -0.287 0.443 0.024 0.268 0.929 -0.566 0.615 
Srsf1 0.316 0.214 0.166 -0.150 0.783 -0.828 0.272 0.011 -1.427 -0.229 
Srsf2 -0.187 0.139 0.202 -0.489 0.115 -0.510 0.390 0.220 -1.379 0.359 
Srsf3 -0.433 0.128 0.005 -0.712 -0.154 -1.020 0.507 0.079 -2.189 0.148 
Srsf6 -0.674 0.220 0.010 -1.153 -0.195 -0.742 0.363 0.065 -1.540 0.056 





Sf1 -0.290 0.126 0.040 -0.564 -0.016 -0.637 0.188 0.007 -1.055 -0.219 
Sf3b1 0.373 0.155 0.033 0.035 0.710 0.737 0.254 0.016 0.172 1.302 
  Heart – Short-term DR Heart – Long-term DR 
    
Mean 




















Hnrnpa0 -0.331 0.180 0.089 -0.720 0.058 0.091 0.158 0.574 -0.254 0.436 
Hnrnpa1 0.210 0.199 0.310 -0.219 0.639 -0.208 0.156 0.206 -0.548 0.132 
Hnrnpa2b1 -0.022 0.109 0.841 -0.257 0.212 0.287 0.129 0.046 0.006 0.569 
Hnrnpd -0.017 0.115 0.884 -0.265 0.231 0.169 0.120 0.184 -0.092 0.431 
Hnrnph3 -0.123 0.086 0.173 -0.309 0.062 -0.007 0.157 0.964 -0.349 0.334 
Hnrnpk 0.234 0.191 0.244 -0.180 0.647 0.142 0.151 0.367 -0.188 0.471 
Hnrnpm -0.149 0.293 0.621 -0.783 0.485 -0.127 0.137 0.372 -0.425 0.171 
Hnrnpul2 -0.126 0.151 0.420 -0.453 0.201 -0.266 0.195 0.197 -0.692 0.159 
Pnisr -0.402 0.135 0.011 -0.694 -0.110 -0.156 0.177 0.396 -0.541 0.229 
Srsf1 -0.241 0.235 0.323 -0.748 0.266 0.004 0.269 0.988 -0.581 0.589 
Srsf2 0.171 0.178 0.353 -0.212 0.555 0.115 0.175 0.523 -0.266 0.496 
Srsf3 -0.103 0.135 0.458 -0.396 0.189 -0.051 0.131 0.704 -0.336 0.234 
Srsf6 -0.064 0.201 0.753 -0.498 0.369 0.607 0.220 0.017 0.128 1.086 





Sf1 -0.147 0.155 0.361 -0.482 0.188 0.044 0.111 0.702 -0.198 0.285 
Sf3b1 0.323 0.300 0.301 -0.326 0.972 -0.160 0.166 0.355 -0.522 0.202 
  Kidney – Short-term DR Kidney – Long-term DR 
    
Mean 




















Hnrnpa0 0.203 0.214 0.362 -0.264 0.669 0.152 0.088 0.108 -0.039 0.343 
Hnrnpa1 -0.438 0.093 <0.001 -0.640 -0.237 -0.332 0.216 0.150 -0.803 0.138 
Hnrnpa2b1 -0.158 0.085 0.086 -0.343 0.026 -0.205 0.196 0.315 -0.632 0.221 
Hnrnpd 0.063 0.087 0.483 -0.129 0.256 0.012 0.132 0.928 -0.276 0.301 
Hnrnph3 -0.085 0.075 0.277 -0.248 0.078 -0.627 0.212 0.012 -1.088 -0.166 
Hnrnpk -0.025 0.066 0.715 -0.169 0.119 -0.020 0.150 0.898 -0.346 0.307 
Hnrnpm 0.330 0.140 0.037 0.024 0.635 0.098 0.195 0.625 -0.327 0.522 
Hnrnpul2 -0.237 0.105 0.043 -0.465 -0.008 -0.192 0.161 0.258 -0.545 0.162 
Pnisr -0.289 0.121 0.034 -0.552 -0.026 0.522 0.149 0.004 0.198 0.846 
Srsf1 0.133 0.066 0.068 -0.012 0.278 -0.189 0.057 0.006 -0.314 -0.064 
Srsf2 0.069 0.101 0.509 -0.151 0.288 0.353 0.232 0.155 -0.153 0.859 
Srsf3 0.094 0.160 0.569 -0.256 0.444 -0.186 0.180 0.322 -0.578 0.206 
Srsf6 0.692 0.144 <0.001 0.378 1.005 0.054 0.175 0.763 -0.327 0.435 





Sf1 0.064 0.115 0.592 -0.188 0.315 0.147 0.122 0.251 -0.118 0.413 
Sf3b1 -0.327 0.150 0.049 -0.653 -0.001 0.328 0.151 0.050 0.000 0.656 
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Supplementary Table S24 (Chapter 5): Changes in splicing factor 
expression with long-term and short-term 40% DR in negative responder 
mice 
Changes in splicing factor expression levels with long-term and short-term DR in brain, heart and 
kidney tissue from mice which display lifespan reduction under 40% DR conditions (TejJ114), by 
ANCOVA. A positive mean difference denotes an increase in expression levels under 40% DR 
conditions when compared to AL feeding. Transcripts showing nominal associations (p<0.05) are 
shown in italic and underlined, those which meet correction for multiple testing (p<0.0045) are 
shown in bold italic and underlined. SE: standard error, 95% CI: 95% confidence intervals. 
 
  Brain – Short-term DR Brain – Long-term DR 
    
Mean 




















Hnrnpa0 0.062 0.200 0.761 -0.373 0.497 0.258 0.332 0.453 -0.472 0.988 
Hnrnpa1 0.032 0.215 0.886 -0.436 0.499 -0.254 0.314 0.435 -0.937 0.430 
Hnrnpa2b1 0.268 0.114 0.037 0.019 0.517 -0.437 0.153 0.014 -0.769 -0.104 
Hnrnpd 0.093 0.116 0.436 -0.158 0.345 -0.462 0.186 0.028 -0.867 -0.058 
Hnrnph3 0.089 0.100 0.392 -0.129 0.307 -0.342 0.151 0.043 -0.670 -0.013 
Hnrnpk -0.281 0.159 0.102 -0.627 0.065 -0.196 0.269 0.481 -0.781 0.390 
Hnrnpm 0.010 0.147 0.949 -0.310 0.329 0.163 0.255 0.535 -0.393 0.719 
Hnrnpul2 0.112 0.086 0.214 -0.074 0.298 -0.193 0.166 0.266 -0.554 0.168 
Pnisr -0.008 0.174 0.965 -0.388 0.372 0.123 0.184 0.517 -0.278 0.524 
Srsf1 -0.247 0.317 0.453 -0.945 0.451 0.222 0.235 0.365 -0.291 0.734 
Srsf2 0.348 0.157 0.046 0.007 0.689 0.237 0.277 0.408 -0.366 0.840 
Srsf3 -0.334 0.184 0.094 -0.735 0.067 0.172 0.204 0.417 -0.273 0.616 
Srsf6 -0.808 0.208 0.002 -1.262 -0.354 0.261 0.149 0.105 -0.064 0.586 





Sf1 -0.407 0.125 0.007 -0.680 -0.134 -0.023 0.213 0.916 -0.487 0.441 
Sf3b1 0.417 0.213 0.074 -0.047 0.882 -0.009 0.340 0.979 -0.750 0.732 
  Heart – Short-term DR Heart – Long-term DR 
    
Mean 




















Hnrnpa0 0.067 0.174 0.705 -0.312 0.447 -0.344 0.099 0.005 -0.561 -0.127 
Hnrnpa1 0.407 0.113 0.004 0.161 0.653 -0.236 0.170 0.189 -0.606 0.134 
Hnrnpa2b1 -0.287 0.073 0.002 -0.448 -0.127 0.258 0.151 0.114 -0.071 0.587 
Hnrnpd -0.316 0.087 0.003 -0.505 -0.127 0.005 0.156 0.975 -0.334 0.344 
Hnrnph3 0.010 0.077 0.895 -0.158 0.178 -0.015 0.116 0.899 -0.268 0.238 
Hnrnpk -0.006 0.165 0.971 -0.365 0.353 0.368 0.181 0.066 -0.028 0.763 
Hnrnpm 0.567 0.187 0.011 0.158 0.975 -0.221 0.249 0.393 -0.763 0.321 
Hnrnpul2 -0.202 0.135 0.159 -0.495 0.091 0.275 0.126 0.049 0.001 0.550 
Pnisr 0.060 0.166 0.724 -0.305 0.425 0.043 0.120 0.725 -0.218 0.304 
Srsf1 0.054 0.189 0.779 -0.357 0.465 -0.079 0.126 0.543 -0.353 0.196 
Srsf2 0.460 0.166 0.017 0.099 0.821 0.071 0.111 0.531 -0.170 0.313 
Srsf3 0.147 0.205 0.489 -0.301 0.594 -0.005 0.107 0.967 -0.240 0.231 
Srsf6 -0.685 0.151 <0.001 -1.014 -0.355 0.318 0.151 0.057 -0.012 0.648 





Sf1 -0.511 0.138 0.003 -0.812 -0.211 -0.342 0.187 0.092 -0.750 0.065 
Sf3b1 -0.259 0.205 0.230 -0.705 0.188 -0.305 0.253 0.252 -0.857 0.247 
  Kidney – Short-term DR Kidney – Long-term DR 
    
Mean 




















Hnrnpa0 0.147 0.195 0.466 -0.276 0.569 0.202 0.194 0.320 -0.225 0.630 
Hnrnpa1 -0.129 0.100 0.216 -0.345 0.086 -0.325 0.125 0.025 -0.600 -0.050 
Hnrnpa2b1 -0.105 0.129 0.433 -0.384 0.175 -0.419 0.125 0.007 -0.698 -0.140 
Hnrnpd -0.095 0.098 0.350 -0.307 0.117 0.013 0.103 0.905 -0.214 0.239 
Hnrnph3 -0.122 0.111 0.293 -0.362 0.118 -0.345 0.201 0.120 -0.800 0.110 
Hnrnpk 0.198 0.128 0.146 -0.079 0.474 0.134 0.170 0.448 -0.240 0.507 
Hnrnpm 0.148 0.109 0.196 -0.087 0.384 -0.054 0.215 0.805 -0.527 0.419 
Hnrnpul2 -0.314 0.135 0.037 -0.605 -0.022 0.171 0.129 0.212 -0.113 0.454 
Pnisr -0.261 0.144 0.094 -0.573 0.051 0.182 0.224 0.432 -0.310 0.674 
Srsf1 0.285 0.073 0.002 0.128 0.442 -0.015 0.081 0.857 -0.193 0.164 
Srsf2 0.151 0.139 0.297 -0.149 0.451 0.048 0.134 0.728 -0.247 0.343 
Srsf3 0.456 0.140 0.006 0.155 0.758 0.126 0.218 0.574 -0.354 0.606 
Srsf6 0.449 0.177 0.025 0.066 0.832 0.283 0.191 0.168 -0.139 0.704 





Sf1 -0.495 0.104 <0.001 -0.720 -0.270 0.173 0.145 0.257 -0.145 0.491 
Sf3b1 -0.557 0.168 0.005 -0.919 -0.195 0.223 0.204 0.297 -0.225 0.672 
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Supplementary Table S25 (Chapter 5): Splicing factor expression according 
to mouse strain 
Differences in splicing factor expression between the lifespan extension (TejJ89) and lifespan 
reduction (TejJ114) responder strains under 40% DR by ANCOVA. A positive mean difference 
denotes higher expression levels in TejJ89 relative to TejJ114 under 40% DR conditions. 
Transcripts showing nominal associations (p<0.05) are shown in italic and underlined, those 
which meet correction for multiple testing (p<0.0045) are shown in bold italic and underlined. SE: 
standard error, 95% CI: 95% confidence intervals. 
 
  Brain – Short-term DR Brain – Long-term DR 
    
Mean 




















Hnrnpa0 -0.446 0.170 0.022 -0.816 -0.077 -1.150 0.358 0.011 -1.960 -0.340 
Hnrnpa1 0.089 0.208 0.675 -0.364 0.542 1.788 0.510 0.008 0.613 2.963 
Hnrnpa2b1 -0.044 0.156 0.780 -0.384 0.295 0.963 0.199 <0.001 0.526 1.400 
Hnrnpd 0.032 0.127 0.808 -0.245 0.309 0.825 0.215 0.003 0.351 1.300 
Hnrnph3 -0.105 0.125 0.418 -0.377 0.168 -1.289 0.314 0.003 -2.014 -0.565 
Hnrnpk 0.102 0.160 0.534 -0.246 0.450 1.691 0.411 0.003 0.761 2.621 
Hnrnpm -0.281 0.148 0.082 -0.604 0.041 -0.200 0.264 0.465 -0.780 0.381 
Hnrnpul2 -0.017 0.109 0.876 -0.254 0.220 0.309 0.109 0.016 0.070 0.549 
Pnisr -0.119 0.160 0.471 -0.468 0.230 0.144 0.190 0.465 -0.274 0.562 
Srsf1 0.229 0.278 0.426 -0.377 0.836 -0.881 0.294 0.012 -1.528 -0.234 
Srsf2 -0.533 0.133 0.002 -0.823 -0.243 -0.801 0.371 0.056 -1.628 0.026 
Srsf3 -0.219 0.135 0.131 -0.513 0.076 -1.281 0.431 0.018 -2.274 -0.288 
Srsf6 -0.084 0.227 0.718 -0.578 0.410 -1.180 0.286 0.002 -1.810 -0.550 





Sf1 0.186 0.138 0.204 -0.115 0.487 -0.687 0.184 0.004 -1.098 -0.276 
Sf3b1 0.245 0.155 0.141 -0.094 0.584 0.715 0.398 0.103 -0.172 1.602 
  Heart – Short-term DR Heart – Long-term DR 
    
Mean 




















Hnrnpa0 -0.374 0.165 0.041 -0.731 -0.017 0.516 0.175 0.012 0.134 0.899 
Hnrnpa1 -0.039 0.164 0.817 -0.393 0.316 -0.230 0.167 0.194 -0.593 0.134 
Hnrnpa2b1 0.194 0.130 0.162 -0.089 0.478 -0.015 0.108 0.893 -0.249 0.220 
Hnrnpd 0.344 0.088 0.002 0.154 0.534 0.107 0.121 0.393 -0.156 0.371 
Hnrnph3 -0.168 0.093 0.096 -0.369 0.034 -0.001 0.130 0.996 -0.284 0.283 
Hnrnpk 0.214 0.163 0.211 -0.138 0.566 -0.093 0.146 0.535 -0.412 0.225 
Hnrnpm -0.733 0.255 0.013 -1.283 -0.183 0.159 0.243 0.526 -0.371 0.690 
Hnrnpul2 0.056 0.158 0.731 -0.286 0.397 -0.572 0.134 0.001 -0.863 -0.282 
Pnisr -0.457 0.183 0.028 -0.856 -0.058 -0.248 0.139 0.099 -0.550 0.054 
Srsf1 -0.338 0.144 0.035 -0.648 -0.028 0.165 0.217 0.462 -0.307 0.636 
Srsf2 -0.224 0.173 0.219 -0.599 0.151 0.073 0.144 0.624 -0.241 0.386 
Srsf3 -0.248 0.152 0.126 -0.576 0.080 0.359 0.093 0.002 0.156 0.561 
Srsf6 0.425 0.172 0.028 0.053 0.797 0.429 0.177 0.032 0.043 0.815 





Sf1 0.191 0.169 0.279 -0.175 0.557 0.402 0.183 0.048 0.005 0.800 
Sf3b1 0.657 0.234 0.015 0.151 1.162 0.008 0.231 0.974 -0.495 0.510 
  Kidney – Short-term DR Kidney – Long-term DR 
    
Mean 




















Hnrnpa0 -0.013 0.208 0.950 -0.463 0.436 -0.264 0.153 0.115 -0.604 0.076 
Hnrnpa1 -0.371 0.092 0.001 -0.569 -0.173 -0.206 0.156 0.217 -0.554 0.142 
Hnrnpa2b1 -0.065 0.150 0.672 -0.389 0.259 -0.001 0.156 0.996 -0.354 0.352 
Hnrnpd 0.123 0.089 0.191 -0.070 0.316 -0.022 0.120 0.856 -0.289 0.245 
Hnrnph3 0.055 0.103 0.605 -0.169 0.278 -0.148 0.247 0.566 -0.718 0.422 
Hnrnpk -0.151 0.132 0.274 -0.436 0.135 0.229 0.148 0.154 -0.101 0.559 
Hnrnpm 0.188 0.111 0.114 -0.051 0.427 0.193 0.237 0.435 -0.335 0.721 
Hnrnpul2 0.093 0.147 0.538 -0.224 0.410 -0.177 0.153 0.274 -0.518 0.164 
Pnisr -0.059 0.149 0.698 -0.381 0.263 0.259 0.160 0.136 -0.097 0.614 
Srsf1 -0.174 0.086 0.065 -0.361 0.012 -0.089 0.100 0.394 -0.311 0.133 
Srsf2 -0.112 0.116 0.352 -0.362 0.138 0.282 0.224 0.236 -0.217 0.781 
Srsf3 -0.280 0.115 0.030 -0.528 -0.033 -0.006 0.234 0.979 -0.527 0.514 
Srsf6 0.279 0.186 0.157 -0.122 0.681 0.072 0.143 0.627 -0.247 0.390 





Sf1 0.552 0.116 <0.001 0.301 0.802 -0.031 0.112 0.785 -0.281 0.218 




Supplementary Table S26 (Chapter 5): Interactions between strain effects 
and 40% DR effects on splicing factor expression 
Shown here are the interaction coefficients between strain effects and DR effects on splicing 
factor transcript expression. A positive coefficient denotes combinatorial effects contributing to 
higher expression levels in TejJ89 relative to TejJ114 under 40% DR conditions. Also shown are 
the postestimation marginal effects for each strain. Positive margins denote an increase in 
expression levels in the respective strain under 40% DR conditions when compared to AL feeding. 
Transcripts showing nominal associations (p<0.05) are shown in italic and underlined, those 
which meet correction for multiple testing (p<0.0045) are shown in bold italic and underlined. SE: 
standard error, 95% CI: 95% confidence intervals. 
Brain – Short-term DR 














Hnrnpa0 Interaction coefficient -0.495 0.308 -1.128 0.138 0.120 
 TejJ89 – Predictive margins -0.407 0.148 -0.711 -0.103  
 TejJ114 – Predictive margins 0.056 0.149 -0.251 0.362  
Hnrnpa1 Interaction coefficient -0.175 0.289 -0.769 0.418 0.549 
 TejJ89 – Predictive margins -0.112 0.139 -0.397 0.172  
 TejJ114 – Predictive margins -0.204 0.140 -0.491 0.083  
Hnrnpa2b1 Interaction coefficient -0.083 0.179 -0.452 0.285 0.646 
 TejJ89 – Predictive margins 0.153 0.086 -0.024 0.330  
 TejJ114 – Predictive margins 0.198 0.087 0.020 0.377  
Hnrnpd Interaction coefficient -0.026 0.211 -0.460 0.409 0.904 
 TejJ89 – Predictive margins 0.048 0.101 -0.160 0.257  
 TejJ114 – Predictive margins 0.012 0.102 -0.199 0.222  
Hnrnph3 Interaction coefficient -0.055 0.170 -0.406 0.295 0.748 
 TejJ89 – Predictive margins 0.087 0.082 -0.081 0.255  
 TejJ114 – Predictive margins 0.175 0.082 0.005 0.344  
Hnrnpk Interaction coefficient -0.012 0.230 -0.485 0.462 0.960 
 TejJ89 – Predictive margins -0.278 0.111 -0.505 -0.051  
 TejJ114 – Predictive margins -0.394 0.112 -0.624 -0.165  
Hnrnpm Interaction coefficient 0.019 0.212 -0.418 0.455 0.930 
 TejJ89 – Predictive margins -0.085 0.102 -0.294 0.125  
 TejJ114 – Predictive margins 0.189 0.103 -0.022 0.400  
Hnrnpul2 Interaction coefficient -0.081 0.155 -0.400 0.238 0.607 
 TejJ89 – Predictive margins 0.080 0.074 -0.073 0.233  
 TejJ114 – Predictive margins 0.107 0.075 -0.048 0.261  
Pnisr Interaction coefficient -0.002 0.257 -0.530 0.526 0.994 
 TejJ89 – Predictive margins 0.075 0.123 -0.178 0.329  
 TejJ114 – Predictive margins 0.192 0.124 -0.064 0.448  
Srsf1 Interaction coefficient 0.493 0.368 -0.265 1.251 0.193 
 TejJ89 – Predictive margins 0.287 0.174 -0.072 0.646  
 TejJ114 – Predictive margins 0.110 0.175 -0.252 0.471  
Srsf2 Interaction coefficient -0.491 0.206 -0.914 -0.067 0.025 
 TejJ89 – Predictive margins -0.254 0.099 -0.457 -0.051  
 TejJ114 – Predictive margins 0.305 0.100 0.100 0.510  
Srsf3 Interaction coefficient -0.061 0.218 -0.509 0.387 0.782 
 TejJ89 – Predictive margins -0.548 0.105 -0.763 -0.333  
 TejJ114 – Predictive margins -0.335 0.106 -0.552 -0.118  
Srsf6 Interaction coefficient 0.249 0.320 -0.409 0.907 0.444 
 TejJ89 – Predictive margins -0.913 0.154 -1.228 -0.597  
 TejJ114 – Predictive margins -0.850 0.155 -1.169 -0.532  
Tra2b Interaction coefficient 0.189 0.152 -0.123 0.502 0.224 
 TejJ89 – Predictive margins -0.049 0.073 -0.199 0.102  












 Sf1 Interaction coefficient 0.134 0.170 -0.215 0.482 0.439 
 TejJ89 – Predictive margins -0.276 0.081 -0.444 -0.109  
 TejJ114 – Predictive margins -0.474 0.082 -0.643 -0.305  
Sf3b1 Interaction coefficient -0.012 0.260 -0.546 0.522 0.964 
 TejJ89 – Predictive margins 0.485 0.125 0.229 0.741  




Supplementary Table S26 (cont.) 
Heart – Short-term DR 














Hnrnpa0 Interaction coefficient -0.407 0.242 -0.904 0.090 0.104 
 TejJ89 – Predictive margins -0.310 0.121 -0.560 -0.061  
 TejJ114 – Predictive margins 0.023 0.125 -0.233 0.279  
Hnrnpa1 Interaction coefficient -0.197 0.221 -0.651 0.258 0.383 
 TejJ89 – Predictive margins 0.242 0.111 0.015 0.470  
 TejJ114 – Predictive margins 0.284 0.114 0.050 0.518  
Hnrnpa2b1 Interaction coefficient 0.280 0.144 -0.016 0.575 0.063 
 TejJ89 – Predictive margins -0.019 0.071 -0.165 0.126  
 TejJ114 – Predictive margins -0.281 0.078 -0.440 -0.121  
Hnrnpd Interaction coefficient 0.291 0.151 -0.018 0.600 0.064 
 TejJ89 – Predictive margins -0.017 0.075 -0.172 0.138  
 TejJ114 – Predictive margins -0.371 0.077 -0.530 -0.212  
Hnrnph3 Interaction coefficient -0.148 0.127 -0.410 0.113 0.254 
 TejJ89 – Predictive margins -0.153 0.064 -0.284 -0.022  
 TejJ114 – Predictive margins 0.023 0.066 -0.111 0.158  
Hnrnpk Interaction coefficient 0.277 0.247 -0.230 0.785 0.272 
 TejJ89 – Predictive margins 0.231 0.124 -0.023 0.486  
 TejJ114 – Predictive margins 0.068 0.127 -0.194 0.329  
Hnrnpm Interaction coefficient -0.750 0.339 -1.446 -0.054 0.036 
 TejJ89 – Predictive margins -0.176 0.170 -0.525 0.173  
 TejJ114 – Predictive margins 0.603 0.175 0.244 0.961  
Hnrnpul2 Interaction coefficient 0.059 0.196 -0.344 0.462 0.767 
 TejJ89 – Predictive margins -0.140 0.098 -0.342 0.063  
 TejJ114 – Predictive margins -0.205 0.101 -0.412 0.003  
Pnisr Interaction coefficient -0.441 0.205 -0.864 -0.019 0.041 
 TejJ89 – Predictive margins -0.417 0.102 -0.626 -0.208  
 TejJ114 – Predictive margins 0.026 0.113 -0.206 0.259  
Srsf1 Interaction coefficient -0.338 0.294 -0.942 0.267 0.262 
 TejJ89 – Predictive margins -0.270 0.148 -0.573 0.033  
 TejJ114 – Predictive margins 0.064 0.152 -0.247 0.375  
Srsf2 Interaction coefficient -0.275 0.233 -0.753 0.203 0.249 
 TejJ89 – Predictive margins 0.183 0.117 -0.056 0.423  
 TejJ114 – Predictive margins 0.446 0.120 0.199 0.692  
Srsf3 Interaction coefficient -0.219 0.238 -0.708 0.270 0.366 
 TejJ89 – Predictive margins -0.113 0.120 -0.358 0.133  
 TejJ114 – Predictive margins 0.202 0.123 -0.050 0.454  
Srsf6 Interaction coefficient 0.584 0.248 0.074 1.093 0.026 
 TejJ89 – Predictive margins -0.131 0.125 -0.386 0.125  
 TejJ114 – Predictive margins -0.576 0.128 -0.838 -0.314  
Tra2b Interaction coefficient 0.138 0.189 -0.250 0.525 0.472 
 TejJ89 – Predictive margins 0.198 0.095 0.004 0.392  












 Sf1 Interaction coefficient 0.335 0.203 -0.082 0.751 0.111 
 TejJ89 – Predictive margins -0.174 0.102 -0.383 0.035  
 TejJ114 – Predictive margins -0.466 0.105 -0.681 -0.252  
Sf3b1 Interaction coefficient 0.604 0.351 -0.117 1.324 0.097 
 TejJ89 – Predictive margins 0.367 0.176 0.006 0.729  





Supplementary Table S26 (cont.) 
Kidney – Short-term DR 














Hnrnpa0 Interaction coefficient 0.051 0.280 -0.523 0.625 0.856 
 TejJ89 – Predictive margins 0.196 0.142 -0.094 0.486  
 TejJ114 – Predictive margins 0.171 0.134 -0.104 0.445  
Hnrnpa1 Interaction coefficient -0.310 0.132 -0.580 -0.039 0.027 
 TejJ89 – Predictive margins -0.496 0.067 -0.633 -0.359  
 TejJ114 – Predictive margins -0.081 0.063 -0.210 0.049  
Hnrnpa2b1 Interaction coefficient -0.054 0.153 -0.368 0.260 0.725 
 TejJ89 – Predictive margins -0.172 0.077 -0.331 -0.013  
 TejJ114 – Predictive margins -0.112 0.073 -0.262 0.038  
Hnrnpd Interaction coefficient 0.152 0.131 -0.117 0.422 0.255 
 TejJ89 – Predictive margins 0.036 0.069 -0.107 0.179  
 TejJ114 – Predictive margins -0.082 0.062 -0.209 0.045  
Hnrnph3 Interaction coefficient 0.033 0.136 -0.246 0.312 0.812 
 TejJ89 – Predictive margins -0.086 0.069 -0.227 0.055  
 TejJ114 – Predictive margins -0.133 0.065 -0.266 0.000  
Hnrnpk Interaction coefficient -0.226 0.146 -0.526 0.074 0.133 
 TejJ89 – Predictive margins -0.004 0.074 -0.155 0.148  
 TejJ114 – Predictive margins 0.171 0.070 0.028 0.314  
Hnrnpm Interaction coefficient 0.192 0.178 -0.173 0.558 0.290 
 TejJ89 – Predictive margins 0.336 0.090 0.151 0.521  
 TejJ114 – Predictive margins 0.136 0.085 -0.039 0.311  
Hnrnpul2 Interaction coefficient 0.088 0.177 -0.275 0.452 0.622 
 TejJ89 – Predictive margins -0.254 0.090 -0.438 -0.070  
 TejJ114 – Predictive margins -0.349 0.085 -0.523 -0.175  
Pnisr Interaction coefficient -0.029 0.183 -0.405 0.346 0.873 
 TejJ89 – Predictive margins -0.284 0.093 -0.474 -0.094  
 TejJ114 – Predictive margins -0.251 0.088 -0.431 -0.072  
Srsf1 Interaction coefficient -0.159 0.105 -0.375 0.057 0.143 
 TejJ89 – Predictive margins 0.127 0.053 0.018 0.237  
 TejJ114 – Predictive margins 0.280 0.050 0.177 0.383  
Srsf2 Interaction coefficient -0.077 0.178 -0.443 0.289 0.668 
 TejJ89 – Predictive margins 0.079 0.090 -0.106 0.264  
 TejJ114 – Predictive margins 0.169 0.085 -0.006 0.344  
Srsf3 Interaction coefficient -0.363 0.204 -0.781 0.055 0.086 
 TejJ89 – Predictive margins 0.119 0.103 -0.092 0.331  
 TejJ114 – Predictive margins 0.445 0.097 0.245 0.645  
Srsf6 Interaction coefficient 0.238 0.225 -0.223 0.699 0.298 
 TejJ89 – Predictive margins 0.744 0.114 0.511 0.978  
 TejJ114 – Predictive margins 0.444 0.107 0.224 0.664  
Tra2b Interaction coefficient -0.145 0.156 -0.466 0.177 0.364 
 TejJ89 – Predictive margins 0.382 0.078 0.222 0.542  












 Sf1 Interaction coefficient 0.554 0.153 0.241 0.867 0.001 
 TejJ89 – Predictive margins 0.091 0.077 -0.068 0.249  
 TejJ114 – Predictive margins -0.488 0.073 -0.637 -0.338  
Sf3b1 Interaction coefficient 0.219 0.222 -0.236 0.674 0.332 
 TejJ89 – Predictive margins -0.346 0.112 -0.576 -0.115  





Supplementary Table S26 (cont.) 
Brain – Long-term DR 














Hnrnpa0 Interaction coefficient -1.057 0.408 -1.902 -0.213 0.016 
 TejJ89 – Predictive margins -0.941 0.212 -1.379 -0.503  
 TejJ114 – Predictive margins 0.134 0.197 -0.273 0.541  
Hnrnpa1 Interaction coefficient 1.652 0.479 0.659 2.644 0.002 
 TejJ89 – Predictive margins 1.478 0.296 0.865 2.091  
 TejJ114 – Predictive margins -0.208 0.208 -0.639 0.223  
Hnrnpa2b1 Interaction coefficient 0.896 0.258 0.365 1.426 0.002 
 TejJ89 – Predictive margins 0.507 0.130 0.239 0.775  
 TejJ114 – Predictive margins -0.408 0.120 -0.655 -0.161  
Hnrnpd Interaction coefficient 0.717 0.270 0.161 1.273 0.014 
 TejJ89 – Predictive margins 0.385 0.136 0.104 0.666  
 TejJ114 – Predictive margins -0.370 0.126 -0.629 -0.112  
Hnrnph3 Interaction coefficient -1.241 0.296 -1.855 -0.627 <0.001 
 TejJ89 – Predictive margins -1.536 0.183 -1.915 -1.156  
 TejJ114 – Predictive margins -0.272 0.129 -0.539 -0.005  
Hnrnpk Interaction coefficient 1.632 0.421 0.760 2.504 0.001 
 TejJ89 – Predictive margins 1.515 0.232 1.035 1.995  
 TejJ114 – Predictive margins -0.063 0.180 -0.436 0.309  
Hnrnpm Interaction coefficient -0.164 0.326 -0.834 0.507 0.620 
 TejJ89 – Predictive margins -0.175 0.165 -0.514 0.164  
 TejJ114 – Predictive margins -0.042 0.152 -0.354 0.271  
Hnrnpul2 Interaction coefficient 0.376 0.210 -0.055 0.808 0.084 
 TejJ89 – Predictive margins 0.096 0.106 -0.122 0.314  
 TejJ114 – Predictive margins -0.239 0.098 -0.440 -0.038  
Pnisr Interaction coefficient 0.026 0.318 -0.629 0.681 0.936 
 TejJ89 – Predictive margins 0.040 0.161 -0.291 0.371  
 TejJ114 – Predictive margins -0.048 0.148 -0.353 0.257  
Srsf1 Interaction coefficient -0.876 0.366 -1.629 -0.123 0.024 
 TejJ89 – Predictive margins -0.776 0.185 -1.157 -0.396  
 TejJ114 – Predictive margins 0.136 0.170 -0.214 0.487  
Srsf2 Interaction coefficient -0.845 0.433 -1.738 0.049 0.063 
 TejJ89 – Predictive margins -0.504 0.237 -0.993 -0.014  
 TejJ114 – Predictive margins 0.247 0.198 -0.161 0.655  
Srsf3 Interaction coefficient -1.204 0.449 -2.135 -0.274 0.014 
 TejJ89 – Predictive margins -0.976 0.272 -1.539 -0.412  
 TejJ114 – Predictive margins 0.224 0.184 -0.158 0.606  
Srsf6 Interaction coefficient -1.052 0.367 -1.807 -0.296 0.008 
 TejJ89 – Predictive margins -0.795 0.185 -1.176 -0.413  
 TejJ114 – Predictive margins 0.408 0.171 0.056 0.760  
Tra2b Interaction coefficient -0.064 0.239 -0.555 0.428 0.792 
 TejJ89 – Predictive margins 0.163 0.121 -0.086 0.411  












 Sf1 Interaction coefficient -0.481 0.274 -1.047 0.085 0.092 
 TejJ89 – Predictive margins -0.603 0.150 -0.914 -0.293  
 TejJ114 – Predictive margins 0.024 0.125 -0.235 0.282  
Sf3b1 Interaction coefficient 0.665 0.422 -0.206 1.536 0.128 
 TejJ89 – Predictive margins 0.658 0.224 1.120 0.000  





Supplementary Table S26 (cont.) 
Heart – Long-term DR 














Hnrnpa0 Interaction coefficient 0.368 0.199 -0.043 0.778 0.077 
 TejJ89 – Predictive margins -0.025 0.096 -0.222 0.172  
 TejJ114 – Predictive margins -0.557 0.096 -0.754 -0.360  
Hnrnpa1 Interaction coefficient 0.016 0.221 -0.437 0.470 0.941 
 TejJ89 – Predictive margins -0.395 0.108 -0.617 -0.172  
 TejJ114 – Predictive margins -0.172 0.108 -0.394 0.051  
Hnrnpa2b1 Interaction coefficient 0.019 0.191 -0.374 0.412 0.922 
 TejJ89 – Predictive margins 0.238 0.094 0.045 0.431  
 TejJ114 – Predictive margins 0.258 0.094 0.065 0.451  
Hnrnpd Interaction coefficient 0.180 0.192 -0.215 0.574 0.358 
 TejJ89 – Predictive margins 0.109 0.094 -0.084 0.303  
 TejJ114 – Predictive margins 0.019 0.094 -0.175 0.212  
Hnrnph3 Interaction coefficient -0.008 0.193 -0.406 0.390 0.968 
 TejJ89 – Predictive margins -0.052 0.095 -0.247 0.143  
 TejJ114 – Predictive margins -0.036 0.095 -0.231 0.159  
Hnrnpk Interaction coefficient -0.247 0.235 -0.730 0.236 0.303 
 TejJ89 – Predictive margins 0.212 0.115 -0.025 0.450  
 TejJ114 – Predictive margins 0.284 0.115 0.047 0.521  
Hnrnpm Interaction coefficient 0.109 0.276 -0.458 0.675 0.696 
 TejJ89 – Predictive margins -0.068 0.135 -0.346 0.210  
 TejJ114 – Predictive margins -0.235 0.135 -0.513 0.043  
Hnrnpul2 Interaction coefficient -0.547 0.236 -1.033 -0.062 0.029 
 TejJ89 – Predictive margins -0.342 0.116 -0.581 -0.104  
 TejJ114 – Predictive margins 0.261 0.116 0.023 0.499  
Pnisr Interaction coefficient -0.228 0.207 -0.652 0.197 0.280 
 TejJ89 – Predictive margins -0.217 0.101 -0.426 -0.009  
 TejJ114 – Predictive margins 0.051 0.101 -0.157 0.259  
Srsf1 Interaction coefficient 0.079 0.281 -0.499 0.657 0.780 
 TejJ89 – Predictive margins 0.034 0.138 -0.250 0.318  
 TejJ114 – Predictive margins -0.112 0.138 -0.396 0.171  
Srsf2 Interaction coefficient 0.051 0.196 -0.351 0.453 0.796 
 TejJ89 – Predictive margins 0.136 0.096 -0.062 0.333  
 TejJ114 – Predictive margins 0.070 0.096 -0.127 0.267  
Srsf3 Interaction coefficient -0.014 0.166 -0.357 0.329 0.934 
 TejJ89 – Predictive margins 0.069 0.080 -0.096 0.233  
 TejJ114 – Predictive margins -0.314 0.080 -0.478 -0.149  
Srsf6 Interaction coefficient 0.303 0.253 -0.217 0.824 0.242 
 TejJ89 – Predictive margins 0.710 0.124 0.454 0.965  
 TejJ114 – Predictive margins 0.266 0.124 0.011 0.521  
Tra2b Interaction coefficient -0.089 0.257 -0.618 0.441 0.733 
 TejJ89 – Predictive margins 0.352 0.126 0.092 0.612  












 Sf1 Interaction coefficient 0.411 0.225 -0.052 0.874 0.079 
 TejJ89 – Predictive margins 0.073 0.111 -0.154 0.301  
 TejJ114 – Predictive margins -0.307 0.110 -0.534 -0.080  
Sf3b1 Interaction coefficient 0.109 0.298 -0.504 0.723 0.717 
 TejJ89 – Predictive margins -0.290 0.146 -0.591 0.011  





Supplementary Table S26 (cont.) 
Kidney – Long-term DR 














Hnrnpa0 Interaction coefficient -0.067 0.211 -0.501 0.368 0.755 
 TejJ89 – Predictive margins -0.016 0.108 -0.237 0.206  
 TejJ114 – Predictive margins 0.306 0.095 0.110 0.503  
Hnrnpa1 Interaction coefficient 0.014 0.245 -0.490 0.519 0.954 
 TejJ89 – Predictive margins -0.486 0.125 -0.744 -0.229  
 TejJ114 – Predictive margins -0.164 0.111 -0.392 0.064  
Hnrnpa2b1 Interaction coefficient 0.184 0.239 -0.309 0.677 0.449 
 TejJ89 – Predictive margins -0.277 0.120 -0.524 -0.030  
 TejJ114 – Predictive margins -0.300 0.112 -0.531 -0.069  
Hnrnpd Interaction coefficient -0.045 0.170 -0.396 0.305 0.792 
 TejJ89 – Predictive margins 0.064 0.087 -0.114 0.243  
 TejJ114 – Predictive margins 0.105 0.077 -0.053 0.264  
Hnrnph3 Interaction coefficient -0.336 0.284 -0.924 0.252 0.250 
 TejJ89 – Predictive margins -0.509 0.139 -0.796 -0.222  
 TejJ114 – Predictive margins -0.414 0.149 -0.722 -0.107  
Hnrnpk Interaction coefficient -0.146 0.218 -0.595 0.303 0.508 
 TejJ89 – Predictive margins 0.162 0.111 -0.067 0.391  
 TejJ114 – Predictive margins -0.050 0.099 -0.253 0.153  
Hnrnpm Interaction coefficient 0.106 0.280 -0.472 0.683 0.709 
 TejJ89 – Predictive margins 0.202 0.143 -0.092 0.497  
 TejJ114 – Predictive margins 0.009 0.127 -0.251 0.270  
Hnrnpul2 Interaction coefficient -0.385 0.216 -0.831 0.061 0.087 
 TejJ89 – Predictive margins 0.074 0.106 -0.145 0.294  
 TejJ114 – Predictive margins 0.259 0.093 0.067 0.452  
Pnisr Interaction coefficient 0.384 0.257 -0.145 0.913 0.147 
 TejJ89 – Predictive margins 0.436 0.131 0.167 0.706  
 TejJ114 – Predictive margins 0.155 0.116 -0.084 0.394  
Srsf1 Interaction coefficient -0.212 0.107 -0.432 0.008 0.058 
 TejJ89 – Predictive margins -0.127 0.054 -0.239 -0.015  
 TejJ114 – Predictive margins -0.012 0.048 -0.111 0.088  
Srsf2 Interaction coefficient 0.365 0.296 -0.245 0.975 0.229 
 TejJ89 – Predictive margins 0.218 0.151 -0.093 0.529  
 TejJ114 – Predictive margins -0.076 0.134 -0.351 0.200  
Srsf3 Interaction coefficient -0.307 0.269 -0.862 0.248 0.265 
 TejJ89 – Predictive margins -0.062 0.137 -0.345 0.221  
 TejJ114 – Predictive margins -0.068 0.122 -0.319 0.182  
Srsf6 Interaction coefficient -0.237 0.251 -0.754 0.279 0.353 
 TejJ89 – Predictive margins 0.180 0.128 -0.083 0.444  
 TejJ114 – Predictive margins 0.093 0.113 -0.140 0.327  
Tra2b Interaction coefficient -0.269 0.329 -0.946 0.408 0.421 
 TejJ89 – Predictive margins -0.072 0.168 -0.417 0.273  












 Sf1 Interaction coefficient -0.049 0.180 -0.421 0.322 0.787 
 TejJ89 – Predictive margins 0.154 0.092 -0.036 0.343  
 TejJ114 – Predictive margins 0.176 0.082 0.008 0.344  
Sf3b1 Interaction coefficient 0.114 0.250 -0.400 0.629 0.651 
 TejJ89 – Predictive margins 0.170 0.127 -0.092 0.432  
 TejJ114 – Predictive margins 0.281 0.113 0.048 0.513  
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Supplementary Table S27 (Chapter 6): Taqman® Low Density Array card 
contents  
Splicing factor target genes, assay IDs and qPCR software settings for each transcript included 
on the Taqman® Low Density Array cards. Endogenous control genes used are shown in bold 
italics. 
Target Assay ID Threshold Baseline Start Baseline End 
HNRNPA0 Hs00246543_s1 0.315 9 21 
HNRNPA1 Hs01656228_s1 0.377 9 24 
HNRNPA2B1 Hs00242600_m1 0.270 9 18 
HNRNPD Hs01086914_g1 0.249 4 21 
HNRNPH3 Hs01032113_g1 0.345 3 21 
HNRNPK Hs00829140_s1 0.360 3 21 
HNRNPM Hs00246018_m1 0.234 3 22 
HNRNPUL2 Hs00859848_m1 0.470 3 21 
AKAP17A Hs00946624_m1 0.145 9 22 
PNISR Hs00369090_m1 0.305 3 19 
SRSF1 Hs00199471_m1 0.191 3 20 
SRSF2 Hs00427515_g1 0.092 3 24 
SRSF3 Hs00751507_s1 0.195 3 22 
SRSF6 Hs00607200_g1 0.293 3 22 
SRSF7 Hs00196708_m1 0.217 3 20 
TRA2B Hs00907493_m1 0.165 3 21 
IMP3 Hs00251000_s1 0.259 3 23 
LSM14A Hs00385941_m1 0.146 3 21 
LSM2 Hs01061967_g1 0.191 3 23 
SF3B1 Hs00202782_m1 0.424 3 20 
18S Hs99999901_s1 0.189 2 6 
GUSB Hs00939627_m1 0.249 8 22 
IDH3B Hs00199382_m1 0.249 3 22 





Supplementary Table S28 (Chapter 6): Associations of splicing factor 
expression with decline in corrected MMSE score as a continuous measure 
Relationships of splicing factor expression levels with decline in corrected MMSE score by 
multivariate linear regression. β-coefficients represent change in log expression per unit change 
in MMSE score. Transcripts showing nominally statistically significant associations (p<0.05) are 
shown in italic and underlined. Those which satisfy Bonferroni correction for multiple testing 
(p<0.0083) are shown in bold italic and underlined. 
MMSE: DECLINE IN TEST SCORE (n = 296) 
  

















HNRNPA0 -0.003 0.001 0.019 -0.006 -0.001 
HNRNPA1 -0.001 0.002 0.476 -0.005 0.002 
HNRNPA2B1 0.000 0.001 0.783 -0.003 0.002 
HNRNPD 0.000 0.001 0.917 -0.003 0.003 
HNRNPH3 -0.001 0.002 0.577 -0.004 0.002 
HNRNPK -0.001 0.002 0.488 -0.005 0.002 
HNRNPM -0.005 0.002 0.006 -0.008 -0.001 
HNRNPUL2 -0.002 0.002 0.137 -0.005 0.001 
AKAP17A -0.005 0.003 0.077 -0.011 0.001 
PNISR 0.001 0.001 0.359 -0.002 0.004 
SRSF1 -0.001 0.001 0.176 -0.003 0.001 
SRSF2 -0.001 0.003 0.612 -0.006 0.004 
SRSF3 0.001 0.002 0.732 -0.004 0.005 
SRSF6 -0.003 0.002 0.076 -0.007 0.000 
SRSF7 0.001 0.001 0.375 -0.002 0.004 
















IMP3 0.002 0.001 0.190 -0.001 0.005 
LSM14A 0.000 0.002 0.964 -0.003 0.003 
LSM2 0.004 0.002 0.111 -0.001 0.008 
SF3B1 0.001 0.002 0.717 -0.003 0.004 
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Supplementary Table S29 (Chapter 6): Further analysis of associations of 
splicing factor expression found with decline in MMSE score 
Relationships of splicing factor expression levels with different subsets of the cohort by 
multivariate linear regression. β-coefficients represent change in log expression per unit change 
in MMSE score. Transcripts showing nominally statistically significant associations (p<0.05) are 
shown in italic and underlined. Those which satisfy Bonferroni correction for multiple testing 
(p<0.0083) are shown in bold italic and underlined. 
SPLICING FACTORS ASSOCIATED WITH DECLINE IN MMSE SCORE 





Full cohort  296 -0.005 0.003 0.077 -0.011 0.001 
FU3 MMSE score >=28  174 -0.012 0.007 0.070 -0.025 0.001 
FU3 Age >= 70  178 -0.005 0.004 0.133 -0.013 0.002 
Non-decliners removed  260 -0.008 0.004 0.036 -0.015 -0.001 
Full cohort - categorised 
Mild decline 103 -0.017 0.025 0.486 -0.066 0.031 
Severe decline 13 -0.153 0.056 0.007 -0.264 -0.041 





Full cohort  296 -0.003 0.001 0.019 -0.006 -0.001 
FU3 MMSE score >=28  174 -0.007 0.003 0.010 -0.012 -0.002 
FU3 Age >= 70  178 -0.004 0.002 0.028 -0.007 0.000 
Non-decliners removed  260 -0.004 0.002 0.007 -0.008 -0.001 
Full cohort - categorised 
Mild decline 103 0.004 0.011 0.702 -0.018 0.026 
Severe decline 13 -0.083 0.025 0.001 -0.133 -0.033 





Full cohort  296 -0.005 0.002 0.006 -0.008 -0.001 
FU3 MMSE score >=28  174 -0.009 0.003 0.011 -0.016 -0.002 
FU3 Age >= 70  178 -0.005 0.002 0.011 -0.009 -0.001 
Non-decliners removed  260 -0.006 0.002 0.005 -0.009 -0.002 
Full cohort - categorised 
Mild decline 103 -0.010 0.013 0.454 -0.036 0.016 




Supplementary Table S30 (Chapter 6): Correlation between different splicing factor expression levels 









































































































































HNRNPA0 1                                      
HNRNPA1 0.161 1                                    
HNRNPA2B1 -0.228 -0.026 1                                  
HNRNPD -0.021 -0.043 0.028 1                                
HNRNPH3 -0.214 -0.096 0.281 0.189 1                              
HNRNPK -0.188 -0.352 0.039 0.221 0.338 1                            
HNRNPM 0.282 -0.049 -0.012 -0.031 -0.292 0.028 1                          
HNRNPUL2 0.226 -0.034 0.062 0.393 0.366 0.201 0.143 1                        
AKAP17A 0.239 -0.117 0.096 -0.246 -0.180 0.131 0.440 -0.047 1                      
PNISR -0.330 0.045 0.027 0.074 0.419 0.126 -0.317 -0.023 -0.270 1                    
SRSF1 0.107 0.152 -0.133 -0.154 0.108 -0.229 -0.164 0.011 -0.241 0.131 1                  
SRSF2 0.080 0.005 -0.189 -0.134 -0.353 -0.017 0.243 0.009 0.179 -0.188 0.071 1                
SRSF3 -0.493 -0.125 0.007 -0.149 -0.030 0.186 -0.205 -0.401 -0.078 0.361 -0.077 -0.038 1              
SRSF6 0.126 0.024 0.143 -0.159 -0.224 -0.216 0.005 -0.143 0.076 -0.308 0.045 -0.025 -0.269 1            
SRSF7 -0.241 0.158 -0.060 -0.179 -0.140 -0.368 -0.218 -0.204 -0.369 0.107 0.195 0.035 0.232 -0.019 1          
TRA2B -0.386 0.107 0.018 -0.192 -0.068 -0.193 -0.369 -0.369 -0.289 0.176 0.058 -0.103 0.451 -0.026 0.498 1        
IMP3 -0.080 0.131 -0.318 -0.090 -0.312 -0.362 -0.125 -0.327 -0.292 -0.068 0.064 0.015 0.246 0.013 0.326 0.318 1      
LSM14A 0.149 -0.126 0.109 -0.020 0.238 -0.181 -0.095 0.362 -0.071 -0.135 0.185 -0.264 -0.507 0.125 -0.174 -0.280 -0.239 1    
LSM2 -0.126 0.120 -0.171 -0.186 -0.337 -0.296 -0.088 -0.441 0.024 -0.104 -0.057 -0.015 -0.006 0.076 0.134 0.156 0.265 -0.050 1  
SF3B1 -0.344 -0.195 -0.049 0.014 0.476 0.260 -0.441 0.009 -0.421 0.505 0.229 -0.257 0.426 -0.287 0.158 0.302 -0.114 0.036 -0.258 1 
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Supplementary Table S31 (Chapter 6): Associations of splicing factor 
expression with alternate measures of cognitive ability 
Relationships between expression levels of splicing factors implicated in decline in MMSE score 
and results of the Trail Making Test A, Trail Making Test B and the Purdue Pegboard Test, by 
multivariate linear regression. For the Trail Making Tests, β-coefficients represent change in log 
expression per minute increased time taken to complete the tests. For the Purdue Pegboard Test, 
β-coefficients represent change in log expression per unit change in total number of pegs placed 
on the board. Transcripts showing nominally statistically significant associations (p<0.05) are 
shown in italic and underlined. Those which satisfy Bonferroni correction for multiple testing 
(p<0.0083) are shown in bold italic and underlined. 
ASSOCIATIONS WITH INCREASE IN TIME TO COMPLETE TRAIL MAKING TEST A 





Full cohort  268 0.057 0.022 0.009 0.014 0.099 
FU3 Lowest quintile removed  224 0.067 0.031 0.035 0.005 0.128 
FU3 Age >= 70  151 0.070 0.027 0.010 0.017 0.124 
Non-decliners removed  247 0.074 0.025 0.004 0.024 0.123 
Full cohort - categorised 
Mild decline 21 0.048 0.045 0.289 -0.041 0.136 
Severe decline 57 -0.049 0.031 0.117 -0.110 0.012 





Full cohort  268 0.028 0.009 0.004 0.009 0.046 
FU3 Lowest quintile removed  224 0.033 0.013 0.015 0.007 0.059 
FU3 Age >= 70  151 0.029 0.011 0.014 0.006 0.051 
Non-decliners removed  247 0.031 0.011 0.005 0.009 0.052 
Full cohort - categorised 
Mild decline 21 -0.013 0.020 0.506 -0.053 0.026 
Severe decline 57 -0.027 0.014 0.044 -0.054 -0.001 





Full cohort  268 0.012 0.011 0.299 -0.010 0.033 
FU3 Lowest quintile removed  224 0.020 0.016 0.214 -0.012 0.051 
FU3 Age >= 70  151 0.021 0.012 0.092 -0.003 0.046 
Non-decliners removed  247 0.024 0.013 0.064 -0.001 0.049 
Full cohort - categorised 
Mild decline 21 0.015 0.023 0.506 -0.030 0.060 





Supplementary Table S31 (cont.) 
ASSOCIATIONS WITH INCREASE IN TIME TO COMPLETE TRAIL MAKING TEST B 





Full cohort  179 0.034 0.025 0.174 -0.015 0.083 
FU3 Lowest quintile removed  159 0.015 0.031 0.636 -0.047 0.077 
FU3 Age > 70  67 -0.007 0.042 0.863 -0.097 0.082 
Non-decliners removed  160 0.019 0.030 0.523 -0.040 0.078 
Full cohort - categorised 
Mild decline 52 0.028 0.035 0.422 -0.041 0.097 
Severe decline 37 -0.001 0.045 0.982 -0.089 0.088 





Full cohort  179 0.011 0.011 0.315 -0.011 0.033 
FU3 Lowest quintile removed  159 0.002 0.013 0.894 -0.024 0.027 
FU3 Age > 70  67 -0.013 0.018 0.463 -0.051 0.024 
Non-decliners removed  160 0.005 0.012 0.672 -0.019 0.030 
Full cohort - categorised 
Mild decline 52 0.002 0.015 0.909 -0.028 0.031 
Severe decline 37 -0.032 0.019 0.084 -0.069 0.004 





Full cohort  179 0.026 0.012 0.036 0.002 0.051 
FU3 Lowest quintile removed  159 0.021 0.015 0.182 -0.010 0.051 
FU3 Age >= 70  67 0.010 0.019 0.629 -0.032 0.051 
Non-decliners removed  160 0.016 0.015 0.288 -0.014 0.045 
Full cohort - categorised 
Mild decline 52 0.006 0.017 0.749 -0.029 0.040 
Severe decline 37 -0.051 0.022 0.022 -0.095 -0.007 
 
ASSOCIATIONS WITH DECLINE IN TOTAL NUMBER OF PEGS PLACED IN PURDUE PEGBOARD TEST 





Full cohort  257 -0.005 0.002 0.012 -0.008 -0.001 
FU3 Lowest quintile removed  212 -0.004 0.002 0.079 -0.008 0.000 
FU3 Age > 70  141 -0.009 0.003 0.002 -0.015 -0.004 
Non-decliners removed  204 -0.005 0.003 0.060 -0.010 0.000 
Full cohort - categorised 
Mild decline 87 -0.062 0.027 0.024 -0.116 -0.008 
Severe decline 48 -0.094 0.035 0.008 -0.164 -0.024 





Full cohort  257 -0.002 0.001 0.047 -0.003 0.000 
FU3 Lowest quintile removed  212 -0.001 0.001 0.101 -0.003 0.000 
FU3 Age > 70  141 -0.004 0.001 0.002 -0.006 -0.001 
Non-decliners removed  204 -0.003 0.001 0.002 -0.005 -0.001 
Full cohort - categorised 
Mild decline 87 -0.004 0.012 0.751 -0.027 0.020 
Severe decline 48 -0.035 0.015 0.025 -0.065 -0.004 





Full cohort  257 -0.002 0.001 0.044 -0.004 0.000 
FU3 Lowest quintile removed  212 -0.002 0.001 0.073 -0.004 0.000 
FU3 Age >= 70  141 -0.002 0.001 0.081 -0.005 0.000 
Non-decliners removed  204 -0.002 0.001 0.242 -0.004 0.001 
Full cohort - categorised 
Mild decline 87 -0.001 0.014 0.926 -0.029 0.027 
Severe decline 48 -0.021 0.019 0.259 -0.058 0.016 
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Supplementary Table S32 (Chapter 6): Correlations between trajectories in 
phenotypic test scores 
Pearson correlations of relationships between calculated change variables for the different 
cognitive and physical measures used in the current study. Part a. shows correlations seen 
between the cognitive measures and part b. the physical measures. 
a. 
  
MMSE: DECLINE IN 
TEST SCORE 
TMT-A: INCREASE 
IN TIME TO 
COMPLETE 
TMT-B: INCREASE 
IN TIME TO 
COMPLETE 
PURDUE PEGBOARD: 
DECLINE IN TOTAL 
NUMBER OF PEGS 
PLACED 
MMSE: DECLINE IN 
TEST SCORE 1 
     
TMT-A: INCREASE IN 
TIME TO COMPLETE -0.381 1 
  
TMT-B: INCREASE IN 
TIME TO COMPLETE 
-0.188 0.322 1   
PURDUE PEGBOARD: 
DECLINE IN TOTAL  
NUMBER OF PEGS 
PLACED 





STRENGTH: DECLINE IN 
EXERTED FORCE (kg) 
EPESE SPPB: DECLINE IN 
COMPOSITE SCORE 
400m FAST WALK: DECLINE 
IN CALCULATED SPEED (m/s) 
MEAN HAND-GRIP 
STRENGTH: DECLINE IN 
EXERTED FORCE (kg) 
1    
EPESE SPPB: DECLINE IN 
COMPOSITE SCORE 0.217 1 
 
400m FAST WALK: DECLINE 
IN CALCULATED SPEED (m/s) 







Supplementary Table S33 (Chapter 6): Associations of splicing factor 
expression with mean hand-grip strength as a continuous measure 
Relationships of splicing factor expression levels with mean hand-grip strength by multivariate 
linear regression. β-coefficients represent change in log expression per Kg change in mean hand-
grip strength. Transcripts showing nominally statistically significant associations (p<0.05) are 
shown in italic and underlined. 
MEAN HAND-GRIP – DECLINE (n = 285) 
  

















HNRNPA0 0.001 0.001 0.664 -0.002 0.003 
HNRNPA1 0.000 0.002 0.885 -0.003 0.003 
HNRNPA2B1 -0.002 0.001 0.134 -0.004 0.001 
HNRNPD 0.002 0.001 0.198 -0.001 0.004 
HNRNPH3 0.001 0.001 0.667 -0.002 0.003 
HNRNPK 0.001 0.002 0.333 -0.002 0.004 
HNRNPM -0.002 0.001 0.256 -0.004 0.001 
HNRNPUL2 0.002 0.001 0.111 0.000 0.005 
AKAP17A -0.006 0.003 0.023 -0.011 -0.001 
PNISR 0.000 0.001 0.707 -0.002 0.003 
SRSF1 -0.001 0.001 0.480 -0.002 0.001 
SRSF2 0.001 0.002 0.771 -0.004 0.005 
SRSF3 0.000 0.002 0.932 -0.004 0.004 
SRSF6 -0.001 0.002 0.469 -0.004 0.002 
SRSF7 0.001 0.001 0.547 -0.002 0.003 
















IMP3 0.001 0.001 0.672 -0.002 0.003 
LSM14A 0.000 0.001 0.759 -0.002 0.003 
LSM2 0.000 0.002 0.876 -0.004 0.004 





Supplementary Table S34 (Chapter 6): Further analysis of associations of 
splicing factor expression found with decline in mean hand-grip strength 
Relationships of splicing factor expression levels with different subsets of the cohort by 
multivariate linear regression. β-coefficients represent change in log expression per Kg change in 
mean hand-grip strength. Transcripts showing nominally statistically significant associations 
(p<0.05) are shown in italic and underlined. Those which satisfy Bonferroni correction for multiple 
testing (p<0.0083) are shown in bold italic and underlined. 
ASSOCIATIONS WITH DECLINE IN MEAN HAND-GRIP STRENGTH 





Full cohort  285 -0.006 0.003 0.023 -0.011 -0.001 
Mean FU3 hand-grip >= 
EWGSOP cutoffs 
 204 -0.007 0.003 0.035 -0.013 0.000 
FU3 Age >= 70  169 -0.011 0.004 0.008 -0.018 -0.003 
Non-decliners removed  229 -0.005 0.004 0.190 -0.012 0.002 
Full cohort - categorised 
Mild decline 74 -0.026 0.029 0.370 -0.084 0.031 





Supplementary Table S35 (Chapter 6): Associations of splicing factor 
expression with alternate measures of physical ability 
Relationships between expression levels of splicing factors implicated in decline in mean hand-
grip strength and physical performance as measured by the Epidemiologic Studies of the Elderly 
– Short Physical Performance Battery (EPESE SPPB) and a timed 400m fast walk, by multivariate 
linear regression. For the EPESE SPPB, β-coefficients represent change in log expression per 
unit decline in composite score. For the 400m fast walk, β-coefficients represent change in log 
expression per unit decline in speed calculated in m/s. Transcripts showing nominally statistically 
significant associations (p<0.05) are shown in italic and underlined. Those which satisfy 
Bonferroni correction for multiple testing (p<0.0083) are shown in bold italic and underlined. 
ASSOCIATIONS WITH DECLINE IN EPESE SPPB COMPOSITE SCORE 





Full cohort  276 -0.011 0.006 0.048 -0.022 0.000 
FU3 Lowest quintile removed  216 -0.002 0.009 0.810 -0.020 0.016 
FU3 Age >= 70  160 -0.014 0.007 0.042 -0.027 -0.001 
Non-decliners removed  244 -0.012 0.006 0.068 -0.024 0.001 
Full cohort - categorised 
Mild decline 61 0.028 0.031 0.356 -0.032 0.089 
Severe decline 46 -0.087 0.034 0.011 -0.155 -0.020 
 
ASSOCIATIONS WITH DECLINE IN CALCULATED SPEED (m/s) DURING 400m FAST WALK 





Full cohort  206 -0.252 0.101 0.013 -0.451 -0.053 
FU3 Lowest quintile removed  183 -0.277 0.112 0.015 -0.499 -0.055 
FU3 Age >= 70  93 -0.172 0.182 0.348 -0.539 0.194 
Non-decliners removed  194 -0.189 0.117 0.109 -0.421 0.043 
Full cohort - categorised 
Mild decline 126 -0.053 0.034 0.118 -0.120 0.014 





Supplementary Data S1 (Chapter 3): Tissue collection procedure for the 
mouse strain comparison study 
Mice were housed in duplex "shoebox" cages. Two to three days prior to sacrifice 
and tissue collection, mouse cages were moved from the mouse room to the 
procedure room. All the mice from one pen (n = 4–5 mice) were sacrificed within 
1–6 minutes of initial disturbance of the home cage. The mice in the remaining 
pen of the home cage were returned to the mouse room and sacrificed 2–4 weeks 
later. Each mouse to be sacrificed was removed from its cage and immediately 
euthanized by CO2 asphyxiation. As soon as the mouse stopped breathing and 
did not exhibit a reflex to a foot pinch, it was bled by cardiac puncture. The liver, 
spleen, kidneys and heart were removed in that order. Next, the skin sample, 
thigh muscle and thymus were removed. Portions of liver, spleen, kidney, skin, 
heart, and skeletal muscle were placed into RNAlater (SigmaAldrich) and 
immediately frozen in liquid nitrogen; the remainder of each tissue was placed in 
Cryo-tubes and frozen directly in liquid nitrogen. Four technicians participated in 
the dissection of each mouse to minimize the time from death to freezing the 
tissue (less than 2 minutes for liver, and less than 3 minutes for each of the 
remaining tissues). All tissues were stored at –80° C.
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Supplementary Data S2 (Chapter 3): Assay identifiers and sequence details for qRT–PCR assays used in this study. 
 
Splicing factors  



















Supplementary Data S2 (cont.) 
Spleen     
Isoform Target(s) - 
UCSC ID 
Assay Name Forward Primer Reverse Primer Probe 
uc009pme.2 ; 
uc009pmd.2 
ATM_13 CGACCTGGGTTTGCATTGG GTGCTAGACTCATGGTTTAAGATTTCAGA CCTCACCGCTGCATTC 
uc012gtj.1 ATM_2 TGCTCTGCAGTGTCTAAGAAACAG TGCCCTTACTCAACTCTTCAACTTC TTTCACCCTGGCATATCG 
uc008toi.1 CDKN2A_1 GCCGCACCGGAATCCT AAGAGCTGCTACGTGAACGT CCCATCATCATCACCTGGTC 
uc008toh.1 CDKN2A_2 CAACGCCCCGAACTCTTTC AAGAGCTGCTACGTGAACGT CCCGATTCAGGTGATGAT 
uc008yrw.1 CHEK2_1 AAGAGACGAATACATCATGTCAAAAACTCT CACTTTCTGACATGTCTTCCTCTCAA ACACGCACCACTTCCA 
uc008yrx.1 CHEK2_2 TGAGTAACAACTCTGAAATCGCACTT CACTTTCTGACATGTCTTCCTCTCAA ACACGCACCACTTTAT 
uc007bju.2 FN1_1 CCCTACTACACTGACACAGCAA GTGTCTGGACCGATATTGGTGAAT ACGGCTGTCCCTCCTC 
uc007bjv.2 ; 
uc007bjy.2 
FN1_25 AGCCCCTGATTGGGAGGAA GTCATACCCAGGGTTGGTGAT AAGACAGTTCAAAAGACCC 
uc008pvj.3 LMNA_1 GACGACGAGGATGGAGAAGAG CGTGAGCGCAGGTTGTACT CCGTGGTTCCCACTGCA 
uc008pvj.3 ; 
uc008pvl.3 
LMNA_13 GTGCGTGAGGAGTTCAAGGA CTGCGCAGCCAACAAGTC AAGGCTCGCAACACCA 
uc008pvk.3 LMNA_2 AAGGCCTTGCTCTCTCTGG CTGCGCAGCCAACAAGTC CTTGGTGTTGCGGCCCT 








TRP53_134 GCAGGGTGTCACGCTTCT TCCGACTGTGACTCCTCCAT CAGTCATCCAGTCTTCG 
uc011xww.1 TRP53_2 GCAGGGTGTCACGCTTCT GCTTCAGGCTTTTCTTGGATTTTCT ACTGGCCGCTTCTC 
uc007jqm.2 TRP53_3 GTTAAAGGATGCCCATGCTACAGA AGTTTGGGCTTTCCTCCTTGATC TCCAGCCTCCAGCCTAG 
uc007rjg.1 VCAN_1 CCAAGTTCCACCCTGACATAAATGT GGATGACCACTTACAATCATATCACTCA ATCGACCTGTCTTGTTTTC 
uc011zck.1 ; 
uc007rji.2 
VCAN_23 CCAAGTTCCACCCTGACATAAATGTTTATATTAT CGTTGAGGCATGGGTTTGTTTTG ACAGGACCTGATCTCTG 
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Supplementary Data S2 (cont.) 
Muscle     
Isoform Target(s) - 
UCSC ID 
Assay Name Forward Primer Reverse Primer Probe 
uc012cdt.1 IL1B_1 TGAAAGCTCTCCACCTCAATGG GCTCATGGAGAATATCACTGGAGAAA TCAACCAACAAGACTCCTC 
uc008mht.1 IL1B_2 GTTCCTGAACTCAACTGTGAAATGC CGTCAACTTCAAAGAACAGGTCATT TCATCACTGTCAAAAGGTG 
uc008mht.1 ; 
uc008mhu.1 
IL1B_23 GACAGTGATGAGAATGACCTGTTCT AGCCCAGGTCAAAGGTTTGG AAGCAGCCCTTCATCTTT 
uc008wuu.1 ; 
uc008wuv.1 
IL6_12 TCAATTCCAGAAACCGCTATGAAGT GTCCCAAGAAGGCAACTGGAT TCTGCAAGAGACTTCC 
uc008wuu.1 ; 
uc008wuw.1 




NFKB1_145 GCATTCTGACCTTGCCTATCTACAA CCTGGCGGATGATCTCCTT CTCTGTCTGTGAGTTGCC 
uc008rly.1 ; 
uc008rlx.1 
NFKB1_15 GAGCCTCTAGTGAGAAGAACAAGAA TTTGCAGGCCCCACATAGTT ACAGGTCAAAATTTGC 




NFKB1_345 TCTGCCTCTCTCGTCTTCCT TCTCCACACCACTGTCACAGA CCCGGAGTTCATCTATG 
uc012cyg.1 NFKB1_4 GAGCCTCTAGTGAGAAGAACAAGAA GCCCCACATAGTTGCAAATCTG CAGGTCAAAAGGCCCC 
uc012cyg.1 ; 
uc008rlx.1 
NFKB1_45 GGAAACTAGTGAACCGAAACCCTTT GCGTTTCCTTTGCACTTCCT CCCTGAAATCAAAGACAAAG 













Supplementary Data S2 (cont.) 
Muscle     
Isoform Target(s) - 
UCSC ID 





STAT1_2456 CGAACTGGATACATCAAGACTGAGT GTTGTCTGTGGTCTGAAGTCTAGAA CTGTGTCTGAAGTCCACCC 
uc007ayb.2 STAT1_5 GCAGAGAGATTTGCCCAGACT GCCGGCTCAGGGTATGG CAGAGCTGAAACGATCACT 
uc007ayc.2 STAT1_6 CTCTTATCCTGCCGTTCTCACTTC GCCGGCTCAGGGTATGG TAGGTCGTTTCAGCTCTGC 
uc008cgr.2 ; 
uc012arb.2 
TNF_12 CACGCTCTTCTGTCTACTGAACTT CTGATGAGAGGGAGGCCATTTG AAGGGATGAGAAGTTCC 
uc008cgr.2 ; 
uc008cgs.2 
TNF_13 CAAAATTCGAGTGACAAGCCTGTAG GCTGCTCCTCCACTTGGT CACGTCGTAGCAAACC 
uc012arb.2 TNF_2 GCCTCCCTCTCATCAGTTCTATG CCAGCTGCTCCTCCACTT CACACTCACAAACCACC 
uc008cgs.2 TNF_3 CACGCTCTTCTGTCTACTGAACTTC TCTGGGCCATAGAACTGATGAGA CCATTTGGGAACTCATCC 
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Supplementary Data S3 (Chapter 3): Alternatively expressed isoforms 
captured by quantitative real‐time PCR assays. 
Additional information describing precisely which alternatively expressed isoforms of analysed 
genes are captured by each probe set. 
ATM TRP53 STAT1 
   
Atm-1,3 Trp53-1,3,4 Stat1-1 
uc009pme.2 uc007jql.2 uc007axy.1 
uc009pmd.2 uc007jqm.2 Stat1-3,4 
Atm-2 uc007jqn.2 uc007axz.1 
uc012gtj.1 Trp53-2 uc007aya.2 
 uc011xww.1 Stat1-2,3,4,5 
CDKN2A Trp53-3 uc007ayd.2 
 uc007jqm.2 uc007axz.1 
Cdkn2a-1  uc007aya.2 
uc008toi.1 VCAN uc007ayb.2 
Cdkn2a-2  Stat1-2,4,5,6 
uc008toh.1 Vcan-1 uc007ayd.2 
 uc007rjg.1 uc007aya.2 
CHEK2 Vcan-2 uc007ayb.2 
 uc011zck.1 uc007ayc.2 
Chek2-1  Stat1-5 
uc008yrw.1 IL1B uc007ayb.2 
Chek2-2  Stat1-6 
uc008yrx.1 Il1b-2 uc007ayc.2 
 uc008mht.1  
FN1 Il1b-2,3 TNF 
 uc008mht.1  
Fn1-1 uc008mhu.1 Tnf-1,2 
uc007bju.2  uc008cgr.2 
Fn1-2,5 IL6 uc012arb.2 
uc007bjv.2  Tnf-1,3 
uc007bjy.2 IL6-1,2 uc008cgr.2 
 uc008wuu.1 uc008cgs.2 
LMNA uc008wuv.1 Tnf-3 
 Il6-1,3 uc008cgs.2 
Lmna-1 uc008wuu.1  
uc008pvj.3 uc008wuw.1  
Lmna-1,3   
uc008pvj.3 NFKB1  
uc008pvl.3   
 Nfkb1-1,4,5  
MYC uc008rly.1  
 uc012cyg.1  
Myc-1 uc008rlx.1  
uc007vyh.2 Nfkb1-1,5  
Myc-1,2,3 uc008rly.1  
uc007vyh.2 uc008rlx.1  
uc007vyg.2 Nfkb1-2  
uc007vyi.1 uc012cyf.1  
 Nfkb1-3,4,5  
 uc008rlw.1  
 uc012cyg.1  
 uc008rlx.1  
 Nfkb1-4,5  
 uc012cyg.1  
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